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Abstract 
Proteins containing FIC (filamentation induced by cAMP) domains are conserved 
through evolution and found ubiquitously in all domains of life and viruses. Fic proteins 
catalyze adenylylation, or AMPylation, the transfer of an adenosine-5’-monophosphate 
moiety (AMP) from an ATP substrate onto a target protein. The adenylylation activity of two 
bacterial proteins, VopS from Vibrio parahaemolyticus and IbpA from Histophilus somni was 
discovered recently. VopS and IbpA are translocated into eukaryotic cells and adenylylate the 
small GTPases RhoA, Rac1 and Cdc42 in the switch I region, resulting in the inhibition of 
downstream effector binding and ultimately collapse of the actin cytoskeleton and cell death. 
Due to their cytotoxic activity in eukaryotic cells but also in bacteria, Fic proteins need to be 
tightly regulated.  
To contribute to the understanding of the regulation mechanism of Fic proteins and 
inhibition of their targets, I applied biochemical, biophysical and mainly X-ray 
crystallographic analysis. This work was achieved in close collaboration with microbiologists.  
In research article I, we show that adenylylation competent Fic proteins containing the 
HxFx[D/E]GNGRxxR motif are inhibited by a conserved α-helix (αinh) that contains a 
[S/T]xxxE[G/N] inhibition motif. The αinh helix can be found on a separate protein that forms 
a tight complex with the Fic protein, or at the N-terminus or C-terminus compared to the Fic 
active site. These three possibilities lead to the classification of Fic proteins into class I, II and 
III, respectively. The strictly conserved glutamate of this motif competes with the binding of 
the γ-phosphate of the ATP substrate of Fic proteins. In research article II, we structurally 
demonstrate that this inhibitory mechanism applies independent of the position of the αinh 
helix relative to the Fic active site motif.  
In the research article III we identify GyrB and ParE, the B-subunits of the bacterial 
topoisomerases DNA gyrase and topoIV, as new bacterial targets for class I Fic proteins. 
Furthermore, we show that the activity of Fic proteins promotes persister formation and that 
the ATPase activity of GyrB is blocked by Fic-mediated adenylylation of GyrB. As the 
structural consequences of ATP hydrolysis in GyrB remained elusive, I revealed in research 
article IV all nucleotide bound states along the ATP hydrolysis pathway by thorough X-ray 
crystallographic analysis. Upon ATP hydrolysis, an obligatory rigid-body domain motion of 
the transducer relative to the ATPase domain occurs in the immediate post-hydrolysis state 
(ADP⋅Pi). 
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In research article V, we dissect the regulation mechanism of the class III Fic protein 
NmFic that contains the αinh helix at the C-terminus. NmFic is in a monomer-tetramer 
equilibrium and structurally unable to bind a target in the tetramer form. Dissociation of the 
tetramer relieves the inhibition of this Fic protein and allows adenylylation of GyrB. 
Interestingly, NmFic is also auto-adenylylated. Auto-adenylylation of NmFic leads to 
conformational changes in the αinh helix and the neighboring α1 helix, with the Fic core being 
unchanged. We show that the presence of the strictly conserved tyrosine Y183 which is auto-
adenylylated is crucial for both Fic protein activities. Thus, we propose that class III Fic 
proteins are tightly regulated by oligomerization and auto-adenylylation via a double-lock 
mechanism. 
The inhibition of bacterial topoisomerases by Fic proteins of class I and III remains to be 
investigated at a structural level. I have shown that adenylylation of GyrB expulses the ATP-
lid loop from its original position and I developed a new strategy to trap the Michaelis-
Menten complex of a Fic protein and its cognate target by using covalent cross-linking of the 
Fic protein with the target via a functionalized ATP substrate. 
Taken together, these results provide the first level of understanding of the regulation of 
FIC domain proteins and Fic-mediated inhibition of bacterial topoisomerases.  
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1. Introduction 
1.1. Bacterial pathogenesis 
1.1.1. Bacterial effector proteins 
To establish a replicative niche in their reservoir host, bacteria have evolved a wide range 
of virulence factors. These effector proteins are secreted by pathogens into host cells via 
designated secretion systems, to manipulate the recipient cell and make it a more favorable 
environment for the replication of the pathogenic bacteria1. Pathogens contain a variety of 
effectors, ranging from the single effector protein CagA in Helicobacter pylori2 to hundreds 
of effectors in the case of Legionella pneumophilae3.  
In the pathogen, effector proteins are inactive due to the lack of a cognate target or 
binding to an inactivating binding partner (antitoxin) that interferes either with target 
recognition or active site obstruction. Also, type III secretion system chaperones of 
translocators interact with hydrophobic patches of the effector proteins (e.g. YopB or VopD 
from Yersinia) that mediate the membrane attachment within the host cells4. 
Bacterial effector proteins can be classified in two major categories. The first one directly 
mimics the host cell activities, where the effector proteins can either be a homologous protein 
or result from convergent evolution, having a similar structure and function but without 
obvious primary sequence identity, e.g. YopE from Yersinia pseudotuberculosis5,6. The 
second category of effector proteins modifies the host proteins by post-translational 
modification thereby subverting host cell activities more indirectly7 (see section 1.1.4.).  
Many bacterial effector proteins target members of the Rho family GTPases, the well-
studied RhoA, Rac and Cdc42. These proteins are key regulators of many cellular processes, 
e.g. cell cycle control or actin cytoskeleton regulation, which makes them ideal targets of 
bacterial effector proteins. Interestingly, some effector proteins act as Rho GTPases mimics 
but others modulate Rho GTPases by covalent modification.  
1.1.2. Secretion systems 
To reach the host cell, bacterial effector proteins need to be transported through the 
pathogen and host-cell membranes. In Gram-negative bacteria, six secretion systems have 
been described. On one-hand, Type I, III, IV and VI secretion systems secrete effector 
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molecules in one-step, across the inner membrane, the periplasm and outer membrane. On the 
other-hand, Type II and V secretion systems secrete effectors in two-steps, first to the 
periplasm and then across the outer membrane. Type III secretion system (T3SS)8 and type IV 
secretion system (T4SS) are the best characterized secretion machineries of effector proteins9.  
T3SS evolved from the bacterial flagellum10 and consists of a secretion apparatus located 
at the inner membrane, a needle filament (injectisome) that crosses the periplasm and outer 
membrane towards the eukaryotic plasma membrane where the translocon is found11.  
Host-interacting T4SS evolved multiple times independently from bacterial conjugation 
systems12 and mediate the translocation of DNA and effector proteins into eukaryotic cells13. 
Canonical type IV secretion systems are composed of 12 different proteins named VirB1-
VirB11 and VirD4. Recent electron microscopy structure of the Type IV secretion system14 
from the Escherichia coli conjugative plasmid R388 reveals a three Megadalton complex 
constituted of VirB3-VirB10 that spans the inner membrane, periplasm and outer membrane. 
This complex can be divided into three subunits: the inner membrane complex constituted of 
VirB3-VirB4, the stalk formed by VirB10 and the outer membrane complex made by VirB7, 
VirB9-VirB10. The exact localization of VirB3-VirB5-VirB6-VirB8 has not yet been 
unambiguously determined. 
1.1.3. Toxin-antitoxin systems 
There are many differences between toxins and effectors: for example, toxins inhibit 
cellular functions whereas effector proteins can modulate host cell functions15. Some toxins 
are found in so-called toxin-antitoxin (TA) systems, which consist of two genes that are 
encoded in an operon. The antitoxin is usually encoded upstream of the toxin16.  
The regulation of toxin-antitoxin systems is crucial for the activity of the system. Three 
major classes of antitoxins regulate the TA loci17: a type I antitoxin is an antisense RNA than 
inhibits the translation of the toxin, a type II antitoxin is a protein that binds to the toxin and 
prevents toxic activity or target binding and a type III antitoxin is an RNA that blocks the 
toxin through direct binding. In type II and III TA systems, the degradation of the more labile 
antitoxin leads to the activation of the toxin that can have several roles such as stabilization of 
genomic parasites, selfish alleles, gene regulation, bacteriophage defense (abortive infection), 
growth control, persister cell formation or programmed cell arrest18. Thereof, phage infection 
and persister formation are the most important functions. 
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A general mechanism of action of effector proteins and toxins is post-translational 
modifications of host cell targets, resulting in alteration of host cell functions.  
1.1.4. Pathogen-mediated post-translational modifications  
Post-translational modification (PTM) is a widespread mechanism used by both 
eukaryotic and bacterial cells to modify target proteins via the covalent attachment or removal 
of functional groups. In particular, post-translational modifications are key strategies used by 
bacterial and viral pathogens to modulate host factors critical for infection. The first evidence 
for pathogen-mediated post-translational modification was given in 1969, when Collier and 
Cole19 showed that Diphteria toxin from Corynebacterium diphteriae ADP-ribosylates the 
host Elongation Factor 2 (EF-2), resulting in the inhibition of translation and subsequent cell 
death.  
In about 45 years of research, many more pathogen-mediated post-translational 
modifications have been described. These modifications range from the addition of a few 
atoms, e.g. a phosphate group, to a polypeptide chain, e.g. ubiquitin. The most occurring 
pathogen-mediated post-translational modification of host cell proteins are phosphorylation, 
acetylation, ADP-ribosylation, adenylylation (AMPylation), glycosylation, eliminylation, 
proteolysis, ubiquitination or SUMOylation/de-SUMOylation, of which all are reversible 
PTMs except eliminylation and proteolysis that are irreversible modifications20-22 (Figure 1.1). 
1.1.4.1. Phosphorylation  
Phosphorylation is the transfer of the gamma-phosphate from ATP substrate onto specific 
amino acids by enzymes called kinases (Figure 1.1.a). The modification of histidine into 
phosphohistidine is transient, with a short half-life in the range of several seconds at acidic 
pH23, whereas the phosphorylation of serine, threonine and tyrosine is more stable24. In 
similar acidic conditions but with elevated temperature (100°C), free phosphoserine or 
phosphothreonine have a half-life of 18h, and phosphotyrosine of about 5 hours25. The 
environment also affects the stability of these phosphorylations, i.e. the pH and surrounding 
amino acids that will affect charge distribution and stabilize the phospho-amino acids, as 
observed in the case of a phosphohistidine with a half-life of 12 days in histone H4 at pH 7.6 
and room temperature26. Phosphorylation is the first PTM that was described in 1954 by 
Burnett and Kennedy27, in mitochondria. YpkA (also called YopO) from Yersinia28, SteC 
from Salmonella, legK1-legK5 from Legionella or OspG from Shigella are various bacterial 
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effector proteins that phosphorylate different eukaryotic target proteins on Ser/Thr residues 
via their kinase domain, subverting host defense processes29.  
Interestingly, the phosphorylation of amino acids is a fully reversible process that can be 
catalyzed by enzymes called phosphatases (Figure 1.1.a). These enzymes catalyze the 
dephosphorylation of previously phosphorylated residues. The type III effector protein YopH 
from Yersinia30 is a protein tyrosine phosphatase (PTP) that is essential for the virulence of 
the bacterium. SptP from Salmonella31 also contains a PTP domain that increases pathogen 
replication. 
1.1.4.2. Acetylation 
Acetylation is the addition of an acetate group on serine, threonine or lysine residues of 
host cell proteins (Figure 1.1.b). YopJ/YopP from Yersinia32 or VopA from Vibrio 
parahaemolyticus33 acetylates MAPK kinases, blocking a phosphorylation acceptor site or the 
ATP binding site of the enzyme, respectively. Listeriolysin O from Listeria monocytogenes 
seems to be involved in the increase of Histone H3 and H4 acetylation but also in the decrease 
of the acetylation of H3, suggesting a function of deacetylation, the reverse process34. 
1.1.4.3. ADP-ribosylation 
ADP-ribosylation was first described for diphteria toxin in the late 1960’s. An ADP-
ribose moiety is transferred from a nicotinamide adenine dinucleotide (NAD+) substrate onto 
target protein (Figure 1.1.c). Cholera toxin (V. cholera) and pertussis toxin (B. pertussis) 
ADP-ribosylate arginine and cysteine residues from G-alphaS, respectively. The C3 toxin 
from Clostridium modifies asparagine residues from Rho or Rac35. Pathogen-mediated ADP-
ribosylation also occurs on a diphtamide (modified histidine) residue from elongation factor 2, 
in the case of diphteria toxin (C. diphteria) or Exotoxin A (P. aeruginosa).  
The modification of these diverse amino acids results in the host cell perturbation, by a 
permanent activation or inactivation of cellular functions. Again, this reaction is reversible 
and ADP-ribose can be removed by ADP-ribosyl hydrolases36, of which the best described is 
the ribosylarginine hydrolase that specifically cleaves ADP-ribose from arginine residues37. 
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Figure 1.1. Pathogen-mediated post-translational modifications. (a) Phosphorylation of hydroxyl groups (Ser, 
Thr or Tyr) by kinase and the reverse reaction dephosphorylation. (b) Acetylation of Lys, Ser or Thr residues 
(depicted as X) by acetyltransferase and the reverse reaction deacetylation by deacetylase, (c) ADP-ribosylation 
of Arg, Cys or Asn residues (X). (d) Adenylylation of Ser, Thr or Tyr side chains by adenylyl-transferase and 
reverse reaction. (e) Glucosylation of hydroxyl groups (Ser, Thr) by glucosyltransferase. (f) Irreversible 
eliminylation of phosphorylated tyrosine side chains, resulting in dehydrobutyrine. (g) Irreversible proteolysis by 
proteases. (h) Ubiquitination and de-ubiquitination of lysine side chains. (i) Similarly to ubiquitination, the 
mechanism of SUMOylation and de-SUMOylation. Modified from 21,22. 
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1.1.4.4. Adenylylation 
Adenylylation or AMPylation, i.e. the transfer of an AMP moiety onto a hydroxyl side 
chain (Figure 1.1.d), is a post-translational modification that has first been described as part of 
the regulation mechanism of glutamine synthetase (described in section 1.2.2.2). Interestingly, 
adenylylation is also a pathogen-mediated PTM that has been demonstrated for the L. 
pneumophilae effector protein DrrA38, which shares the same fold as glutamine synthetase39, 
yet without obvious sequence identity. Additionally, Fic proteins are effectors that constitute a 
new family of adenylyl-transferase with a distinct fold and will be described in section 1.3. 
This PTM will be detailed in section 1.2. and in the context of Fic-mediated adenylylation in 
section 1.4.1. 
1.1.4.5. Glucosylation (glycosylation) 
Pathogen-mediated glucosylation (or glycosylation) consists in the transfer of 
carbohydrate on serine or threonine residues that has only been described for GTPases targets 
(Figure 1.1.e). Toxin A and B (TcdA and TcdB, respectively) from Clostridium difficile 
modify the small GTPase Rho by O-glucosylation on Thr37 (Rac and Cdc42 on Thr35) of the 
switch I region, resulting in the collapse of the actin cytoskeleton40. Additionally, Lgt family 
proteins from Legionella pneumophilae induce cytotoxicity through glycosylation of a serine 
residue in the elongation factor 1A41. 
1.1.4.6. Eliminylation 
Eliminylation is the irreversible reaction catalyzed by phosphothreonine lyase (Figure 
1.1.f). The effector proteins OpsF from Shigella and SpvC from Salmonella are 
phosphothreonine lyases that specifically catalyze an eliminylation reaction on a 
phosphothreonine of MAP kinase (MAPK) that is essential for MAPK activity42,43. The 
reaction is similar to a dephosphorylation by phosphatase but removes also the acceptor 
hydroxyl group such that the threonine can no longer be modified. Phosphothreonine lyase 
converts a phosphothreonine into dehydrobutyrine, an alkene with an unsaturated Cα-Cβ 
double bond43.  
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1.1.4.7. Proteolysis 
Proteolysis is the hydrolysis of polypeptide bonds by a protease, resulting in the cleavage 
of proteins into smaller polypeptides44 (Figure 1.1.g). Some effector proteins, like YopT from 
Yersinia, catalyze this irreversible post-translational modification45. YopT is a cysteine 
protease that cleaves N-terminally to prenylated cysteines that form the membrane anchor of 
small GTPases (RhoA, Rac, Cdc42), resulting in the removal of these signaling hubs from the 
cell membrane and, consequently, breakdown of the actin cytoskeleton46. 
1.1.4.8. Ubiquitination 
Ubiquitination (or ubiquitylation) is the addition of ubiquitin, a 9 kDa protein on lysine 
side-chains of target proteins (Figure 1.1.h). The effector AvrPtoB from Pseudomonas 
syringae functions as an E3 ubiquitin ligase and targets the host protein kinase Fen. Once 
ubiquitinated, Fen is degraded in a proteasome-dependent manner, resulting in a disruption of 
plant immunity47. The effectors SopA from Salmonella and NleL from E. coli mimic 
mammalian E3 ubiquitin ligases and contribute to pathogenicity of their respective bacterium 
via mechanisms that remain to be elucidated48.  
1.1.4.9.  De-SUMOylation 
De-SUMOylation is the removal of a SUMO (small ubiquitin-like modifier) by specific 
desumoylase (proteases) (Figure 1.1.i). The plant pathogen Xanthomonas campestris effector 
protein XopD contains a cysteine protease specific for proteins modified with SUMO, 
resulting in the suppression of plant defenses which promotes successful infection20,49. 
1.1.4.10. Others: Nucleotidylylation, uridylylation, phosphocholination 
Nucleotidylylation, the addition of NMP, i.e. AMP (introduced in section 1.1.4.4. and 
further described in section 1.2. and 1.4.1.), GMP, CMP or UMP onto hydroxyl side chains of 
a target protein has been recently described for the human pathogen Mycobacterium 
tuberculosis50. This enzymatic post-translational modification is mediated by FIC 
(filamentation induced by cAMP) domain proteins.  
A plant pathogen effector from X. campestris, AvrAC, is an urydylyl-transferase with Fic 
fold that specifically transfers an UMP moiety from an UTP substrate in a reaction called 
uridylylylation51.  
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The versatile Fic proteins also catalyze phosphocholination, the transfer of a 
phosphocholine moiety from a CDP-choline substrate52. Fic-mediated post-translational 
modifications will be described further in detail in section 1.4. 
1.2. Adenylylation 
Adenylylation, also called AMPylation, is the covalent transfer of an adenosine-5’-
monophosphate (AMP) moiety from an ATP substrate molecule on a protein, RNA or small 
molecules. A breakthrough in the late 1960’s was the discovery of adenylylation as a stable 
modification crucial for the regulation mechanism of the glutamine synthetase activity (E. 
coli.)53. A less stable, termed transient adenylylation, is a common enzymatic reaction that 
occurs as an activation step in complex enzymatic reaction (tRNA charging, ubiquitination), 
generating AMP as an efficient leaving group.  
There is some controversy on the nomenclature of the AMP transfer reaction in the 
adenylylation field. Adenylation and adenylylation/AMPylation have been used to 
characterize the transfer of an AMP moiety. Since adenylation refers to the transfer of an 
adenyl group, the “radical from adenine”, it is not absolutely correct54. Adenylylation (or 
AMPylation) is more accurate as this is the transfer of an adenylyl group (adenine-ribose-
phosphate) and I will therefore use adenylylation in this context. 
1.2.1. Transient adenylylation 
Transient adenylylation has been shown to occur in many enzymatic reactions, with most 
of them involving the adenylylation of the carboxyl group of amino acids55.  
1.2.1.1. Aminoacyl tRNA synthetases 
Aminoacyl tRNA synthetases (aaRS) catalyze the covalent attachment of an amino acid to 
its cognate transfer RNA (tRNA) molecule, resulting in the formation of an aminoacyl-tRNA 
(aa-tRNA), which is often referred to as tRNA charging. This is the first stage of protein 
synthesis and an obvious pre-requisite for mRNA translation into protein. Most organisms 
have a specific aaRS for each amino acid. tRNA loading is a two-steps reaction that requires 
ATP. In a first step, called activation step, ATP binds to the aaRS active site together with the 
cognate amino acid. The α-carboxyl group of the amino acid attacks the α-phosphate of the 
ATP molecule, resulting in the formation of a 5’-aminoacyl-adenylate (aminoacyl-AMP) that 
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remains bound to the active site. In a second step, called transfer step, the aminoacyl group is 
transferred to the 2’- or 3’-OH of the terminal residue of the amino acid arm (5’-CCA-3’) of 
the tRNA, resulting in a covalent and stable charged tRNA (aa-tRNA) and the release of the 
AMP moiety56. 
1.2.1.2. E1 activating enzymes 
E1 activating enzymes are essential in the context of ubiquitination or SUMOylation. In 
the case of ubiquitination, the C-terminal glycine residue is activated in presence of ATP, 
resulting in the formation of a covalent unstable ubiquitin-adenylate (ubiquitin-AMP) and 
release of PPi. Ubiquitin then binds to a cysteine residue and forms a thiolester bond, with the 
concomitant release of AMP. In a second step, the activated ubiquitin is transferred to E2, the 
ubiquitin carrier protein. Finally, the third step catalyzed by E3, the ubiquitin protein ligase, 
results in the linkage of the C-terminus of ubiquitin to the terminal amino group of a lysine 
side chain57.  
Similarly to aminoacyl-tRNA synthetases, adenylylation of ubiquitin serves as an 
activation step.  
1.2.2. Stable adenylylation 
In contrast to the activation mechanism described for transient adenylylation, stable 
adenylylation is a stand-alone process in which no further reaction is required. A 
counteracting enzyme performing a de-adenylylation is needed to remove the covalently 
bound AMP moiety. 
1.2.2.1. Aminoglycoside nucleotidyl transferases 
Aminoglycosides are a class of highly potent antibiotics that inhibit protein synthesis by 
binding to the ribosome. Kanamycin, gentamicin, neomycin and the first aminoglycoside 
discovered in the 1940’s, streptomycin, are few examples of this class of antibiotics. 
Aminoglycosides bind to the 30S subunit of the ribosome and perturb elongation of the 
nascent chain resulting in premature termination of translation and therefore unachieved 
polypeptide chains58. 
Interestingly, the most prevalent resistance mechanism against aminoglycosides utilizes 
enzymatic modification of the antibiotics. The most widely used modifications are 
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nucleotydylation (including adenylylation), acetylation or phosphorylation, each of them 
being catalyzed by a specific transferase. These aminoglycoside modifying enzymes are often 
plasmid encoded58. 
Two nucleotydyl-transferases (ANT(4′) and ANT(2′′)-I) from Staphylococcus aureus have 
been extensively studied in the context of aminoglycoside modification59. The crystal 
structure of the kanamycin nucleotydyl-transferase ANT(4′) from S. aureus has been solved 
in complex with kanamycin and a non-hydrolysable ATP analog (AMPCPP)60. This enzyme 
is not specific for ATP and can bind any nucleotides, which is in-line with the few 
interactions of the adenine portion with the kanamycin nucleotydyl-transferase. More 
interactions occur in the α, β, and γ phosphate region of the ATP analog moiety. The enzyme 
has also a broad spectrum of aminoglycoside substrates, mainly from the kanamycin and 
neomycin families, resulting in a resistance to a broad spectrum of antibiotics. The 
mechanism deciphered from the crystal structure (PDB: 1KNY) suggests a nucleophilic attack 
from the 4’-OH group of the aminoglycoside on the α-phosphate of the ATP molecule.  
1.2.2.2. The historical case of glutamine synthetase 
Glutamine synthetase (GS) has an essential role in the uptake of ammonia in bacteria. The 
enzyme catalyzes the condensation of ammonia with glutamate to form glutamine. Several 
inhibitors and activators tightly regulate the activity of glutamine synthetase. One of the 
central regulation mechanisms is the adenylylation of glutamine synthetase, which is under 
the control of glutamine synthetase adenylyl transferase (GS-AT) located at the C-terminus of 
the enzyme53 (Figure 1.2.a). This domain catalyzes the adenylylation of a specific tyrosine 
residue (Y397 in Salmonella typhimurium). Interestingly, this enzyme contains an N-terminal 
adenylyl removase (AR) domain that catalyzes the opposite reaction, i.e. the de-adenylylation 
of this residue and a central regulatory (R) domain. Remarkably, both AR and AT domains 
share 24% identity and a β-polymerase fold, characteristic of many adenylyl transferase 
enzymes39. The root mean square deviation (rmsd) between the C-alpha positions of the AR 
and AT domains of this enzyme is 2.4 Å, as revealed by the comparison of both crystal 
structures (PDB: 1V4A and 3K7D, respectively)39,61.  
The regulation mechanism of glutamine synthetase is of high complexity. The enzyme 
forms a dodecamer (12 GS) as observed in the first crystal structure obtained of GS62. The 12 
subunits are organized in a ring form, with a 6-fold axis passing through the hole of the ring. 
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Figure 1.2. Structure and function of the glutamine synthetase adenylyl transferase (GS-AT) and the 
Legionella effector protein DrrA. (a) Structure of GS-AT (PDB: 3K7D) compared to (b) the structure of DrrA 
(PDB: 3NKU), The crucial residues of the catalytic active site G-X11-D-X-D are depicted as green balls, adopted 
from 38. (c) Unexpected complex regulation of glutamine synthetase, taken from 63. (d) Mechanism of GTPase 
inactivation by DrrA, taken from 64. 
This 3D structure also reveals the position of the adenylylated residue, at the interface 
between subunits and close to the active site. It has been demonstrated that the adenylylation 
of Y397 decreases the activity of GS. This residue is located close to the active site of the 
enzyme, but there are, so far, no evidences that adenylylation of GS induces steric clashes 
with the substrate since a crystal structure of GS-AMP is still lacking. The degree of 
inhibition is dependent on the number of adenylylated subunit within the dodecamer. GS-AT, 
the enzyme that adenylylates GS, is activated by glutamine, the product of GS, leading to 
feedback inhibition of glutamine synthetase. Additionally, GS-AT is inhibited by α-
ketoglutarate, the precursor of glutamate, the substrate of GS. The N-terminal adenylyl 
removase (AR) domain of GS-AT deadenylylates GS by phosphorolysis, i.e. the attack of an 
inorganic phosphate on the phosphate of Y397-AMP, forming ADP. The AR domain of GS-
AT is activated by α-ketoglutarate and inhibited by glutamine. But the regulation of glutamine 
synthetase is even more complex and involves a regulatory protein called PII. PII is itself 
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regulated by uridylylation (transfer of an UMP moiety) at a tyrosine residue. GS-AT forms a 
complex with PII in either the uridylylated (PII-UMP) or deuridylylated (PII) form. The GS-
AT/PII-UMP complex stimulates the deadenylylation of glutamine synthetase whereas the 
complex of GS-AT/PII stimulates the adenylylation of glutamine synthetase. The 
uridylylation/deuridylylation of PII is catalyzed by an uridylyltransferase, with the 
uridylylation being activated by α-ketoglutarate and inhibited by glutamine. This unusually 
complex mechanism of regulation of glutamine synthetase is summarized (Figure 1.2.c). The 
tight control of this enzyme is crucial regarding its central metabolic role as an entry point for 
reduced nitrogen.  
1.2.2.3. DrrA, an effector from Legionella pneumophilae 
The bacterial effector protein DrrA (also called SidM) from Legionella pneumophilae38,65 
is a multi-domain protein, with an N-terminal adenylyl-transferase domain, a central guanine 
nucleotide exchange factor (GEF) domain and a C-terminal P4M domain, responsible for 
membrane attachment. The activity of DrrA had been first described as a GEF for Rab165. 
Recently, it has been shown that the N-terminal adenylyl-transferase domain is responsible 
for the cytotoxicity of DrrA (Figure 1.2.d). The crystal structure of the N-terminal domain of 
DrrA has been determined recently38 (PDB: 3NKU). Interestingly, DrrA has a similar fold to 
the C-terminal domain of glutamine synthethase adenylyl transferase (GS-AT) (see previous 
section 1.2.2.2.) (Figure 1.2.b compared to 1.2.a). Mutation of the catalytic active site 
aspartates of the G-X11-D-X-D motif of DrrA abolishes the adenylylation activity of the 
enzyme. Additionally, DrrA specifically adenylylates the conserved tyrosine Y77 of the 
switch II region of the small GTPase Rab1b. The crystal structure of the adenylylated form of 
Rab1 (Rab1-Y77AMP) has been determined (PDB: 3NKV) and doesn’t display significant 
structural changes compared to a native form of Rab1, with the covalently attached AMP 
moiety located close to the surface of the protein. It is undisputed that the N-terminal domain 
of DrrA is responsible for Rab1 adenylylation and induces cytotoxicity in mammalian cells, 
but the exact mechanism of action is not yet clear64. 
1.2.2.4. Fic proteins: a new family of adenylyl-transferases 
Recently, several effector proteins have been described as adenylyl-transferases, with 
similar effect as DrrA. VopS, an effector protein from Vibrio parahaemolyticus, adenylylates 
Rho GTPases, resulting in disruption of downstream signaling in host cells66,67. This 
adenylyl-transferase belongs to a family of protein called Fic proteins (filamentation induced 
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by cAMP) that do neither share sequence identity with glutamine synthetase adenylyl-
transferase nor structural similarities. FIC domain proteins are one of the main focuses of my 
PhD thesis and will be discussed further in detail in the following sections. 
1.3. Fic proteins 
 
Figure 1.3. Fic-mediated interference with cell vialbility. (a) Filamentation of E.coli fic-1 mutant when grown 
at 43°C in presence of 1.5 mM cAMP (right) compared to normal growth and division (left). (b) Effect of VopS 
expression in HeLa cells with from left to right the vector control expressing GFP, expression of GFP-VopS in 
HeLa inducing cell rounding phenotype and expression of the catalytically inactive mutant VopS-H348A fused 
to GFP that behaves like the vector control. (c) Mechanism of Rho GTPases inactivation by VopS. 
Adenylylation of Rac on Thr35 of the switch I region inhibits effector binding and downstream signaling. 
Adopted from 66,68,69. 
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1.3.1. Discovery of the name-giving fic gene 
Fic (filamentation induced by cAMP) has been first described by Utsumi et al.68, in the 
1980’s for an E. coli mutant. They have found that an increase in the intracellular cAMP 
(1.5 mM) level induced cell filamentation in a fic-1 mutant at elevated temperature (43°C), 
and could map a glycine to arginine mutation in the Fic protein (G55R) (Figure 1.3.a). In 
1991, Komano et al.70, showed that a deletion of the fic gene in E. coli resulted in an 
auxotrophic bacteria for p-aminobenzic acid or folate, suggesting that Fic protein is involved 
in the synthesis of this compound. This would indicate that the Fic protein and cAMP are 
involved in the regulation mechanism of cell division via a folate mechanism. In this deletion 
strain, the fic gene was replaced by a kanamycin resistance (Km1) gene. Closer analysis of the 
E. coli fic gene locus showed that the promoter of the pabA (p-aminobenzoate synthase) gene 
lies within the fic gene and was therefore also removed by this deletion mutant. 
Despite these early results68,70-74, the function of FIC domain proteins remained elusive 
until 2009 and the discovery of the adenylyl-transferase activity of the effector protein VopS 
from Vibrio parahaemolyticus66. Concurrently, the catalytic activity of the effector protein 
IbpA from Histophilus somni has been deciphered as adenylylation of Rho GTPases75. 
1.3.2. FIC domain effector proteins  
As already mentioned, the focus on Fic proteins started when the enzymatic activity of 
this family of enzyme has been discovered in 200966. The injection of Vibrio 
parahaemolyticus effector proteins via a functional Type III secretion system into eukaryotic 
host cells induces cell rounding via inhibition of Rho family GTPases76. The injection of a 
single effector, VopS, leads to a similar severe cell rounding phenotype and inhibition of the 
Rho GTPases Rac1, RhoA and Cdc42. A sequence analysis of the C-terminal domain of 
VopS, so-called FIC domain, revealed a strictly conserved histidine residue in a stretch of 
highly conserved amino acids, revealing a putative active site. The mutation of this histidine 
to alanine, thereafter referred as H/A, abolished the cytotoxicity of VopS (Figure 1.3.b). Mass 
spectrometry analysis of Rac1 expressed with VopS revealed a mass shift of 329 Da 
compared to Rac1 co-expressed with the H/A mutant of VopS. This mass corresponds to the 
covalent attachment of a 5’-adenosine monophosphate moiety (AMP) to the Rho GTPase, that 
has been assigned to the threonine 35 (Thr35) of the switch I region of Rac1 or Cdc42 and 
Thr37 of RhoA. Hence, VopS modifies Rho family GTPases by adenylylation in the switch I 
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region, resulting in the inhibition of downstream effector binding by steric hindrance (Figure 
1.3.c). 
Concurrently, another effector protein, IbpA from the respiratory pathogen Histophilus 
somni has been shown to adenylylate the Rho GTPases RhoA, Rac and Cdc42, resulting in 
the disruption of the actin cytoskeleton75.  
Moreover, the FIC domain is conserved from bacteria to human, with the human HypE 
protein (huntingtin yeast-interacting protein E, also called FICD) also catalyzing 
adenylylation75. 
Taken together, these two studies on the Fic proteins VopS, IbpA and HypE set the basis 
of Fic-mediated adenylylation of small GTPases. The consensus active site motif has been 
defined as HPFxxGNGR, with the first histidine of the motif crucial for the catalytic activity 
of Fic proteins66,67,75. 
1.3.3. Three dimensional structure of Fic proteins 
Crystal structures of Fic proteins were solved by structural genomics groups prior to any 
knowledge were gained on the function of these proteins. Four Fic proteins were solved: from 
Helicobacter pylori, - HpFic (PDB: 2F6S), from Neisseria meningitidis - NmFic (PDB: 
2G03), from Bacteroides thetaiotaomicron - BtFic (PDB: 3CUC) and from Shewanella 
oneidensis - SoFic (PDB: 3EQX)77 (Appendix 8.4.). These four structures revealed an alpha-
helical topology. FIC domain proteins, due to their size and compact fold, appeared as an 
ideal substrate for structural studies and crystallographic structure determination. 
The core of the FIC domain is made of four α-helices arranged in an up and down bundle, 
as defined by the Pfam78 protein families database (http://pfam.xfam.org). These four helices, 
numbered α2-α5 in the smaller Fic proteins observed, NmFic or HpFic, are decorated with 
additional helices. Helices α6-α7 lies almost perpendicularly to the Fic core helices (Figure 
1.4.b). The active site motif (Figure 1.4.a), further defined by the HPFx[D/E]GN[G/K]79 motif 
lies in a loop between α-helices α4-α5. A β-hairpin involved in target binding is located 
between helices α2-α3 and is often referred to as FLAP79,80. 
Intriguingly, an alpha helix (called α’) can be encoded N-terminally or C-terminally to the 
Fic active center and completes the Fic core79. The relevance of this α-helix will be discussed 
in section 3.1., research article I and section 3.2., research article II. 
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Figure 1.4. Structure of Fic proteins. (a) Fic active site motif conservation in bacteria and animals, with 
consensus sequence logo. (b) Topology of Fic proteins with standard colors used for all the figures: Fic core in 
red, Fic active site in yellow, helix α’ in dark green, arm domain in orange, FLAP in dark blue, HTH domain in 
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light blue, additional helices in magenta. N or C represents the N-terminus or C-terminus of the crystallized 
fragment, respectively. From left to right, the small NmFic single domain protein, the SoFic protein containing a 
C-terminal HTH domain and the first Fic protein described as adenylylator, VopS. (c) Complex structure of 
IbpA (standard Fic colors) with Cdc42 (green). The inset shows the IbpA active site details with Cdc42 binding 
to the FLAP of IbpA. Main chain-main chain interactions are displayed as dashed lines and residues involved in 
interactions are depicted and the residue number shown. K3670 and L3668 from IbpA form a clamp around the 
adenylylated residue of Cdc42 (Y32). 
A three-dimensional comparison of the structures of Fic proteins revealed a structural 
homology with Doc, a protein of the plasmid addiction system of the bacteriophage P181, and 
with AvrB from Pseudomonas syringae. The Pfam database classifies Fic and Doc proteins 
together. Indeed, Fic, Doc and AvrB share a same fold as displayed in Figure 1.5. 
The crystal structures of VopS82 (PDB: 3LET) and IbpA80 (PDB: 3N3U) confirm the 
three-dimensional structures aforementioned. Fic proteins are often multi-domain proteins. 
For example, SoFic from S. oneidensis contains an N-terminal helix-turn-helix (HTH) 
domain77, often involved in transcription regulation (PDB: 3EQX) (Figure 1.4). The structure 
of the Bartonella effector protein BepA83 (PDB: 2VZA) reveals the same core structure with 
an additional C-terminal oligonucleotide-binding (OB) domain, which function remains 
elusive (Appendix 8.4). 
1.3.4. Active site motif  
The active site has been located in an eight amino acids loop between helices α4-α5 of the 
Fic core that extends in the first helical turn of the helix α5 by four amino acids. This active 
center is conserved in Fic and Doc family proteins.  
The crystal structures revealed an anion-binding nest located at the N-terminal end of the 
helix α5 in Fic proteins. The β-hairpin, together with parts of helices α6-α7 participates in 
forming a pocket for the base of the nucleotide. The conserved first histidine of the 
HPFx[D/E]GN[G/K] motif, present in Fic proteins is crucial for activity82,84,85.  
The catalytic mechanism has been proposed based on the crystal structure of the 
IbpA/Cdc42 complex80. The catalytic histidine acts as a general base that, upon target binding, 
deprotonates the incoming hydroxyl side chain. The deprotonated hydroxyl (O-) poised in line 
with the Pα-Oαβ bond of the ATP substrate, will perform a nucleophilic attack on the alpha-
phosphate, resulting in the covalent transfer of AMP onto the target hydroxyl side chain and 
release of pyrophosphate (PPi). The phenylalanine of the active site loop is buried into the 
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active Fic core and crucial for the folding and conformation of the loop86. The glutamic acid 
(or aspartic acid) coordinates the metal ion (Mg2+) binding, metal that is interacting with the 
α- and β- phosphate of the ATP substrate. The following residues, GNGR, form the anion 
binding pocket, also referred to as anion binding nest87, and accommodates the α- and β- 
phosphates, via main chain interactions of the first turn of helix α5 and side chains or the 
arginine residue. The last residue of the active site motif located at the C-terminus of the 
catalytic loop forms hydrogen bonds with the ribose and locks the nucleotide. This is 
described further in details in section 3.1, research article I and section 3.2, research article 
II. 
The Fic active site can be described as containing several major parts that appear to be 
generally conserved: the hydrophobic base-binding pocket, the anion-hole, the metal binding 
site and the ribose-coordinating subsite88. 
The sequence alignment (Figure 1.4.a) of Fic proteins shows a high conservation of the 12 
residues of the Fic active site motif.  
1.3.5. Target recognition 
Knowledge on the target recognition of Fic proteins was gained with the first complex 
structure80 of a Fic protein, IbpA, with its cognate target, Cdc42. In this complex, the arm 
domain of IbpA participates in the main interactions, with two major interfaces: the first one 
between IbpA and the switch I region of Cdc42 (~ 440 Å2) and the second between IbpA and 
the switch II region of Cdc42 (~ 610 Å2). In the switch I region, where the modifiable 
tyrosine of Cdc42 is located (Y32), Y32 and P34 from Cdc42 make hydrophobic interactions 
with L3668 and K3670 from IbpA (Figure 1.4.c). The leucine and lysine residues from IbpA 
form a clamp that locks the position of the modifiable tyrosine. Three additional main chain-
main chain hydrogen bonds are formed between the FLAP (β-hairpin) of IbpA and the switch 
I region of Cdc42 (Figure 1.4.c). These main chain-main chain interactions have also been 
observed in the AvrB/RIN4 complex (Figure 1.5.b). It is therefore very unlikely that the 
environment of the active site raises target specificity, but more likely that additional domains 
serve the target specificity, i.e. the arm domain in the case of IbpA. Comparison of the 
structure of VopS from Vibrio parahaemolyticus with the structure of IbpA revealed a similar 
arm domain, possibly explaining the shared target between VopS and IbpA, i.e. the small 
GTPases family RhoA, Rac and Cdc42. 
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Figure 1.5. Comparison of the Fold of Doc, AvrB and the Fic protein IbpA. These 3 proteins fold in a 
similar manner, with the core (in red) common to the 3 proteins. (a) Doc (death on curing, standard Fic colors) 
from the Bacteriophage P1 in complex with its cognate antitoxin PhD (prevents host death, green). (b) AvrB 
from the plant pathogen Pseudomonas syringae in complex (standard Fic colors) with its target RIN4 (resistance 
to Pseudomonas maculicula protein 1 [RPM1]–interacting protein, blue)89,90. A threonine (Y166) that is known 
to be phosphorylated is positioned in the binding site of AvrB and the side product of the phosphorylation 
reaction, ADP, is shown (superimposed from PDB: 2NUN). (c) The Fic protein IbpA from Histophilus somni 
(standard Fic colors) in complex with its target Cdc42 (green), revealing the adenylylation of Y32 from the 
switch I region of Cdc42 (for details, see Figure 1.4.). 
1.4. Fic-catalyzed post-translational modifications 
In the 1990’s, Fic proteins were believed to be regulator of the synthesis of p-
aminobenzoate (folate) (see section 1.3.1.). Since 2009, we know that Fic proteins harbor a 
catalytic activity that is called adenylylation, the covalent transfer of an adenosine 5’-
monophosphate on a target hydroxyl group. Nevertheless, Fic proteins are more versatile, and 
can also catalyze different post-translational modifications. Substrates of Fic proteins are 
diverse nucleoside-diphosphate derivatives such as ATP67,75, UTP51, NTP50 or CDP-choline52. 
The modification performed by Fic proteins depends on slight variations in the active site, i.e. 
replacement of some crucial residue involved in substrate binding that will therefore switch 
the substrate specificity. 
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1.4.1. Adenylylation 
Adenylylation is performed by the vast majority of Fic proteins, according to the 
conserved active site motif. This post-translational modification has already been introduced 
in section 1.1.4.4. (Figure 1.1.d and Figure 1.4.c). Many bacterial and eukaryotic effector 
proteins perform adenylylation. VopS from Vibrio parahaemolyticus66, IbpA from 
Histophilus somni75,91, NmFic from Neisseria meningitidis80, HpFic from Helicobacter 
pylori80, BepA from Bartonella henselae83, SoFic from Shewanella oneidensis77 are FIC 
domain proteins of which the adenylylation activity has been demonstrated in vitro. The 
human Fic protein Hype (hungtingtin yeast-interaction protein E, also called FICD) 75,91 and 
its ortholog in Drosophila which has been characterized in more detail 79,92 are also adenylyl-
transferases. The HxFx[D/E]GNGRxxR active site motif is required for Fic-mediated 
adenylylation (see section 3.1., research article I).  
The covalent transfer of an AMP moiety onto target hydroxyl acceptor groups usually 
results in inhibition of downstream signaling in host cells. The transfer of the bulky AMP 
group on Rho GTPase interferes with downstream effector binding67,69,93. 
1.4.2. Nucleotidylylation 
Interestingly, BepA from Bartonella henselae can use ATP, GTP or CTP without any 
distinction83, as shown by in vitro radioactive assays using these different nucleotides with the 
α-phosphate radioactively labeled. VopS also displays equal preferences for ATP and GTP 
and can therefore also serve as a guanylyl-transferase91, whereas the MtFic protein from 
Mycobacterium tuberculosis can utilize all types of nucleotides (ATP, GTP, CTP or UTP). 
All substrates bind to the Fic active site with similar binding free energies ranging from – 6.0 
to – 6.9 kcal/mol, with a slight preference for ATP. Because of the relative abundance of ATP 
(~ 10 mM) in prokaryotic cell (E. coli) over UTP, GTP and CTP (~ 8 mM, 5 mM and 3 mM, 
respectively)94, the natural substrate of MtFic may be ATP and result in an adenylylation 
activity of this Fic protein. The relevance of nucleotidylylation (or NMPylation), i.e. the non-
specific usage of any nucleotide, remains to be investigated50. 
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1.4.3. Uridylylation 
In contrast, uridylylation or UMPylation, the covalent transfer of an UMP moiety onto 
target proteins, uses the specific substrate UTP. AvrAC, a type III effector protein from the 
plant pathogen Xanthomonas campestris, enhances virulence by specifically targeting two 
host kinases of the plant model Arabidopis thaliana51. These two kinases, BIK1 and RIPK, 
are key mediators of the plant immune signaling. Feng et al. demonstrated that the FIC 
domain containing protein AvrAC was not able to use ATP as substrate. Mass spectrometry 
analysis revealed that AvrAC is auto-modified with several components of 306 Da, 
corresponding to the addition of uridine-5’-monophosphate, which was further confirmed by 
in vitro assays using radioactively labeled α-32P-UTP. The uridylylation of BIK1 or RIPK on 
conserved Ser and Thr (Ser236 and Thr237 of BIK1) by the potent AvrAC enzyme occurs on 
critical phosphorylation sites of these kinases. These residues are part of the activation loop of 
the kinases and uridylylated residues are resistant to phosphatase activity. uridylylation acts 
on these kinases as a protection of the phosphorylation sites, preventing the phosphorylation 
of BIK1 and RIPK that is required for subsequent signal transduction. The uridylylation of the 
two kinases BIK1 and RIPK by AvrAC from Xanthomonas has a similar effect as the 
acetylation of the activation loop of human MAP kinases by YopJ from Yersinia, though with 
a different and bulkier group (uridylyl vs acetyl, respectively) covalently attached to the 
hydroxyl acceptor group of the host kinase (see section 1.1.4.2). 
1.4.4. Phosphocholination 
AnkX, a type IV effector protein from the facultative intracellular bacterium Legionella 
pneumophila, prevents microtubule-dependent vesicular transport in the host cell95. AnkX 
catalyzes the phosphocholination, i.e. the transfer of a phosphocholine group from a cytidine-
diphosphate-choline (CDP-choline) substrate onto a target protein, the small GTPase Rab1 or 
Rab3552. The activity of the FIC domain of this large multidomain protein has been probed by 
a mutation of the catalytic histidine of this degenerated HPFxDANGRxxV Fic motif. The 
adaptability of the Fic motif allowed the switch of substrate between ATP and CDP-choline. 
AnkX modifies Rab1 and Rab35 during infection, which modulates membrane transport 
through the endocytic and exocytic pathways of the host cell.  
The substrate, CDP-choline, shares a nucleoside diphosphate group with all other 
substrates known to bind Fic proteins. A thorough structural analysis96 of Fic-mediated 
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phosphocholination revealed the structure of AnkX in the different substrate (CDP-choline, 
PDB: 4BET) and product (CMP/choline, PDB: 4BES or CMP, PDB: 4BER) bound states. In 
AnkX, the Fic motif has the same conformation as in adenylylating Fic proteins (VopS or 
IbpA), with the catalytic histidine playing the same crucial role52,96. The crystal structure of 
the catalytically inactive mutant AnkXH/A in complex with CDP-choline reveals that the 
substrate binds in an inverted manner when compared to the AMP moiety of ATP. 
Additionally, a unique feature of AnkX is the cytidine binding pocket, located at the other end 
of the substrate.  
Furthermore, comparison of the structure of the phosphocholinating enzyme AnkX with 
the adenylylating enzyme IbpA in complex with Cdc42 suggests a similar mechanism of 
phosphoryl transfer that for the adenylylating Fic enzymes. The β-phosphate of CDP-choline 
superimposes with the α-phosphate of the AMP group bound to Y32 of Cdc42 in the 
IbpA/Ccd42 complex80. Furthermore, the structure reveals that the scissile bond in CDP-
choline is the Ρβ-Oαβ compared to the Pα-Oαβ in adenylylating enzymes, which is consistent 
with the transfer of phosphocholine and release of cytidine-monophosphate. Evolutionary, a 
main advantage of the head-to-tail binding of CDP-choline with respect to ATP is that both 
phosphocholination and adenylylation reactions can be achieved using the same catalytic 
residues and therefore reaction mechanisms.  
1.4.5. Phosphorylation 
Structurally related to Fic proteins, Doc has recently been shown to be a new family of 
kinases97,98. Doc, from the toxin-antitoxin system Doc/PhD (death-on curing / prevent host 
death), is a potent inhibitor of bacterial translation that was thought to sterically obstructs the 
A site of ribosome in a non-catalytic manner, but is here refuted. It has been recently shown 
that Doc phosphorylates the elongation factor EF-Tu on a conserved threonine residue 
(Thr382), making it unable to bind aa-tRNAs and therefore inhibiting translation. In vitro 
experiments using α-32P-ATP or γ-32P-ATP revealed that Doc is unable to adenylylate EF-Tu 
and specifically phosphorylates the target protein. Doc preferentially binds EF-Tu, another 
GTPase substrate of the Fic/Doc superfamily, in its GDP-bound form, with a 30-fold higher 
affinity than the GTP analog bound form. The affinity for the substrate AMPPNP or 
GMPPNP has been measured in the millimolar range when no target was present, and 
increased by 105 fold in presence of EF-Tu, suggesting that several residues of the target are 
involved in substrate binding, or that the target binding helps structuring the FLAP (β-hairpin) 
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and therefore increases the target binding. In solution structural analysis by SAXS (small 
angle X-ray scattering) and NMR (nuclear magnetic resonance) reveals the interface between 
Doc and EF-Tu and allows chemical shift mapping of the residues involved in ATP binding, 
respectively. Modeling of the ATP substrate based on the chemical shift upon binding 
predicts that ATP binds more towards the C-terminal part of the active site loop than the N-
terminal, i.e. in an inverted mode compared to the adenylylation competent form.  
Therefore, it is likely that the γ-phosphate of ATP in Doc adopts the position of the α-
phosphate in the adenylylating form, resulting in a transfer of phosphate instead of AMP. The 
plasticity of the Fic active site is an intriguing evolutionary mechanism to generate new 
enzymatic activities. The HxFxDANKR motif of Doc’s active site differs from the 
HxF[D/E]GNGR consensus motif for adenylylation. The mutation of the second glycine of 
the adenylylation competent motif to a lysine is crucial for the inversion of substrate binding 
mode. When superimposing Doc on the IbpA/adenylylated-Cdc42 complex, the lysine K37 
from Doc sterically clashes with the ATP molecule in the adenylylation competent 
conformation. Moreover, the binding of PhD, the cognate antitoxin of Doc, would interfere 
with both substrate (ATP) binding and target (EF-Tu) binding.  
Intriguingly, Doc can also dephosphorylate EF-Tu. Castro-Roa et al. postulated that the 
level of GDP/GTP and the conformation of EF-Tu in the GDP- or GTP-bound form 
participates in the regulation of Doc kinase or phosphatase activity. When Doc 
phosphorylates EF-Tu, the translation is blocked bringing the cells to dormancy. During 
bacterial stasis, the high level of GDP and baseline level of unphosphorylated EF-Tu may 
have restart translation and turn Doc into a phosphatase, but this tempting hypothesis needs to 
be validated. 
Kinase activity has also been speculated for AvrB from Pseudomonas syringae, a protein 
structurally related to Fic/Doc family proteins. AvrB induces the phosphorylation of RIN4, a 
key regulator of the basal host defense responses in the plant model Arabidopsis89,90. Lee et 
al.89 were not able to show any direct phosphorylation of neither RIN4 nor other nonspecific 
substrates by AvrB. Further structural analysis revealed that ADP binds to the active center of 
AvrB90. Interestingly, the substrate binding mode in AvrB is similar to the one described for 
Doc97. AvrB though lacks the catalytic histidine of the active site motif, but a histidine that is 
part of the FLAP (H217) may have evolved to compensate this mutation and thereafter act as 
catalytic histidine. A mutant of this histidine lacks catalytic activity and target binding90. It 
has been proposed that AvrB may act as a “protokinase” that lacks intrinsic phosphor-transfer 
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activity that may be enhanced by association with accessory proteins90. Thought RIN4 binds 
to AvrB and gets phosphorylated in an AvrB-dependent manner, there is no direct evidence of 
a kinase activity of AvrB. 
In summary, the plasticity of the Fic/Doc active center allows the binding of several 
ligands or a single ligand in different conformation, e.g. ATP, yielding different catalytic 
activities of these enzymes bearing the same fold. It has been demonstrated that diphosphate-
nucleoside can bind to the Fic active site in two different “inverted” conformations, either 
with the base towards the N-terminal end motif or towards the C-terminal end of the Fic, 
resulting in adenylylation, uridylylation or phosphocholination and phosphorylation, 
respectively. With the knowledge acquired to date, it can be deduced that Fic/Doc family 
proteins are phosphoryl transferases sharing diphosphate-nucleoside substrates. Noteworthy, 
Fic proteins also tend to preferentially target GTPases88.  
1.5. Regulation of Fic proteins 
Fic proteins, because of their high cytotoxicity in eukaryotic cells or bacteriostatic effect 
in bacteria, need to be tightly regulated. 
To date, apart from a few evidences about Fic protein regulation, most is rather 
speculative. Two mechanisms of regulation seem however possible, via an additional domain 
fused to the Fic protein or via the auto-modification of the Fic protein that has been constantly 
observed in vitro51,79,80,83,99,100. Moreover, the presence of an helix α’ that is found permuted at 
the N-terminus or C-terminus of Fic proteins, already mentioned by Kinch et al.79, plays a key 
role in the regulation of adenylylation competent Fic proteins and will be further described in 
section 3.1., research article I and section 3.2, research article II. 
1.5.1. Domain organization of Fic proteins 
IbpA, HypE, SoFic or AnkX are multi-domains Fic proteins, in contrast with NmFic or 
HpFic that are single domain proteins (Figure 1.6). 
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Figure 1.6. Domain organization of Fic, Doc and AvrB proteins. An example of each investigated protein is 
given next to the scheme of domain organization, except for HTH-Fic, where no protein was studied to date. The 
nomenclature is as follow: Fic: filamentation induced by cAMP, TM: transmembrane, TPR: tetratricopeptide 
repeat, HTH: helix-turn-helix DNA binding domain, Akr: ankyrin repeat, Haem: haemagglutination activity 
domain, Doc: death on curing, AvrB: avirulence protein B. Adopted from 79. 
1.5.1.1. Multiple domain Fic proteins 
IbpA from Histophilus somni is a large multidomain Fic protein. It consists of an N-
terminal filtamentous haemagglutinin-like domain (FHA-like) followed by coiled coils and 
two consecutive Fic domains that have been shown to be functionally redundant, and finally a 
C-terminal cysteine protease domain homologous to YopT from Yersinia75. IbpA is not 
injected into the host cell, but secreted into the environment. The large FHA protein creates a 
fibrillar network around the bacterium. Following the attachment of H. somni to the host cell, 
it is speculated that portions of IbpA (notably the C-terminus containing the FIC domain) are 
pinocytosed by the host cell. The cytoplasm is then exposed to Fic proteins and the 
cytotoxicity of the latter.  
The human HypE protein contains an N-terminal signal sequence and transmembrane 
domain, a central tetratricopeptide repeat (TPR) and a C-terminal Fic domain. The TPR 
domain may serve as a cellular targeting sequence. HypE also targets Rho family GTPases, 
probably unspecifically, but the physiological target and role of HypE are still under 
investigations (personal communication). Histone H3 has recently been identified as a 
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substrate for HypE101 but the physiological relevance of the modification of histone H3 has 
not yet been described. 
The structure of the Fic protein from Shewanella oneidensis, SoFic, has been solved by 
the JCSG joint center for structural genomics77. A helix-turn-helix (HTH) DNA binding 
domain is located at the C-terminal end of SoFic. Interestingly, SoFic forms a dimer in the 
crystal structure that is likely to be physiological and has been predicted as such by the Eppic 
prediction server102. Additionally, the distance between the winged helix-turn-helix domains 
within the dimer may be suitable for double-stranded DNA binding. This HTH may thus 
regulate the expression of the Fic protein. Moreover, other fusions of HTH domains and Fic 
proteins can be found by sequence analysis, with the helix-turn-helix domain either at the N-
terminus or at the C-terminus. According to Kinch et al.79, the HTH domain fused to Fic 
proteins is reminiscent to the N-terminal HTH domain from PhD that regulates the expression 
of the Doc/PhD toxin-antitoxin system103. 
The only known protein that catalyzes phosphocholination, AnkX, contains an N-terminal 
Fic domain and up to twelve predicted ankyrin repeats at the C-terminus. Ankyrin repeats 
consist of 30-34 amino acids residues that have been characterized exclusively in mediating 
protein-protein interactions. In eukaryotes, ankyrin repeats is the second most abundant class 
of interaction mediating proteins, after immunoglobulins104. In the case of bacterial effectors, 
ankyrin repeats may play a similar role, in targeting host factors and contributing to the 
localization of Ank proteins. Interestingly, the loops contained in the helix-turn-helix of 
AnkX are longer that in eukaryotic repeats. To date, the function of most Ank proteins 
remains unknown. In the phosphocholine-transferase AnkX, the ankyrin repeats has a role in 
intramolecular interaction and constrains the Fic domain of AnkX, which is observed for the 
first time in the context of ankyrin repeats. Yet, the exact role of these repeats is unclear and it 
is conceivable that the extended loops of the helix-turn-helix of the ankyrin modules of AnkX 
participate in interactions with the target Rab1. 
VopS doesn’t contain any additional domain except the N-terminal arm domain that has 
been reported to be involved in target specificity. 
1.5.1.2. Single domain Fic proteins 
NmFic from Neisseria meningitidis or HpFic from Helicobacter pylori are single domain 
Fic proteins that need to be self-regulated. Yet, no evidences for such mechanism are 
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available and it remains to be investigated. This will be discussed in the context of section 
3.5., research article V. 
1.5.2. Auto-modification of Fic proteins 
Auto-phosphorylation of kinases is a ubiquitous well-understood mechanism of regulation 
of kinases105-108. Are there any parallels with the auto-modification of Fic proteins?  
The auto-modification has been observed extensively, for all Fic proteins investigated so 
far (Figure 1.7). Nevertheless, the physiological role of this auto-modification remains elusive. 
At first, it has been postulated that the auto-adenylylated Fic proteins observed in radioactive 
assays represent a transient histidine modified intermediate. This would be in favor of a ping-
pong mechanism of AMP transfer catalyzed by Fic proteins, where the Fic catalytic histidine 
is auto-adenylylated in a first step and the AMP moiety is then transferred to the target protein 
in a second step. Such a mechanism would explain why the histidine of the Fic motif is 
crucial for activity, but this hypothesis has been refuted by kinetic analysis of VopS mediated 
adenylylation of Cdc4279, showing that adenylylation is a direct transfer mechanism. In such a 
mechanism, the histidine serves as a general base during catalysis, which is consistent with 
the pH profile of VopS activity, demonstrating that VopS is less active at low pH82.  
Similarly, auto-phosphocholination of AnkX has also been demonstrated. 
Phosphocholination was only observed if a larger excess of CDP-choline was used in the 
reaction sample. Goody et al.100 suggest a phosphocholinated intermediate that is 
hydrolytically unstable and does not accumulate, in-line with a ping-pong mechanism. This is 
in contrast with the direct AMP transfer demonstrated for the adenylylator VopS. But this 
mechanistic difference between these two enzymes is quite surprising, even though the 
transfer occurs on the β-phosphate of CDP-choline for AnkX and the α-phosphate of ATP for 
VopS. Again, this intermediate transfer on the catalytic Fic motif histidine has been refuted by 
the thorough crystallographic work by Campanacci et al.96, demonstrating that the β-
phosphate of the CDP-choline substrate is superimposable with the position of the α-
phosphate of the AMP group in the IbpA-Cdc42 complex structure. This strongly suggests a 
similar mechanism for Fic proteins catalyzing phosphocholination and adenylylation.  
The auto-adenylylation or auto-phosphocholination of Fic proteins are therefore not 
resulting from a transient intermediate formation (His-AMP), but a stable modification of 
serine, threonine or tyrosine residues from the Fic protein itself. Recently, it has been 
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proposed that auto-modification is a side reaction that uses the same mechanism as target 
modification, but targeting residues located in poorly folded regions of the Fic protein located 
outside of the catalytic region96. Thus, the relevance of auto-modification of Fic protein is still 
under debate and will be discussed in the context of section 3.5., research article V. 
Figure 1.7. Auto-modification of Fic proteins. The auto-modification is monitored by in vitro labeling assay 
using α-32P labeled tri-nucleotide substrate and revealed by autoradiography (a-g) or by mass spectrometry 
analysis (h). Auto-adenylylation of (a) NmFic from Neisseria meningitidis and HpFic from Helicobacter pylori, 
(b) Bep2 from Bartonella rochalimae expressed in cell lysate or purified Bep2-Fic, (c) DmFICD from 
Drosophila melanogaster, (d) VopS from Vibrio parahaemolyticus, (e) IbpA-Fic2 from Histophilus somni. 
(f) Auto-uridylylation of AvrAC from Xanthomonas campestris. (g) Auto-adenylylation, auto-guanylylation or 
auto-citydylation of BepA from Bartonella henselae. (h) Auto-phosphocholination of AnkX from Legionella 
pneumophilae revealed by a mass shift (+ 167 Da) upon incubation with the substrate CDP-choline. Adopted 
from 51,79,80,83,99,100. 
1.6. Targets of Fic proteins 
The understanding of the catalytic activity of Fic protein is per se of remarkable interest 
for basic research, but the effect of Fic-mediated activity is via host cell target modification. 
Interestingly, the variety of Fic-mediated post-translational modifications seems to results in 
the modification of a narrow range of protein folds, with a preference for GTPases. 
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1.6.1. Eukaryotic targets 
1.6.1.1. Adenylylated targets 
VopS and IbpA of the pathogens Vibrio parahaemolyticus and Histophilus somni, 
respectively, target the Rho family GTPases RhoA, Rac and Cdc4266,75. This modification 
leads to a cell rounding phenotype in the eukaryotic host cell, via collapse of the actin 
cytoskeleton. IbpA bound Cdc42 appears to mimic the GDP dissociation inhibitor (GDI)-
bound state of Rho GTPases. Both switch I and switch II regions of Cdc42 adopt this 
conformation. IbpA, by exerting a GDI-mimicry activity, can modify Rho GTPases in the cell 
independent of their nucleotide bound states. The arm domain of IbpA and VopS, only 
observed so far in these Fic-proteins, has a crucial role in the affinity for all Rho family 
GTPases. 
In contrast to the rather low target specificity of VopS and IbpA, the effector protein Bep1 
from Bartonella rochalimae specifically adenylylates Rac1 (A. Harms, master thesis 2010)109. 
Bep1 doesn’t contain any arm domain but a so-called Bep-element (A. Harms, master thesis 
2010)109, a β-hairpin located directly N-terminally to the FLAP, only found in several species 
of Bartonella that evolved in parallel and therefore assigned to lineage 3 and lineage 4110. 
This Bep-element may confer target specificity to Rac1 similarly to the arm domain of IbpA 
and VopS for Rho GTPases RhoA, Rac and Cdc42.  
Our group recently developed a new method using isotope-labeled substrate (ATP) 
combined with mass spectrometry based analysis to identify new adenylylated targets99. 
When target hunting using this method, the adenylylator Bep2 from Bartonella rochalimae 
was incubated with crude cell lysates and ATP isotopes. This resulted in the identification of 
the filamenting protein vimentin. This new target was confirmed by further in vitro assays. 
Interestingly, Bep2 targets a new class of protein of the host cell cytoskeleton. Vimentin 
doesn’t show any structural homology to GTPase but is directly regulated by small 
GTPases111. 
Additionally to vimentin, Bep2 also targets β-tubulin from the αβ-tubulin heterodimeric 
complexes112. These complexes can polymerase to form microtubules, crucial components of 
the cytoskeleton, maintaining the structure of the cell but also involved in intracellular 
transport113. An αβ-tubulin-interacting factor called TOG (tumor overexpressed gene) is 
involved in fast microtubule growth114. The adenylylation site of β-tubulin has been mapped 
by mass spectrometry analysis to residues Y106 or T107 of β-tubulin. These residues are 
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involved in interactions with an arginine from TOG115. Interestingly, the modeling of an AMP 
moiety on the tyrosine 106 from β-tubulin doesn’t result in any steric clashes, but rather in 
conceivable interactions between the α-phosphate, the N6 of the adenine ring and the 
hydroxyl groups from the ribose of the transferred AMP group with arginine 116 and 
threonine 118 of TOG and glutamate 410 of β-tubulin, respectively. The adenylylation of 
tubulin by Bep2 may results in a tighter binding of TOG on αβ-tubulin, resulting in a 
sequestration of TOG on αβ-tubulin dimers and altering of microtubules formation (K. Pieles, 
PhD thesis, 2013)112. This hypothesis in currently under investigation by Kathrin Pieles and 
Simon Marlaire in the group of Christoph Dehio.  
The Bartonella henselae effector BepA also adenylylates a host target protein that remains 
to be identified83. 
1.6.1.2. Phosphocholinated targets 
The effector AnkX from Legionella pneumophila transfers a phosphocholine group on a 
conserved serine side chain from Rab1 (Ser79 in Rab1A or Ser76 in Rab1B) and Rab35 
GTPases52. This corresponds to the switch II region of these GTPases. Interestingly, this 
residue in located directly next to the Tyr80 of Rab1A, a residue adenylylated by the 
Legionella effector DrrA, an adenylylator that doesn’t contain any FIC domain. Rab1 and 
Rab35 phosphocholination results in interferences with binding of these two GTPases with 
guanine nucleotide exchange factors (GEFs), which is required for the function of the enzyme. 
This shows that Legionella has evolved two structurally different proteins catalyzing two 
distinct post-translational modifications that modulate the function of host vesicle transport in 
a similar manner. 
1.6.2. Bacterial targets 
1.6.2.1. Phosphorylated targets 
The Doc toxin from the bacteriophage P1 specifically phosphorylates the elongation 
factor EF-Tu at the C-terminal end, not at the switch I or switch II region of GTPases as seen 
for other Fic domain proteins97,98. The phosphorylation of EF-Tu results in the blockage of 
aminoacyl tRNA binding, thus inhibiting translation. 
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1.6.2.2. Adenylylated targets 
Adenylylation of bacterial targets has been recently unraveled by our research groups 
using mass spectrometry analysis coupled to educated guess, by Alexander Harms et al., and 
is developed further in section 3.3., research article III. The adenylylation of bacterial 
topoisomerases by VbhT, the Fic protein from Bartonella schoenbuchensis, the distantly 
related YeFicT from Yersinia enterocolitica or PaFicT from Pseudomonas aeruginosa, results 
in bacteriostasis of our model organism E. coli. These three Fic proteins are Class I Fic 
proteins (as defined by Engel, Goepfert et al., section 3.1., research article I) consisting of a 
FicT protein (toxin) co-expressed with a small FicA protein (antitoxin), of a classical Type II 
TA system. Additionally, NmFic from the Class III Fic protein (as defined by Engel, Goepfert 
et al., section 3.1., research article I) from Neisseria meningitidis also targets bacterial 
topoisomerases. The activity of NmFic will be discussed in section 3.5., research article V. 
1.7. Bacterial type IIA topoisomerases 
Bacterial topoisomerases are a new class of Fic protein targets and therefore a central 
focus of my PhD thesis. DNA topoisomerases control the topology of DNA molecules and 
were first described by James Wang in 1971116.  
1.7.1. General introduction 
Many cellular processes affect the structure of chromosomal DNA. During transcription, 
the structure of double stranded DNA gets positively supercoiled by polymerases and 
helicases117. During replication or recombination events, chromosomal knots or catenates are 
generated118. These two examples result in so-called topological problems, that needs to be 
resolved for cell survival. Topoisomerases are the crucial players in this context, and able to 
alter the DNA topology (Figure 1.8.).  
These fascinating molecular machines manipulate DNA molecules by a mechanism of 
strand passage. In short, a double-stranded DNA molecule is cleaved, generating a DNA 
break, a gap is opened in the cleaved segment and a DNA strand is passed through the break. 
Nature has evolved two major types of topoisomerase, type I creates a single-stranded DNA 
break and type II creates a double-stranded DNA break119.  
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Figure 1.8. Specific activity of DNA gyrase and TopoIV. DNA gyrase introduces negative supercoils into 
covalently closed dsDNA molecules (top). TopoIV decatenates DNA molecules and also relaxes negatively or 
positively supercoiled DNA molecules (bottom). Taken from 120. 
Topoisomerase II are large enzymes of around 400 kDa formed by heterotetramers in 
bacteria and dimers in eukaryotes (Figure 1.9.a-c.). The model DNA gyrase from Escherichia 
coli, formed by GyrA2GyrB2, has been extensively studied. The different structural 
information’s obtained for the DNA gyrase show a three-gates structure that obeys to a two-
gates mechanism.  
GyrB contains several domains: an N-terminal GHKL ATPase domain, a central 
transducer domain and a C-terminal TOPRIM domain, of which each has a specific function. 
The N-terminal domain catalyzes ATP hydrolysis upon ATP-binding mediated dimerization, 
the central domain transfers the signal of ATP hydrolysis and the C-terminal domain is 
involved in DNA-binding. GyrA contains an N-terminal winged helix domain that contains 
the catalytic tyrosine, followed by a so-called tower or shoulder domain, a coiled-coil and a 
C-terminal DNA binding domain (CTD) (Figures 1.9.a and 1.9.b.). 
1.7.2. Distinct roles/functions of DNA gyrase and TopoIV 
Two paralogues type IIA topoisomerase are encoded in the bacterial genome, DNA gyrase 
and topo IV (Figure 1.8.). These two topoisomerases are not functionally redundant and have 
distinct functions. Supercoiling of DNA is crucial for cell viability and compacting the DNA. 
Most DNA molecules occur as negatively supercoiled. Negative supercoiling prepares DNA 
for processing that requires the separation of DNA strands such as replication or transcription, 
by providing energy for DNA-protein interactions. Positive DNA supercoiling is as efficient 
for condensation of DNA material but it makes the strand separation more difficult121. DNA 
gyrase introduces negative supercoils into covalently closed dsDNA molecules, which results 
in a maintained chromosome during transcription.  
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Figure 1.9. Domain architecture and structure of type IIA topoisomerases. (a) Comparison of the domain 
organization of bacterial DNA gyrase and eukaryotic topoisomerases II. (b) Structure of DNA gyrase from 
Thermus thermophilus (same color code as in (a)) compared with (c) the structure of yeast topoIIA bound to a 30 
base-pair dsDNA molecule. (d) Crystal structure of the 43-kDa N-terminal fragment of GyrB (GyrB43) in 
complex with AMPPNP shown as ribbon and semi-transparent surface. Inset of the ATP binding site with 
crucial residues depicted. Adopted from 122,123,124. 
Distinctly, topo IV removes catenants and knots125,126, separating daughter chromosomes 
after replication127.  
These two enzymes are structurally related and both form heterotetramer: GyrA2GyrB2 for 
DNA gyrase and ParC2ParE2 for topo IV. 
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1.7.3. Structure of type II DNA topoisomerases 
Bacterial topoisomerases form A2B2 heterotetramer (GyrA2GyrB2). Structural information 
for each domain is available from high-resolution crystallographic structures.  
Wigley et al.123 obtained the first structural information of DNA gyrase, by crystallizing 
the 43-kDa N-terminal fragment of GyrB (GyrB43). This revealed a tight dimer containing 
two domains, an N-terminal GHKL-type ATPase domain, and an additional domain, termed 
transducer domain, that delimits a hole (N-gate chamber) of about 20 Å diameter123 (Figure 
1.9.d).  
Several residues from different domains form the ATP binding site of GyrB. The GHKL-
ATPase domain of GyrB constitutes the scaffold of the binding site, together with the N-
terminal arm domain of GyrB and two residues from the transducer domain. The phosphates 
groups of the ATP analog ligand are bound to the amine groups of a glycine-rich loop, found 
at the N-terminus of an α-helix. The N-terminal arm interacts with the adenine ring, thus the 
two protomers of the dimer participate in ATP binding. The two residues, glutamine 335 and 
lysine 337 from the transducer domain protrude into the ATPase domain binding site and 
interact directly or via a water-molecule with the γ-phosphate of the ligand. This may provide 
a mechanism of signaling of the ATP hydrolysis event123.  
GyrA, on the other end, is specialized in DNA binding with its C-terminal β-pinwheel 
DNA binding domain. GyrA dimerization forms the C-gate.  
Recently, knowledge on the entire structural organization of topoisomerases has emerged, 
for the yeast (Saccharomyces cerevisiae) topoIIA (yTopoII) obtained by X-ray 
crystallography128 at low resolution (4.4 Å) and for the bacterial DNA gyrase of Thermus 
thermophilus by cryo-electron microscopy122, revealing the architecture of this 
macromolecule (Figure 1.9.b-c.). Interestingly, the comparison of the domain organization in 
these both structures, from yeast or the bacteria T. thermophilus reveals the same domain 
architecture. This revealed the orientation of the ATPase and transducer domains respectively 
to the DNA-gate. The structure of GyrB43 obtained in complex with AMPPNP by Wigley et 
al. already revealed a crossover of the C-terminal helices. The electron density shows that the 
ATPase and transducer domains are located at the top of the DNA gate and that the following 
TOPRIM domain in the sequence of either yTopoII or GyrB is swapped. The ATPase region 
of one protomer within the dimer contacts the TOPRIM domain of its partner, confirming the 
role of the C-terminal crossover helix of the transducer domain in closing the N-gate chamber. 
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The cryo-electron microscopy map obtained for T. thermophilus DNA gyrase reveals the 
position of the C-terminal β-pinwheels DNA binding domain. This demonstrates how DNA is 
asymmetrically wrapped around these domains. The data show how the ATPase domain and 
the β-pinwheel domains cooperate through their spatial proximity to introduce negative 
supercoils (Figure 1.9.b-c.).  
1.7.4. DNA gyrase mechanism  
Type II topoisomerases operate via a so-called two-gates mechanism, even though the 
structures of DNA gyrase revealed three gates. The N-gate is found at the interface formed by 
GyrB2, the DNA-gate at the center of the enzyme, formed by GyrA2GyrB2, and the C-gate is 
formed by a GyrA2 dimer. At the beginning of the catalytic cycle of the topoisomerase, a 
double-stranded segment of DNA, called the G-segment (gate segment) binds to the DNA 
gate, in the cleavage-ligation region129, also termed A’-region of the enzyme130. This is the 
segment that will be cleaved by conserved tyrosine of the winged helix domain of GyrA, 
resulting in a covalent bond between the G-segment and GyrA. A second segment of DNA, 
called the T-segment (transport segment) then binds to the enzyme131,132. This segment gets 
trapped in the N-gate, after closing of this gate by dimerization of the N-terminal 
ATPase123,124 domains of GyrB upon ATP binding129,133. Hydrolysis of a first ATP molecule 
triggers conformational changes coupled to the opening of the DNA-gate. This opening is 
dependent on the flexion of the coiled coil arms or GyrA134, resulting in a separation of the 
winged helix domains of GyrA, located at the DNA-gate interface135. The G-segment is 
passed from the N-gate via the cleaved G-segment in the DNA-gate to the C-gate136,137. The 
G-segment is then resealed and the DNA-gate closed. The opening of the C-gate leads to the 
release of the T-segment. Hydrolysis of the second ATP bound to the GyrB dimer and 
products release reset the enzyme, now ready for another cycle of strand passage (Figure 
1.10). 
This complex mechanism confers unidirectionallity of strand passage from the N-gate to 
the C-gate, via the cleaved double stranded DNA segment bound to the DNA-gate. The 
control of this reaction is believed to be via the ATP hydrolysis mechanism and the timed and 
coordinated opening and closing of the three gates. 
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Figure 1.10. Mechanism of type IIA topoisomerases. GyrB is depicted in yellow (ATPase and transducer 
domains) and orange (Toprim domain), GyrA is depicted in blue. First, the G-segment binds to the DNA-gate 
(step 1). Upon ATP binding, the T-segment gets trapped in the N-gate (step 2). Upon cleavage of the G-segment 
and concomitant ATP hydrolysis, the T-segment gets pushed through the G-segment into the C-gate (step 3). 
Upon Pi and ADP release, the N-gate reopens which reset the enzyme (step 4). Taken from 138. 
Yet, the exact role and consequences of ATP hydrolysis are still under debate128,139 and 
will be further discussed in section 3.4., research article IV, providing new high resolution 
structural evidences of domain motions upon ATP hydrolysis in E. coli GyrB. 
1.7.5. The proposed role of ATP binding and hydrolysis in DNA gyrase 
ATP hydrolysis is required for the introduction of negative supercoils into relaxed DNA 
molecules of from positively supercoiled DNA to negatively supercoiled138,140-145. Structural 
information has been gathered on different nucleotide states bound to the ATPase domain of 
topoisomerases. Conformational changes were observed in some cases. The structure of the 
human topoII (type IIA topoisomerase) has been determined in complex with AMPPNP (a 
non hydrolysable ATP analog) or with ADP146, and the archaeal TopoVI (type IIB 
topoisomerase) with many nucleotide states from AMPPNP, ADP⋅Pi to ADP147,148.  
ATP binding, first, is required for dimerization of the N-gate, which can be structurally 
explained by the presence of an N-terminal “arm” or “strap” domain. This arm, a 15 amino 
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acids stretch, extends from the N-terminus of one protomer and embraces its partner. 
Interestingly, mutation of crucial residues of this arm, i.e. Tyr5 that directly interacts with the 
ATP bound to the active site, abolishes the dimerization. Also, a deletion of this 15 amino 
acids strap abolishes the propensity to dimerize124. 
Secondly, it is undisputed that ATP hydrolysis leads to conformational changes. Baird et 
al.144, showed that the hydrolysis of one ATP molecule is sufficient for DNA gyrase activity. 
For that purpose, they observed in a mutant (E66Q) of yeast topoII the binding of ATP but 
slow hydrolysis event, resulting in a twenty-fold decrease of decatenation. It shows that ATP 
hydrolysis is required to accelerate strand passage. Generating a heterodimer of wild-
type/E66Q-mutant yeast topoII only reduces the decatenation by a two-fold factor, suggesting 
that one hydrolysis event is sufficient to stimulate strand passage. 
Conclusions concerning the direct effect of ATP hydrolysis, i.e. production of ADP⋅Pi, 
and/or Pi release were drawn from the crystal structures of human topoII in complex with 
AMPPNP or ADP and from the archael topoVI structures along the ATPase cycle.  
The structure of N-terminal domain of the human topoII146 (hTopoII) reveals a similar 
dimer as observed for the bacterial GyrB fragment123. The comparison of the hTopoII in 
complex with AMPPNP (PDB: 1ZXM) and in complex with ADP (PDB: 1ZXN) reveals 
rotation of the transducer domain relative to the ATPase domain, resulting in a larger N-gate 
hole upon hydrolysis. The authors attributed this domain reorganization to the hydrolysis and 
subsequent phosphate release event. Noteworthy, a close inspection of the nucleotide binding 
site reveals a sulfate ion next to the ADP product and may therefore mimic an ADP⋅Pi state. 
The quaternary structure rearrangement involves a conformational change of the QTK loop, 
part of the transducer domains that protrudes into the ATP binding site and mediates contacts 
with the nucleotide. This loop and particularly its conserved lysine residue has been described 
as a sensor and relay residue for the nucleotide bound status of the enzyme. 
For the archaeal topoVI structures, the situation is quite different. A conformational 
change is observed between the monomeric nucleotide-free (apo) or ADP-bound structure and 
the other nucleotide bound states (AMPPNP, ADP⋅AlF4, ADP⋅Pi or also ADP in the dimer 
state)147,148. Here, the ADP structure can adopt both conformation, i.e. the monomer or dimer 
form. Interestingly, the conformation of the equivalent residues of the QTK loop of human 
topoII, called switch loop, is changed dramatically depending on the nucleotide state. This 
results in a domain reorientation, with the transducer domain rotating respectively to the 
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ATPase domain by around 11°. It is here postulated that this domain rearrangement serves to 
communicate the status of the ATPase site to the cleavage-ligation region of the enzyme, the 
DNA-gate, resulting in G-segment cleavage and opening. Yet, the molecular mechanisms of 
Pi release are not fully understood139. Nowadays, it seems to be believed in the topoisomerase 
field that ATP hydrolysis serves to guide DNA towards negative supercoiling122, therefore 
providing unidirectionallity in the strand passage mechanism.  
In the context of bacterial DNA gyrase, the structures of the 43-kDa N-terminal fragment 
(GyrB43) of E. coli in complex with nucleotides along the ATP hydrolysis pathway will be 
discussed in section 3.4., research article IV. 
1.7.6. DNA gyrase is a toxin target 
The well-characterized CcdB toxin from the CcdB/CcdA toxin-antitoxin (TA) system 
targets DNA topoisomerase149. CcdB (control of cell death protein B) is encoded on the F 
plasmid from E. coli that is remarkably maintained in bacterial cell lines, even with its very 
low copy number. The role of the TA systems on the F plasmid is the maintenance of this 
plasmid in daughter cells during cell division by a post-segregation killing mechanism. CcdA 
(antitoxin) and CcdB (toxin) are two small proteins encoded in an operon and forms a very 
tight complex. Post-segregationnal killing mechanisms are based on the different stability of 
the expressed toxin and antitoxin proteins. It has been shown that the Lon protease is involved 
in the degradation of the CcdA antitoxin, which results in an active CcdB toxin. This toxin 
causes activation of the SOS system and ultimately leads to bacterial cell death, via targeting 
of the subunit A of DNA gyrase (GyrA). A CcdB dimer binds to a GyrA dimer with a 
dissociation constant (Kd) of around 0.4 nM150, therefore inhibiting the DNA gyrase. The 
mechanism of GyrA poisoning by CcdB has been elucidated using structural informations of 
a GyrA2/CcdB2 complex (PDB: 1X75)151,152 (Figure 1.11.a-b.). This structure shows that a 
CcdB dimer binds to GyrA in its open conformation, i.e. an open conformation of the DNA 
gyrase DNA-gate. This demonstrates that CcdB can bind to GyrA just after DNA cleavage 
and before T-segment passage. Ultimately, it results in an inhibition of DNA gyrase by CcdB 
induced covalent DNA gyrase/G-segment complex that locks the DNA molecule on the 
gyrase. Thus, this blocks the cellular polymerases153,154, leading to double-stranded DNA 
breaks that induce the SOS response and ultimately cell death155. 
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Figure 1.11. Structural insight into the inhibition of DNA gyrase by toxins or antibiotics. (a) CcdB (black) 
binds to GyrA dimer (14 kDa fragment, blue) in an opened conformation and prevents the closure of the GyrA 
dimer (PDB code: 1X75). (b) Model of GyrA (59 kDa fragment, light blue) based on the open conformation of 
yeast topoII in the opened conformation shows an embedded CcdB (PDB code: 1BGW). (c) Novobiocin (Nov, 
black C atoms) bound to the 43-kDa fragment of GyrB (PDB code: 1KIJ) compared to (d) ATP (yellow C 
atoms) bound to the same fragment of GyrB (PDB code: 1EI1). Note the different conformation of the ATP lid 
loop disrupted by novobiocin binding and the type of interactions, mostly hydrophobic for novobiocin and polar 
for the ATP substrate. (e) Inhibition of DNA gyrase by criprofloxacin (Cipro, black C atoms) bound to GyrA and 
double-nicked double-stranded DNA (one strand with violet C atoms and the other with blue C atoms) (PDB 
code: 2XCT). Ciprofloxacin stacks between two base pairs. Note the position of the Y123F mutant of the 
catalytic tyrosine that has been demonstrated to form a covalent bond with the 5’ -end of the cleaved dsDNA 
molecule. Ciprofloxacin prevents the attack of the 3’-hydroxyl group of the DNA molecule, resulting in dsDNA 
breaks. 
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Other plasmid-encoded proteins like microcin B17 or the ParE toxin also poison DNA 
gyrase156. It is likely that more, yet unrevealed toxins, also target DNA gyrase. Section 3.3., 
research article III focused on Class I Fic toxins (as defined in section 3.1., research article I) 
that inhibit (but do not poison) bacterial topoisomerases by adenylylation to subvert DNA 
topology and promote persistence. 
1.7.7. DNA gyrase is a valuable drug target 
DNA gyrase is the only enzyme able to introduce negative supercoils dependent on ATP 
hydrolysis, which makes it unique in the pool of DNA topoisomerases. As such, bacterial 
DNA gyrase is a valuable antibiotic target157,158. A distinction can be made between catalytic 
inhibitors of DNA gyrase (i.e. aminocoumarins) or DNA gyrase poisons (i.e. quinolones)159. 
Aminocoumarin drugs like novobiocin are potent competitive inhibitors of DNA gyrase, 
blocking the ATP binding in the ATPase domain of GyrB160,161. Novobiocin tightly binds to 
the ATPase domain of GyrB and ParE (E. coli) with an affinity (Ki) of 14 nM and 110 nM, 
respectively. They are natural compounds isolated from Streptomyces species. High-
resolution crystal structures of GyrB in complex with aminocoumarin provided important 
information on the binding mode of the inhibitor (Figure 1.11.c compared to the ATP binding 
mode in Figure 1.11.d).  
Quinolones target GyrA resulting in inhibition of supercoiling, double stranded DNA 
breaks and ultimate bacterial killing, a similar effect than the toxin CcdB, but the interaction 
of quinolones and CcdB with GyrA are distinct. Quinolones are the most successful 
antibacterial compounds targeting the DNA gyrase, of which ciprofloxacin is a very potent 
inhibitor that is bactericidal. Many quinolones have been commercialized with success. 
Quinolones inhibit DNA supercoiling and relaxation mediated by DNA gyrase via a covalent 
bond between the catalytic tyrosines of GyrA and the 5’ end of the cleaved dsDNA molecules. 
Again, high-resolution X-ray structures provided valuable structural information about the 
binding sites of quinolones on DNA gyrase (Figure 1.11.e). To summarize, quinolones like 
ciprofloxacin and the CcdB toxin are poisoning DNA gyrase and are therefore intrinsically 
bactericidal.
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2. Aim of my Thesis 
Fic proteins catalyze adenylylation, the transfer of an AMP moiety onto a target protein. 
Expression in E. coli of the Fic protein from Neisseria meningitidis or Bartonella 
schoenbuchensis, NmFic or VbhT respectively, results in severe growth defect of the model 
organism E. coli. This phenotype correlates with the adenylylation of bacterial 
topoisomerases. 
The aim of my PhD thesis, started in October 2010, was to decipher the regulatory 
mechanism of Fic proteins and contribute to the understanding of Fic-mediated target 
inhibition.  
For that purpose, I first focused on class III Fic protein (NmFic from N. meningitidis) that 
contains a C-terminal inhibition motif, undergoes oligomerization and auto-adenylylation. I 
also focused on the target of NmFic: the B subunit of bacterial DNA gyrase (GyrB), a type 
IIA topoisomerase. 
I used, amongst others, mainly X-ray crystallography, biochemical and biophysical 
analysis to unravel the details of the regulation mechanism of Fic proteins and Fic-mediated 
target inhibition. 
Results  
 46 
  
Results 
 
 47 
 
 
 
 
 
 
Results 
 
 
 
 
 
 
  
Results  
 48 
 
Results | Research article I 
 
 49 
3. Results 
3.1. Research article I (Engel, Goepfert et al., Nature, 2012) 
 
Adenylylation control by intra- or intermolecular active-site obstruction in Fic proteins 
 
Philipp Engel*, Arnaud Goepfert*, Frédéric V. Stanger, Alexander Harms, Alexander 
Schmidt, Tilman Schirmer & Christoph Dehio 
* These authors contributed equally to this work 
 
Nature, Volume 482, Issue 7383, 2012 Jan 22nd, Pages 107-110  
 
 
3.1.1. Statement of my own contributions 
I contributed to the research article I by cloning most of the recombinant plasmids used in 
this work. I expressed, purified crystallized and determined the structure of NmFicwt in 
complex with AMPPNP, the inhibited form of NmFic. I took part to the experimental design, 
in particular the design of structure-based mutations of the different Fic proteins tested for 
relief of inhibition. I participated in the data analysis of the structures determined in the frame 
of this study. I also participated in the production of the Supplementary Movie that 
summarizes the findings of this publication from a structural point of view. 
The manuscript was written by Philipp Engel, Arnaud Goepfert, Tilman Schirmer and 
Christoph Dehio. 
 
3.1.2. “Adenylylation control by intra- or intermolecular active-site obstruction in 
Fic proteins”  
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doi:10.1038/nature10729
Adenylylation control by intra- or intermolecular
active-site obstruction in Fic proteins
Philipp Engel1{*, Arnaud Goepfert1,2*, Fre´de´ric V. Stanger1,2, Alexander Harms1, Alexander Schmidt3, Tilman Schirmer2
& Christoph Dehio1
Fic proteins that are defined by the ubiquitous FIC (filamentation
induced by cyclic AMP) domain are known to catalyse adenylyla-
tion (also called AMPylation); that is, the transfer of AMP onto a
target protein. In mammalian cells, adenylylation of small
GTPases through Fic proteins injected by pathogenic bacteria
can cause collapse of the actin cytoskeleton and cell death1,2. It is
unknown how this potentially deleterious adenylylation activity is
regulated in the widespread Fic proteins that are found in all
domains of life and that are thought to have critical roles in
intrinsic signalling processes. Here we show that FIC-domain-
mediated adenylylation is controlled by a conserved mechanism
of ATP-binding-site obstruction that involves an inhibitory
a-helix (ainh) with a conserved (S/T)XXXE(G/N) motif, and that
in this mechanism the invariable glutamate competes with ATP
c-phosphate binding. Consistent with this, FIC-domain-mediated
growth arrest of bacteria by the VbhT toxin of Bartonella schoen-
buchensis is intermolecularly repressed by the VbhA antitoxin
through tight binding of its ainh to the FIC domain of VbhT, as
shown by structure and function analysis. Furthermore, structural
comparisons with other bacterial Fic proteins, such as Fic of
Neisseria meningitidis and of Shewanella oneidensis, show that ainh
frequently constitutes an amino-terminal or carboxy-terminal
extension to the FIC domain, respectively, partially obstructing
the ATP binding site in an intramolecular manner. After mutation
of the inhibitory motif in various Fic proteins, including the human
homologue FICD (also known as HYPE), adenylylation activity is
considerably boosted, consistentwith the anticipated relief of inhibi-
tion. Structural homology modelling of all annotated Fic proteins
indicates that inhibition by ainh is universal and conserved through
evolution, as the inhibitorymotif is present in 90%of all putatively
adenylylation-active FIC domains, including examples from all
domains of life and from viruses. Future studies should reveal how
intrinsic or extrinsic factors modulate adenylylation activity by
weakening the interaction of ainh with the FIC active site.
In two Fic proteins, IbpA and VopS, that are translocated by patho-
genic bacteria into host cells, the ubiquitous FIC domain has been
shown to catalyse adenylylation1–4. The crystal structure of the effector
domain IbpA(FIC2) in complexwith its adenylylated host target Cdc42
has been reported5 and a catalytic mechanism has been proposed5,6.
IbpA- or VopS-mediated adenylylation of Rho-family GTPases
abolishes downstream signalling in human cells and, thus, causes actin
cytoskeleton collapse and cell death1,2. By contrast, overexpression of a
human Fic protein with similar target specificity, HYPE, had only a
marginal effect1. This suggests that the potentially deleterious adenyly-
lation activity is tightly regulated in HYPE and probably in most of the
almost 3,000 Fic proteins that are proposed to have important roles in
intrinsic signalling processes in bacteria, archaea and eukaryotes.
VbhT is a bacterial Fic protein of the mammalian pathogen
B. schoenbuchensis7,8. It is composed of an N-terminal FIC domain
and a C-terminal BID domain (Fig. 1a). The BID domain facilitates
protein translocation intomammalian or bacterial target cells through
a type IV secretion systemor conjugationmachinery9, respectively, but
the target cell and functional role of VbhT are unknown. VbhT arrests
growth when expressed in Escherichia coli (Fig. 1c and Supplementary
Fig. 1a). Growth arrest is repressed by mutation of histidine to alanine
(VbhT(H136A)) in the conserved FIC motif HXFX(D/E)GNGRXXR.
Inother Fic proteins, this signaturemotif has been shown tobe essential
for target protein adenylylation activity1,2,10, therefore suggesting that
toxicity is related to adenylylation of endogenous proteins. Indeed,
wild-type VbhT, but not VbhT(H136A), catalysed in vitro adenylyla-
tion of a putative E. coli target protein of approximately 80 kilodaltons
(kDa) (Fig. 1d). Furthermore, E. coli cells showed filamentation after
expression of wild-type VbhT, but not of VbhT(H136A) (Supplemen-
tary Fig. 2). A similar phenotype has been described for what is thought
to be a hyperactive mutant of the E. coli Fic protein11. Co-expression of
VbhT with VbhA, encoded by the small open reading frame vbhA
*These authors contributed equally to this work.
1Focal Area Infection Biology, Biozentrum, University of Basel, CH-4056 Basel, Switzerland. 2Core ProgramStructural Biology and Biophysics, Biozentrum, University of Basel, CH-4056 Basel, Switzerland.
3ProteomicsCoreFacility,Biozentrum,University ofBasel, CH-4056Basel, Switzerland. {Presentaddress:Departmentof EcologyandEvolutionaryBiology,YaleUniversity,NewHaven,CT06520-8106,USA.
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Figure 1 | The small protein VbhA represses the toxic effect (growth arrest)
that is mediated by the adenylylation activity of VbhT in E. coli. a, Genetic
organization of the type-IV-secretion-system-associated locus of B.
schoenbuchensis, which is composed of the overlapping vbhA and vbhT genes.
The FIC and BID domains that are encoded by vbhT are shown in different
colours. Protein translations of the regions encoding the conserved motif of
VbhA and the FIC motif of VbhT are depicted. b, Protein alignment of VbhA
and a subset of the 158 homologues that are encoded upstream of fic loci in
different bacteria (see also Supplementary Fig. 4). The most conserved region
shows a (S/T)XX(I/L)EG consensus. Sequence accessions and strain
designations are given in Supplementary Fig. 4. c, Growth of E. coli on lysogeny
broth (LB) plates after IPTG-induced expression of different VbhT and VbhA
constructs. Expression ofVbhT shows a toxic effect, whereas bacterial growth is
not affectedwhenVbhT(H136A) is expressed orwhenVbhT andVbhA are co-
expressed (VbhT–VbhA). All E. coli strains revealed normal growth without
induction. Growth curve experiments in LB gave analogous results
(Supplementary Fig. 1). d, Adenylylation assay with crude cell lysates of E. coli
ectopically expressing the same constructs as in panel c.
2 F E B R U A R Y 2 0 1 2 | V O L 4 8 2 | N A T U R E | 1 0 7
Macmillan Publishers Limited. All rights reserved©2012
Results | Research article I 
 
 51 
 
immediately upstream of vbhT (Fig. 1a), completely repressed VbhT
toxicity, as shown by wild-type-like bacterial growth, normal cell
morphology, and inhibition of VbhT-dependent adenylylation (Fig. 1
and Supplementary Figs 1a and 2). We also observed VbhT-mediated
toxicity and its repression by VbhA in B. schoenbuchensis, the natural
carrier of this toxin and antitoxin, and in the related species Bartonella
henselae (Supplementary Fig. 3).
The inhibitory action of VbhA on the VbhT toxin, and the genetic
organization of the respective genes in an operon are reminiscent of
toxin–antitoxin modules that are found in many bacterial genomes,
often associated withmobile genetic elements12. A comprehensive ana-
lysis of the upstream region of FIC-domain-encoding genes (PFAM
pf02661) identified 158 bacterial vbhA homologues that probably
function as antitoxins. Although the sequences are rather diverse, a
central (S/T)XX(I/L)EG motif is conspicuous (Fig. 1b and Sup-
plementary Fig. 4). The high-resolution (1.5 A˚) crystal structure of
VbhA in complex with the FIC domain of VbhT (VbhT(FIC)) (Sup-
plementary Table 1) shows that VbhA is folded into three anti-parallel
helices that tightly embrace VbhT(FIC) (Fig. 2a) with the N-terminal
helix (ainh), adopting a location that is analogous but distinct to that of
the antitoxin Phd in its complex with Doc13 (Supplementary Fig. 5).
Doc is a Fic protein with a degenerate, probably adenylylation-
incompetent FIC motif14 that may have adopted another toxic activity
(Supplementary Information, section 1). The VbhA antitoxin motif
locates to the C-terminal part of ainh and is positioned close to the
putative ATP-binding site10 at the N-cap of the helix that follows the
active loop of VbhT(FIC). This suggests that the antitoxin competes
with ATP binding. VbhA residues Ser 20 and Glu 24 of the inhibitory
motif form a hydrogen bond and a salt bridge, respectively, with the
conserved Arg147 of VbhT following the active loop.
Intriguingly, structural comparisonwith other bacterial Fic proteins
of known fold (Fic proteins from S. oneidensis (SoFic)14,15 and from
N. meningitidis (NmFic)14 (Fig. 2b, c), and from Bacteroides theataio-
taomicron (BtFic)14 and from Helicobacter pylori (HpFic)14 (Sup-
plementary Fig. 6)) reveals that a structural equivalent of ainh can be
part of theFICdomain fold itself.Moreover, theseproteins also showthe
SXXXE(G/N) inhibitory motifs that are, with respect to the FIC active
site, arranged exactly as in the VbhA-VbhT(FIC) complex. Along the
polypeptide chain, however, these ainh occur at two distinct locations
either in the N-terminal part (SoFic and BtFic) or at the C terminus
(NmFic and HpFic). Thus, Fic proteins containing ainh can be grouped
into three classes (Fig. 2d) depending on whether ainh is provided by an
interacting antitoxin (class I) or whether it is part of the FIC fold as an
N-terminal helix (class II) or a C-terminal helix (class III).
To investigate the distribution of class II and class III Fic proteins, we
predicted the structures of all PFAM FIC domain entries by homology
modelling (Supplementary Information, section 1). Including the class I
proteins that are identified above, two-thirds of all Fic proteins were
classified (Fig. 2e and Supplementary Table 2), with a strong dominance
of class II, the class to which human HYPE belongs (Supplementary
Tables 3 and 4). The proportion of classified Fic proteins increases to
90% when considering only adenylylation-competent Fic proteins that
are defined by compliance with the HXFX(D/E)GNGRXXR motif
(Supplementary Text). This suggests co-evolution of catalytic and
inhibitory function. The inhibition motifs that are derived from Psi-
Blast (class I) and structural predictions (classes II and III) are shown in
Fig. 2f with the overall consensus being (S/T)XXXE(G/N). The strict
conservation of the glutamate is striking and indicates that the observed
ionic interaction with the second arginine of the conserved FIC motif
(Figs 2a–c) is crucial for inhibition. Phylogenetic distribution of class I
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Figure 2 | Structures and classification of Fic proteins according to the
position of the inhibitory motif along the polypeptide chain. Structures are
shown in cartoon (FIC core as defined by PFAM, red; active site loop with
histidine, yellow; inhibitory helix (ainh) with SXXXE(G/N) motif, green) with
important residues in full. a, Complex of VbhT(FIC) with antitoxin VbhA
(green).b, SoFic (from S. oneidensis, PDB code 3EQX)withC-terminal domain
omitted. c, NmFic (from N. meningitidis, PDB code 2G03). d, Linear
organization ofmotifs in the proteins presented in panels a–c. e, Distribution of
the three Fic protein classes for the entire family in the PFAM database (left)
and the subset of Fic proteins with the conserved FIC motif HXFX[(D/
E)GNGRXXR that is likely to convey adenylylation activity (right; see also
Supplementary Information, section 1). f, Sequence profiles for the inhibition
site of the three Fic protein classes.
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and class III Fic proteins indicates that each is of monophyletic origin
(Supplementary Fig. 7). Fic proteins with a degenerate FIC motif are
dispersed over the tree, with the exception of the large cluster of Doc-
like toxins. This suggests that there is recurrent degeneration of the
conserved FIC motif with concomitant loss of adenylylation activity.
Consistent with this, deterioration of the FIC motif seems to correlate
with the absence of a recognizable inhibitory motif (Supplementary
Fig. 7). Fic proteins with a degenerate FIC motif may display catalytic
activities different from adenylylation, such as phosphocholination, as
reported for the Legionella pneumophila effector AnkX16.
Owing to our discovery of the prevalence of the inhibitory motif in
Fic proteins, we carried out a detailed analysis of its functional and
structural role. For this, NmFic (class III, Fig. 2c)was chosen, as it is the
smallest active Fic family protein with known crystallization condition
(Supplementary Table 1). As reported before6, NmFic exhibits in vitro
auto-adenylylation activity (Fig. 3d). The acceptor site was traced to
Y183 of ainh by mass spectrometry (Supplementary Information,
section 1, and Supplementary Fig. 8). On the basis of the location of
Y183 relative to the active site, auto-adenylylation is probably cata-
lysed intermolecularly after partial unfolding or detachment of ainh.
Addition of E. coli lysate to NmFic did not reveal additional bands on
the autoradiograph, and this indicated that there are no NmFic targets
inE. coli or that the activity ofNmFic is inhibited. The latterwas shown
to be correct as mutation of the inhibitory motif (S182A/E186A,
NmFic(SE/AA)) resulted in transfer of radioactivity onto an ,80-kDa
E. coli protein and enhanced auto-adenylylation with an additional
acceptor site (Y188; Fig. 3d and Supplementary Fig. 9). Deletion of the
entire ainh helix (NmFic(D8)) led to similar target protein adenylylation,
proving that the activity resides in the FIC domain core. However, only
weak auto-adenylylation was apparent owing to the lack of the acceptor
tyrosines in this deletion mutant (Fig. 3d and Supplementary Fig. 8c).
To investigate the inhibitorymechanism, crystals ofNmFic proteins
were soaked with the non-hydrolysable ATP analogue adenylyl
imidodiphosphate (AMPPNP) (Supplementary Table 1). TheNmFic–
AMPPNP structure revealed nucleotide binding but with the c-
phosphate disordered (Fig. 3a). Notably, the orientation of the a-
phosphate seems to be non-productive, as the position that is in line
with the scissile Pa-O3a bond is occluded by H107 and N113 (Sup-
plementary Fig. 10a and Supplementary Movie). To reveal the situ-
ation in an inhibition-relievedmutant, the structure ofNmFic(SE/AA)
was determined to 3.0 A˚ (Supplementary Fig. 11). Electron density was
lacking forainh, indicating disorder, whereas the nucleotide conforma-
tion was well defined. In the NmFic(D8)–AMPPNP structure, the
same nucleotide conformation was observed (Fig. 3b) and, owing to
its high resolution (1.7 A˚), the structural basis for the observed relief of
inhibition in these mutants became evident. Whereas the adenosine
moiety adopts the same position as in the wild-type, the c-phosphate
of the nucleotide is bound to R118, occupying the same position as the
carboxylate of the inhibitory E186 in the wild type. As a consequence,
the a-phosphate is found to be re-oriented, and the new orientation
permits in line attack of a target side chain onto the a-phosphorus to
accomplish AMP transfer (Fig. 3c, Supplementary Fig. 10 and Sup-
plementary Movie).
The exact role of the inhibitory glutamate was investigated further
by mutagenesis of Fic proteins from the three regulatory classes. In
wild-type NmFic, Ca and Cb of the glutamate are close to the position
that is attained by the c-phosphate position in NmFic(D8) (Fig. 3c).
Still, an E to G single point mutant may provide sufficient space and
main-chain flexibility to allow c-phosphate binding. Indeed, similar to
NmFic(D8)and NmFic(SE/AA), the mutant NmFic(E186G) resulted
in growth inhibition of E. coli (Supplementary Fig. 1b). Likewise, co-
expression of VbhT(FIC) and VbhA(E24G), as representatives for
class I, caused E. coli growth defects (Supplementary Fig. 1a). We also
included SoFic, a bacterial class II protein, in this analysis. Consistent
with the effects of E to G single point mutants in NmFic and VbhA,
mutant SoFic(E73G) revealed a negative effect on E. coli growth
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Figure 3 | Structure and function of wild-type and mutant NmFic reveals a
general inhibition mechanism corroborated by HYPE protein analysis.
a, Active site of NmFic with bound ATP analogue AMPPNP. The c-phosphate
seems to be disordered and has not beenmodelled. b, Active site of NmFic(D8)
with boundAMPPNP andMg21. The c-phosphate occupies the position taken
by E186 of the SXXXEGmotif in the wild-type (as shown in a). Also shown are
2Fo2 Fc maps that are contoured at 1.2s and cover the ligands. c, Surface
representation of the active site of NmFic(D8) with modifiable Y32 (yellow) of
the Cdc42 switch1 loop (green) in a position that is obtained from a
superposition of the active site loops of NmFic over the IbpA(FIC2)–Cdc42
complex5. d, Autoradiography of an SDS gel after incubation of wild-type and
mutantNmFicwith [a-32P]ATP in the presence or absence of E. coli lysate. The
mutants, but not the wild-type, catalyse AMP transfer onto E. coli target
proteins. e, Scheme of a general inhibitionmechanism for Fic proteins. The ainh
helix (green) with the (S/T)XXXE(G/N) motif prevents productive ATP
binding. It is only after dissociation of the helix that the ATP c-phosphate
attains the position close to a conserved arginine (indicated by ‘‘R’’) of the FIC
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histidine as proposed before5. f, g, Autoradiography after incubation of
HYPE(FIC) with a-32P-ATP in the presence or absence of Cdc42 (f) or GST-
tagged Rac1 (GST–Rac1) (g). HYPE(FIC/E234G) shows enhanced auto-
adenylylation and target adenylylation. HYPE(FIC)* denotes a degradation
product of HYPE(FIC).
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(Supplementary Fig. 1c) and strongly enhanced auto-adenylylation
(Supplementary Fig. 12). A similar marked effect on auto-adenylyla-
tion was observed after mutation of the corresponding residue in
human HYPE (HYPE(FIC/E234G)), another class II protein (Fig. 3f,
g). It is known that HYPE catalyses Cdc42 and Rac1 adenylylation1,4.
The rather low adenylylation activity of wild-type HYPE on these
substrates is markedly enhanced in the HYPE(FIC/E234G) mutant
(Fig. 3f, g), demonstrating that the relief of inhibition by ainh enhances
not only auto-adenylylation but also AMP transfer onto bona fide
protein targets.
From this study a general mechanism for the inhibition of the FIC-
domain-mediated adenylylation has emerged that invokes a glutamate
finger from ainh to inter- or intramolecularly block part of the ATP
binding site (Fig. 3e). Dissociation of the toxin–antitoxin complex
(class I) or intramolecular loosening of the contact between ainh and
the FIC domain active site (classes II and III) allows ordered binding of
the entire ATP moiety with the a-phosphate in an orientation that is
productive for accepting an incoming target hydroxyl side chain.
Class I proteins might exert functions similar to the classical
bacterial toxin–antitoxin modules12, whereas class II and III Fic
proteins seem to regulate intrinsic cellular functions that are related
to physiological adaptation and cell homeostasis. Conservation of class
II Fic proteins in all three kingdoms of life (Supplementary Table 2)
emphasizes the important role of the regulatorymechanismsdescribed
here. How the adenylylation activity is activated by weakening the
interaction of ainh with the FIC active site in class II and class III Fic
proteins is one of many important questions for future research. We
also anticipate our study to be a starting point for rational approaches
to modulate the adenylylation activities of Fic proteins—approaches
that should aid in elucidating the diverse biological functions of these
widespread signalling proteins.
METHODS SUMMARY
Toxicity experiments were performed with E. coli strain MG1655, which encodes
an IPTG (isopropyl-b-D-thiogalactoside)-inducible T7 polymerase (strain
AB472). Protein expression was controlled by the addition of either 100mM
IPTG (induction) or 1% glucose (repression). A PSI-BLAST search for homolo-
gues with VbhA of B. schoenbuchensis was conducted to identify Fic proteins
belonging to class I. Class II and class III proteins were classified by structure
predictions using the program HHpred17. We analysed all 2,189 proteins of the
FIC PFAM family (pf02661, release 24). Adenylylation assays were carried out
using bacterial crude cell lysates for VbhT constructs or purified proteins for
NmFic, SoFic and HYPE constructs. For structure determination, VbhA and
VbhT(FIC) were co-expressed in the BL21(DE3) strain of E. coli, and NmFic,
SoFic(D8) and NmFic(SE/AA) in the BL21-AI strain of E. coli. VbhA-
VbhT(FIC) andNmFic were purified by affinity chromatography followed by size
exclusion chromatography. An additional anion exchange chromatography step
was performed forNmFic(D8)andNmFic(SE/AA).Diffraction datawere collected
at beamline X06SA of the Swiss Light Source. For NmFic(D8)andNmFic(SE/AA),
we obtained phases by molecular replacement using the NmFic structure (PDB
code 2G03) as a search model. The VbhA–VbhT(FIC) complex was solved by
molecular replacement using a fragment of BepA (PDB code 2JK8).
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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METHODS
Identification of VbhA homologues. VbhA of B. schoenbuchensis was queried
against a database composed of translated open reading frames (.10 amino acids)
identified in the 500-bp upstream region of all fic loci (PFAM release 24, 2,189
proteins). Nine rounds of Psi-Blast were performed and hits with an E-value,1
manually validated.
E. coli toxicity tests and cell filamentation. E. coli AB472, a derivative of
MG1655, was transformed with VbhT-expressing plasmids and always handled
in LB containing 1% glucose. A single colony was picked, resuspended in 20ml of
LB and plated on LB plates containing 100mM IPTG (induction) or 1% glucose
(repression). Plates were incubated overnight at 37 uC. Growth curves were
acquired by measuring optical density of liquid cultures in LB containing 100
mM IPTG that had been inoculated from overnight cultures of single colonies
and were grown at 30 uC with continuous shaking. Cell filamentation was visua-
lized by co-transformation of plasmid pC10E that constitutively expresses GFP
and examined using fluorescence microscopy.
Conjugation experiments for VbhT toxicity tests in Bartonella. Plasmids were
introduced into Bartonella strains by conjugation from E. coli using three-parental
mating. Bartonella strains were grown for 36–48 h at 35 uC with 5% CO2 on
Columbia base agar plates supplemented with 5% defibrinated sheep blood and
100mgml21 streptomycin. E. coli b2150 that harbours helper plasmid pRK2013,
and E. coli b2150 that contains the VbhT-expressing plasmid were grown over-
night at 37 uC in LB supplemented with 50mgml21 kanamycin or 30mgml21
chloramphenicol, respectively, and both media were also supplemented with dia-
minopimelic acid (DAP) and 1% glucose. After 16 h of incubation, E. coli strains
were diluted 1:50 in fresh LB medium and grown to a opticial density (OD) at
595 nm (OD595nm) of 0.4–0.8. Subsequently, each E. coli strain was diluted to
OD595nm of 0.25, washed once and resuspended in supplemented M199
medium (containing 10% FCS and 1% glucose). Bartonella strains were collected
in 1ml and resuspended in 60ml of M199 (OD595nm 5 1). Each Bartonella sus-
pension wasmixed with 20ml of E. coli b2150 that harbours pRK2013 and 20ml of
E. coli b2150 that harbours the VbhT-expressing plasmid. The conjugation mix
was distributed on a conjugation filter on a columbia blood agar (CBA) plate
supplemented with 150ml DAP and 150ml 1% glucose. After 6 h of incubation
under Bartonella growth conditions as described before, the bacteria were washed
off the filter with 1ml supplemented M199. Dilutions of bacterial suspensions
were plated on lysogeny broth agar (LA) supplemented with DAP, 1% glucose and
30mgml21 chloramphenicol for selecting donors, on CBA supplemented with
1.2mgml21 chloramphenicol for selecting transconjugants, and on CBA supple-
mented with 100mgml21 streptomycin for selecting recipients. Agar plates were
incubated under Bartonella growth conditions and colony-forming units were
counted after 1 day for donors and after 7 days for recipients and transconjugants.
In vitro adenylylation assay. Adenylylation activity of VbhT was assessed in an
assay using lysates of ectopically expressing E. coli. Bacterial pellets were resus-
pended in reaction buffer (50mMTris-HClpH8.0, 150mMNaCl, 0.1mMEGTA,
15mMMgCl2, 140mgml
21 RNase A and protease inhibitor cocktail (Roche)) and
lysed by sonication. After clearing lysates by centrifugation, supernatants were
used for experimentation or stored at220 uC.
Adenylylation reactions were prepared by supplementing 15ml supernatant
from expression cultures with 10mCi [a-32P]ATP (Hartmann Analytic) and
25ml blank E. coli supernatant. Adenylylation activity of NmFic and SoFic con-
structs was assessed by incubating 60mg purified protein with 10mCi [a-32P]ATP
(Hartmann Analytic) and 25ml blank E. coli supernatant. Reactions were incu-
bated for 1 h at 30 uC, resolved by SDS–PAGE, and adenylylation was probed by
autoradiography. ForHYPE(FIC) assays, 15 ng of pure proteinwas incubatedwith
1.6mg of purified GTPases.
Protein expression and purification. pFVS0011 vector (encoding VbhA and
VbhT(FIC)) was transformed into E.coli BL21 (DE3). E. coli cultures were grown
at 37 uC in LB medium supplemented with 50mg ml21 of kanamycin to an
OD595nm of 0.6 before induction with 0.3mM IPTG for 16 h at 23 uC. Vectors
pFVS0015 (carrying the NmFic gene), pFVS0016 (encoding NmFic(D8)),
pFVS0037 (encoding NmFic(SE/AA)) were transformed into BL21-AI cells.
Cells were incubated overnight in 750ml LBmedium that was supplemented with
50mgml21 kanamycin and 1% glucose at 23 uC at 200 r.p.m. until OD595nm of 2 was
reached. Bacterial pellets were resuspended in terrific broth medium containing
50mgml21 kanamycin to obtain anOD595nm of approximately 1. Protein expression
was induced at 23 uC with 0.1% arabinose and 0.5mM IPTG for 23h at 200 r.p.m.
Plasmids harbouring HYPE(FIC) and SoFic constructs were transformed in E. coli
Rosetta (DE3) cells and BL21-AI cells, respectively. The proteins were expressed as
described for NmFic.
Cells containing overexpressed VbhA–VbhT(FIC) and NmFic were resus-
pended in lysis buffer containing 20mM Tris (pH7.5), 250mM NaCl and
25mM imidazole and disrupted using French press. Cell debris was pelleted by
ultracentrifugation and the supernatant was applied to a His-Trap column (GE
Healthcare). The stable complex was eluted with a gradient of elution buffer
containing 20mM Tris (pH7.5), 250mM NaCl and 500mM imidazole. The
protein was then concentrated and injected on a Superdex 75 16/60 gel filtration
column (GE Healthcare) equilibrated with 10mM Tris (pH7.5) and 100mM
NaCl. The pure proteins were concentrated to 6mgml21 for VbhA–VbhT(FIC)
and 53mgml21 for NmFic.
The same purification protocol was used for NmFic(D8) and NmFic (SE/AA),
but with an additional intermediate purification step. After affinity purification,
the proteins were adjusted to 20mM Tris (pH8.5), 25mM NaCl, applied to a
Resource-Q anion exchange column (Amersham Biosciences) and eluted with a
linear gradient of NaCl. Peak fractions were concentrated and further purified by
gel filtration chromatography. Purified proteins in 10mM Tris (pH 7.8), 100mM
NaCl were concentrated to 30mgml21 for NmFic(D8) and 51mgml21 for
NmFic(SE/AA). SoFic and SoFic(E73G) were purified as described previously15.
HYPE(FIC), HYPE(FIC/H295A) and HYPE(FIC/E234G) were purified in the
same way as NmFic. GST-tagged Cdc42 and Rac1 were expressed and purified
as described previously18,19.
Crystallization. All crystals were obtained at 20 uC (except for NmFic crystals,
which were obtained at 4 uC) using the hanging-drop vapour diffusion method
after mixing 1ml protein solution with 1ml reservoir solution. VbhA–VbhT(FIC)
andNmFic(SE/AA) crystallized in 23% (w/v) PEG 3350 and 0.2M di-ammonium
tartrate, and were cryoprotected with 25% (w/v) PEG 3350, 0.2M di-ammonium
tartrate and 10%glycerol. NmFic crystallized in 5% 2-propanol, 0.1MMESpH6.0
and 0.1MCa-acetate, and was transferred into 8% 2-propanol, 0.1MMES pH 6.0,
0.1M Mg-acetate and 15% glycerol, then into 30% glycerol for cryoprotection.
NmFic(D8) crystallized with 44% (v/v) PEG 600, 0.1 M Na-citrate pH5.6. No
cryoprotection was needed for data collection. In each case, the substrate analogue
complex was produced by crystal soaking for 2 h with 10mM AMPPNP, 10mM
MgCl2.
Structure determination. Statistics of data collection and refinement are given in
Supplementary Table 1.Diffraction datawere collected at beamlineX06SA (PXIII)
of the Swiss Light Source (l5 1.0 A˚) at 100K on aMAR CCD detector, processed
using MOSFLM20, and scaled with SCALA21. The structures were determined by
molecular replacement (PHASER22) using a BepA fragment (PDB code 2JK810,
residues 30–194) or the uncomplexed NmFic structure (PDB code 2G03, unpub-
lished, Midwest Center for Structural Genomics) as models for structure solution
of VbhA–VbhT(FIC) and the different NmFic proteins, respectively. A structure
solution of wild-type andmutant NmFic in complex with AMPPNP was straight-
forward, whereas a weak solution (RFZ5 5.1, TFZ5 3.6) with poor phasing
power was obtained for VbhA–VbhT(FIC). The partial model lacking VbhA
was refined by rigid-body refinement using REFMAC5 (ref. 23) with three bodies
to an Rfree of 52%. Model extension using the module AutoBuild of the PHENIX
package24 yielded an almost complete model (R/Rfree5 30.8%/35.2%). The
remainder of the molecule was traced manually with COOT25 and then by full
refinement using PHENIX24. TheRamachandran plot showed thatmore than 99%
of the residues are in favoured regions of the four structures. The figures were
generated with Dino (http://www.dino3d.org).
Prediction of inhibition motif in Fic proteins. All Fic proteins (PFAM release
24, 2,189 proteins) were subjected to a profile-to-profile comparison with
sequences from the PDB using HHpred17. HHpred builds an alignment of homo-
logues for each query sequence by using iterations of PSI-BLAST searches against
the non-redundant database. Secondary structures are then predicted on the PSI-
BLAST alignment using PSIPRED26. On the basis of this data, a profile Hidden
MarkovModel (HMM) is generated. Each query profile is compared with the pre-
computedHMMs of the proteins in the PDB to identify structural homologues. In
terms of query profiles, the PDB profiles include secondary structure information
derived from their three-dimensional structure. We analysed the pairwise profile
alignments of each Fic proteinwith the eight different Fic familymembers deposited
in the PDB. A Fic protein was predicted to belong to class II or class III if the
templates’ inhibitory motifs were aligned to a corresponding query sequence in
the profile alignments (see Supplementary Information, section 1).
Phylogenetic analysis of Fic proteins. Phylogenetic trees of the Fic family were
inferred with FastTree 2 (ref. 27) and RAxML 7.0.4 (ref. 28). Trees were built on
the amino acid alignment provided by the PFAMdatabase.Unaligned overhanging
ends were trimmed off and identical sequences were reduced to one representative.
We used local support values based on the Shimodaira–Hasegawa test to estimate
the reliabilityof the tree inferredwith FastTree2. TheRaxML treewas inferredusing
the PROTMIXWAGF model and 25 rate categories.
Liquid chromatography–mass spectrometry analysis. 2.5mM of purified
NmFic, NmFic(D8) or NmFic(SE/AA) were incubated in reaction buffer
(10mM Tris, pH8, 100mM NaCl) in the presence or absence of 50mM ATP
and 50mM MgCl2 for 1 h. Proteins were reduced in 5mM TCEP, alkylated in
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10mM iodacetamid and digested with sequencing grade trypsin (Promega). The
generated peptides were purified with C18 Microspin columns (Harvard
Apparatus) and analysed using liquid chromatography–mass spectrometry
(LC–MS) or MS on an easy nano-LC system coupled to an LTQ-Orbitrap-
Velos mass spectrometer (both from Thermo-Fisher Scientific), as recently
described29 using a linear gradient from 95% solvent A (0.15% formic acid, 2%
acetonitrile) and 5% solvent B (98% acetonitrile, 0.15% formic acid) to 35% solvent
B over 40min. The data acquisition mode was set to obtain one high-resolution
MS scan in the Fourier Transform (FT) part of the mass spectrometer at a reso-
lution of 60,000 (full width at half maximum) andMS–MS scans in the linear ion
trap of the 20 most intense ions. The resulting MS2 scans were searched against a
N.meningitidis protein database containing the target protein sequence, including
NmFic and NmFic(SE/AA) sequences, that was obtained from EBI (http://www.
ebi.ac.uk) using the SEQUEST search algorithm provided in the Proteome
Discoverer software package (Thermo-Fisher Scientific). In silico trypsin digestion
was performed after lysine and arginine (unless followed by proline), with a tol-
erance of twomissed cleavages in fully tryptic peptides. Database searchparameters
were set to allow phosphoadenosine modification (1329.05252Da) of threonine
and tyrosine residues as variable modification and carboxyamidomethylation
(157.021464Da) of cysteine residues as fixed modification. The fragment mass
tolerance was set to 0.8Da and the precursor mass tolerance to 15 p.p.m.
Strain construction. For toxicity experiments, the vbhT wild-type gene
(FN645515) from B. schoenbuchensis R1 was cloned into pRSF-Duet1
(pPE0017, His6-tagged vbhT). VbhT(H136A) (pPE0034) was constructed by
introducing a two-base-pair point mutation in the FIC motif of vbhT of
pPE0017, as described elsewhere30. Plasmid co-expressing VbhT and VbhA
(VbhT/VbhA) was constructed by cloning vbhA (FN645515) amplified from B.
schoenbuchensisR1 into pRSF-Duet1 (pPE0020,HA-tagged vbhA). vbhTwas then
cloned into pPE0020, resulting in pPE0021. To construct VbhT-expressing plasmids
for Bartonella, vbhT from B. schoenbuchensis R1 was cloned into vector pMMB206
(ref. 31) (pVbhT, HA-tagged vbhT). pVbhT(H136A) was constructed from pVbhT
as described before.
The in-frame deletion of the complete vbhA/vbhT operon in B. schoenbuchensis
(Bsch DvbhA/vbhT) was generated as described previously by a two-step gene
replacement procedure9. The mutagenesis vector pPE3005 was constructed by
ligating a cassettewith the flanking regions of the in-framedeletion into pTR10009.
For protein purification, the full-length vbhA gene and part of the vbhT gene
encoding the FIC domain (vbhT(FIC)), amino acid residues 1–198, His6-tagged)
were amplified from plasmid pPE0021 and cloned into the pRSF-Duet1 vector
(pFVS0011). VbhA(E24G)/VbhT(FIC) expression plasmid (pFVS0065) was
generated by introducing a two-base-pairmutation in pFVS0011. TheNmFic gene
was amplified with an N-terminal His6-tag from N. meningitidis from coding
region of amino acid residues 11–191 and from coding region of amino acid
residues 11–167 to generate plasmids expressing NmFic (pFVS0015) and
NmFic(D8) (pFVS0016), respectively. The S182A/E186A double mutant
construct (NmFic(SE/AA)) was generated by introducing two subsequent point
mutations in pFVS0015. The E186G mutant construct (NmFic(E186G)) was
generated by the same approach. The SoFic gene was amplified from plasmid
(ASU biodesign institute, Clone ID SoCD00104192) and cloned with an
N-terminal His6-tag into pRSF-Duet1 (pFVS0040). The SoFic(E73G) plasmid
(pFVS0058) was generated by introducing a two-base-pair point mutation in
pFVS0040. GST–HYPE(E234G) (pFVS0064) was generated by introducing point
mutations in the plasmid containing GST–HYPE. From these plasmids, shorter
constructs (HYPE(FIC), HYPE(FIC/E234G) and HYPE(FIC/H295A)) only
carrying the FIC domain of HYPE (from amino acids 187 to 437) were generated.
For the expression of human Cdc42 and Rac1, the Cdc42–Q61L and Rac1–Q61L
coding sequences were amplified from plasmid pRK5myc L61 Cdc4232 and
pRK5FLAG L61 Rac1 (ref. 32) and cloned into pGex6p1 with an N-terminal
GST-tag, resulting in pAH088 and pAH060, respectively. The wild-type variants
ofCdc42 andRac1were generated from themutant constructs through polymerase
chain reaction (PCR)-based site-directed mutagenesis30 (resulting in pAH059 and
pAH071). All primers and the resulting vectors are summarized in Supplementary
Tables 5 and 6.
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1. Supplementary Text 
1.1 Defining an adenylylation competent FIC signature motif 
Based on sequence conservation, previous mutagenesis results, and the structure of the 
competent NmFic(8)/AMPPNP complex (Supplementary Fig. 10b), we have defined the 
HxFx[D/E]GNGRxxR profile as the crucial core motif for catalytically active Fic proteins 
with respect to adenylylation. The histidine residue (H) has been shown in several studies1,2 to 
be essential for activity and probably acts as a general base for deprotonation of the target 
side-chain hydroxyl group2,3. The phenylalanine (F) is part of the hydrophobic core and 
important for correct positioning of the active loop. It remains unclear whether other 
hydrophobic residues could replace the phenylalanine. Strikingly, all Fic proteins so far 
shown to exhibit adenylylation activity harbour a phenylalanine at this position. The 
carboxylic side-chain of the aspartic/glutamic acid (D/E) probably coordinates the divalent 
cation (Mg2+ or Mn2+) that is required for activity (data not shown). However, in the 
competent substrate complex structure (Supplementary Fig. 10b) it is partly disordered. As 
predicted before2 and confirmed by the competent AMPPNP complex structure 
(Supplementary Fig. 10b), the three backbone amide nitrogens of GNG are involved in - and 
- phosphate binding. No other residue than a glycine is allowed for the two G positions, 
since side-chains would clash with the core of the protein or the ATP substrate, respectively. 
The asparagine side-chain is involved in positioning of the -phosphate and establishes two 
H-bonds with the backbone amide and carbonyl group of the active site phenylalanine 
residue. Finally, the two arginines are forming a salt-bridge with the - and -phosphate, 
respectively (Supplementary Fig. 10b).  For all residues of the motif, single point mutants 
have been constructed except for the first glycine and first arginine that showed reduced or 
negligible auto-adenylylation and/or target adenylylation1-5, thereby highlighting the 
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importance of these conserved residues. Thus, based on current structural and biochemical 
knowledge, we can assume that Fic proteins with a motif conforming to the consensus 
HxFx[D/E]GNGRxxR are likely to represent AMP transferases. In contrast, proteins 
divergent from this motif have most probably lost adenylylation activity. 
 
1.2 Prediction and analysis of the three regulatory classes of Fic proteins 
While class I proteins were identified by Psi-Blast for the detection of VbhA-homologous 
peptides encoded in the upstream region of fic loci, we used a structure based approach to 
detect class II and class III Fic proteins. The program HHpred predicts structures of distant 
homologs from proteins deposited in structure databases6. The analysis is based on a profile-
to-profile comparison of Hidden Markov Models (HMMs) generated from Psi-Blast and 
secondary structure predictions (see Online Methods). We conducted an HHpred analysis for 
each protein in the FIC family (PFAM release 24, 2,189 proteins) using the protein structure 
database PDB. The PDB contains structures of FIC domains from eight different proteins: (i) 
3dd7, DocH66Y of prophage P1 in complex with the C-terminal domain of Phd; (ii) 2jk8, 
BepA of Bartonella henselae, a type IV secretion system effector protein; (iii) 3n3u, IbpA of 
Histophilus somni, a protein secreted into host cells; (iv) 3let, VopS of Vibrio 
parahaemolyticus, a Type III secretion system effector protein; (v) 2f6s, Fic protein of 
Helicobacter pylori (HpFic); (vi) 2g03, Fic protein of Neisseria meningitidis (NmFic); (vii) 
3eqx, Fic protein of Shewanella oneidensis (SoFic); (viii) 3cuc, Fic protein of Bacteroides 
thetaiotaomicron (BtFic). For all Fic proteins analyzed with HHpred, we detected significant 
structural homology with these eight FIC domain structures in the PDB. Based on the 
corresponding HHpred alignments, we validated each Fic protein for the presence of an N-
terminal (class II) or C-terminal (class III) inhibition motif. Fic proteins were predicted to fall 
into one of these two classes, if the structural alignments with the two structural prototypes of 
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a class (for class II, SoFic and BtFic; for class III, NmFic and HpFic ) included the region 
comprising their inhibition motif. The segment of the query sequence aligning with the 
inhibition motifs of a given class was then identified as the putative inhibition motif of the 
query protein. Only proteins for which both alignments predicted the same inhibition motif 
were categorized into the corresponding class. 
Supplementary Tables 4a-e show that for most proteins, predicted to fall into one of 
the two classes, the corresponding template structures resulted in the highest homology scores 
among the eight Fic proteins in our HHpred analysis. Further, the inhibition motifs 
independently predicted from the two template structures, turned out to be the same for most 
Fic proteins. Finally, only four proteins were identified to belong to more than one of the 
three classes. Altogether, this demonstrates the high specificity of our analysis for the 
prediction of these regulatory features.  
Strikingly, the consensus sequence of all motifs from class I, II, and III converges 
towards the general inhibition motif [S/T]xxxE[G/N]. The glutamate (E24 of VbhA), thereby, 
displays the most conserved amino acid, which is consistent with the presented mechanism of 
inhibition (Fig. 3).  
As mentioned in the main text, in comparison to the entire family, the total number of 
proteins predicted to fall into one of the three regulatory classes is significantly increased in 
the subset of Fic proteins harbouring the adenylylation-competent FIC motif 
HxFx[D/E]GNGRxxR (see Supplementary Text 1.1). Thus, the inhibition motif seems to be a 
specific feature of proteins with adenylylation activity and indicates co-evolution of these two 
functional features. In contrast to this general trend, the relative number of class I proteins 
(regulated by an antitoxin-like protein) decreases in the subset of Fic proteins with a 
conserved FIC motif. This can be explained by the fact that a significant fraction of class I 
comprises proteins from E. coli and related species which harbour a serine instead of an 
Results | Research article I 
 60 
 
W W W. N A T U R E . C O M / N A T U R E  |  5
SUPPLEMENTARY INFORMATION RESEARCH 
 
Page 5 of 31 
asparagine and a leucine instead of arginine (1st position) in the active loop. It remains to be 
elucidated whether HxFx[D/E]GSGLxxR either can still mediate adenylylation or has evolved 
another activity which is regulated by a similar mechanism as adenylylation. 
Interestingly, class I and III are restricted to bacteria (which present 90% of all Fic 
proteins), while in archaea and eukaryotes only class II inhibition motifs were predicted 
(Supplementary Table 2). Most of the metazoan Fic proteins including the human homolog 
HYPE as well as some of the fungal Fic proteins are predicted to contain a class II regulatory 
motif suggesting that this regulatory mechanism of adenylylation activity is conserved in all 
domains of life. 
 
1.3 Prediction of regulatory classes for selected Fic proteins 
The classification based on the presence/absence of an inhibition motif is listed in 
Supplementary Table 3 for a subset of Fic proteins which were previously studied. For VopS, 
the effector protein of Vibrio parahaemolyticus, our analysis did not predict an inhibition 
motif. This is in agreement with the 3D structure of VopS3, which does not reveal any 
regulatory helix positioned next to the FIC active site.  
In case of the second bacterial virulence factor for which adenylylation activity in 
eukaryotic host cells was described, IbpA4, our analysis predicted an N-terminal inhibition 
motif (class II). However, the 3D structure of IbpA does not show this predicted inhibition 
motif to be located in the active center of the FIC domain1. Thus, our prediction for IbpA may 
be a false positive. Both VopS and IbpA are translocated into eukaryotic host cells, where 
they adenylylate proteins of the Rho family GTPases. This leads to the collapse of the actin 
cytoskeleton and subsequently to cell death4,5. In general, effector proteins of bacterial 
pathogens that aim at killing or dramatically subverting the cells of their eukaryotic hosts (e.g. 
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immune cells) by adenylylation of cellular targets might not need to be regulated. Further, due 
to their specificity for eukaryotic targets, they may not be toxic for the bacterium before 
translocation and would thus not require an inhibited state.  
However, for effector proteins of Bartonella, our Psi-Blast analysis identified 
homologs of VbhA located upstream of the effector gene loci. In contrast to VopS and IbpA, 
the effector proteins of Bartonella seem to have a much more subtle effect on host cells7. It 
remains to be elucidated whether for Bartonella effector proteins co-translocation of a VbhA-
homolog into host cells allows regulation of adenylylation activity. 
Like the bacterial virulence factors IbpA or VopS, the human Fic protein HYPE, was 
shown to adenylylate the GTPases RhoA, Rac1, and Cdc424. The conserved N-terminal 
inhibition motif identified for HYPE and other mammalian Fic proteins might explain why 
HYPE, in contrast to IbpA or VopS, did not show any cytotoxic effect on mammalian cells4. 
Thus, the here-identified regulatory mechanism might be essential for the tight regulation of 
mammalian Fic proteins and their integration into key signaling pathways of mammals.  
Doc proteins share the same structural fold as Fic proteins and are thus grouped into 
the FIC PFAM family (which is also referred to as Fic/Doc family). They constitute the toxins 
of toxin-antitoxin modules homologous to the post-segregational killing system Doc/Phd of 
Bacteriophage P18. In our phylogenetic analysis (Supplementary Fig. 7), Doc proteins form a 
separate cluster clearly distinct from the remaining Fic proteins. Furthermore, their core motif 
(Supplementary Table 3) is highly divergent from the adenylylation competent motif as 
defined above (see Supplementary Text 1.1). Consistently, our HHpred and Psi-Blast analyses 
did not identify any adenylylation-inhibiting motif for Doc-related proteins. Nevertheless, 
Doc activity is inhibited by the antitoxin Phd which binds in a similar way as VbhA to VbhT 
(Supplementary Fig. 5). Doc-mediated toxicity on bacteria results from binding to the 30S 
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ribosomal subunit, but the exact underlying mechanism of Doc-mediated toxicity remains 
elusive and adenylylation activity has not been reported9. Still, inhibition of Doc toxicity by 
mutation of the histidine in the central motif of the FIC domain indicates its involvement in 
mediating the toxic effect10.  For Doc as well as for other Fic proteins carrying a motif 
divergent from the adenylylation-competent consensus profile, the FIC domain could mediate 
other enzymatic activities11. Catalytic versatility of the FIC domain fold would further explain 
why this protein family is so abundant in a wide range of organisms. 
 
1.4 Mass spectrometry (MS) results for the identification of the auto-
adenylylation site of NmFic 
In order to specifically pinpoint the location of the adenylylation in the FIC domain and to 
verify the results obtained for the adenylylation assay (Fig. 3d), a mass spectrometric analysis 
of the trypsinized NmFic protein samples was performed. As apparent from Supplementary 
Fig. 8a, the majority of the adenylylation could be identified at position Y6 in the displayed 
peptide sequence. Additional conformation was obtained by the identification of the same 
adenylylation site on the same peptide containing the C-terminal glycine as consequence of 
incomplete proteolysis (Supplementary Fig. 8b). However, due to the close proximity of the 
tyrosine residues, it cannot be excluded that Y7 or Y8 are also modified. Comparative 
analysis of the NmFic and NmFic(8) mutant clearly indicates a strong increase in 
adenylylation for this domain (Supplementary Fig. 8c). Notably, we covered the whole 
protein sequence by MS analysis and could only identify adenylylation at the C-terminal 
tyrosine residues of this protein, indicating exclusive adenylylation of this protein at these 
sites and confirming the results obtained in Fig. 3d. 
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 MS analysis of the NmFic(SE/AA) mutant revealed a higher degree of adenylylation, 
which is indicated by the identification of more and multiple adenylylated peptide species 
(Supplementary Fig. 9), again, confirming the observations made in Fig. 3d. 
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Supplementary Figure 1. Growth curves of E. coli MG1655 expressing different 
constructs of (a) VbhA-VbhT, (b) NmFic, or (c) SoFic. Cultures were inoculated with 5 µl 
of an overnight culture and induced with 100 µM IPTG. Bacterial growth was measured by 
monitoring the optical density at 600 nm every 30 minutes. All experiments were carried out 
in quadruplicates. 
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Supplementary Figure 2. Cell filamentation of E. coli upon expression of VbhT is 
repressed by co-expression of VbhA. Fluorescence microscopy of E. coli harbouring a GFP-
reporter plasmid (pC10E) in addition to the same VbhA-VbhT-expression plasmids as 
presented in Fig. 1c (scale bar, 5 µm). Cell filamentation of E. coli observed upon VbhT 
expression is not evident for VbhT(H136A) or VbhA-VbhT. 
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Supplementary Figure 3. Conjugation of VbhT expression plasmids into Bartonella 
schoenbuchensis and Bartonella henselae reveals toxicity of VbhT in the absence of 
vbhA. Conjugation frequencies are given by the number of transconjugants per recipient as 
determined by dilution plating and counting of colony forming units on media selective for 
either transconjugants or recipients. Conjugation of a plasmid expressing VbhT wild-type 
(pVbhT) into B. schoenbuchensis wild-type (Bsch wt) resulted in a conjugation frequency of 
about 10-5. In contrast, conjugation of the same plasmid into B. schoenbuchensis harbouring a 
deletion of the complete vbhA-vbhT operon (Bsch vbhA-vbhT) or into B. henselae wild-type 
(Bhe wt), which does not encode vbhA, gave no transconjugants in four and three independent 
experiments, respectively. This resulted in conjugation frequencies < 10-7 (when taking the 
detection threshold in our experiments into account). The inability to conjugate the plasmid 
into these strains was dependent on a functional FIC motif: a plasmid expressing VbhT with 
an adenylylation-deficient FIC motif (pVbhT(H136A)) could be conjugated into Bsch vbhA-
vbhT and Bhe wt with a similar frequency as into Bsch wt. 
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Supplementary Figure 4. Protein alignment of translated ORFs with homology to VbhA 
encoded in the upstream region of fic gene loci. We used Psi-Blast to query the VbhA 
protein sequence against all translated ORFs (>10 aa) found in the 500 bp upstream of loci 
encoding Fic proteins. In total, this analysis identified 158 ORFs with homology to VbhA. 
127 ORFs are overlapping with the corresponding fic gene, together constituting putative 
operons. From the remaining 31 ORFs, 20 are less than 100 bp away from the annotated start 
codon of the fic gene. In the depicted alignment, sequences identical to each other were 
reduced to one representative resulting in 87 aligned sequences including VbhA. Overhanging 
ends were trimmed. Start and end positions of the aligned sequences are indicated. The 
consensus sequence logo is depicted on top of the alignment indicating the conserved central 
motif. The alignment was generated with MUSCLE12 (implemented in Geneious v5.3.6) and 
manually curated. Shading of amino acids indicates degree of conservation. Sequences used 
in the alignment of Fig. 1b are highlighted in red color. 
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Supplementary Figure 5. Comparison of FIC domain folds and FIC/antitoxin 
interactions. a, VbhA-VbhT(FIC) from B. schoenbuchensis. The VbhT(FIC) structure is 
highly similar to that of BepA(FIC)2 (rmsd of 1.6 Å for 169  C-positions, panel c). b, 
Doc/Phd from Bacteriophage P113, PDB code 3dd7). c, BepA(FIC) from B. henselae2. 
Representations of the structures as in Fig. 2.
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Supplementary Figure 6. Fic protein structures BtFic (BT2513 from Bacteroides 
thetaiotaomicron, PDB code 3CUC) (a) and HpFic (HP1159 from Helicobacter pylori, 
PDB code 2F6S) (b). Structures are shown in cartoon representation as in Fig. 2 (Fic core as 
defined by PFAM, red; active site loop with histidine, yellow; inhibitory helix (inh) with C-
terminal SxxxEG motif, green; termini labeled with N and C) with important residues in 
full. Note that BtFic and HpFic are class II and III Fic proteins, respectively, and are close 
structural homologs of SoFic(Fig. 2b) and NmFic (Fig. 2c).  
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Supplementary Figure 7. Phylogenetic trees of Fic proteins. a, Approximately-maximum-likelihood tree inferred with FastTree2. 
Local support values were calculated as implemented in FastTree214 using the Shimodaira-Hasegawa test. Circles indicate branches 
with local support values > 0.9. b, Maximum-likelihood tree inferred with RAxML15 using the PROTMIXWAG model. Dark and light 
grey coloring on the inner circle indicates the presence (conserved) or absence (degenerate) of the adenylylation competent motif, 
respectively. The outer circle depicts the class assigned to each Fic protein conforming the coloring of Fig. 2e. The large cluster of Doc-
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like proteins lacking the conserved FIC motif is indicated. An interactive version of the tree with species and accession number labels 
for each leaf can be accessed via the following link http://itol.embl.de/shared/Engel2011. 
 
Results | Research article I 
 72 
 
W W W. N A T U R E . C O M / N A T U R E  |  1 7
SUPPLEMENTARY INFORMATION RESEARCH
 
 
Page 18 of 31 
like proteins lacking the conserved FIC motif is indicated. An interactive version of the tree with species and accession number labels 
for each leaf can be accessed via the following link http://itol.embl.de/shared/Engel2011. 
 
 
 
Page 19 of 31 

 

 

 

	 

 

 	


 
!#"
 
!#
	 

"
 


	 


 
"

 
200 300 400 500 600 700 800 900 1000
m/z
0
100
200
300
400
In
te
ns
ity
 [c
ou
nt
s]
 (1
0^
3)
     Extracted from: V:\Schmidt_Group\MS-data\A-Velos\2011\03\A11-03127.raw   #4256   RT: 17.89
     ITMS, CID, z=+3, Mono m/z=672.26294 Da, MH+=2014.77427 Da, Match Tol.=1.2 Da
#&

$
#

$
 #
$
 #
$
#&%'#%'#&

$
#%'"#&

$
#
$	
!#%'"#&
$
#%' #
$

#

$
#
$

#&
$

"#
$
#&
$
300 400 500 600 700 800 900 1000
m/z
0
2
4
6
8
10
12
In
te
ns
ity
 [c
ou
nt
s]
 (1
0^
3)
     Extracted from: V:\Schmidt_Group\MS-data\A-Velos\2011\03\A11-03161.raw   #3293   RT: 17.77
     ITMS, CID, z=+3, Mono m/z=653.26007 Da, MH+=1957.76566 Da, Match Tol.=1.2 Da









	

	
		
		
	


	

0&'-,1%*/,/,(
$2-
!$
	
' +%+-(#$,%1.


	

0&'-,1%*/,/,(
$2-
!$
	
' +%+-(#$,%1*
 
 
	
 
 
Supplementary Figure 8. LC-MS/MS analysis of adenylylated NmFic protein. a, 
MS/MS-spectrum of the fully cleaved peptide GIEQSYYYEGYEK at a charge state of 3 
using CID. The identified adenylylation sites are underlined in the peptide sequence and 
indicated in red. All correctly assigned y- and b- fragment ions are indicated in blue and red, 
respectively, unassigned fragment ions are shown in gray. b, MS/MS-spectrum of the 
incompletely cleaved peptide GIEQSYYYEGYEKG showing the same modification. c, 
Extracted ion chromatograms of the fully cleaved peptide displayed in panel a for the 
different samples analyzed. 
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Supplementary Figure 9. LC-MS/MS analysis of adenylylated NmFic(SE/AA) protein. 
Four MS/MS-spectra are displayed showing the most significant adenylylated peptide 
sequences identified in the NmFic(SE/AA) mutant. The identified adenylylation sites are 
underlined in the peptide sequence and indicated in red. All correctly assigned y- and b- 
fragment ions are indicated in blue and red, respectively, unassigned fragment ions are shown 
in gray. 
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Supplementary Figure 10. AMPPNP binding to NmFic and NmFic(8). The stereoviews 
of NmFic (a) and NmFic(8) (b) show the detailed interactions of the nucleotide with the Fic 
active site with H-bonds marked by stippled lines in aquamarine. The structure represenations 
show similar views as in Figs 3a and b, but with the N-terminal end of helix 5 shown in full 
to visualize the capping interactions of the - and -phosphate with the helix. Additionally, 
the position that would have to be adopted by a target hydroxyl group for productive 
nucleophilic attack inline with the scissile P-O3 bond is indicated by a small red sphere 
(marked X) with the X - P distance set to 3.0 Å. (c) Superposition of NmFic (gray carbons) 
and NmFic(8) (orange carbons). 
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Supplementary Figure 11. Crystal structure of NmFic(SE/AA). The schematic cartoon of 
chain A is shown in the same representation as in Fig. 2a. Note that (as in all other 15 
molecules of the asymmetric unit) helix inh which follows 7 is disordered as evidenced by 
missing electron density. The AMPPNP substrate analog, however, is fully resolved and 
found in the same conformation and orientation as in the corresponding 
NmFic(8)/AMPPNP structure (Fig. 3b). The ligand has been omitted from phasing. The 
2Fo-Fc density map is shown in grey (1.2 ), the Fo-Fc map in green (3.0 ). 
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Supplementary Figure 12. Autoradiography of an SDS-gel after incubation of SoFic and 
SoFic(E73G) with -32P-ATP in the presence or absence of E. coli lysate. Auto-
adenylylation is drastically increased in the SoFic(E73G) mutant. SoFic* indicates a 
truncated version of SoFic as evidenced by mass spectrometry. No target bands are revealed 
upon incubation with E. coli lysate. It is conceivable that the target is a small, unresolved 
peptide or DNA. 
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3. Supplementary Tables 
Supplementary Table 1. Data collection and refinement statistics. 
 
 VbhA-VbhT(FIC) NmFic NmFic(8) NmFic(SE/AA) 
Data collection     
Space group C2 P6422 P21 P21 
Cell dimensions       
    a, b, c (Å) 106.34, 40.37, 73.79 148.96, 148.96, 75.80 73.94, 65.03, 75.99 110.31, 136.92, 114.66 
    , ,   (°)  90.00, 121.40, 90.00 90.00, 90.00, 120.00 90.00, 107.08, 90.00 90.00, 100.26, 90.00 
Resolution (Å) 45.21-1.50(1.58-1.50) * 65.35-2.15(2.27-2.15) * 37.03-1.7(1.79-1.70) * 87.07-3.02(3.19-3.02) * 
Rsym or Rmerge 6.3(23.8) 9.3(46.9) 6.9(37.3) 11.2(35.2) 
I/I 9.1(2.0) 18.5(4.0) 9.8(2.6) 6.9(2.2) 
Completeness (%) 96.2(74.8) 99.1(93.9) 97.7(95.4) 89.0(43.1) 
Redundancy 3.8(2.0) 13.6(8.8) 4.0(3.5) 3.8(2.1) 
     
Refinement     
Resolution (Å) 15.0-1.50 15.0-2.15 15.0-1.7 15.0-3.02 
No. reflections 41,211(4,622) 27,218(3,678) 73,865(10,470) 58,488(4,120) 
Rwork/ Rfree 18.0/21.5 18.8/21.3 15.9/19.7 22.2/24.8 
No. atoms     
    Protein 2173 1681 5076 21120 
    Ligand/ion 2 TAR 1 ANP 4 ANP, 4 MG, 4 P6G 16 ANP 
    Water 255 189 424 - 
B-factors     
    Protein 22.1 37.2 18.4 66.4 
    Ligand/ion 22.2 44.8 34.6 36.5 
    Water 31.1 47.8 24.4 - 
R.m.s deviations     
    Bond lengths (Å)  0.012 0.012 0.010 0.009 
    Bond angles (º) 1.3 1.2 1.3 1.1 
*Highest resolution shell is shown in parenthesis.  
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Supplementary Table 2. Distribution of Fic proteins from different domains of life in the three regulatory classes I to III. 

 Data analyzed Distribution of Fic proteins into the different regulatory classes I to III  
    class I
d class IIe class IIIf no class class I and II  class I and III  class II and III  
Domain Dataseta Proteinsb Domainsc # % # % # % # % # % # % # %
All 
FIC family   
   



   	   
  
  
conserved FIC motif    
 		  	          
Bacteria 
FIC family  	 
	  	 
      
  
  
conserved FIC motif 
 
 
 		 	 	          
Archaea 
FIC family 	 	              
conserved FIC motif                
Eukaryota 
FIC family 
 
              
conserved FIC motif 	 	   
    
 		      
Viruses 
FIC family 
 
        	      
conserved FIC motif 	 	              
Unclassg 
FIC family      
          
conserved FIC motif                
Otherg 
FIC family          
      
conserved FIC motif                
a we analyzed the entire FIC PFAM family (PFAM release 24) as well as a subset of Fic proteins harbouring an adenylylation-competent core motif (conserved FIC motif, 
HxFx[D/E]GNGRxxR), 
bnumber of proteins analyzed,  
cnumber of domains analyzed; two proteins harbour two FIC domains, 
dclass I, antitoxin-like ORF harbouring inhibition motif, 
eclass II, N-terminal inhibition motif, 
fclass III, C-terminal inhibition motif, 
g”Unclass” stands for unclassified Fic proteins, “Other” comprises three Fic proteins from plasmid sequences sampled from the environment 
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Supplementary Table 3. Prediction of class I, class II, and class III inhibition motifs for selected Fic proteins. 
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
Supplementary Table 4. Classification of all PFAM FIC domain-containing proteins according to the presence of an antitoxin or an intrinsic 
inhibition motif. Due to its bulkiness, the table is provided as an extra file in Excel format on http://www.nature.com/nature. 
Results | Research article I 
 
 79 
 
SUPPLEMENTARY INFORMATION
2 4  |  W W W. N A T U R E . C O M / N A T U R E
RESEARCH
 
Page 28 of 31 
 
Supplementary Table 5. List of primers used in this study.
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Supplementary Table 6. List of plasmids constructed in this study. 
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Binding Mode for Adenylyltransferases with Fic Fold
Arnaud Goepfert1,2, Fre´de´ric V. Stanger1,2, Christoph Dehio1*, Tilman Schirmer2*
1 Focal Area Infection Biology, Biozentrum, University of Basel, Basel, Switzerland, 2 Focal Area Structural Biology and Biophysics, Biozentrum, University of Basel, Basel,
Switzerland
Abstract
The ubiquitous FIC domain is evolutionarily conserved from bacteria to human and has been shown to catalyze AMP
transfer onto protein side-chain hydroxyl groups. Recently, it was predicted that most catalytically competent Fic proteins
are inhibited by the presence of an inhibitory helix ainh that is provided by a cognate anti-toxin (class I), or is part of the N-
or C-terminal part of the Fic protein itself (classes II and III). In vitro, inhibition is relieved by mutation of a conserved
glutamate of ainh to glycine. For the class III bacterial Fic protein NmFic from Neisseria meningitidis, the inhibitory
mechanism has been elucidated. Here, we extend above study by including bacterial class I and II Fic proteins VbhT from
Bartonella schoenbuchensis and SoFic from Shewanella oneidensis, respectively, and the respective E-.G mutants.
Comparative enzymatic and crystallographic analyses show that, in all three classes, the ATP substrate binds to the wild-
type FIC domains, but with the a-phosphate in disparate and non-competent orientations. In the E-.G mutants, however,
the tri-phosphate moiety is found reorganized to the same tightly bound structure through a unique set of hydrogen bonds
with Fic signature motif residues. The c-phosphate adopts the location that is taken by the inhibitory glutamate in wild-type
resulting in an a-phosphate orientation that can be attacked in-line by a target side-chain hydroxyl group. The latter is
properly registered to the Fic active center by main-chain b-interactions with the b-hairpin flap. These data indicate that the
active site motif and the exposed edge of the flap are both required to form an adenylylation-competent Fic protein.
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Introduction
Adenylyl transferases (ATases) utilize adenosine triphosphate
(ATP) to covalently modify proteins, nucleic acids, or small
molecules with adenosine monophosphate (AMP), a reaction
known as adenylylation or AMPylation. The ubiquitous FIC
domain (pfam 02661) found in proteins of all domains of life and
viruses has only recently been shown to confer ATase activity.
Thus, the bacterial T3SS effector protein VopS from Vibrio
parahaemolyticus and the surface antigen IbpA from Histophilus somni
covalently attach the bulky AMP moiety onto a specific threonine
or tyrosine, respectively, of the switch I region of Rho family
GTPases [1,2]. This abrogates binding of downstream effectors
and results in actin cytoskeleton collapse and concomitant cell
detachment and death. Mutational and bioinformatics analysis
indicated that Fic proteins containing a strictly conserved
HxFx(D/E)GNGRxxR signature motif in the active center
typically display adenylylation activity [1,2,3,4,5], while Fic
proteins with an active center deviating from this consensus are
considered to have adopted different activities. Indeed, the host-
targeted effector protein AnkX of Legionella pneumophila exhibiting
an HxFxDANGRxxV signature motif displays phosphocholina-
tion activity towards the GTPase Rab1 [6].
The FIC domain is structurally characterized by a conserved
central core of four helices (a2 to a5) that is flanked by three
helices (a1, a6 and a7) found in diverse dispositions in different Fic
proteins [3,7]. Helices a4 and a5 are joined by a loop that together
with the N-terminal cap of helix a5 forms the active center
represented by a signature motif with the consensus sequence
HxFx(D/E)GNGRxxR. The catalytic mechanism of adenylylation
was deduced from the crystal structure of the second FIC domain
of IbpA in complex with the adenylylated Cdc42 target [4] and
from biochemical studies [5] and shown to involve nucleophilic
attack of the target side-chain hydroxyl onto the ATP a-
phosphate. The triphosphate binding site at the anionic nest at
the N-terminus of helix a5 was characterized by the crystal
structure of BepA from Bartonella henselae in complex with
pyrophosphate, the side product of the reaction [3]. An ATP
substrate complex structure was obtained recently for the Fic
protein of Neisseria meningitidis [8] corroborating the catalytic
mechanism. The histidine of the signature motif is critical for
deprotonation of the incoming target hydroxyl group [5], whereas
the phenylylanine is part of the hydrophobic core of the domain.
The remaining residues of the motif are involved in ATP/Mg2+
binding and loop stabilization [3,8].
We recently demonstrated that the Fic protein VbhT from
Bartonella schoenbuchensis causes bacterial growth arrest when
overexpressed in Bartonella or E. coli and that this effect can be
repressed by co-expression with the anti-toxin VbhA, a small
protein encoded upstream of VbhT [8]. As shown by structure
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analysis, VbhA forms a tight complex with the FIC domain of
VbhT with the conserved glutamate (Einh) from the inhibitory
helix ainh partly obstructing the ATP binding site, which gave a
first clue regarding the inhibitory mechanism mediated by VbhA
binding.
Exhaustive bioinformatic analysis coupled with homology
modeling revealed that the (S/T)xxxE(G/N) signature motif of
ainh is not only found in several other putative anti-toxin sequences
coded immediately upstream of Fic proteins, but is often part of
the FIC domain itself either preceding helix a1 or immediately
following helix a7 [8]. Thus, a classification system was introduced
grouping the Fic proteins for which an anti-toxin with an
inhibitory helix ainh had been found into class I and those with
an equivalent of ainh in the N- or C-terminal part of the Fic
protein into classes II and III, respectively. Indeed, 90% of the Fic
proteins with the canonical FIC signature motif could be classified
accordingly, suggesting that all these enzymes are inhibited in their
enzymatic activity.
The physiological stimulus or condition for relief of ainh-
mediated inhibition is not yet known. For T4SS Fic proteins of
class I (such as VbhT or BepA [9]), however, it appears likely that,
for injection into host cells, the Fic protein has to unfold and will
be translocated without the antitoxin. For class II and III proteins,
detachment, unfolding, or proteolytic cleavage of the ainh helix
may cause relief of inhibition. In fact, a truncation mutant of the
class III Fic protein from N. meningitidis (NmFic) lacking the entire
C-terminal ainh helix showed strong ATase activity and allowed to
study the catalytic and inhibitory mechanism in detail [8]. A more
subtle means to relieve inhibition, which is applicable to Fic
proteins of all three classes, is the replacement of the inhibitory
glutamate by glycine. In vivo, such E-.G mutations showed a
detrimental effect on bacterial growth [8]. For the human HYPE
protein (class II), the corresponding mutant protein catalyzed
in vitro AMP transfer to the small GTPases Rac1 and Cdc42,
whereas only marginal effect was seen with the wild-type proteins
[8].
Here, we assayed in a systematic approach Fic representatives of
the three Fic classes and their E-.G mutants for in vitro
adenylylation showing that the mutation causes inhibition relief
across the Fic classes. Binding of ATP substrate or AMPPNP
substrate analog to the wild-type and the E-.G mutant proteins
was studied by protein crystallography to reveal the inhibitory
mechanism and to get further insight into catalysis. This yielded a
consistent molecular mechanism that most likely applies to most
adenylylation competent Fic proteins irrespective of class.
Materials and Methods
Cloning
The full-length vbhA gene and part of the vbhT gene (amino acid
residues 1–248, His6-tagged) were amplified from plasmid
pPE0021 and cloned into the pRSF-Duet1 vector leading to
plasmid pAG0077 (VbhA/VbhT(FIC)). The full-length vbhA gene
and part of the vbhT gene encoding the FIC domain (amino acid
residues 1–198, His6-tagged) were PCR-amplified from plasmid
pPE0021 and cloned into the pRSF-Duet1 vector (pFVS0011). A
two-base pair mutation is then introduced in pFVS0011 to obtain
plasmid pFVS0065 (VbhAE24G/VbhT(FIC)). The fic gene of
Neisseria meningitidis was PCR-amplified with an N-terminal
His6-tag from Neisseria meningitidis from coding region of amino
acid residues 11–191 to generate plasmid expressing NmFic
(pFVS0015). The E186G mutant construct (NmFicE186G,
pFVS0059) was generated by introducing a two-base pair
mutation in pFVS0015. The fic gene of Shewanella oneidensis was
PCR-amplified from plasmid (ASU biodesign institute, Clone ID
SoCD00104192) and cloned with an N-terminal His6-tag into
pRSF-Duet1 (pFVS0040). The SoFicE73G plasmid (pFVS0058)
was generated by introducing a two-base pair point mutation in
pFVS0040.
Protein Expression and Purification
Vectors pAG0077 (VbhA/VbhT(FIC)), pFVS0040 (SoFic) and
pFVS0015 (NmFic) were transformed into E.coli BL21 (DE3). E.
coli cultures were grown at 37uC in LB medium supplemented with
50 mg/ml of kanamycin to an OD595 of 0.6 before induction with
0.3 mM IPTG for 16 h at 23uC. Vectors pFVS0065 (VbhAE24G/
VbhT(FIC)), pFVS0059 (NmFicE186G), pFVS0058 (SoFicE73G)
were transformed into BL21-AI cells. Cells were incubated in
750 ml LB medium supplemented with 50 mg/ml kanamycin and
1% glucose at 37uC at 200 rpm until an OD595 value of 1.5 was
reached. Bacterial pellets were resuspended in 1 L of Terrific
Broth media containing 50 mg/ml21 kanamycin. Protein expres-
sion was induced at 23uC with 0.1% arabinose and 0.1 mM IPTG
for 23 h at 200 rpm.
Cells containing overexpressed VbhA/VbhT(FIC) and NmFic
were resuspended in lysis buffer containing 20 mM Tris (pH 7.5),
250 mM NaCl, and 25 mM imidazole and disrupted using French
press. Cell debris were pelleted by ultracentrifugation and the
supernatant was applied to a His-Trap column (GE Healthcare).
The proteins were eluted with a gradient of elution buffer
containing 20 mM Tris (pH 7.5), 250 mM NaCl, and 500 mM
imidazole. The proteins were then concentrated and injected on a
Superdex 75 16/60 gel filtration column (GE Healthcare)
equilibrated with 10 mM Tris (pH 7.6) and 100 mM NaCl. The
pure proteins were concentrated to 3.7 mg/ml for VbhA/
VbhT(FIC) and 30 mg/ml for NmFic.
The same purification protocol as described above was used for
VbhAE24G/VbhT(FIC) and NmFicE186G with an additional
intermediate purification step. After affinity purification, the
proteins were adjusted to 20 mM Tris (pH 8.5), 25 mM NaCl,
applied to a Resource-Q anion exchange column (Amersham
Biosciences), and eluted with a linear gradient of 1 M NaCl. Peak
fractions were concentrated and further purified by gel filtration
chromatography. Purified proteins in 10 mM Tris (pH 7.6),
100 mM NaCl were concentrated to 4.1 mg/ml for VbhAE24G/
VbhT(FIC) and 33 mg/ml for NmFicE186G. Cells containing
overexpressed SoFic and SoFicE73G were resuspended in lysis
buffer containing 50 mM HEPES (pH 8.0), 50 mM NaCl, 1 mM
TCEP, 10% glycerol and 10 mM Imidazole and disrupted using
French press. Cell debris were pelleted by ultracentrifugation and
the supernatant was applied to a His-Trap column (GE
Healthcare). The proteins were eluted with a gradient of elution
buffer containing 50 mM HEPES (pH 8.0), 50 mM NaCl, 1 mM
TCEP, 10% glycerol and 300 mM imidazole. The proteins were
then concentrated and injected on a Superdex 75 16/60 gel
filtration column (GE Healthcare) equilibrated with 20 mM
HEPES (pH 8.0), 200 mM NaCl and 1 mM TCEP. The pure
proteins were concentrated to 21.8 mg/ml for SoFic and 12 mg/
ml for SoFicE73G.
Protein Crystallization
For crystallization, the hanging-drop vapor diffusion method
was used with 1 ml protein solution mixed with 1 ml reservoir
solution. The VbhA/VbhT(FIC) and VbhAE24G/VbhT(FIC)
complexes were concentrated to 3.7 mg/ml and 4.1 mg/ml,
respectively, and crystallized at 20uC using a reservoir solution
composed of 15% (w/v) PEG 4000, 0.1 MMES pH 6.5. Whereas,
the wild-type crystal was soaked with 5 mM ATP, and 5 mM
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MgCl2, the mutant was co-crystallized with 10 mM ATP, and
10 mM MgCl2. For data collection, crystals were transferred to
reservoir solutions supplemented with 20% glycerol and flash
frozen in liquid nitrogen. SoFic and SoFicE73G were concentrated
to 21.8 mg/ml and 12 mg/ml, respectively, and co-crystallized
with either 5 mM ATP or 5 mM AMPPNP and supplemented
with 5 mM MgCl2 in a solution composed of 21% (w/v) PEG
3350 and 0.2 M NaF pH 7.1 at 4uC. For data collection, crystals
of the protein-ligand complex were cryoprotected by transfer to a
reservoir solution supplemented with 15% (v/v) PEG 200 and
flash cooled in liquid nitrogen. For crystallization of NmFicE186G
(33 mg/ml), a reservoir solution composed of 4 M potassium
formate, 0.1 M Bis-Tris propane pH 9.0, 2% (w/v) PEG MME
2000 was used. Crystals were soaked with 5 mM AMPPNP and
5 mM MgCl2 and then cryoprotected with 20% glycerol prior
flash-cooling in liquid nitrogen.
Data Collection, Structure Determination, and
Refinement
Diffraction data were collected at the Swiss Light Source at
100 K and processed using XDS [10]. The structures were solved
by molecular replacement using the apo structures of VbhA/
VbhT(FIC) (PDB code 3SHG), SoFic (PDB code 3EQX) or
NmFic (PDB code 2G03) as search models using Phaser [11].
Several rounds of iterative model building and refinement were
performed using Coot [12] and PHENIX [13] or REFMAC5
[14], respectively. 5% of the data were excluded from refinement
and used for cross-validation. The geometry of the final model was
assessed using MolProbity [15] showing .99% of the residues in
the core and allowed regions of the Ramachandran plot. Data
collections and refinement statistics are summarized in Table 1.
The atomic coordinates and structure factors of VbhA/
VbhT(FIC)/ATP, VbhAE24G/VbhT(FIC)/ATP, SoFic/ATP, So-
FicE73G/AMPPNP, and NmFicE186G/AMPPNP have been de-
posited in the Protein Data Bank under accession codes 3ZC7,
3ZCB, 3ZCN, 3ZEC and 3ZLM, respectively. The figures were
generated with Dino (A. Philippsen unpublished, http://www.
dino3d.org).
In vitro Adenylylation Assay
Adenylylation activity of VbhA/VbhT(FIC), SoFic and NmFic
constructs was assessed by incubating 125 ng, 1.25 mg and 2.5 mg
of purified protein, respectively, with 10 mCi a-32P-ATP (Hart-
mann Analytic) in a buffer containing 50 mM Tris pH 8.0,
150 mM NaCl, 0.1 mM EGTA, 15 mM MgCl2, and protease
inhibitor cocktail (Roche). Reactions were incubated for 1 h at
30uC, resolved by SDS–PAGE, and subjected to autoradiography.
Results
Constitutive Inhibition is Relieved by Truncation of the
Inhibitory Glutamate in All Three Fic Classes
For the comparative structure/function study on the inhibitory
mechanism of Fic proteins from the various classes we chose as
representatives the FIC domain of VbhT (residues 1 to 198) from
Bartonella schoenbuchensis in complex with its cognate antitoxin
VbhA (VbhA/VbhT(FIC); class I), Fic protein SO_4266 from
Shewanella oneidensis (SoFic; class II) and Fic protein NMB0255
from Neisseria meningitidis (NmFic; class III).
Auto-adenylylation is a convenient read-out to assess adenylyla-
tion activity of Fic proteins. It does not require the presence of a
physiological protein target that may, in fact, not yet been known
as in the case of SoFic. Autoradiographies of SDS-PAGE gels after
incubation with a-32P-ATP (Fig. 1) show that auto-adenylylation is
virtually absent in the wild-type Fic proteins of all three classes, i.e.
for VbhA/VbhT(FIC), SoFic, and NmFic (see also ref. 8), but is
drastically boosted in the respective E-.G mutants suggesting a
common inhibitory mechanism.
ATP Binds to Wild-type Fic Proteins in Disparate and
Catalytically Incompetent Conformations
Fig. 2 shows the high-resolution structures of VbhA/VbhT(FIC)
(class I) and SoFic (class II), both in complex with ATP. Whereas
VbhA/VbhT(FIC) crystallized isomorphously to the unliganded
wild-type crystals ([8], PDB code 3SHG), SoFic yielded crystals of
monoclinic space group, i.e. distinct to the orthorhombic form of
the apo structure ([16], PDB code 3EQX). In the two structures
the nucleotide is clearly visible, albeit with elevated B-factors
(40 A˚2) in VbhA/VbhT(FIC). Only marginal structural changes
are induced upon substrate binding (rms deviations between the
Ca-positions of apo and complex form of 0.4 A˚ and 0.8 A˚ for
VbhA/VbhT(FIC) and SoFic, respectively).
In both structures the ATP substrate is found at analogous sites
(Fig. 2) with the base filling a pocket formed by a4, a6, and the b-
hairpin flap, the ribose 39-hydroxyl H-bonded to the conserved
glutamate of ainh, and the triphosphate moiety interacting with the
anionic nest formed by the N-terminus of a5. The same binding
mode has been observed for class III NmFic [8]. In all three
structures, also the ribose 29-hydroxyl is forming an H-bond, but
to non-homologous protein side-chains. Similarly, the binding sub-
site for the base is not conserved on the residue level. However, in
each case, hydrophobic residues are contributed by helix a6 and
by the flap. A weak H-bond is formed between the adenine N3
and N133 in VbhT(FIC). A homologous interaction (with N104) is
found in NmFic [8].
Most relevant for catalysis is the orientation of the a-phosphate
that has to be accessible for nucleophilic attack by the target side-
chain hydroxyl group. In VbhA/VbhT(FIC) and SoFic, as in
NmFic [8], the position that is in-line with the scissile Pa-O3a
bond is not accessible for an attacking group (Fig. 2). Such a group
positioned there would severely clash with atoms of the enzyme.
Thus, in Fic proteins of all three classes, catalytically non-
competent orientation of the a-phosphate appears to be the reason
for the lack of adenylylation activity.
Interestingly, while the a-phosphate is locked in a secured
position in each of the structures, it shows distinct orientations
among the three proteins that can be traced back to differences in
the binding mode of the b- and c-phosphates (Fig. 2C). Though
interacting with the same protein groups (anionic nest; histidine,
asparagine, and first arginine of the signature motif), the detailed
H-bonding patterns are different (e.g. the main chain amide of the
second glycine of the motif interacts with the bridging O3b in
VbhA/VbhT(FIC), and with the non-bridging O1b in SoFic).
It seems that during convergent evolution of ainh-mediated
adenylylation inhibition in the different Fic protein classes no strict
constraints for the ATP binding mode were operational apart from
the requirement for a non-competent orientation for the reacting
phosphate.
Truncation of the Inhibitory Glutamate Allows the ATP
Substrate to Bind in a Catalysis Competent Conformation
Relief of Fic protein inhibition was achieved previously by
expression of VbhT without its cognate antitoxin VbhA or by
replacing in NmFic the SxxxE inhibition motif by AxxxA or –
most drastically - by deleting the entire ainh [8]. The conserved
glutamate of ainh, Einh, was identified to be crucial for the
inhibitory effect, since mere truncation of its side-chain (E-.G
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mutation) rendered recombinantly overexpressed Fic proteins of
all three classes toxic to E. coli [8].
In vitro, the mutation has a drastic effect in that auto-
adenylylation is boosted in all three representative Fic proteins
(Fig. 1). This opens the door for studying the action of any active
Fic protein in vivo, even without knowing the physiological stimulus
for inhibition relief.
To reveal the underlying inhibition relief mechanism, crystal
structures of the three mutant proteins in complex with ATP or
AMPPNP were determined to high resolution. Although, in
solution the mutants show auto-adenylylation, no such modifica-
tion is observed in the crystal structures. For NmFicE186G this is
not surprising, since the complex structure has been obtained by
soaking and auto-adenylylation would require partial unfolding of
ainh carrying the modifiable tyrosine (Y183) [8]. The VbhAE24G/
VbhT(FIC) and SoFicE73G complexes were co-crystallized. Since
we do not see adenylylated residues, the extend of modifications
may be either minor, locate to flexible loops or only the
unmodified fraction may have crystallized. Figs. 3A–C show that
in all three cases, the nucleotide is well resolved and, in contrast to
Table 1. Data collection and refinement statistics.
Protein VbhA/VbhT(FIC) VbhAE24G/VbhT(FIC) SoFic SoFicE73G NmFicE186G
Ligand ATP ATP ATP AMPPNP AMPPNP
PDB code 3ZC7 3ZCB 3ZCN 3ZEC 3ZLM
Data collection
Wavelength (A˚) 1.000 0.979 0.979 0.979 1.000
Detector MAR225 CCD PILATUS 2M MAR225 CCD MAR225 CCD PILATUS 2M
Space group C2 C2 P21 P212121 P6422
Cell dimensions
a, b, c (A˚) 106.5, 40.6, 73.7 106.5, 40.3, 73.9 37.8, 164.9, 70.2 71.3, 80.6, 141.8 149.1, 149.1, 76.4
a b c (u) 90.0, 121.6, 90.0 90.0, 121.4, 90.0 90.0, 94.4, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 120.0
Resolution (A˚) 45.422.1 (2.222.1) 45.421.9 (2.121.9) 35.521.7 (1.821.7) 42.722.2 (2.322.2) 49.322.0 (2.122.0)
Rsym or Rmerge (%) 8.5 (33.8) 5.7 (33.4) 4.4 (41.3) 10.5 (52.8) 6.3 (72.7)
CC(1/2) (%) 99.8 (93.6) 99.9 (93.1) 99.9 (87.1) 99.8 (90.3) 100.0 (97.9)
I/s 18.9 (5.7) 14.5 (3.4) 22.9 (3.4) 17.6 (4.5) 31.1 (5.7)
Completeness (%) 99.2 (92.3) 99.2 (97.0) 99.5 (96.7) 100.0 (100.0) 99.9 (100.0)
Multiplicity 5.4 (4.9) 3.6 (3.6) 3.9 (3.4) 7.4 (7.5) 21.4 (22.6)
Refinement
Resolution (A˚) 15.022.10 30.021.94 15.021.70 15.022.20 30.022.00
No. reflections 15,769 (2,342) 18,923 (1,355) 93,100 (2,837) 42,085 (3,956) 32,490 (2,338)
Rwork/Rfree [%] 16.6/23.0 19.4/23.4 16.7/20.2 16.5/21.1 18.2/19.9
Mol./a.u 1 1 2 2 1
No. atoms
Protein 2172 2011 5961 5984 1458
Ligand/ion 1 ATP 1 ATP, 1 MG 2 ATP 2 ANP, 1 MG 1 ANP, 1 MG
Water 226 134 981 695 135
Average B (A˚2)
Protein 22.0 25.0 21.9 20.7 45.9
Ligand/ion 39.7 27.5/11.4 21.9 12.9/28.9 40.1/64.8
Water 28.4 32.1 33.7 28.0 49.3
R.m.s deviations
Bond lengths (A˚) 0.007 0.011 0.008 0.009 0.010
Bond angles (u) 1.0 1.3 1.2 1.2 1.2
Values for the highest resolution shell are shown in brackets.
doi:10.1371/journal.pone.0064901.t001
Figure 1. AMP transfer catalyzed by Fic proteins and their
inhibition-relieved variants. Autoradiography of VbhA/VbhT(FIC),
SoFic and NmFic (wt, wild type; E/G, E-.G mutant) after incubation with
radioactively labeled a-32P-ATP.
doi:10.1371/journal.pone.0064901.g001
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Figure 2. Crystal structures of wild-type Fic proteins representing classes I to II in complex with ATP substrate. (A) VbhA/VbhT(FIC), (B)
SoFic. Structures are shown in cartoon representation (red, FIC core as defined by PFAM; yellow, active site loop and N-terminal end of helix a5; dark-
green, inhibitory helix ainh). In (A), the fold of the antitoxin is shown in dark-green and steel-blue. Selected residues are shown in full with the
inhibitory glutamate (E24 or E73, respectively) colored in dark. The 2Fo-Fc simulated annealing omit maps covering the ligand are contoured at 1.1 s.
In both structures, the orientation of the a-phosphate prevents nucleophilic attack of a putative target side-chain hydroxyl onto the ATP substrate,
since the position inline with the scissile Pa-O3a bond (magenta star) is unattainable. C) Stereo view of the superposition of the ATP nucleotides
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the wild-type complexes, shows a unique conformation and
relative position within the binding site (Fig. 3D).
While the base and ribose moieties interact with the mutant in
the same way as with the wild-type proteins (compare with Fig. 2,
see also Fig. 3a in [8] for NmFic), the triphosphate has adopted a
strongly curved conformation with the terminal c-phosphate
approaching closely the ribose moiety and forming a tight salt-
bridge with the second arginine of the FIC motif (R(2): R147,
R209, or R118, respectively).
The position and orientation of the triphosphate is defined by a
multitude of specific interactions (Fig. 3A–C). In all structures, the
a- and b-phosphate moieties form four H-bonds with the four
exposed backbone amide groups of the compound anion binding
nest [17] at the N-terminal end of helix a5. In addition, the first
arginine of the signature motif (R(1): R144, R206, or R115,
respectively) forms a salt-bridge with the b-phosphate involving
two H-bonds and the asparagine of the motif (N142, N204, or
N113, respectively) interacts with a non-bridging oxygen of the a-
phosphate.
In all the structures, a magnesium ion is present albeit with high
B-factor for NmFicE186G (63 A˚
2). The metal bridges the a- and b-
phosphate and is coordinated in addition by the conserved D/E
residue of the Fic signature motif in VbhAE24G/VbhT(FIC) and
SoFicE73G (E140, D202, respectively). It is particularly well
resolved in the former structure where three well-defined water
molecules complete its octahedral coordination shell (Fig. 3A).
Interestingly, the divalent cation is observed only in the
adenylylation competent complexes, but not in the wild-type
complexes. Indeed, magnesium is indispensable for Fic mediated
ATase activity (data not shown) and is probably important for fine-
tuning of the a- and b-phosphate orientation within the compound
anion binding nest and for stabilization of the transition state.
Overall, the three structures display a unique mode of ATP
binding that can be attained only in the mutants, since the c-
phosphate effectively adopts the position that is taken by the
inhibitory glutamate in the wild-type proteins (Fig. 4). Most
relevantly, the reorganization of the triphosphate in the binding
site results in a a-phosphate orientation that is now prone for in-
line attack by an incoming target side-chain (Fig. 3D). Clearly, the
conservation of this binding mode across the FIC classes shows
that it is essential for FIC function.
shown in panel A and B with AMPPNP from the complex structure of the class III NmFic protein (PDB 3S6A [8]) within the active site of the VbhA/
VbhT(FIC) complex (same as in panel A). The nucleotides of the various complexes are distinguished by their colors (white for the ATP bound to
VbhA/VbhT(FIC), green for the ATP bound to SoFic, and blue for the AMPPNP of the NmFic complex. Note that the AMPPNP c-phosphate in NmFic is
found disordered [8] and therefore not shown. The residues of the HxFx(D/E)GNGRxxR Fic signature motif are labeled, the two glycine and the two
arginine residues are distinguished by a "1" or "2" in brackets. The phenylalanine (not shown) is part of the hydrophobic core. The inhibitory
glutamate from ainh is labeled as Einh.
doi:10.1371/journal.pone.0064901.g002
Figure 3. Crystal structures of E-.Gmutated Fic proteins representing classes I to III in complex with substrate or substrate analog.
A, VbhAE24G/VbhT(FIC) in complex with ATP/Mg
2+; B, SoFicE73G, C, NmFicE186G, both in complex with AMPPNP/Mg
2+. Representation as in Fig. 2 with
magnesium ions shown as magenta spheres. The 2Fo-Fc simulated annealing omit maps covering the nucleotide/Mg2+ ligands are contoured at 1.1
s. D, Stereo view of the superposition of the ligand structures shown in panels B and C onto the VbhAE24G/VbhT(FIC) complex (same as in panel A).
Note that the nucleotides of the various complexes are distinguished by their carbon color (VbhAE24G/VbhT(FIC) ATP in green, SoFicE73G AMPPNP in
orange and NmFicE186G AMPPNP in pink). The residues of the HxFx(D/E)GNGRxxR signature motif are labeled as in Fig. 2C with the phenylalanine not
shown. Also shown is the modifiable hydroxyl side-chain Y32 of Cdc42 (blue) after superposition of the IbpA(FIC2)/Cdc42 complex [4] onto VbhAE24G/
VbhT(FIC). For the superposition, only the Fic active site loops were used. The a-phosphate moieties appear well-suited for in-line attack of the target
hydroxyl group (broken line in magenta).
doi:10.1371/journal.pone.0064901.g003
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Target Registration to the FIC Active Site
The conservation of the FIC active site and the ATP substrate
binding mode prompts for a precise alignment of the incoming
side-chain hydroxyl with the scissile Pa-O3a bond. The beta-
hairpin flap partly covering the active site appears to represent a
"target dock" that ensures this precise positioning of the target
backbone stretch immediately following the modifiable hydroxyl
side-chain and thus registers the side-chain to the active site as has
been proposed before (2). This was deduced mainly from the only
known Fic protein/target complex structure IbpA(FIC)/Cdc42 [4]
where the AMPylated Y32 of Cdc42 is part of a segment (switch 1
loop) in extended conformation and complements inter-molecu-
larly the b-hairpin of the flap (Fig. 5A).
This notion is further corroborated by the structure of the wild-
type VbhA/VbhT(FIC) complex presented here that revealed
additional density close to the flap above the active site (Fig. 5B).
This was interpreted as a four residue peptide in extended
conformation that is associated antiparallely to the edge of the
two-stranded b-hairpin of the flap via three main chain-main
chain H-bonds. Location and side-chain densities are consistent
with the peptide representing residues 203 to 206 of a symmetry
mate (note that the ordered part of the VbhT(FIC) construct ends
with residue F197). Very similarly, peptide density is present at an
equivalent location in the A-chain of SoFicE73G and could be
attributed to the N-terminus (residues 0 to 3) of a symmetry related
B-chain as also reported for the isomorphous crystal structure of
wild-type SoFic (Fig. 5C) [16].
Figure 4. Comparison of triphosphate nucleotide structures as bound to wild-type and E-.Gmutated Fic proteins from class I to III.
Stereo views of the ligand structures after superposition of the FIC domains (not shown). Also shown is the inhibitory glutamate of the wild-type
structures. A, ATP as bound to VbhA/VbhT wild-type (white) and the E24G mutant (dark green). B, ATP and AMPPNP as bound to SoFic wild-type
(green) and the E73G mutant (orange), respectively. C, AMPPNP as bound to NmFic (blue) and the E186G mutant (pink). Note that the AMPPNP c-
phosphate in NmFic is found disordered [8] and therefore not shown.
doi:10.1371/journal.pone.0064901.g004
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Comparison of Figures 5A–C suggests that a tyrosine instead of
the valine in position 203 of the symmetry related VbhT(FIC)
chain or of the tryptophan in position 3 of the symmetry related
SoFic chain would indeed be well poised to attack the ATP a-
phosphate. Furthermore, it has been shown for IbpA that the side-
chains of the target dock residues Leu3668 and Lys3670 form a
hydrophobic clamp that fix the target tyrosine side-chain (Fig. 5C)
[4]. Side-chains of residues I83 and K85 in VbhT(FIC) and
residues T143 and L145 in SoFic, that hold the valine and
tryptophan, respectively, may in a similar way clamp down the
modifiable side-chain (Fig. 5A–B). Taken together, these observa-
tions show that the flap has propensity for peptide binding as it is
well known for exposed beta-sheet edges in other proteins
[18,19,20] and ensures productive alignment of the target
hydroxyl side-chain with the bound ATP substrate.
Probably, sequence independent positioning of the backbone
flanking the modifiable target residue confers an evolutionary
advantage. While exposed loops in extended conformation of
many proteins may easily dock to the flap, other parts of the
enzyme would confer target affinity and specificity (as seen in the
IbpA(FIC)/Cdc42 complex [4]) that were free to adopt during
evolution without compromising on the catalytic mechanism.
Notably, peptide registration to the active site via main-chain
interactions is known also for serine proteases [21] and protein
kinases [22,23].
Discussion
The vast majority of Fic proteins are characterized by a
conserved HxF[D/E]GNGRxxR active site motif and catalyses
adenylylation, an enzymatic activity that involves nucleophilic
attack of a target hydroxyl group onto the a-phosphate of ATP.
Productive AMP transfer therefore relies on the proper juxtapo-
sition of the reaction partners. The inhibition-relieved (E-.G)
mutant structures of Fic proteins from the three distinct classes
shed light on the importance of the active site [D/E]GNGRxxR
residues to enable catalytically competent ATP substrate binding.
Indeed, in the three classes, these residues, by way of a large
hydrogen-bonding network, enable a unique mode of ATP
binding to orientate favorably the a-phosphate relative to the
target side-chain hydroxyl group (Fig. 3). The latter is registered to
the FIC active site in-line with the scissile Pa-O3a bond via
sequence-independent main chain-main chain interactions with
the target dock at the edge of the FIC flap (Fig. 5). Thus, the FIC
active site and the target dock are two indivisible structural
elements that have been exposed to high functional constraints to
ensure productive catalysis. Fic proteins with degenerated active
site signature motifs and/or devoid of a flap-like structure are
likely to have adopted new functions.
In Fic proteins of the three inhibition classes, the inhibitory
glutamate plays the same role. It out-competes the c-phosphate for
binding to arginine R(2) of the FIC signature motif (Fig. 4). This
results in an a-phosphate orientation that does not permit an
attack of the incoming target side-chain hydroxyl group.
Interestingly, though the active sites are structurally well
conserved, the nucleotide triphosphates show variation in their
binding to the Fic proteins of the three classes (Fig. 2). This is in
contrast to the uniform binding mode found in the inhibition
relieved mutants (Fig. 3) and shows that the mode of ATP binding
to the inhibited enzyme per se was not under evolutionary
constraints.
Knowledge of the universal catalytic and inhibitory mechanism
of Fic mediated AMP transfer will now pave the way for further
studies towards the physiological roles of Fic proteins and
particularly the identification of their protein targets. It may also
prompt rational structure based design of small molecule inhibitors
targeting the ATP binding pocket or novel peptides that mimic the
inhibitory helix to neutralize bacterial virulence factors which kill
their host via uncontrolled Fic-mediated adenylylation activity.
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Figure 5. Sequence independent registration of peptide or target protein to the FIC flap. The bound peptide/protein segment (blue) and
the target dock (brown) are shown in full. Main chain-main chain H-bonds are depicted as stippled lines. A, Product complex of IbpA(Fic2) with Cdc42
target [4]. Tyrosine 32 from the switch1 region of Cdc42 is adenylylated. B, VbhA/VbhT(FIC) complexed with residues 203 to 206 of a symmetry
related molecule. The 2Fo-Fc simulated annealing omit map covering the residues 203 to 206 is contoured at 1.1 s. Note that the preceding 7
residues are disordered and not shown. C, SoFic complexed with residues 0 to 4 of a symmetry related molecule (PDB 3EQX) [16]. The side-chains of
residues 0, 1 and 4 are disordered and not displayed for clarity reason. Note that Y32 in panel A, V203 in panel B and W3 in panel C are in equivalent
positions.
doi:10.1371/journal.pone.0064901.g005
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Summary 
Research on the large family of Fic proteins containing a FIC (filamentation induced by 
cAMP) domain has primarily studied scattered representatives that had secondarily evolved 
into host-targeted virulence factors of bacterial pathogens. However, most Fic proteins are 
genuine bacterial proteins whose functions have remained unknown. Here we uncover one 
major group of bacterial Fic proteins as toxins of a conserved toxin-antitoxin gene family that 
act via the adenylylation of DNA gyrase and topoisomerase IV (topo IV), the two bacterial 
type IIA topoisomerases. Adenylylation inactivates both targets in vitro. In vivo, Fic toxins 
robustly disable topo IV, resulting in DNA catenation and knotting, while the level of gyrase 
inhibition causing DNA relaxation differs among diverse representatives. Subversion of DNA 
topology by Fic toxins causes a reversible growth arrest and promotes the formation of 
multidrug-tolerant persister cells. The activation of a Fic toxin-antitoxin system in vivo was 
found to depend on protease Lon. 
 
Highlights 
- One group of ubiquitous FIC domain proteins form a conserved toxin-antitoxin family 
- Fic toxins inhibit DNA gyrase and topoisomerase IV activities via adenylylation 
- Target inhibition distorts cellular DNA topology causing reversible growth arrest 
- Fic toxins induce a phenotypic switch to the multidrug-tolerant persister state 
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Introduction 
Fic proteins containing a FIC (filamentation induced by cAMP) domain are found in all 
kingdoms of life and typically catalyze adenylylation (also known as AMPylation), the 
covalent transfer of an adenosine-5’ monophosphate (AMP) moiety onto target proteins 
(Engel et al., 2012; Kinch et al., 2009). They are particularly abundant in prokaryotes with 
around 20’000 representatives (InterPro domain IPR003812), indicating that Fic proteins are 
pervasive, yet understudied players in the physiology of diverse microbes. Previous research 
on Fic proteins focused on a few scattered representatives that had secondarily evolved into 
host-targeted virulence factors and that in part displayed peculiar biochemical activities such 
as phosphocholination or uridylylation (Feng et al., 2012; Mukherjee et al., 2011; Yarbrough 
et al., 2009). 
We recently showed that the prevalent adenylylation activity of Fic proteins is controlled 
by a conserved inhibitory α-helix that binds into the FIC domain active site and forces the 
ATP substrate to bind in an adenylylation-incompetent state (Engel et al., 2012). Fic proteins 
could be grouped into three major classes (I-III) based on the positioning of this α-helix 
relative to the FIC domain core, and the release of that inhibition always resulted in bacterial 
growth arrest (Goepfert et al., 2013b). These results were reminiscent of the enigmatic 
“filamentation induced by cAMP” phenotype caused by a mutant of the prototypic 
Escherichia coli Fic protein that gave the name to the domain family (Utsumi et al., 1982). 
Fic of E. coli belongs to class I of Fic proteins which is defined as having their inhibitory 
α-helix in a separate small protein that is typically encoded upstream of the fic gene with 
slight overlap (Engel et al., 2012). This genetic arrangement and the inhibition of toxic class I 
Fic proteins via binding to a separate “anti-toxin” are hallmarks of type II toxin-antitoxin 
modules (TA modules) (Gerdes and Maisonneuve, 2012; Goepfert et al., 2013a). Type II TA 
modules comprise a toxin that blocks cell growth and an antitoxin protein that controls toxin 
activity by tight binding until it is degraded in response to nutritional and environmental 
stresses (Brzozowska and Zielenkiewicz, 2013). Bacterial chromosomes encode multitudes of 
type II TA modules (Pandey and Gerdes, 2005) that have been proposed to exert many 
different functions including post-segregational killing, bacteriophage defense, and 
programmed cell death (Magnuson, 2007; Van Melderen, 2010). The only known common 
function of TA systems is that of bacterial persistence (multidrug tolerance) (Gerdes and 
Maisonneuve, 2012; Schuster and Bertram, 2013). We recently described the TA-like 
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appearance of class I Fic proteins and introduced a new nomenclature terming the FIC domain 
toxins FicT (previously Fic; e.g., EcFicT for Fic of E. coli) and the antitoxins FicA 
(previously YhfG) (Goepfert et al., 2013a). Interestingly, the Doc toxin of the Doc-Phd toxin-
antitoxin system of bacteriophage P1 was recently shown to be a kinase that inhibits bacterial 
growth via the phosphorylation of EF-Tu (Castro-Roa et al., 2013). Doc represents a remote, 
deeply branching clade of Fic proteins that is believed to derive from canonical, adenylylating 
Fic proteins via inversion of the nucleotide substrate binding site and appearance of a novel 
antitoxin, Phd, that inhibits Doc by blocking substrate binding (Castro-Roa et al., 2013; Engel 
et al., 2012; Garcia-Pino et al., 2008). Their evolutionary connection to Doc and their 
toxin/antitoxin-like features suggested that also the original, primordial class I Fic proteins 
form a type II TA system that acts via the adenylylation of targets within bacteria (Goepfert et 
al., 2013a). However, the molecular function and biological role of the ubiquitous, yet 
enigmatic FicTA modules remained elusive. 
Here we characterize FicTA modules as a toxin-antitoxin system that targets DNA gyrase 
and topoisomerase IV via adenylylation of an invariant tyrosine at their ATP binding site. 
Adenylylation fully inhibits both targets in vitro and reversibly arrests bacterial growth. Using 
a wide range of different techniques we show that Fic toxin expression results in strong DNA 
knotting and catenation combined with a varying degree of DNA relaxation in E. coli, 
indicating that Fic toxins can inactivate both targets in vivo. Remarkably, we find that the 
impairment of cellular physiology due to Fic toxin activity converts bacteria into multidrug-
tolerant persister cells. Moreover, we show that activation of a FicTA system in vivo depends 
on protease Lon. 
 
Results 
Ectopic expression of Fic toxins results in a reversible inhibition of bacterial growth that 
depends on adenylylation 
We previously established the VbhTA system of Bartonella schoenbuchensis as a model 
for class I Fic proteins and demonstrated that the antitoxin VbhA inhibits the adenylylation 
activity of the VbhT toxin as well as the associated growth inhibition in Escherichia coli 
(Engel et al., 2012). Since VbhT is unique among class I Fic proteins in that it harbors a 
C-terminal type IV secretion signal (called BID domain), we decided to investigate the 
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molecular and biological functions of VbhT along with a more typical representative of class I, 
i.e., the YeFicTA system of Yersinia enterocolitica str. 8081 (see Extended Results in the 
Supplemental Information). For comparison, we also included the PaFicTA system of 
Pseudomonas aeruginosa PAO1, a very distant homolog. 
We observed strong inhibition of E. coli growth upon expression of VbhT or YeFicT from 
a single-copy vector in the absence of their VbhA or YeFicA antitoxins, respectively (Figures 
1A and 1B). This effect was dose-dependent (Figure 1C) and required the Fic toxins’ 
adenylylation activity because mutation of the catalytic histidine within the FIC domain 
signature motif HXFX(D/E)GNGRXXR into alanine (“H/A” mutants) abolished Fic toxicity 
(Figure 1A). Subsequent expression of the cognate antitoxins reversed the growth inhibition 
(Figure 1D), demonstrating that Fic toxin activity leads to a classical bacteriostatic condition 
that is a common feature of many TA systems (Pedersen et al., 2002). We note that the 
ectopic expression of VbhT appears to be less potent in growth inhibition than that of YeFicT 
or the FIC domain of VbhT alone (VbhT(fic); Figures 1B and 1C), possibly due to differential 
expression of the constructs or because the BID domain of VbhT sterically reduces toxin 
activity. 
Fic toxins adenylylate GyrB and ParE of different bacteria 
To unravel the molecular mechanism of the reversible growth inhibition caused by the Fic 
toxins’ adenylylation activity we next aimed at uncovering the identity of the adenylylated 
target(s). For this purpose we performed in vitro adenylylation assays with lysates of E. coli 
that had expressed VbhT and used a pull-down approach similar to the one published by 
Grammel et al. (2011) for target identification. Though we failed to achieve significant 
enrichment of potential targets, we serendipitously discovered an adenylylated peptide that 
belonged to GyrB of E. coli (data not shown). The theoretical molecular weight of GyrB 
(89.95 kDa) fits well with the apparent molecular weight of the bona fide endogenous target 
adenylylation detected by autoradiography in adenylylation assays with VbhT (Figure 2A and 
our previous work (Engel et al., 2012)) which we calculated to be approximately 90 kDa 
using the ImageQuant software (Molecular Dynamics). Ectopic expression of GyrB both of E. 
coli or B. schoenbuchensis unambiguously showed that this protein is adenylylated by VbhT 
in bacterial lysates in vitro (Figure 2A). Given the very high similarity in sequence, structure, 
and function to GyrB (Bellon et al., 2004) we further suspected that its paralog ParE may also 
be targeted by VbhT. Indeed, like for GyrB, ectopic expression of ParE of E. coli and 
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B. schoenbuchensis clearly demonstrated adenylylation by VbhT (Figure 2A). However, 
unlike for GyrB, no adenylylation of endogenous ParE is detectable by visual inspection of 
autoradiographs of our adenylylation experiments with cleared lysates of E. coli expressing 
VbhT (Figure 2A). We believe that this discrepancy is caused by differential target abundance 
with each cell of E. coli containing approximately 10 times more molecules of GyrB than of 
ParE (Alexander Schmidt, personal communication). 
GyrB and ParE are the B subunits of the two bacterial type IIA topoisomerases DNA 
gyrase and topoisomerase IV (topo IV) which control cellular DNA topology by maintaining 
negative supercoiling respectively removing DNA catenation and knotting. Therefore, they 
are essential for all cellular activities involving the processing of closed circular DNA like 
bacterial chromosomes (Sissi and Palumbo, 2010). Due to their vital role for bacterial 
physiology the type IIA topoisomerases are the target of several groups of antimicrobials, 
bacteriocins, as well as the CcdBA and ParDE type II TA systems (Sissi and Palumbo, 2010). 
These toxins, the bacteriocins, as well as quinolone-based antimicrobials are poisons that 
prevent resealing of the DNA cleavage inherent to type II topoisomerase activity and 
ultimately result in cell death (Chen et al., 1996; Deghorain et al., 2013; Heddle et al., 2001). 
In contrast, aminocoumarin drugs like novobiocin merely inactivate the enzymes by blocking 
their ATP binding which abrogates the cellular control of DNA topology but does not directly 
trigger cell death (Hardy and Cozzarelli, 2003).  
Adenylylation at the ATP binding site inhibits DNA gyrase and topo IV in vitro  
Using mass spectrometry, we identified the adenylylation sites on GyrB and ParE of 
E. coli to be homologous tyrosines 109 and 105, respectively (Figure S2). This residue is 
involved in ATP binding as part of the “ATP lid” and highly conserved among type IIA 
topoisomerase B subunits (Brino et al., 2000; Wigley et al., 1991). Since their functionality 
generally depends on concurrent ATP hydrolysis (Bates et al., 2011), we hypothesized that 
adenylylation may inactivate DNA gyrase and topo IV by interfering with the ATPase cycle, 
which could explain the marked growth arrest upon Fic toxin expression. We therefore 
assayed the hydrolysis of ATP by a GyrB ATPase model construct (Ali et al., 1993) and 
found that adenylylation indeed completely blocked the target’s ATPase activity (Figure 2B). 
Subsequently, we used recombinant DNA gyrase and topo IV to assess the effect of 
adenylylation on the signature activities of both targets on suitable DNA substrates in vitro. 
As expected, adenylylation prevented supercoiling of a relaxed reporter plasmid by DNA 
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gyrase and decatenation of kDNA, a meshwork of catenated DNA rings, by topo IV (Figure 
2C). Interestingly, the slow kinetics of ATP hydrolysis inhibition upon addition of VbhT to 
GyrB (apparent in Figure 2B) and the requirement to pre-incubate VbhT and gyrase or topo 
IV prior to addition of their respective DNA substrates in order to achieve full inhibition 
(Figure 2C) suggest that Fic toxins may be slow enzymes at least in vitro. 
Fic toxins achieve only partial inhibition of DNA gyrase in vivo 
We then investigated whether Fic toxins also inactivate DNA gyrase and topo IV in vivo. 
Any inhibition of DNA gyrase would decrease the negative supercoiling of cellular DNA. We 
therefore used plasmid pAH160, a high-copy number vector originally designed for 
rhamnose-inducible protein expression, isolated from E. coli expressing Fic toxins to directly 
visualize changes in DNA topology via high-resolution agarose gel electrophoresis with 
chloroquine to resolve negative supercoiling (see Experimental Procedures). As expected, the 
treatment of E. coli with a high concentration of novobiocin that completely inactivates DNA 
gyrase resulted in collapse of the negative supercoiling (Figure 3A). However, a dose of Fic 
toxin expression that impaired bacterial growth (two hours of full induction; see Figure 1B) 
caused only a slight stretch of the topoisomer distribution towards DNA relaxation. This 
result was not consistent with a strong inhibition of DNA gyrase by Fic toxins in vivo and 
therefore seemed to contradict our in vitro results. However, we suspected that the transient 
nature of local DNA relaxation for the single topological domain of our simple reporter 
plasmid may have masked more prominent effects of a potential partial inhibition of DNA 
gyrase by VbhT and YeFicT. We therefore used another reporter plasmid encoding a 
relaxation-induced PgyrB::gfpmut2 GFP promoter fusion to record any DNA gyrase 
inhibition inside single cells by flow cytometry. For validation, we confirmed that E. coli 
harboring this plasmid showed dose-dependent induction of GFP fluorescence upon inhibition 
of DNA gyrase with different concentrations of novobiocin (Figure 3B). In this system the 
expression of VbhT or YeFicT resulted in a rather weak, but detectable induction of GFP 
fluorescence, while VbhT(fic) elicited a stronger response (Figure 3B). However, Rovinskiy, 
Agbleke et al. (2012) convincingly argued that plasmid-based assays may generally 
underestimate the physiological effects of an incomplete DNA gyrase inhibition. We therefore 
constructed a chromosomal PgyrB::gfpmut2 reporter and measured the effect of Fic toxin 
expression on the supercoiling of the nucleoid. Like with the plasmid-based assay (Figure 3B), 
the treatment with different concentrations of novobiocin caused a dose-dependent induction 
of GFP fluorescence, while Fic toxin expression only resulted in weak (VbhT and YeFicT) or 
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moderate (VbhT(fic)) DNA relaxation (Figure 3C). These findings mirror our results from 
high resolution agarose gel electrophoresis and thus indicate that VbhT and YeFicT are 
unlikely to achieve levels of DNA gyrase inhibition in vivo that would greatly contribute to 
growth inhibition. The more prominent effect with the VbhT(fic) construct may be due to 
differences in expression or reflect an evolution of the VbhT FIC domain to stronger activity 
in order to partially compensate for the hindrance by its BID domain. Despite that, VbhT(fic) 
is not a more potent toxin than YeFicT (Figure 1B and 1C), suggesting that DNA gyrase 
inhibition is no necessary driving force of Fic toxicity.  
Robust inhibition of topo IV by Fic toxins in vivo 
The inactivation of topo IV is known to result in DNA knotting and catenation which 
induce a classical phenotype called par hallmarked by cell filamentation and the sequestration 
of unsegregated DNA at the cell center (Kato et al., 1990). We therefore used fluorescence 
microscopy to study cell shape and DNA partitioning in E. coli expressing Fic toxins 
(Figure 4A). As expected from our biochemical data, the expression of YeFicT, VbhT, or 
VbhT(fic) greatly inhibited DNA segregation and bacterial cell division, resulting in a strong 
par phenotype (Figure 4A and 4B). Interestingly, the nucleoids in cells expressing VbhT(fic) 
and YeFicT – but not VbhT – are highly condensed which may indicate super-condensation 
as a stress response (Meyer and Grainger, 2013). As an independent readout for topo IV 
inhibition in vivo we re-analyzed the pAH160 samples that had been used for the detection of 
DNA relaxation by high resolution agarose gel electrophoresis (see Figure 3A). After nicking 
to remove all supercoiling the samples were run on plain agarose gels to resolve DNA 
knotting and catenation. Plasmid isolated from E. coli that had expressed any of the Fic toxin 
constructs showed detectable DNA knots and a clear ladder of catenanes with various node 
numbers evidencing robust topo IV inhibition (Figure 4C and 4D). The seemingly weak 
extent of all DNA knotting with pAH160 is likely an artifact of the small size of this reporter 
plasmid (4359 bp) and still evidences considerable knotting of the nucleoid, since the 
topological entanglement and size of chromosomal DNA greatly favor knotting and 
complicate unknotting compared to small plasmids (Witz et al., 2011). We therefore conclude 
that the growth inhibition upon VbhT and YeFicT expression is primarily caused by the 
inhibition of topo IV via consequent distortions of DNA topology.  
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Bacterial genetics confirm that Fic toxin expression impairs DNA segregation and 
replication fork movement 
It is intuitive that the catenanes formed upon Fic toxicity would impair DNA segregation 
and cell division. Consistently, we find that the inactivation of topoisomerase III or XerCD 
recombination which can both partially complement a topo IV deficiency in DNA segregation 
makes E. coli hypersensitive to Fic toxicity (Figure 5A). Moreover, others have shown that 
the inactivation of topo IV results in an inhibition of DNA replication and transcription via 
DNA knotting as well as an impaired topological control of replication forks that is 
aggravated in different ways by DNA gyrase inhibition (Deibler et al., 2007; Khodursky et al., 
2000; Lopez et al., 2012; Witz et al., 2011; Witz and Stasiak, 2010). DNA knots continuously 
arise in the tangled nucleoid from random strand passages that occur whenever cellular DNA 
handling cuts open the chromosome, e.g., during processes of replication, recombination, or 
repair, and they cannot be removed in the absence of functional topo IV (Deibler et al., 2001). 
We therefore expected that the viability of bacteria expressing Fic toxins should depend on 
replication fork repair and restart via fork reversal and various recombination pathways. 
Indeed, we found that E. coli deficient in the recABCD or ruvABC machineries were 
hypersensitive to Fic toxicity (Figure 5A). Importantly, the same genes are also involved in a 
number of different DNA repair pathways on top of recombinational fork repair, e.g., the 
processing of double-strand breaks. We therefore verified that the single inactivation of recA 
(which is essential for double-strand break repair (Wigley, 2013)) does not abolish the 
reversibility of Fic toxicity in our experimental system (Figure 5B). However, the dual 
inactivation of exonuclease V and homologous recombination which represent the two 
branches of replication fork restart after fork reversal results in detectable lethality upon Fic 
toxin expression (recB as well as recDA mutant in Figure 5B). We therefore conclude that 
frequent replication fork arrest impairs chromosome replication during Fic toxicity (De 
Septenville et al., 2012). Fork arrest is a main trigger of the SOS response, a cascade of genes 
whose expression is induced upon DNA damage (Erill et al., 2007). We indeed detected an 
activation of the SOS response upon Fic toxin expression, but these effects were clearly 
distinct from the strong activation observed with gyrase poisons like ciprofloxacin or the 
CcdB toxin (Figure 5C). Though most factors encoded by SOS genes are more or less directly 
involved in DNA repair, the SulA protein expressed in response to severe DNA damage 
directly blocks cell division via the inhibition of septation (Huisman et al., 1984), thus buying 
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overtime for DNA repair functions. Irreversible blocks of cell division via SOS activation and 
SulA were proposed to be involved in a number of toxicity phenomena like thymineless death 
(Fonville et al., 2010). Similarly, we find that – under the relatively low level of Fic toxicity 
that we used – the inability to launch the SOS response (in a lexA3 mutant) or the inactivation 
of sulA made the bacteria considerably more tolerant to Fic toxin expression than the control 
strain (Figure 5A). However, the contribution of the SOS response to growth inhibition is 
only minor at the higher levels of Fic toxicity that we generally used for phenotypic 
characterization (Figure S3A and S3B), suggesting that SulA-mediated growth inhibition is 
no necessary component of Fic toxicity. 
A distant homolog shows the same activities and phenotypes as YeFicT and VbhT 
To confirm DNA gyrase and topo IV inhibition as the general mechanism of class I Fic 
toxins we finally compared the results obtained with VbhT and YeFicT to those with PaFicT 
of Pseudomonas aeruginosa PAO1, a very distant homolog (see Extended Results). As 
expected, PaFicT expression in E. coli results in bacterial growth inhibition which requires 
the native FIC domain active site and is inhibited by the cognate PaFicA antitoxin (Figure 6A 
and Figure 6B). The expression of PaFicT induces a par phenotype (Figure 6C) and results in 
considerable DNA gyrase inhibition that is even stronger than the one achieved with 
VbhT(fic) (Figure 6D and Figure 6E). Like novobiocin, PaFicT induces strong DNA knotting 
but no catenation, suggesting that the expression of this toxin causes a strong inhibition of 
both type IIA topoisomerases and thereby immediately stops DNA replication (Figure 6F) 
(Khodursky et al., 2000). In conclusion, our results show that diverse Fic toxins target DNA 
gyrase and topo IV to inhibit bacterial growth. While VbhT, YeFicT, and PaFicT all appear to 
achieve a strong inhibition of topo IV upon expression in E. coli, the extent of DNA gyrase 
inhibition varied for the different toxins. 
Fic toxins induce persister formation in Escherichia coli 
Given that TA system activation is the main path for the generation of persisters, i.e., 
bacterial cells exhibiting multidrug tolerance, we wondered whether Fic toxins could have a 
biological role in this context (Gerdes and Maisonneuve, 2012). We therefore expressed 
VbhT and YeFicT in E. coli and subsequently challenged the bacteria with either of three 
antibiotics (ciprofloxacin, kanamycin, or ampicillin) that kill via entirely different 
mechanisms. Remarkably, while the antibiotic treatment eliminated all but 1 in 10’000 of the 
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cells in the vector control, 10% of the bacteria expressing Fic toxins survived for any drug 
(Figure 7A). Under physiological conditions toxin activity is generally unleashed via 
protease-mediated antitoxin degradation in response to certain triggers or stochastically in a 
subpopulation of cells (Brzozowska and Zielenkiewicz, 2013; Maisonneuve et al., 2013). We 
therefore asked whether any of the proteolytic systems in E. coli could activate Fic toxins in 
vivo to inhibit bacterial growth. Interestingly, lac-driven ectopic expression of the yeficAT 
module resulted in detectable growth inhibition, suggesting that one or more of the resident 
proteases in E. coli degrade part of the YeFicA pool inside the cells (Figure 7B). After the 
biochemical investigation of YeFicA degradation by E. coli proteases was not conclusive 
(data not shown), we tested E. coli mutants that are deficient in ClpP, HslV, or Lon protease 
activities and found that the growth inhibition upon yeficAT overexpression was fully 
dependent on Lon. Consistently, a targeted activation of Lon via the stringent response with 
DL-serine hydroxamate aggravated the growth defect in clpP and hslV mutants as well as the 
control strain, while the lon mutant was unaffected (Figure 7B). It is well established that Lon 
controls the majority of bacterial TA systems and recent work demonstrated that it is itself 
stochastically activated in part of the population to drive persister formation via TA system 
activation (Brzozowska and Zielenkiewicz, 2013; Maisonneuve et al., 2013). We therefore 
conclude that YeFicTA and its homologs are a classical type II TA system that acts via a 
novel mechanism, the inactivation of type IIA topoisomerases via adenylylation of their B 
subunits. 
 
Discussion 
In this study we characterized diverse representatives of class I Fic proteins and showed 
that they act as toxins of FicTA toxin-antitoxin modules. We determined the conserved 
molecular mechanism by which class I Fic toxins disable bacterial physiology as the 
adenylylation and concomitant inactivation of DNA gyrase and topo IV which are 
individually essential for bacterial growth. VbhT, YeFicT, and PaFicT all caused a robust 
inhibition of topo IV upon expression in E. coli, but the extent of DNA gyrase inhibition 
differed, possibly reflecting divergent histories of host adaptation. Though a robust inhibition 
of topo IV alone is sufficient to inhibit bacterial growth, any additional inhibition of DNA 
gyrase aggravates this effect because both decatenation and unknotting activities of topo IV 
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are guided by the negative supercoiling of the nucleoid (Witz et al., 2011; Witz and Stasiak, 
2010).  
Mechanistically, Fic toxins therefore resemble the distantly related Doc toxin that blocks 
translation via the phosphorylation of EF-Tu (Castro-Roa et al., 2013). The other known 
topoisomerase-targeting TA systems CcdBA and ParDE are bactericidal plasmid addiction 
modules that trigger lethal double-strand breaks by poisoning gyrase activity via non-covalent 
interaction with the A subunit (Deghorain et al., 2013). Importantly, the only weak activation 
of the SOS response (Figure 5C) and the reversibility of bacterial growth inhibition (Figure 
1D) even upon recA deficiency (Figure 5B) exclude such a poisoning mechanism for Fic 
proteins. Instead, these toxins are enzymes that merely inhibit topoisomerase activity by post-
translational modification of the B subunits. Consequently, Fic toxins do not kill bacterial 
cells, but induce a reversible bacteriostatic condition that is known as bacterial persistence 
and features multidrug tolerance. Various toxin-antitoxin modules are known to promote 
persister formation by mechanisms mostly involving interference with translation or 
membrane integrity (Maisonneuve and Gerdes, 2014; Wang et al., 2012). Here we show for 
the first time that also the collapse of bacterial DNA topology provides a path to the persister 
state that is independent of the SOS response triggered by DNA damage. Future studies will 
further elucidate the molecular mechanism of persister formation via topoisomerase inhibition.  
 
Experimental Procedures 
Bacterial strains and plasmids 
E. coli strains and plasmids used and constructed in the course of this study are described 
in the Supplemental Information. All primers are listed in Table S1. All vectors and all details 
of their construction are listed in Table S2. 
 
Toxicity tests 
Unless stated differently, experiments were performed with E. coli K-12 MG1655 
ΔecficAT (AHE573) and derivatives using a two-plasmid system with toxin genes under Plac 
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control and antitoxin genes under Para control. Detailed procedures are described in the 
Supplemental Information.  
 
Persister assays 
Bacterial persistence was quantified similarly as described by Dörr et al. (2010) using a 
procedure that is described in detail in the Supplemental Information.  
 
Protein expression and purification 
Different VbhT constructs were expressed and purified as described previously (Engel et 
al., 2012). Details as well as the procedures for other constructs are described in the 
Supplemental Information.  
 
ATP hydrolysis assay 
The ATPase activity of GyrB was monitored using an FPLC coupled assay analyzing the 
nucleotide composition of the sample (Zähringer et al., 2011) based on the conditions 
described by Brino et al. (2000). For details, see the Supplemental Information.  
 
Identification of AMPylation sites by LC-MS analysis 
Recombinant E. coli DNA gyrase and topo IV (TopoGEN Inc.) were adenylylated in vitro 
with purified VbhT(fic)-VbhA(E/G), tryptically digested, C18-purified, and analysed by LC-
MS/MS as described previously (Engel et al., 2012). Mass tolerance was set to 15 ppm for 
precursor ions and 0.6 Da for fragment ions. Converted MS data were searched using Mascot 
against a SwissProt E. coli decoy database containing target sequences of VbhTA. Search 
results were evaluated using Scaffold 3 (Proteome Software). 
 
 
Results | Research article III 
 
 107 
In vitro adenylylation assays 
The adenylylation activity of Fic proteins was assessed using cleared lysates of ectopically 
expressing E. coli and [α-32P]-ATP (Hartmann Analytic) as described previously (Engel et al., 
2012).  
 
In vitro topoisomerase assays 
In vitro supercoiling or decatenation assays of recombinant DNA gyrase or topoisomerase 
IV of E. coli (TopoGEN Inc.) were performed according to the supplier’s recommendations. 
Details of the experimental procedure are described in the Supplemental Information.  
 
Flow cytometry with GFP promoter fusions 
The response of PgyrB (for DNA relaxation (Menzel and Gellert, 1983)) and PsulA (for 
SOS induction) promoters to Fic toxin expression was probed using plasmid-encoded gfpmut2 
promoter fusions of the collection created by Zaslaver et al. (2006) and pUA139, the parental 
plasmid without promoter, or chromosomal derivatives thereof (AHE1156 and AHE1158; see 
Strain Construction). For details, see the Supplemental Information. 
 
High-resolution agarose gel electrophoresis 
Changes in cellular DNA topology upon Fic toxin expression were assessed using the 
pAH160 reporter plasmid isolated from snap-frozen samples of E. coli AHE938 cultures with 
the Wizard Plus SV Minipreps DNA Purification kit (Qiagen). Details of the experimental 
procedure for high-resolution agarose gel electrophoresis to resolve DNA supercoiling, 
knotting, and catenation are described in the Supplemental Information.  
Fluorescence microscopy 
E. coli AHE573 that had expressed Fic toxins for 2 hours were stained with membrane 
dye FM4-64 (Molecular Probes) ad 2.5 µg/ml and DNA dye DAPI (4’,6’-diamidino-2-
phenylindole, Roche) ad 5 µg/ml for 30 minutes in LB medium in the dark and then 
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transferred onto microscopy slides coated with 1% agarose. Images were acquired using an 
Olympus IX71 microscope equipped with a CoolSnap HQ2 camera, LED illumination, and a 
100x phase contrast objective (all from Applied Precision). Filter sets were Ex: 390/18, Em: 
435/48 (DAPI) and Ex: 542/27, Em: 594/45 (TRITC). Snapshots were taken using SoftWorx 
5.5 software and the pictures were adjusted for publication using ImageJ 
(http://rsbweb.nih.gov/ij/download.html) and Photoshop CS5 extended 12.0.4x64 (Adobe). 
For quantification at least 100 cells per strain and experiment were evaluated regarding cell 
shape and DNA segregation. 
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Figure 1. Fic toxins reversibly inhibit bacterial growth. (A) VbhT and YeFicT, but not catalytically 
inactive mutants (H/A), inhibit E. coli growth on LB agar plates in the absence of cognate VbhA or 
YeFicA antitoxins. The signature motifs of all FicTA modules investigated in this study are compared 
in Figure S1. (B) We followed the colony forming units (c.f.u. / ml) of exponentially growing E. coli 
cultures in which Fic toxin expression had been induced with 2000 µM of isopropyl 
β-D-thiogalactopyranoside (IPTG). The curves show a marked growth inhibition by YeFicT or only 
the FIC domain of VbhT (VbhT(fic)) and a lower potency of VbhT.(C) E. coli harboring plasmids for 
the expression of Fic toxins under Plac control were spotted onto agar plates containing different 
concentrations of IPTG. The decrease in c.f.u. depended on the dose of Fic toxin expression and 
mirrored the differential potency of the Fic toxin constructs as shown in (B). (D) The c.f.u. / ml of 
exponentially growing E. coli cultures harboring plasmids for the expression of toxins under Plac and 
cognate antitoxins under Para control were monitored over time after the induction of Fic toxin 
expression by spotting on LB agar plates containing glucose (to inhibit toxin expression) or arabinose 
(to induce antitoxin expression). We find that the growth inhibition by Fic toxins, but not gyrase-
poisoning toxin CcdB, is reversed by subsequent antitoxin expression. Weaker Fic toxicity in (D) 
compared to (B) is likely the consequence of leaky antitoxin expression. All data points and error bars 
are mean and s.d. of biological triplicates. 
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Figure 2. Fic toxins adenylylate DNA gyrase and topo IV which results in target inhibition in 
vitro. (A) Cleared lysates of E. coli that had expressed different VbhT constructs or target candidates 
were mixed, incubated with [α-32P]-ATP to trace adenylylation, and then analyzed using SDS-PAGE 
and autoradiography. The autoradiograph (top) shows VbhT auto-adenylylation (58 kDa; green arrow) 
and adenylylation of endogenous GyrB (90 kDa; red arrow) as well as ectopically expressed GyrB and 
ParE of E. coli and B. schoenbuchensis (as GST-fusions; black arrows). The Coomassie stain (bottom) 
of the same gel shows the presence of all ectopically expressed proteins (green: VbhT, magenta: 
VbhA, black: GST-GyrB and GST-ParE). Using mass spectrometry we mapped the adenylylation sites 
to be tyrosine 109 in E. coli GyrB and tyrosine 105 in E. coli ParE (Figure S2). (B) The ATPase 
activity of an N-terminal GyrB construct was assayed as the production of ADP by FPLC. The data 
show that adenylylation inhibits the ATPase activity of GyrB, albeit with slow kinetics (note the slow 
cessation of ADP production with VbhT). (C) The supercoiling and decatenation activities of 
recombinant DNA gyrase and topo IV were probed by monitoring the supercoiling (sc) of relaxed 
pBR322 (rel) and the decatenation of highly catenated kDNA (cat) into monomers (Mrel) in vitro. 
The targets were pre-incubated with different Fic toxin constructs for one hour prior to the addition of 
DNA substrates. The agarose gel resolving the reaction products shows that both enzymes are fully 
inhibited by adenylylation as well as by novobiocin, though no considerable effect of adenylylation 
was apparent without pre-incubation, suggesting that Fic toxins are slow enzymes at least in vitro 
(data not shown). All data points and error bars are mean and s.d. of biological triplicates. oc = open 
circular (nicked) plasmid. In (B) and (C) VbhT, VbhT_H/A, and VbhTA denote corresponding 
constructs of VbhT(fic)A for technical reasons (see Extended Experimental Procedures). 
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Figure 3. Fic toxins achieve only partial inhibition of DNA gyrase in vivo. (A) Reporter plasmid 
pAH160 was analyzed by high resolution agarose gel electrophoresis (in presence of 12.5 µg/ml 
chloroquine to resolve negative supercoiling) following isolation from E. coli that had expressed 
different Fic toxin constructs for two hours. The gel shows only a slight stretching of the pAH160 
topoisomer distribution towards DNA relaxation (arrows), indicative of weak inhibition of DNA 
gyrase, while high concentrations of novobiocin (Nov; 100 µg/ml) fully abrogate the negative 
supercoiling. (B) The induction of a relaxation-sensitive PgyrB::gfpmut2 module on a reporter plasmid 
was analyzed by flow cytometry in E. coli that had expressed different Fic toxin constructs for two 
hours. While novobiocin elicits a dose-dependent response (10 µg/ml fully inhibit DNA gyrase in 
acrA-deficient E. coli (Khodursky et al., 2000)), only a weak or intermediate induction of GFP 
expression is apparent with Fic toxins (p<0.01, unequal variance t-test). (C) A chromosomal 
PgyrB::gfpmut2 module was used to assay nucleoid relaxation as described for the plasmid sensor in 
(B). Similarly, a significant but weak relaxation can be detected for VbhT or YeFicT, while the 
VbhT(fic) construct elicits a stronger induction of GFP fluorescence (all (p<0.05, unequal variance t-
test). All data points and error bars are mean and s.d. of biological triplicates. 
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Figure 4. Fic toxin expression results in robust inhibition of topo IV in vivo. (A) E. coli that had 
expressed different Fic toxin constructs for two hours were stained with FM4-64 (membranes; red) 
and DAPI (DNA, blue) and analyzed by fluorescence microscopy. Fic toxin expression induces a “par” 
phenotype with cell filamentation and unsegregated nucleoids, indicative of strong topo IV inhibition. 
(B) Classification and quantification of the par phenotype show stretched nucleoids with VbhT and 
condensed nucleoids with VbhT(fic) and YeFicT. All data points are mean values of three independent 
experiments with error bars denoting s.d. (C) Nicking of the DNA samples used for Figure 3A 
separates nicked (nic) / linear (lin) dimers (D) and monomers (M) and reveals catenation (Dcat) and 
knotting (Mknt, arrows) upon Fic toxin expression. High concentrations of novobiocin (100 µg/ml, 
Nov100) immediately inactivate DNA gyrase (note collapsed supercoiling in Figure 3A) and topo IV, 
leading primarily to DNA knotting in the absence of DNA replication. (D) A lane plot was created for 
the gel shown in (C) using ImageJ (http://rsbweb.nih.gov/ij/download.html). Two bands of monomeric, 
knotted pAH160 reporter plasmid (arrows) are clearly visible for VbhT, VbhT(fic), and YeFicT 
expression as well as upon for treatment with 100 µg/ml novobiocin (inhibiting topo IV) but are 
absent in controls. 
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Figure 5. Fic toxin expression impairs DNA segregation and blocks replication fork movement 
(A) The differential susceptibility of various E. coli K-12 single gene mutants and an isogenic lexA3 
strain harboring Fic toxin as well as antitoxin vectors (to improve plasmid stability in hypersensitive 
strains via leaky expression) was quantified by forming the ratio of c.f.u. obtained on LB agar 
supplemented with 400 µM IPTG (to induce Fic toxin expression) over those on LB agar without 
IPTG (top) and subsequent normalization to the ratio obtained with lamB that served as an internal 
control (bottom). We detect an increased sensitivity to VbhT expression in mutants defective for 
XerCD recombination (xerC / xerD) or topoisomerase III (topB) which can partially complement topo 
IV regarding decatenation (Cox et al., 2000; Grainge et al., 2007; Perez-Cheeks et al., 2012). 
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Moreover, bacteria with defects in replication fork reversal, homologous recombination, and Holliday 
junction processing (recA, recB, ruvA, ruvC) are hypersensitive to Fic toxicity, while the sole 
inactivation of recD, part of Exonuclease V, or recG, one of the factors that can drive replication fork 
reversal, did not have a clear effect. Conversely, the inability to induce the SOS response (lexA3) or 
suppress cell division following SOS induction (sulA) makes E. coli more tolerant under the 
conditions tested (p<0.05, unequal variance t-test). n.s. = not significant (B) The reversibility of Fic 
toxicity (see Figure 1D) was assayed in different E. coli mutants by induction of antitoxin expression 
on LB agar plates subsequent to Fic toxin expression in liquid culture. Fic toxicity is reversible in the 
lamB control and recA / recD / ruvC single mutants (log change of c.f.u. ≥ 0), while dual inactivation 
of exonuclease V as well as homologous recombination activities in recB or recDA mutants results in 
detectable lethality (values ≤ 0), indicative of replication fork reversal driving fork repair after 
blockade (De Septenville et al., 2012). (C) The induction of the SOS response was probed using flow 
cytometry recording fluorescence from a plasmid-encoded PsulA::gfpmut2 module with a procedure 
identical to the detection of DNA relaxation via a PgyrB::gfpmut2 reporter (Figure 3B). The results 
show that YeFicT expression leads to some activation of the SOS response, but much weaker than 
gyrase-poisoning toxin CcdB or DNA-damaging drugs like ciprofloxacin (all p<0.05, unequal 
variance t-test), while the effects of VbhT expression were not significant (n.s.). The expression of 
inactive toxin mutants (FicT_H/A or CcdB_G100E) had no effect. All data points are mean values of 
three independent experiments with error bars denoting s.d. 
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Figure 6. The PaFicTA system shows phenotypes similar to those observed with VbhTA and 
YeFicTA. (A) The c.f.u. / ml of exponentially growing E. coli cultures harboring plasmids for the 
expression of toxins under Plac and cognate antitoxins under Para control were monitored over time. 
Toxin expression was induced with 2000 µM of IPTG in all cultures at t=0 and the results were 
compared for the presence and absence of a simultaneous induction of antitoxin expression with 0.2% 
L-arabinose. While the vector control and PaFicT_H/A expression showed no difference, the 
expression of PaFicT in the absence of PaFicA induction resulted in growth inhibition. (B) The growth 
inhibition of exponentially growing E. coli cultures in which PaFicT expression had been induced with 
2000 µM of (IPTG) at t=0 was compared to the effects of other Fic toxins (see Figure 1B). Expression 
of the PaFicT construct resulted in a decrease of c.f.u. / ml by four logs that is most similar to the 
results obtained with the VbhT(fic) construct. Weaker growth inhibition with PaFicT in (A) compared 
to (B) is likely the consequence of leaky PaFicA expression. (C) Cell shape and DNA segregation of E. 
coli that had expressed PaFicT were analyzed as shown for the other toxins in Figure 4A (membranes: 
red, DNA: blue). The condensed nucleoid morphology and only weak filamentation upon PaFicT 
expression mostly resemble the phenotype obtained upon VbhT(fic) expression (see Figure 4A). (D) 
The induction of a plasmid-encoded (top) or chromosomal (bottom) PgyrB::gfpmut2 module upon 
PaFicT expression was monitored as described for the other toxins in Figure 3B and Figure 3C. 
Expression of PaFicT results in strong DNA relaxation that is even more pronounced than the effects 
of VbhT(fic) expression, evidencing an ample inhibition of DNA gyrase (p<0.01, unequal variance t-
test). (E and F) The DNA topology of a pAH160 reporter plasmid was analyzed using high resolution 
agarose gel electrophoresis as shown for the other toxins in Figure 3A and Figure 4C. The near-
complete relaxation of plasmid DNA upon expression of PaFicT as revealed by chloroquine agarose 
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gel electrophoresis (E) is even stronger than the relaxation obtained with VbhT(fic), confirming the 
results shown in (D). An electrophoretic analysis of nicked reporter plasmid in (F) shows that PaFicT 
expression results in DNA knotting, but no detectable catenation. These results indicate a strong 
inhibition of both DNA gyrase and topo IV by PaFicT which rapidly inhibits DNA replication and 
thus the formation of catenanes (like novobiocin; (Khodursky et al., 2000)). All data points are mean 
values of three independent experiments with error bars denoting s.d. 
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Figure 7. Fic toxin expression induces persister formation and can be activated in vivo by Lon. 
(A) Exponentially growing E. coli were induced to express Fic toxins for two hours and then 
challenged with a lethal concentration of one of three different antibiotics for three more hours so that 
only persisters would survive. C.f.u. / ml were determined before and after drug challenge; the data 
show a 1,000fold increased proportion of persisters in E. coli expressing Fic toxins (p<0.001, unequal 
variance t-test). This effect is largely independent of the weak SOS activation by Fic toxins (Figure 
S3C; see Figure 5C). (B) E. coli harboring a plasmid-encoded yeficAT module under Plac control were 
induced with 2000 µM IPTG and c.f.u. were recorded over time. It is apparent that the ectopic 
coexpression of yeficAT results in growth inhibition unless lon is inactivated. The growth defect is 
aggravated by Lon activation via the stringent response (+SHX = DL-serine hydroxamate). We 
confirmed that YeFicT toxicity is not generally reduced in the lon mutant and did not detect a similar 
effect with vbhAT(fic) (Figure S4A and S4B). All data points are mean values of three independent 
experiments with error bars denoting s.d. 
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Supplemental Information 
Extended Results 
Using a panel of diverse model proteins to study Fic toxins 
In our previous work we established VbhT of Bartonella schoenbuchensis as a model 
system for class I FIC domain proteins and showed that its cognate antitoxin VbhA inhibits 
both the adenylylation activity of VbhT as well as the associated growth inhibition in E. coli 
(Engel et al., 2012). However, while most class I Fic proteins singly comprise a FIC domain, 
VbhT uniquely harbors a discernable type IV secretion signal at its C-terminus, a BID (Bep 
Intracellular Delivery) domain. BID domains are present in relaxases of a number of 
conjugation systems as well as the closely related host-targeted effectors of the genus 
Bartonella (Schulein et al., 2005), suggesting that VbhT may be secreted into a target cell 
(prokaryotic or eukaryotic) by the Vbh type IV secretion system (T4SS) encoded close-by. It 
was therefore possible that VbhT could have secondarily acquired a new function which may 
or may not rely on a different / altered biochemical activity than that of the other class I Fic 
proteins. We therefore decided to study VbhT along with other, more typical representatives 
to elucidate the molecular function and biological role of these proteins. 
The prototypic EcFicT protein of Escherichia coli was the first Fic protein to be described 
and the “filamentation induced by cAMP” phenotype of its fic-1 allele gave the name to the 
domain family (Utsumi et al., 1982). Being a genuine E. coli protein, EcFicT would have 
been an ideal candidate for a biological characterization in this classical model organism 
along with VbhT. However, we found that EcFicT is unlikely to be representative of the bulk 
of class I Fic proteins because it belongs to an atypical subgroup that is only found in 
Enterobacteria and harbors a secondarily deteriorated FIC domain active site motif (Figure 
S1). Consequently, EcFicT did not show adenylylation activity or inhibit bacterial growth 
(our unpublished results). However, we still used a ΔecficAT derivative of E. coli str. K-12 
substr. MG1655 for most experiments to exclude functional crosstalk of any kind between 
endogenous EcFicTA and the other model systems. 
Instead of EcFicT we decided to characterize YeFicT of Yersinia enterocolitica str. 8081, 
an organism closely related to E. coli (Thomson et al., 2006). YeFicT has 37% protein 
sequence identity to EcFicT and 32% protein sequence identity to the FIC domain of VbhT of 
B. schoenbuchensis. Most importantly, YeFicT appears to be an average single-domain class I 
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Fic protein with a conserved FIC domain active site motif. Though not originally annotated in 
genome of Y. enterocolitica str. 8081, we identified the small ORF yeficA encoded upstream 
of yeficT with slight overlap as a candidate antitoxin with inhibitory α-helix and identical 
length to vbhA. 
Finally, we studied a rather distant relative of our other model proteins to assess whether 
our findings may generally apply to all class I Fic proteins. For this purpose we chose PaFicT 
of Pseudomonas aeruginosa PAO1 with 22.1%, 16.6%, and 22.0% protein sequence identity 
in the conserved regions to YeFicT, EcFicT, and VbhT, respectively. Like for YeFicT, we 
identified the small ORF paficA encoded upstream of paficT with slight overlap that may 
serve as an antitoxin. Interestingly, the signature motifs of both the FIC domain in PaFicT 
(HXFX(D/E)GNGRXXL with a leucine instead of the final arginine) and PaFicA 
(SXXXD(G/N)) with an aspartate instead of the glutamate) slightly diverge from the 
canonical motifs as defined by Engel, Goepfert et al. (2012) (see Figure S1). 
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Extended Experimental Procedures 
Bacterial handling and growth conditions.  
Escherichia coli were transformed with one or more plasmids using TSS transformation 
(Chung et al., 1989) and always handled in LB liquid or solid medium containing appropriate 
antibiotics as well as 1% w/v D-glucose to suppress basal expression of any construct prior to 
the inoculation of experimental cultures. Unless stated differently, experiments were 
performed with exponentially growing derivatives of E. coli K-12 harboring pNDM220 
derivatives (encoding Fic toxin constructs) and, whenever indicated, pBAD33 derivatives 
(encoding Fic antitoxins) as well as occasional other plasmids. For the enumeration of colony 
forming units (c.f.u.) bacterial cultures were serially diluted and spotted on LB agar plates 
which were thereafter incubated at 37°C for up to several days before counting. Selection for 
different genotypes or plasmid maintenance was performed with ampicillin ad 30 µg/ml 
(pNDM220 and derivatives) or 100 µg/ml (pGex-6p1 and derivatives), chloramphenicol ad 
34 µg/ml, gentamicin ad 20 µg/ml, kanamycin ad 50 µg/ml, and tetracycline ad 12 µg/ml. 
 
Plasmid Construction 
Plasmids were constructed using standard procedures of restriction-based cloning or 
sequence- and ligation-independent cloning (SLIC) with enzymes obtained from New 
England Biolabs. For phenotypic analyses, toxin genes or ficAT modules were cloned into 
pNDM220 (Gotfredsen and Gerdes, 1998) under control of a particularly tight Plac (for 
pAH154 or pAH157 series, respectively) and antitoxin genes were cloned into pBAD33 under 
control of ParaB (for pAH153 series), resulting in a two-plasmid expression system as it was 
used previously for the analysis of toxin-antitoxin interactions (Jorgensen et al., 2009). The 
yeficA and paficA antitoxin genes were identified as ORFs encoded by nucleotides 1’867’230-
1’867’042 and 1’480’066-1’479’788 in the genomes of Yersinia enterocolitica str. 8081 
(NC_008800) and Pseudomonas aeruginosa PAO1 (NC_002516.2), respectively. YeFicT and 
PaFicT are proteins YP_001005954.1 and NP_250057.1. For biochemical analyses and 
protein purification, toxins and / or antitoxins were cloned into pRSFDuet-1 (Novagen) and 
target candidates as glutathione S-transferase (GST) fusions into pGex-6p-1 (GE Healthcare). 
Point mutations and deletions were introduced via PCR into suitable template plasmids as 
described by Liu and Naismith ( 2008). Occasional sub-cloning of PCR products was 
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performed using the StrataClone blunt PCR cloning kit (Agilent). Plasmid construction was 
always confirmed by DNA sequencing.  
 
Strain Construction 
E. coli strains used for phenotypic analyses were generated from E. coli str. K-12 substr. 
MG1655 and protein expression was performed in E. coli BL21 or derivatives. Strains were 
constructed using the method of Datsenko and Wanner (2000). For the deletion of ecficAT in 
E. coli K-12 MG1655 the original locus was amplified with prAH361/362, sub-cloned, and 
the deletion allele was produced via amplification with prAH359/360. Subsequent allelic 
replacement via a kanR / sacB cassette (amplified from pJM05 (MacKichan et al., 2008) with 
prAH363/364) in the ecficAT locus resulted in strain AHE573 (E. coli str. K-12 substr. 
MG1655 ΔecficAT. The deletion allele was constructed in a way to not affect expression of 
downstream gene pabA by leaving the last 55bp of the ecficT gene. The lexA3 allele was 
moved via P1vir transduction from E. coli K996 (CGSC#: 7786) into AHE573 or, to yield a 
strain isogenic with the KEIO collection (Baba et al., 2006), into E. coli BW25113 (CGSC#: 
7636) with selection for the malE::tn10 marker close-by, resulting in AHE961 (E. coli K-12 
ΔecficAT lexA3 malE::tn10) and AHE963 (E. coli BW25113 lexA3 malE::tn10). The endA 
gene in AHE573 was replaced by the inactive endA* allele of BL21 (DE3) Gold (Agilent) to 
inactivate endonuclease I and improve the quality of isolated plasmids for high resolution 
agarose gel electrophoresis, resulting in AHE745 (E. coli K-12 ΔecficAT endA*). Primers 
were prAH351/352 to amplify endA or endA* and prAH366/367 for the locus-specific 
double-selectable cassette. The acrA gene in AHE745 was replaced with a gentamicin 
resistance cassette (amplified with prAH559/560 from pRS96 (Schulein et al., 2005)) to 
obtain a highly novobiocin-sensitive strain as it was used by Hardy and Cozzarelli (2003) 
(AHE938, E. coli K-12 ΔecficAT endA* acrA::genR). For the construction of a chromosomal 
DNA relaxation sensor we first trimmed the promoter fragment of the pPgyrB::gfpmut2 
vector of Zaslaver et al. (2006) down to the PgyrB promoter as listed by RegulonDB (Schein 
et al., 2006) by site-directed mutagenesis with primers prAH909/910, creating plasmid 
pPgyrB::gfpmut2_v1. A cassette containing a kanamycin cassette as well as the 
PgyrB::gfpmut2 module was amplified from pPgyrB::gfpmut2_v1 using primers 
prAH925/926 and integrated into the gapC locus of AHE938 using lambda Red 
recombineering, creating strain AHE1158 (E. coli K-12 ΔecficAT endA* acrA::genR 
Results | Research article III 
 
 127 
gapC::PgyrB::gfpmut2_v1). A promoterless control was created analogously using plasmid 
pUA139 as the template for amplification, creating strain AHE1156 (E. coli K-12 ΔecficAT 
endA* acrA::genR gapC::pUA139). The construction of all strains was confirmed by DNA 
sequencing. 
 
Toxicity tests 
Experiments were generally performed with E. coli K-12 MG1655 ΔecficAT (AHE573) 
and derivatives or, when indicated, single gene mutants of the KEIO collection (Baba et al., 
2006). The growth of E. coli expressing Fic toxins was qualitatively assessed on LB agar 
plates inducing Fic toxin expression with 2000 µM of Isopropyl β-D-thiogalactopyranoside 
(IPTG) in presence or absence of 0.2% w/v L-arabinose to induce antitoxin expression. For 
growth curves, Fic toxin expression was induced at t = 0 with 2000 µM of IPTG and the 
change in c.f.u. (on LB agar plates containing 1% D-glucose) was quantified by normalization 
to the c.f.u. at t = 0. When appropriate, the c.f.u. counts on plates containing 0.2% L-
arabinose were enumerated in parallel. When indicated, the stringent response was induced 
with DL-serine hydroxamate (Sigma) ad 0.5 mg/ml. Differences in the susceptibility of 
various E. coli single gene mutants of the KEIO collection to Fic toxicity were assessed using 
the continuous expression of VbhT with 400 µM IPTG induction and the lamB mutant as an 
isogenic control. We chose this relatively low level of lac promoter induction and VbhT 
instead of YeFicT to avoid problems with saturating toxicity, leaky expression (especially in 
hypersensitive mutants), and an insufficient dynamic range to detect both increased and 
decreased susceptibility. The reversibility of Fic toxin expression by antitoxin induction upon 
plating on 0.2% L-arabinose with different E. coli mutants (Figure 5B) was tested after 90 
minutes of Fic toxin induction to reliably detect both VbhT and YeFicT toxicity (see Figure 
1D).  
 
Persister assays 
E. coli that had expressed Fic toxins for two hours were challenged with lethal 
concentrations of one of three different antibiotics (0.5 µg/ml ciprofloxacin, 50 µg/ml 
kanamycin, or 100 µg/ml ampicillin) so that only persisters would survive. Ampicillin was 
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added in combination with 10 µg/ml clavulanate to inactivate the β-lactamase encoded on 
pNDM220 and derivatives (Vakulenko et al., 1998). Three hours after drug challenge the 
bacteria were washed extensively in LB medium containing 20 mM MgSO4 and plated in 
serial dilutions on LB agar plates containing 1% D-glucose. Persister frequencies were 
calculated by forming the ratio of c.f.u. counts after and before drug challenge.  
 
Protein Expression and Purificaiton 
VbhT constructs were generally expressed and purified as described previously (Engel et 
al., 2012). For purification, VbhT was expressed in form of truncated constructs devoid of the 
BID domain and together with its VbhA antitoxin for technical reasons (Engel et al., 2012). 
Note that purified “active” VbhT therefore indicates the presence of mutant VbhA(E24G) that 
is unable to inhibit the adenylylation activity of VbhT. The N-terminal 43 kDa fragment 
(1-392) of E. coli GyrB (Ali et al., 1993) was expressed from pFVS0109 in E. coli BL21 
(DE3). Cultures were grown at 37°C in LB medium supplemented with 50 µg/ml of 
kanamycin and 0.1% D-glucose to an OD600 of 0.6 and then protein expression was induced 
with 0.35 mM IPTG for 16h at 23°C. Subsequently, bacteria were pelleted and resuspended in 
lysis buffer containing 50mM Tris pH 7.5, 1 mM EDTA, 5 mM DTT and disrupted using 
French press. Cell debris was removed by ultracentrifugation and the supernatant applied to a 
His-trap column (GE Healthcare). Proteins were eluted with a gradient of elution buffer 
containing 50mM Tris pH 7.5, 1 mM EDTA, 5 mM DTT and 500 mM imidazole. The protein 
was then concentrated and injected on a Superdex 75 16/60 gel filtration column (GE 
Healthcare) equilibrated with 50 mM Na-phosphate buffer pH 7.2, 1 mM EDTA and 5 mM 
DTT. 
 
ATP hydrolysis assay 
50 µM of a well-characterized N-terminal 43 kDa fragment of GyrB (Ali et al., 1993) was 
incubated with 10 µM of purified VbhT constructs (i.e., 5-fold excess of target), 1 mM ATP, 
and 1 mM MgCl2 for up to 120 minutes. At 0, 2, 10, 60 and 120 minutes, an aliquot of each 
reaction was boiled for 5 minutes at 99°C and spun down at 16 000 g for 5 minutes to pellet 
the precipitated proteins. The supernatant composed of nucleotides was loaded on a 
Resource Q column (GE Healthcare) equilibrated with 5 mM ammonium bicarbonate pH 9.0. 
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Nucleotides were eluted with a gradient of elution buffer containing 1 M ammonium 
bicarbonate pH 9.0. Samples were analyzed by FPLC and nucleotide peak areas were 
integrated using the Unicorn software (GE Healthcare). The ATPase activity of GyrB was 
visualized as the production of ADP over time. 
 
In vitro topoisomerase assays  
Supercoiling and decatenation activities of recombinant type IIA topoisomerases of E. coli 
(TopoGEN Inc.) were performed according to the supplier’s recommendations with one unit 
of enzyme per reaction and supplemented with novobiocin ad 5 µg/ml (to fully inhibit both 
topoisomerases) or 50 pmol of different purified constructs of VbhAT(fic) as indicated. 
Reactions were incubated for 30 minutes at 30°C and then 0.54 µg of relaxed pBR322 (DNA 
gyrase / supercoiling assays) or kDNA (topo IV / decatenation assays) was added. After 
incubation at 37°C for one hour the reactions were stopped with Universal Stop Buffer and 
treated with proteinase K to resolve any potential DNA – protein linkages. The DNA was 
purified by chloroform – isoamyl alcohol extraction, resolved by electrophoresis in 1.1% 
agarose gels, stained with the GR Green Nucleic Acid Stain (Biolabo SA), and imaged at a 
Safe Imager (Invitrogen) equipped with an EOS 40D camera (Canon). Recombinant DNA 
gyrase and topo IV, DNA substrates, and 5x Universal Stop Buffer were obtained from 
TopoGEN Inc. (Columbus, Ohio). 
 
Flow cytometry with GFP promoter fusions 
GFP fluorescence (excited at 488 nm) and forward scatter of exponentially growing 
E. coli AHE938 (with plasmid reporters) or AHE1156 / AHE1158 (chromosomal reporters) 
were recorded with a FACSCalibur flow cytometer (Becton Dickinson) two hours after drug 
treatment or the induction of Fic toxin expression. Data of ca. 25’000 cells per sample were 
analyzed using the FlowJo software (Tree Star) to obtain mean GFP fluorescence and mean 
forward scatter values. Fluorescence values were corrected for background fluorescence at the 
given experimental condition (determined with E coli AHE938 harboring pUA139 or 
AHE1156). Subsequently, we removed distortions of apparent fluorescence caused by 
differences in cell size via normalization to the forward scatter because Renggli et al. (2013) 
recently demonstrated that the distortions of both values show a strong linear correlation. 
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High-resolution agarose gel electrophoresis 
For the analysis of DNA supercoiling, topoisomers of our pAH160 plasmid reporter were 
separated in gels containing 1% of agarose (Eurogentec) and 12.5 µg/ml of chloroquine 
(AppliChem) at 1.5 V/cm in the dark. Gels were washed extensively in water to remove 
chloroquine, stained with the GR Green Nucleic Acid Stain (Biolabo SA), and imaged at a 
Safe Imager (Invitrogen) equipped with an EOS 40D camera (Canon). As a control for DNA 
relaxation we treated reporter pAH160 with topoisomerase I (New England Biolabs) as 
suggested by the supplier. For the analysis of DNA catenation and knotting, plasmid 
supercoiling was removed by nicking with Nt.BbvCI (New England Biolabs) and topoisomers 
were resolved and visualized as described above without chloroquine. The presence of 
pNDM220 derivatives (size > 10’000 bp) in all samples did not impede analysis due to their 
low abundance and the huge size difference to pAH160 (4359 bp). 
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Figure S1. Comparison of FicA and FicT signature motifs of FicTA modules investigated in this 
study, Related to Figure 1. Protein sequences of FicA and FicT homologs were aligned using 
ClustalW (implemented in Geneious v.7.0.5), manually curated, and the signature motifs were 
extracted for illustration. Shading of amino acids indicates the degree of conservation according to the 
Blosum62 score matrix. The sequence alignments show that only EcFicT largely diverges from the 
canonical HXFX(D/E)GNGRXXR motif of Fic proteins as defined by Engel, Goepfert et al. (2012) 
(see also Extended Results in the Supplemental Information). All four FicA homologs contain an 
(SXXXE(G/N)) motif with the inhibitory glutamate being a chemically similar aspartate in PaFicA. 
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Figure S2. VbhT adenylylates Tyr109 and Tyr105 of E. coli GyrB and ParE, respectively, 
Related to Figure 2. Ion series and MS/MS spectra for detected adenylylated residues on GyrB (A, B) 
and ParE (C, D) are shown (see Experimental Procedures). The identified modified residue is marked 
in red. SEQUEST Xcorr search scores, peptide charge states and peptide sequence are shown in (B) 
and (D). 
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Figure S3. The minor SOS induction by Fic toxins does not greatly contribute to growth 
inhibition or persister formation, Related to Figure 5 and Figure 7. (A and B) We quantified the 
differential susceptibility of E. coli lexA3 and sulA mutants as well as the lamB control to Fic toxicity 
by forming the ratio of c.f.u. obtained on LB agar supplemented with different concentrations of IPTG 
(to induce Fic toxin expression) over those on LB agar without IPTG. Both for VbhT (A) and YeFicT 
(B) the data show that the SOS response contributes to growth inhibition only at low levels of ficT 
expression and plays no role at 2000 µM of IPTG that we generally used for phenotypic 
characterization. (C) The persister formation of a lexA3 derivative of AHE573 was quantified as for 
the parental strain (Figure 7A) and still revealed greatly increased fractions of persister cells upon Fic 
toxin expression (p<0.05, unequal variance t-test), showing that an inability to launch the SOS 
response does not greatly affect the phenotype. We note an unexpectedly increased tolerance of the 
vector control to ampicillin compared to AHE573 (Figure 7A), but an identical effect can also be seen 
in the data of Dörr et al. (2009) (figure 1, panel D) with the same concentration of ampicillin (100 
µg/ml) and the same duration of drug challenge (3h). Data points are mean values of three independent 
experiments with error bars denoting s.d. 
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Figure S4. Additional results on Fic toxin activation by antitoxin degradation in vivo, Related to 
Figure 6. (A) The experiment of Figure 6B was repeated with vbhAT(fic) instead of yeficAT. No 
growth inhibition that would evidence toxin activation in vivo can be detected. (B) The experiment of 
Figure 6B was repeated with yeficT instead of yeficAT expression. The data show that the lon mutant 
is not less susceptible to Fic toxicity than the other mutants. 
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Table S1. List of oligonucleotides used in this study. Related to Experimental 
Procedures. 
Primer name Sequence (5'-3') 
prAH116 GAATGCGTTGGCCCCGTTTCGAGAAGGTAATGGACGTAC 
prAH127 CCTTCTCGAAACGGGGCCAACGCATTCAATTCGCCCATG 
prAH260 GAGCGGGATCCATGTCGAATTCTTATGACTCC 
prAH262 CTCCCGCTCGAGTTAAATATCGATATTCGCCGC 
prAH286 GAGCGAGATCTATGACGCAAACTTATAACGCT 
prAH288 CTCCCGCTCGAGTTAAACCTCAATCTCCGCCA 
prAH289 GAGCGGGATCCATGAGTGATGAAACAACCTCA 
prAH291 CTCCCGCTCGAGTTAGATATCAAGATTGGCAACA 
prAH351 CATAATCGCGTAGTTCGTGG 
prAH352 ATATGGTTGGCGGCATCTTC 
prAH359 GCGCGGGCGCACTGCAGATGATATTTA 
prAH360 GCAGTGCGCCCGCGCGAGAAATCATTA 
prAH361 GATTTCGGTTACGCGGTATTT 
prAH362 GAATAACGTCAAGGGAGATC 
prAH363 GGTAGTTATCCTTTCCGCTAAAGTCCTGCCGTAATGATTTCTCGCGCGGGCGACATCATAACGGTTCTGG 
prAH364 CAGATTCCCCGGCTTCGCTTACCACTTTGCTAAATATCATCTGCAGTGCGGGAATCGAAATCTCGTGATG 
prAH366 CCAAAACAGCTTTCGCTACGTTGCTGGCTCGTTTTAACACGGAGTAAGTGCGACATCATAACGGTTCTGG 
prAH367 GGTTGTACGCGTGGGGTAGGGGTTAACAAAAAGAATCCCGCTAGTGTAGGGGAATCGAAATCTCGTGATG 
prAH412 ATCCTCCAAAATCGGATCTGGAAGTTCTGTTCCAGGGGCCCCTGGGATCCATGAGCGATAATAATAAAGATCTT 
prAH413 CCGAAACGCGCGAGGCAGATCGTCAGTCAGTCACGATGCGGCCGCTCGAGTTAGATATCGAGATTATGAGCAA 
prAH447 TTAATGTTATCGCCCCTTTCCGTGAAGGTAATGG 
prAH448 CACGGAAAGGGGCGATAACATTAAGATCAGAATAGTA 
prAH485a GAGCGGGGATCCATAGGAGGAACAATTTTGTGAACAGCGATAAATACGG 
prAH487 CTCCCGCGAATTCTTAACGAATACAGCGGGCG 
prAH488 GAGCGGGGTACCATAGGAGGAACAATATGACGAGTCTGGCTGAGAA 
prAH489 CTCCCGCAAGCTTTCACCGCGAACTCGGCTG 
prAH490 GAGCGGGGTACCATAGGAGGAACAATATGTTGAGCGAGGAAGAAATC 
prAH491 CTCCCGCAAGCTTTCATATTTCCTCACGTTTTATC 
prAH496 GAGCGGGGTACCATAGGAGGAACAATATGAAGCAGCGTATTACAGTG 
prAH497 CTCCCGCAAGCTTTCACCAGTCCCTGTTCTCG 
prAH515 GAGCGGAGATCTATAGGAGGAACAATTTTGTGAGGAAATATGAGGGTAG 
prAH516 CTCCCGCGAATTCTTACCTTGTAATTCCCTTTGAAG 
prAH521 GAGCGGGGATCCATAGGAGGAACAATTTTATGCAGTTTAAGGTTTACACC 
prAH522 CTCCCGCGAATTCTTATATTCCCCAGAACATCAG 
prAH551 GTTCTGGGAAATATAAGAATTCACTGGCCG 
prAH552 TTATATTTCCCAGAACATCAGGTTAATG 
prAH559 CATTGACCAATTTGAAATCGGACACTCGAGGTTTACATATGAACAAAAACGCCAAGGATCTGATGGCGC 
prAH560 TAAAGAAATTAGGCATGTCTTAACGGCTCCTGTTTAAGTTAAGACTTGGATTAGGTGGCGGTACTTGGG 
prAH755 TGAATTTACATAAGAATTCACTGGCCGTCG 
prAH756 GTGAATTCTTATGTAAATTCAGTGAGGTTTCTA 
prAH909 GATTAACCCAAGTATAAAGAAGGAGATATACATATGAGTAAAGGAG 
prAH910 GTATATCTCCTTCTTTATACTTGGGTTAATCCGTTATTTTACCCTT 
prAH925 CCTCCGCCGAGAAATCGCAGGCGCATCTTGATGCTGGTGCGAAGAAGGTGGTATCATCAACAGGCTTACCC 
prAH926 GCGGAGGTTTTTTCCTCCGCCTGTGCGCGTCAGAGTTTAGCGAATTTTTCCATAGACAGCCTGAAACAGG 
prAH933 TCATCCACTCCCGCAAGCTTCCAGGTATCTCTTT 
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prAH935 GAGCGGGGTACCATAGGAGGAACAATTTTATGAGTTTCGATCCCTTTGG 
prAH936 CTCCCGCGAATTCTTAGGGTTCGGAGTCGG 
prAH937 CTTTGCGGCGCCCTTTCTAGACGGCAAC 
prAH938 GAAAGGGCGCCGCAAAGCAAAGAAGTCC 
prAH945 GAGCGGGGTACCATAGGAGGAACAATATGGAAAGGGGTTTACCG 
prAH950 GTTCGAGGAATGGTACCGAGCTCGAATT 
prAH952 ACCATTCCTCGAACAATATGGAAAGGGGTTTA 
prFVS107 GGGAATTCCATATGCATCACCATCACCATCACTCGAATTCTTATGACTCCTCCAG 
prFVS114 CGACCTCGAGTTAGGTCATTTCACGCGCGCGACG 
 
This table lists all oligonucleotides used for the construction of strains and plasmids in this 
study. 
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Table S2. List of vectors used in this study. Related to Experimental Procedures. 
 
This table lists all plasmids used throughout this study and contains all relevant details of their 
construction.  
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Abstract
Type II DNA topoisomerases are essential enzymes that catalyze topological rearrangement of double-stranded DNA using
the free energy generated by ATP hydrolysis. Bacterial DNA gyrase is a prototype of this family and is composed of two
subunits (GyrA, GyrB) that form a GyrA2GyrB2 heterotetramer. The N-terminal 43-kDa fragment of GyrB (GyrB43) from E. coli
comprising the ATPase and the transducer domains has been studied extensively. The dimeric fragment is competent for
ATP hydrolysis and its structure in complex with the substrate analog AMPPNP is known. Here, we have determined the
remaining conformational states of the enzyme along the ATP hydrolysis reaction path by solving crystal structures of
GyrB43 in complex with ADP?BeF3, ADP?Pi, and ADP. Upon hydrolysis, the enzyme undergoes an obligatory 12u domain
rearrangement to accommodate the 1.5 A˚ increase in distance between the c- and b-phosphate of the nucleotide within
the sealed binding site at the domain interface. Conserved residues from the QTK loop of the transducer domain (also part
of the domain interface) couple the small structural change within the binding site with the rigid body motion. The domain
reorientation is reflected in a significant 7 A˚ increase in the separation of the two transducer domains of the dimer that
would embrace one of the DNA segments in full-length gyrase. The observed conformational change is likely to be relevant
for the allosteric coordination of ATP hydrolysis with DNA binding, cleavage/re-ligation and/or strand passage.
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Introduction
Type II DNA topoisomerases are essential enzymes that
catalyze topological rearrangement of double-stranded DNA
(dsDNA) to maintain chromosomes in an appropriate state. In
particular, DNA gyrase introduces negative supercoils into
covalently closed dsDNA molecules using the free energy
generated by ATP hydrolysis. Bacterial DNA gyrase is a prototype
of this family composed of two subunits (GyrA, GyrB) and forms a
(GyrAGyrB)2 dimer of around 400 kDa.
The dimerization interface is composed of three contact areas
or gates (N-, DNA-, C-gate) that open-up successively and in a
coordinated fashion to allow DNA passage (Fig. 1). The current
view on the enzymatic mechanism is the following two-gate
mechanism (reviewed in [1–5]). The enzymatic cycle starts by the
binding of a segment of double-stranded DNA (gate-segment, G)
to the DNA-gate, followed by the trapping of another segment
(transfer-segment, T) through the ATP-actuated closure, i.e.
dimerization, of the N-gate. Subsequent cleavage of the G-
segment and opening of the DNA-gate allows transfer of the T-
segment through the gate. Finally, the G-segment gets resealed
and the T-segment is released by opening of the C-gate.
The GyrB subunit is comprised of three domains: the N-
terminal ATPase domain (GHKL family), the transducer domain,
and the C-terminal TOPRIM domain. First insight into the
detailed structure of bacterial topoisomerases was obtained with
the crystal structure of a 43 kDa N-terminal fragment of E. coli
GyrB (GyrB43) that comprises the ATPase domain and the central
transducer domain [6]. The structure showed a tight dimer with
contacts mainly mediated by the ATPase domains (N-gate). The
dimer delimits a central hole with a diameter of 20 A˚, large
enough to accommodate double-stranded DNA (Fig. 1).
The structure was determined in the presence of the substrate
analog AMPPNP that is bound to the canonical site of the GHKL-
type ATPase domain, but also interacts with the QTK loop of the
transducer domain and an N-terminal "brace" of the other subunit
of the dimer. Latter interaction explains why only the dimeric
form of the GyrB43 fragment is competent for ATP hydrolysis as
evidenced by the greater than first-order dependence of the
reaction-rate on enzyme concentration [7] and how the presence
PLOS ONE | www.plosone.org 1 September 2014 | Volume 9 | Issue 9 | e107289
Results | Research article IV 
 
 143 
 
of ATP stabilizes the closed conformation of the N-gate in GyrB
[8].
The different steps of DNA gyrase action have to be tightly
coordinated. In particular, G-segment cleavage and translocation
of the T-segment should occur only after N-gate closure to prevent
non-productive DNA cleavage and to ensure unidirectional
segment translocation. Thus, not surprisingly, it could be shown
that e.g. ATP hydrolysis is stimulated by the presence of DNA [9].
The question arises whether the ATP hydrolysis event per se, i.e.
the post-hydrolysis state prior to product release, can be sensed by
the enzyme to facilitate or even energize the next catalytic step. In
this context it is noteworthy that the substrate is found deeply
buried in the GyrB active site without an obvious exit route for the
products [6].
Structures of type II topoisomerases have been determined
previously for archael topoVI-B’ in complex with various
nucleotides [10,11] and for human topoII (htopoII) in complex
with AMPPNP and ADP [12], highlighting some of the
structural changes occurring along the ATP hydrolysis
pathway. Both studies discuss the central role of the conserved
lysine (K337 in E. coli GyrB) that is proposed to sense the
nucleotide state and to relay this information to the center of
the enzyme.
Here we report the structures of bacterial GyrB43 in complex
with (i) the pre-hydrolysis analog ADP?BeF3, (ii) the post-hydrolysis
ADP?Pi and (iii) the product ADP. Compared to the AMPPNP
complex structure [6,13], the post-hydrolysis state, i.e. the ternary
complex of GyrB43 with ADP and Pi, shows a substantial domain
reorientation, the significance of which is discussed in the context
of full-length DNA gyrase.
Materials and Methods
Cloning
The gene of E. coli gyrB (residues 1-392) was amplified by PCR
from E. coli genomic DNA using the primer set prFVS107/
prFVS114 (59-GGGAATTCCATATGCATCACCATCACCAT-
CACTCGAATTCTTATGACTCCTCCAG-39 and 59-CGA-
CCTCGAGTTAGGTCATTTCACGCGCGCGACG-39). The
DNA sequence corresponding to the N-terminal His6-tag is in
italics. The amplified DNA fragment was then simultaneously
digested with NdeI and XhoI and ligated in the MCS2 of the
pRSFDuet-1 vector (Novagen) digested with the same restriction
enzymes, resulting in plasmid pFVS0109.
Protein expression, extraction and purification
The pFVS0109 plasmid was transformed into Ca2+-competent
E. coli BL21 (DE3). Cells were grown at 37uC in LB medium
supplemented with 50 mg/mL of kanamycin and 0.1% glucose to
an OD600 of 0.6 before induction with 500 mM isopropyl 1-thio-
D-galactopyranoside (IPTG) for 5 hours at 37uC. Cells were then
harvested by centrifugation. Cells containing overexpressed
GyrB43 were resuspended in lysis buffer containing 50 mM Tris
pH 7.5, 1 mM EDTA, 5 mM DTT and 5 mM imidazole and
disrupted using French press. Cell debris were pelleted by
ultracentrifugation at 200 000 g and the supernatant was applied
to two 1 mL HisTrap column (GE Healthcare) plugged in series.
The protein of interest was eluted with a gradient of elution buffer
containing 50 mM Tris pH 7.5, 1 mM EDTA, 5 mM DTT and
500 mM imidazole. The eluted fractions containing GyrB protein
were then loaded on a 5 mL HiTrap Q column (GE Healthcare)
pre-equilibrated with loading buffer (50 mM Tris pH 7.5, 1 mM
Figure 1. Domain architecture of E. coli DNA gyrase and model of DNA gyrase mechanism. (a) Domain architecture of E. coli DNA gyrase.
GyrB is composed of an ATPase (yellow), a transducer (orange) and a toprim (red) domain. GyrA is composed of a winged-helix (WHD, blue), a tower
(blue), a coiled-coil (light purple) and a b-pinwheel (b-PW, purple) domain. (b) A double-stranded DNA segment (G-segment) is captured at the DNA-
gate, the N-gate is open to allow access of the T-segment. (c) Upon ATP binding, the ATPase domains dimerize and the T-segment gets trapped. (d)
This is followed by ATP hydrolysis, G-segment cleavage, DNA-gate opening and T-segment translocation. The domain colored in light-grey represents
the transducer domain in the preceding orientation. The mechanistic details of this step are not clear, in particular whether prior to Pi release the
enzyme conformation is changed and how ATP hydrolysis and DNA passage are coordinated. For clarity, the coiled-coil and b-pinwheel domains of
GyrA are omitted in (b-d). Adopted from references [3,5].
doi:10.1371/journal.pone.0107289.g001
Structure of GyrB43 in Complex with ADP?Pi
PLOS ONE | www.plosone.org 2 September 2014 | Volume 9 | Issue 9 | e107289
Results | Research article IV 
 144 
 
EDTA, 5 mM DTT). Proteins were eluted with a gradient of
elution buffer containing 50 mM Tris pH 7.5, 1 mM EDTA,
5 mM DTT and 1 M NaCl. The protein was then concentrated
and injected on a Superdex 75 16/60 gel filtration column (GE
Healthcare) equilibrated with 50 mM Na-phosphate pH 7.2,
1 mM EDTA and 5 mM DTT. The different batches of pure
protein leading to the crystallization of GyrB in complex with
ADP?Pi, ADP?BeF3 or ADP were concentrated to 36 mg/mL.
GyrB43/nucleotide complexes crystallization
Crystals were obtained at 20uC using the sitting-drop vapour
diffusion method after mixing 0.2 mL protein solution with 0.2 mL
reservoir solution equilibrating against a reservoir of 80 mL. For
crystallization of GyrB43 in complex with ADP?Pi, the protein
solution was prepared by incubating GyrB with a 15 fold molar
excess of ATP and MgCl2. This allowed the ATPase reaction to
start and produce the reaction products: ADP?Pi. GyrB43 in
complex with ADP?Pi crystallized after one week in 0.1 M tri-
ammonium citrate pH 6.5 and 25% (w/v) PEG 2000. Crystals
were soaked in the reservoir solution supplemented with 20%
glycerol for cryoprotection. The protein sample leading to the
crystallization of GyrB43 in complex with ADP was prepared
similarly to the ADP?Pi sample. GyrB43 in complex with ADP
crystallized after a week in 10% (w/v) PEG 20000, 20% (v/v) PEG
MME 550, 0.02 M each carboxylic acid, 0.1 M bicine/Trizma
base pH 8.5 (Morpheus screen [14]). For crystallization of GyrB43
in complex with ADP?BeF3, a prerequisite is the formation of a
stable ADP?BeF3 complex. This was achieved by incubating
20 mM ADP with 500 mM NaF and 100 mM BeCl2 for 16 hours
at 4uC [8]. The protein solution was prepared by incubating
GyrB43 with a 15 fold molar excess of ADP?BeF3 and MgCl2.
Crystals grew after a week in 0.2 M NaF, 0.1 M Bis-Tris propane
pH 6.5 and 20% (w/v) PEG 3350. Crystals were soaked in the
reservoir solution supplemented with 20% glycerol for cryoprotec-
tion. All crystals were then flash frozen in liquid nitrogen and
stored until data collection.
Data collection, processing, structure determination and
refinement
Diffraction data were collected at the Swiss Light Source
(Villigen, Switzerland) at 100 K and processed using XDS [15]
and scaled either with XSCALE [15] or aimless [16]. GyrB43
structures were solved by molecular replacement using the
previously published structure of the 43-kDa N-terminal fragment
of GyrB (PDB entry 1EI1 [13]) as search model using Phaser [17].
Several rounds of iterative model building and refinement were
performed using Coot [18] and Refmac5 [19] or PHENIX [20].
5% of the data were excluded from refinement and used for cross-
validation. For the remodeling of the sulfate and asparagine side
chain of human topoIIA in complex with ADP?SO4 (PDB code:
1ZXN), the re-refined model was obtained from the PDB_REDO
databank [21]. Iterative model building and refinement was
performed as described above. The geometry of the final model
was assessed using MolProbity [22] showing .99% of the residues
in the core and allowed regions of the Ramachandran plot. Data
collections and refinement statistics are summarized in Table 1
and Table 2, respectively.
Structure analysis
Superimpositions were made using Modtrafo (T. Schirmer
unpublished, http://www.biozentrum.unibas.ch/schirmer/
modtrafo). Root mean square deviation (RMSD) were calculated
using lsqman [23]. To obtain the change in domain orientation,
the different structures were superimposed on their respective
ATPase domains. Then, the respective transducer domains were
superimposed and the resulting rotation matrix analyzed by
Modtrafo in terms of polar angles (V, Q, k) with V, Q defining the
orientation of the rotation axis and k the rotation angle.
Figures were prepared with Dino (A. Philippsen unpublished,
http://www.dino3d.org).
Accession numbers
Coordinates and structure factors have been deposited in the
Protein Data Bank (PDB) with accession numbers 4PRX, 4PU9
and 4PRV for GyrB43?ADP?Pi, GyrB43?ADP?BeF3 and Gyr-
B43?ADP, respectively. The re-refined and corrected coordinates
of htopoII?ADP?SO4 have been deposited in the PDB with
accession number 4R1F.
Results
Overall structures
To understand better the effect of ATP hydrolysis on the
mechanism of GyrB at the atomic level, we aimed to obtain
further structures along the reaction pathway, in particular the
ADP?Pi complex structure representing the post-hydrolysis state. A
43 kDa N-terminal fragment of GyrB from E. coli (GyrB43)
comprising the ATPase and the transducer domain [6,13] was
overexpressed and purified. The fragment was found to be
competent for ATP hydrolysis as assessed by an FPLC based
nucleotide quantification method [24] yielding kcat and Km values
of 2.7?1023 s21 and 0.45 mM, respectively. These values are
similar to those determined previously for this fragment [7,13].
GyrB43 was crystallized in presence of ATP substrate (12.5 mM)
that was expected to get hydrolyzed to ADP and Pi. In addition, a
high background phosphate concentration (50 mM sodium
phosphate buffer) was employed to saturate the c-phosphate
binding site.
Crystals of orthorhombic space group C2221 with one
monomer per asymmetric unit were obtained that diffracted to
1.8 A˚. Data collection statistics are given in Table 1. The structure
was solved by molecular replacement using the structure of
GyrB43 (E. coli) in complex with AMPPNP that had been
determined in a different space-group previously (PDB entry 1EI1
[13], Fig. 2a), as search model. The electron density map (2Fo-Fc)
calculated with the molecular replacement phases showed well-
defined density for the ATPase domain, but rather poor density for
the transducer domain. The difference density (Fo-Fc) showed
disagreement in the QTK loop region (334–337), which is the part
of the transducer domain that extends into the ATP-binding
pocket. These observations provided the first indication of a global
conformational change.
Rigid- and jelly-body refinement improved the electron density
in the transducer domain and caused a drop in the Rfree from
46.7% to 35.1%. Subsequently, residues 330–340 comprising the
QTK loop were rebuilt based on a respective omit-map. An ADP
and an adjacent phosphate molecule could be placed unambig-
uously in the map. Final refinement yielded a GyrB43?ADP?Pi
model (Fig. 2b) with Rwork and Rfree values of 16.3% and 20.3%,
respectively (Table 2). The model comprises all residues from 4 to
378 except segment 304–314 at the tip of the transducer domain.
In addition, the structures of GyrB43 in complex with
ADP?BeF3 (2.4 A˚) and in complex with ADP (2.0 A˚) were solved.
In both cases, plate-like crystals of the same C2221 space-group,
but with cell constants distinct to those of the GyrB43?ADP?Pi
form were obtained. Both structures (Figs. 2c, d) were solved by
molecular replacement using the same search model (PDB entry
Structure of GyrB43 in Complex with ADP?Pi
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1EI1) as for the aforementioned structure of the GyrB43?ADP?Pi
complex. Again, the ligands could be unambiguously modeled into
the Fo-Fc maps. Data collection statistics are given in Table 1.
The quality of the electron density maps allowed the tracing of
95% and 94% of the polypeptide chain except segments 305–315,
389–392 for GyrB43?ADP?BeF3 and 303–315, 387–392 for the
structure of GyrB43?ADP, respectively. Final refinement statistics
are given in Table 2.
Rigid domain reorientations
Structural comparisons of the individual domains of the three
newly determined GyrB43 structures in complex with ADP?Pi,
ADP?BeF3 and ADP with the previously published structure of
GyrB43?AMPPNP reveals that both the transducer and the
ATPase domain structures are virtually identical in all complexes
with root mean square deviation (rmsd) values between 0.32 and
0.57 A˚ (Table 3). Still, there are considerable conformational
changes between the structures as evident from Fig. 2. In
particular, the hole delimited by the two transducer domains of
the dimer is larger in GyrB43?ADP?BeF3 and GyrB43?ADP?Pi
than in the GyrB43?AMPPNP [6,13] and GyrB43?ADP struc-
tures.
Changes in the arrangement of the two domains are revealed
when superimposing the subunits on their ATPase domains
(Fig. 3), showing large differences in the respective Ca atoms
positions of the transducer domains. The largest rmsd (2.9 A˚)
occurs between the ternary GyrB43?ADP?Pi complex and the
restrained GyrB43?AMPPNP substrate complex (Figs. 3a, c and
Table 3). The domain re-arrangement is a relative 12u rotation
(without translation component) with the rotation axis oriented
roughly along the long axis of the monomer and passing through
the domain interface (Fig. 3a). Thereby, the transducer b-sheet
rolls over the C-terminal helix of the ATPase domain (residues 222
to 232). This part of the interface is mostly hydrophobic.
Interacting residues close to the rotation axis are e.g. L197,
I222, V226 of the N-terminal and A255, V322 of the C-terminal
domain. Interestingly, a rotation about approximately the same
axis but by only 6u is needed to superimpose the transducer
domain of GyrB43?ADP?BeF3 onto that of GyrB43?AMPPNP
(Fig. 3b, c). No domain reorientation is observed for the binary
GyrB43?ADP complex. Table 3 shows that upon superposition of
the ATPase domain the transducer domain is still well aligned
(rmsd of Ca positions: 0.8 A˚).
To further characterize the long-range structural changes,
intra-subunit distances were measured within the dimer struc-
tures. The changes in the distances are given in Fig. 4. Upon
ATP hydrolysis, the QTK loops (Q335 and T336) of the two
subunits get closer together at the dimerization interface, whereas
residues at the surface of the N-gate chamber (N294, L282) or the
C-terminal end (D377) of the transducer domain considerably
increase their inter-subunit distance (by up to 7 A˚) (see morphing
in Movie S1). Accordingly, we define the conformations of the
GyrB43?ADP?BeF3 and the GyrB43?ADP?Pi complex "semi-
open" and "open", respectively (Fig. 2). Latter structural change
may well have relevance for the communication of the ATP
hydrolysis event to the core of the gyrase enzyme (see Discussion).
Crystal packing analysis
In general, variation in protein domain arrangements observed
in non-isomorphous crystals can be due to distinct crystal packing
Table 1. Data collection statistics.
GyrB43 in complex with ADP?Pi GyrB43 in complex with ADP?BeF3 GyrB43 in complex with ADP
X-ray source SLS X06SA (PXI) SLS X06DA (PXIII) SLS X06DA (PXIII)
X-ray detector Pilatus 6M Pilatus 2M Pilatus 2M
Wavelength (A˚) 1.0000 0.9793 1.0000
Space group C 2 2 21 C 2 2 21 C 2 2 21
Cell dimensions a, b, c (A˚) 77.6, 131.6, 92.4 88.1 143.2 79.9 88.2, 142.5, 79.1
Matthews coefficient (A˚3Da21) 2.9 3.1 3.1
Solvent content (%) 57.9 59.3 59.3
Molecules in asymmetric unit 1 1 1
Resolution limits (A˚) 46.19–1.80 (1.86–1.80) 44.08–2.40 (2.49–2.40) 75.03–2.00 (2.07–2.00)
Rmerge
{(%) 9.9 (112.5) 7.0 (32.8) 7.1 (59.4)
Rmeas
`(%) 10.4 (115.5) 7.6 (35.1) 7.7 (67.0)
CC 1/2 99.9 (80.5) 99.9 (97.4) 99.9 (93.7)
,I/s(I). 16.4 (2.0) 21.1 (6.1) 21.4 (3.3)
Total reflections 4739415 (429913) 1379915 (139976) 1929676 (179839)
Unique reflections 449052 (49261) 209072 (19966) 309053 (39203)
Wilson B-factor 25.0 36.3 23.5
Multiplicity 10.7 (10.1) 6.9 (7.1) 6.4 (5.6)
Completeness (%) 99.7 (97.4) 99.6 (99.5) 88.2 (95.8)
Mosaicity 0.16 0.46 0.19
Numbers in parentheses belong to the outer shell.
{Rmerge = ghklgi |Ii(hkl) - ,I(hkl).|/ghklgi Ii(hkl), where Ii(hkl) is the observed intensity for a reflection and ,I(hkl). is the average intensity obtained from multiple
observations of symmetry-related reflections.
`Rmeas = ghkl [N/(N-1)]1/2 gi |Ii(hkl) - ,I(hkl).|/ghklgi Ii(hkl), where Ii(hkl) is the observed intensity for a reflection, ,I(hkl). is the average intensity obtained from
multiple observations of symmetry-related reflections and N is the number of observations of intensity I(hkl).
doi:10.1371/journal.pone.0107289.t001
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forces. Therefore, the various crystal packings were analyzed in
detail.
The GyrB43?ADP?Pi crystal form is distinct to that of the
published GyrB43?AMPPNP structure [13], still the molecular
packings are related (Fig. 5). Despite the distinct intra-dimer
distance between the transducer domains (marked by a black dot
in Fig. 5a), GyrB43 dimers are arranged to similar layers (Fig. 5a)
due to a conserved ATPase-transducer domain crystal contact
with an interface of ,490 A˚2 (Fig. 5b). Layers are packed onto
each other according to the crystallographic 21 axes along b via
weak ATPase-ATPase contacts mediated by the "base" of this
domain. These interactions are dissimilar between the two crystal
forms with a smaller area in the GyrB43?AMPPNP form (218 A˚2)
compared to the GyrB43?ADP?Pi form (387 A˚
2). Transducer
domains are very weakly or not at all involved in inter-layer
contacts in the AMPPNP or ADP?Pi complex, respectively.
The similarity in packing is reflected in relations between cell
parameters/symmetry elements of the two forms (Fig. 5c). In the
Table 2. Refinement statistics.
GyrB43 in complex
with ADP?Pi
GyrB43 in complex
with ADP?BeF3
GyrB43 in complex
with ADP
htopoII in
complex with ADP?SO4
PDB code 4PRX 4PU9 4PRV 4R1F
Resolution limits (A˚) 46.19–1.80 (1.86–1.80) 44.08–2.40 (2.49–2.40) 75.03–2.00 (2.07–2.00) 30.00–2.51 (2.60–2.51)
Rwork * (%) 16.3 (23.7) 21.9 (28.0) 20.7 (38.5) 20.2 (27.6)
Rfree **(%) 20.3 (34.2) 27.3 (35.3) 25.9 (43.3) 24.1 (34.5)
Number of non-hydrogen atoms 39063 29979 39015 129360
macromolecules 29787 29899 29861 129093
ligands 39 32 28 133
solvent 237 48 126 134
Protein residues 363 374 369 1647
R.m.s.d from ideal
Bond lengths (A˚) 0.022 0.016 0.018 0.012
Bond angles (u) 2.11 1.97 1.89 1.46
Ramachandran favored *** (%) 98 93 97 95
Ramachandran outliers *** (%) 0.28 0.81 0.27 0.54
Clashscore *** 1.09 4.32 2.13 5.35
Average B values (A˚2) 30.3 42.2 29.5 64.3
macromolecules 30.0 42.4 29.6 64.5
ligands 21.3 30.0 22.3 56.0
solvent 36.1 40.3 29.8 55.1
Numbers in parentheses refer to the outer shell.
* Rwork = ghkl|| Fobs| - |Fcalc||/ghkl|Fobs|
** Rfree is the R value calculated for 5% of the data set that was not included in the refinement.
*** Molprobity.
doi:10.1371/journal.pone.0107289.t002
Figure 2. Conformational states of GyrB43 along the ATP hydrolysis reaction path. The various states have been trapped by co-
crystallization with the appropriate nucleotides. The dimeric structures are shown in cartoon representation with semi-transparent molecular surface
overlaid. Subunits are distinguished by a slight variation in colour hue. View perpendicular to the molecular dyad. (a) AMPPNP complex (PDB entry
1EI1 [13]), (b) ADP?Pi complex, (c) ADP?BeF3 complex and (d) ADP complex. Note the distinct opening angles defined by the two transducer domains
with the AMPPNP and ADP complexes in a "closed" conformation, the ADP?BeF3 complex in a "semi-open" and the ADP?Pi complex in "open"
conformation.
doi:10.1371/journal.pone.0107289.g002
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P21212 form (GyrB43?AMPPNP), the molecular dyad symmetry of
GyrB43 is non-crystallographic, whereas, in the C2221 form, it
coincides with the crystallographic 2-fold symmetry along the long
axis (b axis). The positions of local two-fold symmetry axis of
GyrB43?AMPPNP are depicted in green on Fig. 5c. In space
group P21212, the symmetry is broken by a slight shift of the local
symmetry axis along the horizontal direction (Fig. 5c) by 5% to
x= 0.29 compared to its theoretical position at a quarter in space
group C2221.
Concerning the GyrB43?ADP complex, the structure was
obtained in a crystal form unrelated to that of GyrB43?AMPPNP.
Still the two structures are virtually identical (see preceding
section) ruling out any crystal packing artifacts. Finally, the
GyrB43?ADP?BeF3 crystal structure was obtained in a form
isomorphous to that of GyrB43?ADP. Thus, the observed domain
rotation can be attributed to the presence of the BeF3 moiety.
Altogether, one can conclude that the observed distinct relative
orientations of the transducer domains are most likely not due to
any crystal packing artifacts, but should be a direct consequence of
the distinct complexation states of the ATP pocket.
Ligand binding
In the following, we describe in detail the structural changes in
GyrB43 that accompany ATP hydrolysis and are coupled to the
observed domain orientations. As described first for GyrB43 in
complex with AMPPNP [6,13], the nucleotide is deeply buried in
the core of the ATPase domain, with the triphosphate moiety
located at the N-terminal end of helix a6 (residues 118–126). The
active sites of both E. coli GyrB43?AMPPNP complex structures
[6,13] are virtually identical (Fig. S1) although the structure
determined by Brino et al. (PDB code: 1EI1) [13] contains a
mutation (Y5S) in the N-terminal arm. Furthermore, inter-species
comparison between GyrB from E. coli (PDB code: 1EI1) [13] and
Mycobacterium tuberculosis (PDB code: 3ZKB) [25] reveals a very
well conserved ligand-protein interaction network (Fig. S1).
Figures 6a and 7a show that the terminal c-phosphate moiety is
held firmly in place with its terminal oxygens forming a multitude
of H-bonds with main-chain amide nitrogens of the N-terminus of
helix a6 and of the preceding glycine-rich loop. Furthermore, the
phosphate forms a salt-bridge with K337 from the transducer
domain and interacts indirectly via a water molecule with Q335
(also from the transducer domain) and with E42. Q335, in turn,
forms an H-bond with the main-chain carbonyl of residue 26 from
the ATPase domain (Fig. 6a and Fig. S3a). In the unreleased
GyrB43?AMPPNP structure [6], Q335 forms a direct H-bond
with the gamma-phosphate of the ligand and lacks the interaction
with carbonyl 26.
The structure of GyrB43 in complex with ADP and Pi shows the
immediate post-hydrolysis state at high resolution (1.8 A˚) (Fig. 6b,
Fig. S3b and Fig. 7b). Although the distance between the b- and
the now liberated distal phosphorus is found significantly increased
by 1.5 A˚ to 4.5 A˚, all protein - ligand interactions are virtually
unchanged compared to the AMPPNP complex. In particular,
despite inverted configuration, two of the oxygens of the
phosphate ion (O2, O3) are bonded to the same main-chain
amide nitrogens 115–116 and 118–119 as the c-phosphate in the
AMPPNP complex (compare panels (a) and (b) of Figure 6). The
phosphate oxygen O3 forms a short H-bond (2.50 A˚) with the
terminal phosphate of ADP. In the small GTPase Rab11, an
analogous interaction (between GDP and Pi) has been identified by
crystallography [26] and by FTIR [27]. The phosphate oxygen
O4, the oxygen that evidently has been added upon hydrolysis,
projects out of the binding site and interacts with the d-nitrogen
group of H116. Furthermore, it forms a water mediated H-bond
with Q335 from the transducer domain. The side-chain amino-
group of K337 has moved by 1.0 A˚, but is still within H-bonding
distance to the now liberated phosphate group. Strikingly, the
position of the QTK loop (residues 335–337) with respect to the
ligand(s) is considerably distinct in the pre- and post-hydrolysis
structure (by about 2.5 to 3 A˚) (Fig. 6). This is due to the relative
rigid-body motion of the transducer domain described previously.
The movement appears to avoid a clash (1.7 A˚) that would occur
between the Q335 side-chain in AMPPNP complex position and
the liberated phosphate group (Fig. 6c). Noteworthy, the side-
chain cannot escape sidewise, since its movement is severely
restricted by hydrophobic residues of the ATP lid loop (residues
99–120, shown in surface representation in Fig. 7). Rather, the
glutamine side-chain amide group finds a new favorable position
3.5 A˚ apart, where it interacts with its counterpart of the other
subunit (Q335*) and main-chain carbonyl 25 of the ATPase
domain.
The atom positions of the ADP?BeF3 ligand in the respective
complex are almost indistinguishable to that of the AMPPNP
ligand (Fig. S2a compared with Fig. 6a and stereoviews in Fig. S3a
compared with Fig. S3c). The substituents of the beryllium atom
are arranged tetrahedrally and the beryllium - b-phosphorus
distance (2.9 A˚) is only marginally shorter than the c – b-
phosphorus distance (3.1 A˚). The only major difference is the loss
Table 3. Pair-wise fit of GyrB43 domains after superposition of the ATPase domains (regular) or transducer domains (italics).
rmsd (A˚) of ATPase domain (20-220)
rmsd (A˚) of transducer domain (221–392) AMPPNP ADP?BeF3 ADP?Pi ADP
AMPPNP 0.422 0.389 0.393
ADP?BeF3 0.565 0.328 0.317
1.592
ADP?Pi 0.391 0.423 0.354
2.875 1.579
ADP 0.501 0.369 0.354
0.644 1.519 2.891
The values give the rmsd (A˚) of the corresponding Ca positions. When superimposing the ATPase domains dimer, the pairwise rmsd range from 0.46 A˚ to 0.93 A˚.
doi:10.1371/journal.pone.0107289.t003
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of the (indirect) interaction with Q335 due to the aforementioned
transducer domain rotation. Finally, the structure of the
GyrB43?ADP complex is globally (Table 3) and locally (Fig. S2b
and Fig. S3d) almost identical to that of GyrB43?AMPPNP
(Fig. 6a and Fig. S3a). The only difference is the presence of a
water molecule in the approximate position of the absent c-
phosphate. As expected from the unchanged domain organization,
the Q335 side-chain interacts with residue 26 in the same way as
in the AMPPNP complex structure.
Figure 3. Structure comparison of (a) GyrB43?ADP?Pi (magenta) and (b) GyrB43?ADP?BeF3 (violet) with GyrB43?AMPPNP (shown as
a dimer with yellow/grey colour with molecular dyad in black). The structures are superimposed on their ATPase domain (residues 20–220).
The rotation axes for the domain reorientation of the transducer domain with respect to the ATPase domain are indicated. These form an angle of
21.5u and 14.5u with the molecular dyad for GyrB?ADP?Pi and GyrB?ADP?BeF3, respectively. The insets show the QTK loop of the transducer domain
that is rotated relative to the ATPase domain in response to the nucleotide state (dashed lines); Q: Q335, K: K337. (c) Stereoview of the overlay of the
three aforementioned structures.
doi:10.1371/journal.pone.0107289.g003
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In the three newly solved structures, a magnesium ion is found
coordinated by the a- and b-phosphate moieties, one water
molecule and the side-chain of N46. In the ADP?Pi complex, the
coordination of the cation seems somewhat distorted to an
additional weak interaction with the orthophosphate (O4 - Mg2+
distance: 3.1 A˚).
Summarizing, the detailed analysis of the ATP binding site
revealed pronounced changes in the vicinity of the c-phosphate
subsite upon ATP hydrolysis. How these relate to the observed
rigid body motions, which in turn seem crucial for the
coordination of gyrase activity will be discussed below.
Discussion
The endergonic process of negative DNA supercoiling is driven
by ATP hydrolysis [28]. ATP binding to the ATPase domain of
the GyrB subunit causes N-gate closing and ensures directional
transfer of the trapped DNA T-segment through the DNA-gate.
Closure of the N-gate may also exert a pinching force that is
mediated by the transducer domains on the trapped DNA segment
to facilitate transfer through the DNA-gate [3]. It has been
demonstrated that ATP hydrolysis occurs sequentially for yeast
topoisomerase II [29]. Hydrolysis of the first ATP molecule is
sufficient for the catalysis of DNA cross-passage, while only upon
hydrolysis of the second ATP molecule the ATPase domains
dissociate to reset the enzyme. In contrast, B. subtilis GyrB
appears to hydrolyze ATP synchronously [30]. Considering the
close homology, a similar mechanism would be expected also for
bacterial DNA gyrase.
Here, we have studied the nucleotide-state dependent confor-
mations of GyrB43 prior to nucleotide release, i.e. prior to ATPase
domain dissociation, with the aim to provide further and detailed
structural information about the coordination of ATP hydrolysis
and strand passage.
Nucleotide-dependent topoisomerase II conformations
The triphosphate-nucleotide complexed conformations of the
ATPase/topoisomerase fragments match closely for the bacterial
[6,13], eukaryotic [12], and archaeal [10,11] structures. It has
been dubbed "restrained" conformation [11] due to the tight
packing of the transducer domain against the ATPase domain and
the multiple interactions of the ligand with the ATP binding site.
These include interactions with the ATP lid loop, the N-terminal
segment of adjacent subunit and the glycine rich loop that tightly
embraces the c-phosphate. Moreover, residues of the QTK loop
(being part the transducer domain) are also engaged in ATP
binding. For the slightly truncated subunit B of archaeal
topoisomerase VI (topoVI-B’), comparison of the restrained
(dimeric) AMPPNP complex with the "relaxed" (monomeric)
nucleotide-free state revealed a relative reorientation of the two
domains [11] giving a first hint for the potential of allosteric
communication via these domains. In the dimeric structures of
topoVI- B’, the ADP, ADP?Pi and the ADP?AlF4 complexes all
showed the restrained conformation [11]. This suggested that ATP
hydrolysis would elicit no large-scale structural response in topoVI.
In contrast, human topoisomerase II shows a semi-open ADP
complex characterized by an 8u outward rotation of the transducer
domain when compared with its restrained/closed AMPPNP
conformation [12] (Fig. S4a). Closer inspection and re-refinement
of the original structure (PDB code: 1ZXN), however, revealed
that the c-phosphate binding subsite is not empty, but occupied by
a sulfate ion in 3 of the 4 molecules of the asymmetric unit (the
active site of the fourth molecule contains a glycerol molecule).
The corrected structure (Fig. S4b) with improved statistics (Rwork/
Figure 4. Quantification of nucleotide induced structural changes within dimeric GyrB43. (a) Inter-subunit distance changes between
symmetry related residues of selected transducer domain Ca-atoms. The changes have been calculated relative to the AMPPNP complex structure,
green bars indicate an increase in distance, red bar indicate a decrease. (b) Cartoon representation of dimeric GyrB43 (ADP?Pi state) with the residues
used for the calculations in (a) indicated. View along the symmetry axis from the C-terminal side.
doi:10.1371/journal.pone.0107289.g004
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Rfree (%) of 20.2/24.1) has been deposited in the Protein Data
Bank (PDB code: 4R1F). Thus, the structure apparently represents
an ADP?SO4 mimic of the post-hydrolysis state and the domain
rotation may well be of functional relevance (Fig. S4, see also
below).
For bacterial gyrase, all of the conformational states along the
ATP hydrolysis pathway are now known. The canonical,
restrained structure is attained both in presence of AMPPNP
[6,13] and ADP, as for topoVI-B’. This indicates that the c-
phosphate is not required to restrain the conformation of the
enzyme. The effect of ATP hydrolysis would then be the
Figure 5. GyrB43 crystal packing of the P21212 (left, GyrB43?AMPPNP complex) and the C2221 (right, GyrB43?ADP?Pi complex)
form. (a) The molecular packing is shown within a slab perpendicular to b and centered at y = 1/4. In both forms, dimers are oriented with their
molecular dyads parallel to b (viewing direction). In the P21212 form (left) the molecular dyad is local (green elliptical symbol), in the C2221 form
(right) the molecular dyad is crystallographic (black symbol). In each case, neighbouring dimers are related by horizontal 2-fold screw-axes. Black
spheres represent the position of residue D377 at the end of the transducer domain (also depicted in Fig. 4b). (b) Details of the major crystal contact
formed in both packings between the transducer domain and the ATPase domain of a symmetry related dimer. (c) Representation of the symmetry
elements, same view as in panel (a). Unit cells are indicated by solid line. With respect to the arrangement of symmetry elements, the dashed
rectangle of the scheme at the right is equivalent to the unit cell of the left scheme. Local symmetry elements are indicated in green.
doi:10.1371/journal.pone.0107289.g005
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enhancement of nucleotide dissociation to reset the enzyme to the
monomeric ATPase state [5]. This is in contrast to, e.g., small
GTPases that act like a "loaded spring" and switch to a relaxed
state upon GTP hydrolysis and phosphate release [31].
Here, we have shown for the bacterial GyrB43 fragment that
there is an additional effect of ATP hydrolysis that occurs prior to
phosphate release and may be of functional significance. The
ADP?Pi post-hydrolysis state is characterized by a virtually
unchanged ATPase dimer structure, but with the transducer
domains reoriented as rigid bodies by 12u relative to their position
in the substrate analog complex (see morphing in Movie S1).
Interestingly, also human topoII may undergo a similar
structural transition as inferred by the comparison of the respective
AMPPNP and ADP?SO4 complexes (Fig. S4). As for bacterial
gyrase, the pivot of the motion is at the center of the interface
between the C-terminal ATPase domain helix and the transducer
b-sheet, but the direction of the rotation axis is different (Fig. S4a).
In contrast, the archaeal topoisomerase IIB enzyme topoVI
exhibits no structural change upon ATP hydrolysis [11]. This can
be attributed to a distinct QTK loop with only the lysine
conserved in this distantly related topoisomerase family (Fig. S5),
see below.
The conformational change observed in GyrB43 can be traced
back to the significant, but small (1.5 A˚) increase in the distance
between the b-phosphate and the terminal c-phosphate or
phosphate moiety, respectively. The direct structural consequences
of the shifted c-phosphate position on the local organization of the
binding site and particularly on the position of the QTK loop will
be discussed in the following section.
The central role of the QTK loop in bacterial and
eukaryotic topoisomerases (topoisomerases IIA)
All topoisomerases IIA studied so far adopt the restrained/
closed conformation in complex with tri-phosphate substrate
analogs. In contrast, the post-hydrolysis complex has adopted the
open state, since the phosphate would severely clash with Q335
from the QTK loop of the transducer domain in the restrained
state (Fig. 6c). Close inspection of the restrained structure reveals
that such strain cannot be relieved by a simple side-chain rotation
of the tightly buried glutamine. Also, there is no apparent route for
the phosphate to leave the binding site, since the previously
described tunnel [13] seems too narrow (Fig. 7). Instead, the
observed movement of the entire transducer domain appears
mandatory to accommodate the post-hydrolysis state in which the
side-chain of Q335 forms a new set of H-bonds, i.e. with its
symmetry mate Q335* and a main-chain carbonyl of the ATPase
domain.
Thus, Q335 appears to fulfill a central role by acting as a two-
state switch in response to the nucleotide state of the ATPase
domain. Indeed, an early biochemical in vivo study on E. coli
Figure 6. Structures of the GyrB43 nucleotide binding site as determined for (a) the substrate analog complex GyrB43?AMPPNP
(PDB entry 1EI1 [13]) and (b) the post-hydrolysis complex GyrB43?ADP?Pi with Fo-Fc omit map shown at a contour level of 3.0 s.
Note the distinct interaction of the QTK loop (transducer domain) with the 25–26 loop (ATPase domain) in the two states. The rotation axis for the
relative domain reorientation is shown as straight line (same in Fig. 3a) (c) Stereoview of the superimposition of the structures shown in (a) and (b)
after superposition on their ATPase domain. The exclamation mark indicates the steric clash that would occur between Q335 in the AMPPNP complex
conformation (yellow) with the Pi moiety of the post-hydrolysis state (magenta).
doi:10.1371/journal.pone.0107289.g006
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gyrase [9] had already identified this glutamine as indispensable
for the regulation of ATP hydrolysis by DNA binding. A later
study on a QTK deletion mutant of human topoII again showed
deregulation of the enzyme with DNA cleavage no longer
controlled by the nucleotide state of the enzyme [32].
The equivalent of the QTK loop in archaea carries no
glutamine (Fig. S5) and exhibits a distinct main-chain geometry
[10]. Therefore, the nucleotide-binding pocket is considerably
more spacious. This explains why the post-hydrolysis state can be
accommodated in the restrained conformation and why no ATP
hydrolysis induced structural changes have been observed [11].
Whether also in archaeal topoisomerases the event of ATP
hydrolysis can be signaled to the core of the enzyme remains to be
investigated.
Coordination of ATP hydrolysis and supercoiling activity
Modification of DNA topology needs the coordinated catalysis
of various steps. Therefore, it is not surprising that DNA binding
positively affects ATPase activity as shown for E. coli gyrase [33].
The simplest explanation for this allosteric regulation is that T-
segment binding to the N-gate chamber of gyrase induces a
change in the relative disposition of the two transducer domains
which in turn is coupled to local changes in the ATPase active site
[29]. Since the transducer domain carries the active lysine (K337),
a reorientation of the transducer domain with respect to the
ATPase dimer with the bound ATP substrates should indeed affect
ATP hydrolysis.
Such DNA induced domain reorientation has, to our knowl-
edge, not yet been observed directly. It is likely, however, that for
such communication the in-built domain mobility described in
detail here is exploited again. In the restrained state, the side-chain
amino-group of K337 is in H-bonding distance to the c-phosphate
of the substrate analog and, thus, probably capable to stabilize the
negative charge of the transition state [9]. In the other, open
conformation of the enzyme, the K337 amino-group is pulled out
of the nucleotide pocket by 1.0 A˚, probably sufficient to
significantly de-tune the enzyme [9].
Is there signaling also in the opposite direction, from the active
sites of the ATPase dimer to the core of the enzyme? This could
then synchronize ATP hydrolysis with the other catalytic steps.
Here, we have shown by detailed structural studies that prior to
phosphate release a well-defined, obligatory state is attained and
that this post-hydrolysis state is characterized by a significantly
increased distance between the distal transducer ends of the
GyrB43 fragment. We propose that this ATP hydrolysis induced
movement initiates a series of events starting with G-segment
cleavage that would be followed by DNA-gate opening and T-
segment passage. The refined mechanistic scheme for the
enzymatic cycle of full-length gyrase based on the current two-
gate model [2] is shown in Fig. 8. It has been suggested that part of
the free energy generated by ATP hydrolysis may be used to
actively push the T-segment through the DNA gate [3]. This
would indeed be consistent with the observed rigid-body
rearrangement.
Figure 7. Surface representation of GyrB43 demonstrating the deeply buried nucleotide (stick model). View along the narrow tunnel
leading to nucleotide. (a) GyrB43?AMPPNP complex, (b) GyrB43?ADP?Pi complex. The insets show close-ups of the nucleotide sites with the ATP lid
loop (residues 99–120) and the adjacent subunit of the dimer in surface representation (same colour codes as Fig. 2). Note, that upon ATP hydrolysis
glutamine 335 cannot escape "downwards" to relieve a clash with the Pi moiety due to the presence of the ATP lid. Instead the entire transducer
domain moves to the side.
doi:10.1371/journal.pone.0107289.g007
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Supporting Information
Figure S1 Comparison of various GyrB structures in
complex with AMPPNP. (a) Superimposition of the E. coli
GyrB43?AMPPNP structure determined by Wigley et al. (un-
released, personal communication, note that AMPPNP had been
modeled as ATP) [6] in brown onto our reference structure E. coli
GyrB43?AMPPNP determined by Brino et al. (PDB code: 1EI1)
[13] in yellow. (b) Superimposition of M. tuberculosis Gyr-
B?AMPPNP in blue-green onto our reference structure E. coli
GyrB43?AMPPNP (PDB code: 1EI1) [13] in yellow. Structure of
the ligand binding site of (c) E. coli GyrB?AMPPNP determined by
Wigley et al. and (d) M. tuberculosis GyrB?AMPPNP (PDB code:
3ZKB). Hydrogen bonds are depicted as grey dashed lines. (e)
Close-up stereoview of the active sites of the two structures shown
in (a). (f) Close-up stereoview of the active sites of the two
structures shown in (b).
(TIF)
Figure S2 Details of the binding sites of GyrB43 in
complex (a) with ADP?BeF3 and (b) ADP. H-bonds are
depicted by dashed grey lines. The Fo-Fc omit electron density
maps are shown at a contouring level of 3.0 sigma.
(TIF)
Figure S3 Stereoviews of the details of the binding sites
of GyrB43 in complex with (a) AMPPNP, (b) ADP?Pi, (c)
ADP?BeF3 and (d) ADP. H-bonds are depicted by dashed grey
lines. The Fo-Fc omit electron density maps are shown at a
contouring level of 3.0 sigma.
(TIF)
Figure S4 (a) Superimposition of the human topoII in complex
with AMPPNP (PDB entry 1ZXM, dark blue) and in complex
with ADP (light blue) [12]. (b) Active site details of htopoII in
complex with AMPPNP (left) or ADP?SO4 (right), with the Fo-Fc
omit electron density map for ADP, SO4 and Mg
2+ shown at a
contouring level of 3.0 sigma. (c) Stereoview of the structures
shown in (b) after superposition on their ATPase domain. The
exclamation mark indicates the steric clash that would occur
between Q376 in the AMPPNP complex conformation (dark blue)
with the SO4 moiety of the post-hydrolysis mimic state (light blue).
(TIF)
Figure S5 Sequence alignment of the region encom-
passing the QTK loop from representative species of
bacteria, eukaryotes and archaea. The QTK loop is strictly
conserved in topoIIA but absent from topoIIB.
(TIF)
Figure 8. Refined mechanistic scheme of DNA gyrase activity, based on reference [2], representation as in Fig. 1. The N-gate of the
GyrA2GyrB2 heterotetramer with bound G-segment at the central DNA-gate (top) closes upon ATP binding thereby trapping a T-segment in the
upper chamber (step a). Hydrolysis of the two ATP molecules causes a 12u rotation of the respective transducer domains relative to the ATPase
domain (step b). We propose that this conformational change is coupled to DNA gate opening and T-segment translocation. Subsequent Pi release
would be coordinated with G-segment re-ligation and DNA-gate closure (step c). Finally, ADP release results in dissociation of the ATPase domains
and a reset of the enzyme (step d).
doi:10.1371/journal.pone.0107289.g008
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Movie S1 Morphing between the GyrB43?AMPPNP
complex (PDB entry 1EI1 [13]) and the post-hydrolysis
complex GyrB43?ADP?Pi, shown in cartoon representa-
tion with semi-transparent molecular surface overlaid
with the same colors as in Fig. 2 (AMPPNP state in
yellow and ADP?Pi state in magenta). The molecular two-
fold axis is shown as a black line. Views perpendicular (left) and
along (right) the molecular dyad.
(MOV)
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Abstract 
Fic proteins containing the HxFx[D/E]GNGRxxR motif catalyze adenylylation, the 
transfer of an AMP moiety from ATP onto target proteins. This activity has severe 
consequences on the cellular stability and appears to be tightly controlled. Recently, it has 
been shown that adenylylation-competent Fic proteins are specifically inhibited by an α-helix 
(αinh), which can be found at different locations relative to the Fic active site. Mutation of the 
conserved glutamate of the inhibitory motif relieves the inhibition of Fic proteins. Yet, it has 
remained unclear how intrinsic and extrinsic factors contribute to the control of Fic protein 
activation.  
Here, we investigate the heterologous expression of the class III Fic protein NmFic of 
Neisseria meningitidis in Escherichia coli that causes a severe growth defect. We report the 
structural and functional characterization of NmFic and its activation mechanism. We find 
that NmFic is in a monomer–tetramer equilibrium. Both, the target docking site and the active 
site, are located towards the center of this tetramer and are accessible only in the monomeric 
form. Mutation of crucial residues at the interfaces that disrupts the tetramer activates the 
protein. Furthermore, we show that trans-auto-adenylylation of NmFic leads to significant 
conformational changes and that the presence of the auto-adenylylated tyrosine Y183, part of 
the αinh helix, is required for the activity of the Class III Fic protein. We also show that 
adenylylation of the bacterial target GyrB from the DNA gyrase complex by NmFic blocks 
negative supercoiling of DNA and bacterial cell division.  
Overall, these data provide the first insight into an intrinsic regulatory mechanism of a Fic 
protein via oligomerization and auto-adenylylation.  
  
Results | Research article V 
 164 
Introduction 
Fic proteins containing FIC domains (pfam 02661) are found in all kingdoms of life as 
well as in viruses. They have originally been described to be involved in filamentation 
induced by cAMP (1), but until recently, their molecular role had remained elusive. 
Yarbrough et al. (2) deciphered the catalytic activity of the Type III effector protein VopS 
from Vibrio parahaemolyticus as adenylylation of the host cell Rho GTPases, resulting in 
collapse of the actin cytoskeleton and subsequent cell death. Enzymatically, Fic proteins 
containing the canonical HxFx[D/E]GNGRxxR motif catalyze adenylylation (or AMPylation), 
the covalent transfer of an AMP moiety from an ATP substrate onto a target protein (3, 4).  
Fic proteins with an active site deriving from this consensus sequence likely catalyze 
other post-translational modifications. AnkX from Legionella pneumophila harbouring an 
HxFxDANGRxxV motif has been shown to catalyze the phosphocholination of the small 
GTPase Rab1 (5, 6). Doc of bacteriophage P1, a protein related to the Fic family proteins, 
contains the HxFxDANKRxxL active site motif, conferring a kinase activity and the 
phosphorylation of the translation elongation factor EF-Tu (7, 8). 
The crystal structures of several FIC domain proteins have been determined (3, 9-12). 
Fic/Doc proteins contain a conserved central core of four helices that is flanked by additional 
Fic elements found in different positions (13). A loop joining the third and fourth helix of the 
Fic core forms the Fic active site motif. The complex structure of the Fic protein from 
Histophilus somni (IbpA) with its cognate target (Cdc42) reveals the stabilization of the 
modified residue by the β-hairpin region of the Fic protein, thus making the FLAP (or 
β-hairpin) a critical region of the Fic protein for target binding. The catalytic mechanism of 
Fic-mediated adenylylation has been inferred from this structure, where the catalytic histidine 
of the active site motif acts as a general base and deprotonates the attacking hydroxyl group, 
which in turn performs a nucleophilic attack on the α-phosphate of the ATP substrate. This 
results in the formation of a covalent phosphodiester bond between the AMP moiety and the 
modified amino acid. 
The activity of Fic proteins is tightly regulated. A conserved inhibition motif, part of an 
inhibitory alpha-helix (αinh), is located in the close vicinity of the active site (3). It has been 
demonstrated that the strictly conserved glutamate of this motif plays a key role in obstructing 
the γ-phosphate position of the ATP substrate, therefore inhibiting competent substrate 
binding in adenylylating Fic proteins. Interestingly, this inhibition motif is either found on a 
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separate small protein that forms a tight complex with the Fic protein, or at the N-terminus or 
C-terminus compared to the Fic active site within the same polypeptide chain (3, 12). These 
three possibilities lead to a classification of Fic proteins into class I, II and III, respectively (3, 
12). The mutation of this glutamate residue to glycine relieves the inhibition of Fic proteins, 
thus increasing the adenylylation activity (3, 12).  
Yet, the intrinsic or extrinsic factors that affect the conformation of this inhibitory α-helix 
and therefore the catalytic activity have not been investigated. This regulation may depend on 
additional domains found in multi-domain Fic proteins or localization of Fic proteins fused to 
a signal sequence. For the single domain class III Fic proteins, scattered through all classes of 
proteobacteria likely due to horizontal gene transfer, the regulation mechanism is most 
probably inherent. Interestingly, the class III Fic protein NmFic from Neisseria meningitidis 
(N. meningitidis) is auto-adenylylated on two tyrosine residues, Y183 and Y188, located in 
the vicinity of the inhibition motif (3). The strictly conserved tyrosine Y183 is buried, 
pointing towards the Fic core. Modeling of auto-adenylylation of this residue results in steric 
clashes, suggesting a conformational change upon auto-adenylylation. 
Recently, it has been shown that Fic proteins also target bacterial proteins (3) which 
results in bacterial growth arrest. ParE of the topoIV complex and GyrB of the DNA gyrase 
complex are adenylylated by the Class I Fic protein VbhT from Bartonella schoenbuchensis 
(Harms et al., in preparation).  
We here show that the class III Fic protein NmFic, containing the αinh helix at the C-
terminus, specifically adenylylates GyrB, resulting in growth arrest. We report the structure-
function characterization of the regulation mechanism of the class III Fic protein NmFic via a 
new double-lock mechanism. Interestingly, NmFic forms a tetramer with the active site and 
target binding-site buried in the center of the tetramer, inaccessible for target binding. NmFic 
undergoes a monomer-tetramer equilibrium where the active and target binding sites are 
accessible in the monomeric form. Disruption of the tetramer by repellant mutations results in 
bacterial growth arrest by activation of the Fic protein. Ultimately, we show that auto-
adenylylation of the conserved tyrosine Y183 leads to drastic conformational changes, e.g. of 
the αinh helix, that are crucial for the class III Fic protein activity. We anticipate that this 
double-lock mechanism by oligomerization and auto-adenylylation is conserved through all 
class III Fic proteins.  
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Material and Methods 
Plasmid construction 
pRSF-Duet1 derivatives were cloned as described previously (3) and used for over-
expression of proteins for purification. For phenotypic analyses, nmfic genes were cloned into 
pNMD220 (14) under the control of a particularly tight Plac. Site-directed mutagenesis was 
performed following the protocol described by Zheng et al. (15). A list of used plasmids and 
respective oligonucleotides can be found in Table S1 and Table S2.  
Expression – Isotope labeling – Purification 
Plasmids pFVS0015, pFVS0051, pFVS0083, pFVS0109, pFVS0135, pFVS0137, 
pFVS0138, pFVS0143 were transformed into E. coli BL21 (λDE3) cells. Plasmids pFVS0059, 
pFVS0125, pFVS0126 and pFVS0134 were transformed into E. coli BL21 AI cells. NmFic 
and GyrB43 (residues 1-392) proteins were expressed and purified as described previously in 
(3) or (16), respectively. For NMR analysis, [U-13C,15N]-labeled NmFic was obtained by 
growing the expression cells in M9 minimal media (17) supplemented with (15NH4)Cl 
(Cambridge Isotope Labs) and D-[13C]-glucose (Sigma Aldrich) using standard NmFic 
expression and purification conditions. 
SEC-MALLS analysis 
Size exclusion chromatography coupled to multi-angle laser light scattering (SEC-
MALLS) was employed for the determination of the oligomeric state and elution 
concentration of NmFic wild-type and various mutants at different concentrations. SEC-
MALLS analysis was performed as described previously (18). The column was equilibrated 
in 10 mM Tris pH 7.6 and 100 mM NaCl at 4°C.  
SEC-MALLS derived apparent mass values (MWapp) for NmFicwt, NmFicE102R (mutant 1) 
and NmFicE156R (mutant 2) measured in a range of various elution concentrations were fitted 
simultaneously to obtain the dimerization affinities (KD1 and KD2), assuming that both 
interaction interfaces are independent. Therefore, NmFicE102R and NmFicE156R are assumed to 
form only dimers, as one of the interfaces was mutated, and NmFicwt is in monomer-tetramer 
equilibrium, which involves both interfaces. The equilibria were modeled as fast-exchange 
processes with respect to the timescale of chromatographic separation, since all the samples 
yielded a single MALLS peak. The theoretical MWapp values were calculated from mass 
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concentrations (cm,i) and molecular weights (MWi) of populated species (monomer and dimer 
for the interface mutants; monomer, dimers, trimer and tetramer for the other NmFic 
variants): 
!"!"" = !!,!!!!! !!,!! !!!!!!! 1  
The global non-linear least-squares fitting was performed using Levenberg-Marquardt 
algorithm (19, 20). All routines were implemented in the Python language using NumPy and 
SciPy numerical libraries (21). 
Monomer-tetramer equilibrium analysis 
The equilibrium concentrations of individual species for NmFicwt were calculated using 
numerical solution of the set of mass action law equations (22) describing the monomer-
tetramer oligomerization scheme (Fig. S3). The reaction extents were used as state variables 
and inequality constraints were imposed to ensure the correctness of the results. Optimization 
of reaction extents values was accomplished using Sequential Least SQuares Programming 
(SLSQP) method (23) as implemented in the SciPy library (21). 
Spotting experiment 
Escherichia coli K-12 MG1655 were transformed with pNDM220 derivative plasmids 
using TSS transformation (24) and handled in LB liquid medium containing appropriate 
antibiotics as well as 1% (w/v) D-glucose to suppress basal expression before the inoculation 
of experimental cultures. For the counting of colony forming units (CFU/mL), bacterial 
cultures were serially diluted and spotted on LB agar plates containing 0, 50 µM, 100 µM, 
250 µM, 500 µM, 1000 µM or 2000 µM of isopropyl β-D-thiogalactopyranoside (IPTG) and 
30 µg/mL ampicillin which were then incubated at 37°C.  
In vitro adenylylation assay 
Adenylylation assays were performed using crude cell lysate of ectopically expressing E. 
coli as described previously (3) or using purified proteins as described in (12). Adenylylation 
activity of NmFic was assessed by incubating 5 µM NmFic protein with 10 µCi [α-32P]-ATP 
(Hartmann analytic) and 25 µM GyrB43. In addition to radioactively labeled ATP, 62.5 µM 
of cold ATP was added and 200 µM of novobiocin, a potent inhibitor of GyrB43 to prevent 
immediate hydrolysis of ATP by GyrB43. 
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In vivo Supercoiling assay 
In vivo supercoiling assays were performed as described previously (Harms et al., in 
preparation). 
 
NMR spectroscopy 
NMR experiments were performed on a Bruker AscendII 700 MHz spectrometer running 
Topspin 3.0 and equipped with a cryogenically cooled triple-resonance probe. All 
experiments were performed in NMR-buffer (25 mM MES, 150 mM NaCl, pH 6.5) at 25°C. 
For the sequence-specific backbone resonance assignments of NmFic and adenylylated-
NmFic, the following experiments were recorded: 2D 15N-1H TROSY-HSQC (25), 3D HNCA 
(26, 27), 3D HNCACB (26-28), 3D HNCO (29), and 3D HN(CA)CO (30). For the analysis of 
the dynamic properties of NmFic and adenylylated-NmFic the following experiments were 
measured: 15N{1H}-NOE (31), T1(15N) (32), TRACT (33). NMR data were processed with 
PROSA (34) and analyzed with CARA, XEASY (35), and Topspin3.0 (Bruker Biospin). 
Nonlinear least-square fits of relaxation data were done with Matlab (MathWorks). R2(15N) 
values were derived from Ra(15N) and Rb(15N). Error bars for R1(15N), Ra(15N), and Rb(15N) were 
calculated by a statistical bootstrapping scheme and error bars for the 15N{1H}-NOE from the 
spectral noise. Secondary chemical shifts were calculated relative to the random-coil values of 
Kjaergaard and Poulsen (36). 
The chemical shift changes of the amide moiety upon ATP were fitted by non-linear 
regression analysis to Equation 2 by using standard software. ∆obs corresponds to the chemical 
shift difference at a given titration point and ∆max is the maximal chemical shift difference at 
the last titration point. 
∆!"#= ∆!"# !! + ! !"# ! + ! !"#$% ! − (!! + ! !"# ! + ! !"#$% !)! − (4 !"#$% ! !"# !)!2 !"#$% ! !!!!!!!(2) 
Crystallization 
NmFicE156R and NmFicE156R,Y183F (10 and 8 mg/mL, respectively) crystallized in 500 µL of 
precipitant solution containing 10 mM Tris pH 7.8 and 100 mM NaCl using the batch 
crystallization method at 4°C. 
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All other crystals were obtained using the sitting-drop vapor-diffusion method by mixing 
0.2 µL protein solution with 0.2 µL reservoir solution equilibrating against a reservoir of 
80 µL at 20°C except NmFicwt (tetramer form) that crystallized in 7% (v/v) 2-propanol, 0.1 M 
MES pH 6.0, 0.05 M calcium acetate at 4°C. NmFicE102R crystallized after one month in 8% 
(v/v) Tacsimate pH 6.0, 20% (w/v) PEG 3350 and NmFicE102R,E156R crystallized after ten days 
in 8% (v/v) Tacsimate pH 5.0, 30% (w/v) PEG 1500. NmFicY183F,E186G crystallized in 0.1 M 
Tris pH 8.0, 30% (w/v) Jeffamine M-600 pH 7.0. For data collection, crystals were 
cryoprotected by soaking into a reservoir solution supplemented with 15-30% glycerol and 
subsequently flash-frozen in liquid nitrogen.  
 
Structure determination 
X-ray data were collected at the Swiss Light Source (Villigen, Switzerland) on beamline 
X06SA (PXI) or X06DA (PXIII) at 100 K and a wavelength of 1.000 Å or 0.800 Å (Table 1). 
Diffraction data were indexed and integrated using iMosflm (37) or XDS (38) and 
subsequently merged and scaled using XSCALE (38) or aimless (39). NmFicwt diffracted to 
3.10 Å. NmFicE156R, NmFicE102R and NmFicE102R,E156R diffracted to 0.99 Å, 2.35 Å and 1.90 Å, 
respectively. NmFicY183F,E186G and NmFicE156R,Y183F respectively diffracted to 2.20 Å and 1.00 Å. 
Data collection and processing statistics are summarized in Table 1. Structures were 
determined by molecular replacement using Phaser (40) with NmFicwt (PDB: 3S6A (3)), 
devoid from ligand or ordered solvent, as search model. Several rounds of model building and 
refinement were performed using Coot (41) and Refmac5 (42) or phenix.refine (43). 5% of 
the data were excluded from refinement and used for cross-validation. The geometry of the 
final model was assessed using MolProbity (44) showing > 99% of the residues in the core 
and allowed regions of the Ramachandran plot. Final refinement yielded NmFic models with 
reasonable Rwork/Rfree values for their respective resolution ranges (45). Refinement statistics 
are summarized in Table 2. 
 
Figures were prepared with Dino (A. Philippsen unpublished, http://www.dino3d.org). 
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Results 
NmFic undergoes a monomer–tetramer equilibrium 
Crystals of NmFicwt grown at high protein concentration belong to the space group P65 
and contain four molecules per asymmetric unit. These four molecules form a non-
crystallographic 222 tetramer that contains two equivalent dimers (Fig. 1 (a,b) and Fig. S1 
(b)). The same tetramer form is observed for NmFic∆8, a deletion mutant of the αinh helix (α8) 
that had been previously determined from non-isomorphous crystals (3). Isologous contacts 
are observed at the interfaces of NmFicwt between subunits A-B, C-D and A-D, B-C, 
respectively (Fig. 1). The first interface (buried surface area of 420.3 +/- 1.1 Å2) forms 
hydrophobic interactions and two symmetrical salt-bridges between residues R149 and E156 
of two neighboring monomers (Fig. 1 (d)). The second interface (826.1 +/- 11.3 Å2) forms the 
same type of interactions, with salt-bridges between residues R71 and E102 (Fig. 1 (c)). The 
residues involved in these interfaces are conserved in class III Fic proteins as shown by the 
multiple sequence alignment (Fig. S2). Consequently, analysis of the oligomeric state of 
NmFicwt in solution revealed the presence of multimeric forms in a concentration dependent 
manner (Fig. S1 (a)). Size exclusion chromatography coupled to multi-angle laser light 
scattering (SEC-MALLS) was performed, revealing a single peak that varies in elution 
volume and apparent molar mass (from 22 kDa to 88 kDa) with varying total protein 
concentration. This shows that the protein is in a monomer–tetramer equilibrium in fast 
exchange with respect to the timescale of chromatographic separation (Fig. 2 (a)).  
The Fic active site is located in the center of the tetramer and the β-hairpin forming the 
target-binding site (FLAP) is deeply buried (Fig. 1 (a,b,e), yellow and light blue, respectively). 
Modeling of the binding of a small target fragment based on the superimposition of the 
IbpA/Cdc42 complex structure (PDB: 4ITR (10)) on the FLAP region of NmFic reveals 
several steric clashes (depicted by stars on Fig. 1 (e)). It is therefore well conceivable that 
NmFic in this tetrameric form is incompetent for target binding and that a lower oligomeric 
state, i.e. monomer or dimer, is the active species. 
To test this hypothesis, we engineered variants of NmFic carrying single amino acid 
mutations (glutamic acid to arginine) of the salt-bridges formed at both dimerization 
interfaces, NmFicE102R and NmFicE156R. The crystallographic structures of NmFicE102R and 
NmFicE156R were determined (Tables 1-2). These structures reveal that the dimerization 
interfaces are maintained as in the tetrameric wild-type protein (Fig. 3). The interface areas 
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for NmFicE102R and NmFicE156R are 418.6 Å2 and 779.4 Å2, respectively, and thus virtually 
identical to the tetramer (420.3 ± 1.1 Å2 and 826.1 ± 11.3 Å2, respectively). Residue E102 is 
involved in a salt-bridge with E71 of the FLAP in the wild-type protein and the mutation 
NmFicE102R leads to an increase in flexibility of the FLAP region as evidenced by the lack of 
electron density for residues 62–77. The high-resolution structure (0.99 Å) of NmFicE156R 
reveals the exact same dimer as observed within the tetrameric crystal form (RMSD of 0.989 
Å for Cα atoms).  
The multimerization equilibrium of these two proteins, as well as the double mutant, was 
assessed by SEC-MALLS. As expected, these mutants do not form a tetrameric species, but 
undergo a monomer–dimer equilibrium (22 kDa – 44 kDa) via the remaining interface (Fig. 2 
(a)). The combination of both mutations in NmFicE102R,E156R reveals a constant mass of 22 kDa 
(monomer) at various protein concentration (Fig. 2 (a)). From these data, the dimerization 
constants (Kd) for NmFicE102R (mutant 1) and NmFicE156R (mutant 2) were determined to Kd1 = 
7.4 ± 1.4 µM and Kd2 = 59.9 ± 11.8 µM, respectively. Note that the smaller dimerization 
interface features the higher affinity. The independent global fitting of the monomer–dimer–
tetramer equilibrium of the wild-type protein yielded 7.6 ± 1.1 µM and 61.3 ± 8.8 µM for KD1 
and KD2, respectively (Fig. S3, Fig. 2 (a) and Table 3). These values are virtually identical in 
the precision of the experiment, indicating directly that the two interfaces are not connected 
by cooperativity. Based on the dissociation constants, the concentration-dependences of 
monomeric, dimeric, trimeric and tetrameric species of NmFicwt were calculated (Fig. 2 (b)). 
At total NmFic concentrations below 2 µM, NmFic is mostly present as monomers, whereas 
above this threshold, tetrameric species populate. Importantly, since most protein is 
sequestered as tetramers, the monomer concentration reaches a value of just 5 µM at a total 
NmFic concentration of 1 mM (Fig. 2 (b)). In contrast, the monomer concentrations in the Fic 
mutants are much larger, with 60 µM and 150 µM for mutant 1 (NmFicE102R) and mutant 2 
(NmFicE156R) respectively at 1 mM total concentration (Fig. 2 (c) and S4). As monomer and 
tetramer are the predominant species, the monomer-tetramer equilibrium of NmFicwt can also 
be fitted with a single effective dissociation constant KDef of 21.8 ± 1.0 µM (Table 3). 
NmFic targets GyrB of the DNA gyrase complex 
As the next step, we aimed to identify the target of NmFic within E. coli. VbhT, a Fic 
protein from the α-proteobacteria Bartonella schoenbuchensis adenylylates its own ParE and 
GyrB, as well as the homologous proteins from E. coli (Harms et al., in preparation). In turn, 
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though VbhT adenylylates both proteins, the in vivo supercoiling activity of GyrB is only 
faintly affected by VbhT when the decatanation activity of ParE is drastically inhibited by the 
expression of the Fic protein VbhT. Because of the similar growth defect phenotype of E. coli 
induced by expression of VbhT and the inhibition-relieved mutant of NmFic (NmFicE186G) (3, 
12), we tested the adenylylation of E. coli GyrB and ParE by NmFicE186G. Interestingly, this 
inhibition-relieved mutant of the class III Fic protein from N. meningitidis (3, 12) specifically 
adenylylates E. coli GyrB but not ParE, suggesting a different mechanism of the bacterial 
growth inhibition (Fig. 4 (a)). Furthermore, NmFicE186G adenylylates GyrB of N. meningitidis 
stronger than the homologous in E. coli (Fig. 4 (a)). Mutation of the adenylylated tyrosine 
109 from E. coli GyrB (to alanine or phenylalanine) completely abolishes the adenylylation of 
GyrB, showing that GyrB is specifically adenylylated on this residue. The tyrosine 109 from 
GyrB is located in the N-terminal ATPase domain of GyrB and conserved in bacterial 
topoisomerases. This residue is part of the ATP lid-loop (46) and involved in a weak contact 
with the N3 of the adenine ring of the ATP substrate of GyrB (47). The adenylylation of 
GyrB results in the inhibition of ATP hydrolysis (Harms et al., in preparation), which is 
required for the DNA supercoiling activity of DNA gyrase that is essential for bacterial 
growth (48, 49).  
Like novobiocin at the high concentration of 100 µg/mL, the expression of NmFicE186G in 
E. coli results in collapse of the negative supercoiling of a reporter plasmid (Fig. 4 (b)). No 
effect can be observed with the catalytically inactive NmFicH107A,E186G mutant, showing that the 
observed loss of supercoiling activity directly results from the adenylylation of GyrB by the 
inhibition-relieved mutant NmFicE186G (Fig. 4 (b)). This is in contrast with the effect of VbhT 
on GyrB, which does not inhibit the in vivo supercoiling activity of GyrB (Harms et al., in 
preparation).  
Tetramerization deficient mutants induce growth defects and adenylylate GyrB  
Knowledge of the target enabled us to evaluate the activity of NmFic mutants of the 
dimerization interfaces in vitro by adenylylation assay. For in vivo characterization (E. coli 
model), bacteria (E. coli K12 MG1655) were transformed with plasmids containing nmfic 
genes, grown in liquid culture, and serial dilutions of exponentially growing bacteria were 
spotted on LB-agar plates supplemented with increasing amounts of IPTG (form none to 
2 mM) (Fig. 5 (a)). Colony forming units were counted allowing the quantification of 
bacterial growth defect upon expression of the different NmFic mutants. Compared to the 
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wild-type or the catalytically inactive mutant in which the first histidine of the Fic active site 
motif has been mutated (2), NmFicE102R (mutant 1), NmFicE156R (mutant 2) and NmFicE102R,E156R 
(monomer) mutants show a severe growth defect in dependence of the induction level (Fig. 5 
(a,b)). This growth defect was quantified for each mutant, resulting in the loss of 1.5, 3.0, and 
1.5 log10 CFU/mL of viability for NmFicE102R, NmFicE156R and NmFicE102R,E156R, respectively. 
In addition to the loss in colony number, the colonies exhibited a drastically smaller size (Fig. 
5 (a)). Furthermore, expression of the combination of the dimerization interface mutants with 
the H107A mutation (catalytically inactive) abolishes the growth defect of E. coli, similarly to 
the expression of wild-type tetrameric NmFic (Fig. 5 (a,b)). These observations evidence that 
the catalytic activity of NmFic is responsible for the growth defect of bacteria expressing the 
dimerization interface mutants. In vitro, an adenylylation assay revealed that purified NmFic 
mutants of the dimerization interface adenylylate the target GyrB (N-terminal fragment 
containing the ATPase and transducer domains). These results are in agreement with the in 
vivo results, clearly showing that the catalytically inactive mutants are unable to transfer 
radioactively labeled α-32P-AMP on GyrB (Fig. 5 (c) and Fig. S5). These observations rely so 
far on the total concentration of NmFic proteins expressed for in vivo quantification or the 
total concentration of pure protein in the in vitro assays. 
It is interesting to compare the growth defect to the NmFic monomer concentration rather 
than the total concentration. For that purpose, a conversion factor (ratio) between IPTG and 
total NmFic concentration was applied, with a concentration of 100 µM of inducer (IPTG) 
leading to 1 µM of total NmFic protein (Fig. 6 (a)), based on different IPTG/NmFictotal ratios 
that were tested graphically (Fig. 6 (b) and Fig. S6 (a-c)). At this ratio, the concentration of 
monomer in the NmFicwt (forming tetramer) stays rather low (< 1 µM) at a total NmFic 
concentration of 10-20 µM. This is in contrast with the mutant 1, mutant 2 and monomer 
mutant, in which the monomer concentration is very close to the total NmFic concentration. 
Fig. 6 (b) shows that for NmFicwt, a sufficient concentration of monomeric Fic protein cannot 
be achieved with the maximal level of induction that can be used experimentally. This points 
towards a threshold level of NmFic that can be tolerated by the cell and here not obtained in 
wild-type NmFic, where the tetramer acts as a sponge that stores the active NmFic species. 
Taken together, these results reveal a first level of regulation of NmFic by oligomerization. 
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Structural investigation of auto-adenylylated NmFic by NMR 
To understand the effect of auto-adenylylation of NmFic, we investigated the changes 
induced by auto-modification of a catalytically inactive monomer mutant 
(NmFicE102R,H107A,E156R) in solution using high-resolution nuclear magnetic resonance (NMR). 
NmFic is auto-adenylylated on two tyrosines positioned in the close vicinity of the conserved 
inhibitory glutamate, that is part of the αinh helix (helix 8) (3). Modeling of auto-adenylylation 
on tyrosine 183 and 188 results in steric clashes with the Fic core, suggesting a putative 
conformational change upon auto-adenylylation of NmFic. Intriguingly, tyrosine Y183 is 
strictly conserved in class III Fic proteins. We obtained well-dispersed NMR spectra for a 
native and an auto-adenylylated sample (inactive monomer mutant that was adenylylated by 
the addition of trace amounts of hyperactive NmFicΔ8, Fig. S7). Sequence-specific resonance 
assignments were obtained for 95% and 93% for native and adenylylated NmFicE102R,H107A,E156R, 
respectively. Analysis of the chemical shift changes upon auto-adenylylation revealed that the 
helix 1, the inhibitory helix 8 (αinh) and the FLAP region (Fig. 7) are the most affected regions 
upon adenylylation. The changes in the helix 1 are highly likely a direct result of the auto-
adenylylation of helix 8 possibly leading repulsion of both helices from the Fic core. This 
movement will then lead to the activation of NmFic by active-site opening, with auto-
adenylylation being the intrinsic factor that expulses the inhibition motif from the ATP 
binding site, relieving the inhibition of class III Fic proteins. We used the chemical shifts of 
the backbone 13Cα and 13Cβ nuclei to identify the secondary-structure elements of both 
NmFic forms in solution. NmFic features eight α-helices in solution, that corresponds in their 
number and positioning to the crystalline structure (Fig. S8). In addition, residues 62–66 of 
the FLAP region exhibit a small β-sheet. These secondary elements remain upon adeny-
lylation, showing only a slight decrease of about 15% percent of helical content in helix 1. 
The opening of the γ-phosphate binding site upon adenylylation, leads to a two-fold 
increase of the affinity of ATP binding compared to the native unadenylylated form, with 
respective dissociation constants of 4.0 ± 1.2 mM and 7.8 ± 1.1 mM (Table 4 and Fig. S9). 
These constants are rather high, but are in excellent agreement with similar observations for 
Doc, the toxin of bacteriophage P1 that phosphorylates EF-Tu, with a KD of 7.2 mM for an 
ATP analog in the absence of target. Strikingly, upon pre-formation of a Doc–EF-Tu complex, 
the affinity for the substrate increases by ~ 105-fold to 0.26 µM (7). This effect can be 
deduced to the fact that the FLAP region is responsible for target binding but also needs to 
provide important residues for ATP binding and the base-binding pocket. We observed a high 
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degree of flexibility in the FLAP-region on the picosecond–nanosecond timescale by 
measurement of 15N{1H}-NOE measurements. This dynamic behavior was further evidenced 
by a reduction in the T1-relaxation time as well as by the absence of electron density in this 
region in crystal structures. Therefore a significant increase of the substrate affinity upon 
GyrB binding and subsequent stabilization of the FLAP to enhance ATP binding in-line with 
the Doc–EF-Tu interaction can be expected. 
Presence of the auto-adenylylated tyrosine 183 of NmFic is required for activity 
To investigate further the role of auto-adenylylation, we mutated the tyrosine 183 and 
tested the effect in vivo. Since NmFicwt is known to be inhibited by a tight tetramer formation, 
we investigated the effect of Y183 on the inhibition-relieved mutant NmFicE186G (3, 12). 
Comparison of NmFicE186G to NmFicY183F,E186G shows that the growth defect phenotype of 
NmFicE186G is completely abolished by the Y183F mutation (Fig. 8 (a)). To rule out any 
significant structural changes upon Y183F mutation, we compared the crystal structures of 
both aforementioned proteins. Both structures are very similar, with root mean square 
deviation (RMSD) of 0.306 Å for the Cα atoms (0.684 Å for all atoms) after superimposition 
(50) (Fig. 8 (b)). These in vivo and structural results clearly indicate that the auto-
adenylylation of residue Y183 is crucial for the activity of the protein. Additionally, the 
combination of mutants of the dimerization interface (mutant 1, mutant 2 and monomer 
mutant) with the mutation of Y183 also re-established normal growth of E. coli cells (Fig. 8 
(a)), while leading to no structural changes as evidenced by the RMSD of 0.228 Å for the Cα 
atoms (0.428 Å for all atoms) for the mutant 2 (NmFicE156R) and the mutant 2 Y183F 
(NmFicE156R,Y183F) obtained at 1.0 Å resolution (Fig. 8 (c)). 
The SEC-MALLS analysis of the inhibition-relieved NmFicE186G mutant reveals a less 
stable tetramer that NmFicwt (Fig. 9 (a) and Table 3) with a tetramerization KDef of 190.0 ± 9.5 
µM (NmFicE186G) compared to 21.8 ± 1.0 µM (NmFicwt), albeit the mutation is far away from 
oligomerization interfaces. A double mutation Y183F, E186G has an opposite effect, making 
the tetramer much tighter (Table 3). There may be an effect of auto-adenylylation on the 
lower affinity of NmFicE186G since the purified protein is expected to be partially auto-
modified, as revealed by an increased A260/A280 ratio (data not shown). The monomer 
concentration of the E186G mutant compared to the total concentration reveals that this 
mutant, even though still forming a tetramer, has monomer levels very close to the dimer 
mutants (Fig. 9 (b)).  
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Altogether, combination of solution NMR analysis, crystallographic analysis and in vivo 
growth analysis reveals that the auto-adenylylation of NmFic is a required mechanism of 
relief of inhibition in class III Fic proteins. This layer of control is accompanied by the 
regulation through tetramerization to tightly control the adenylylation of the target GyrB. 
 
Discussion 
Fic proteins need to be tightly regulated due to their highly toxic activity both in the 
prokaryotic and eukaryotic cells (2, 3) (Harms et al., in preparation). The crystal structure 
shows that tetrameric Fic can not be competent for target binding, due to burying of the target 
binding site in the core of the tetramer. On a first level of regulation, disassembly of the 
tetrameric state is thus essential for activation of the Fic protein. Our activation model 
assumes that the cell can compensate for the deleterious effects of a small intracellular 
concentration of monomeric NmFic, up to a level at which the inhibition of DNA gyrase by 
NmFic is not bacteriostatic. In vitro oligomerization analysis yields a maximal level of 2 µM 
for monomeric Fic. This value could be modulated in vivo, due to molecular crowding effects 
in the cytosol or additional binding partners that would facilitate the tetramer formation. A 
level of 1-2 µM of monomer, corresponding to 600-1200 molecules per bacteria, would be 
sufficient to inhibit the 1300 GyrB molecules (A. Schmidt, personal communication), thus the 
DNA gyrase machinery and negative supercoiling in the cell, resulting in cell growth arrest. 
Dimers and monomers of NmFic are toxic for E. coli, but the toxicity does not accumulate 
from dimers to monomer (Fig. 5). At rather low concentration, the concentration of monomer 
is very close to the total protein concentration (Fig. 2 (c)), and therefore no significant 
difference is expected. The mutant 1 and monomer are less toxic than the mutant 2, which can 
not be rationalized from the interfaces. Nonetheless, both mutant 1 and monomer mutant 
harbor the E102R mutation, residue that is located below the target binding site (FLAP) and 
may contribute to target binding, since it is unlikely that three main chain–main chain 
hydrogen bonds of the FLAP are sufficient for target binding and specificity. Alternatively, 
this mutation may also slightly alter GyrB binding. We can not exclude that a dimer (mutant 1, 
mutant 2 or both) is/are also active in a natural environment. Nonetheless, the low abundance 
of these species within the monomer-tetramer equilibrium of wild-type NmFic (Fig. 2 (b)) 
makes it highly unlikely that the dimers have a major role in the activity of NmFic in the cell.  
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The neutralization of toxic proteins is a common scheme in biology. Binding of antitoxins 
to toxins is a quite common way to neutralize toxins of all kind prior to their intended 
activation in time or location. The E. coli relB/RelE protein complex is a characteristic 
example of such a toxin-antitoxin system (14). The relBE toxin-antitoxin system acts as 
transcriptional autoregulation system. In the case of nutritional starvation, transcription from 
the relBE operon gets dramaticaly increased and the level of RelB antitoxin is reduced by 
Lon-dependent proteolysis, a common mechanism of antitoxin degradation (51). The 
liberation of the RelE toxin results in cellular growth arrest (52). Keeping a protein in an 
inactivated oligomeric state, like tetramerization for NmFic, is an elegant way to control 
protein function that can be activated directly by an external trigger. In this case, the protein 
acts as its own antitoxin. Similar activation mechanism can also be found for the bacterial 
chaperone trigger factor, directly interacting in the monomeric form with a large variety of 
nascent chains on the ribosome (53), which is in the cytosol in a monomer-dimer equilibrium 
that can be modulated depending on the growth conditions (54, 55). Trigger factor dimerizes 
with an apparent KD of 18 µM, in the same range as the effective KDef of NmFicwt (21.8 ± 1.0 
µM). Furthermore, the plant Ultraviolet-B radiation photoreceptor UVR8, responsible for 
adaptation to UV, is inactive as a dimer but active as a monomer. In the ground state, inactive, 
UVR8 is present as a homodimer that monomerizes within seconds of UV-B irradiation (56). 
The active monomer then interacts with COP1, resulting in changes in gene expression, 
acclimation and UV-B tolerance (57).  
A second level of control is provided by auto-adenylylation of NmFic. We propose that 
this auto-adenylylation is the intrinsic factor that expulses the strictly conserved glutamate of 
the inhibition motif, thus relieving the inhibition of class III Fic proteins. This is evidenced by 
in vivo effects of the mutation of the strictly conserved Y183 within class III Fic proteins. 
Additionally, the investigation of the auto-adenylylation in solution by NMR reveals chemical 
shift changes of residues belonging to the αinh helix, the helix that is responsible for the 
inhibition of competent ATP binding (3, 12). Changes in the chemical shifts of the helix α1 
are likely an effect of the movement of helix α8, since this is the adjacent helix that will be 
affected by the introduction of the adenylylation on Y183. The observed changes within the 
FLAP is likely due to the binding of the target in the auto-adenylylated form, whereas the 
target here is the intermolecular helix α8. 
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Is there a link between the oligomerization and auto-adenylylation? First, it is worth 
noting that a target cannot bind to the tetrameric form of NmFic, i.e. here the helix 8 acting as 
an intermolecular target. Auto-adenylylation occurs via binding of the helix α8 (αinh) on the 
FLAP of another monomer and covalent transfer of AMP on the tyrosine 183. Once auto-
adenylylated, the helix α8 cannot fold back to its original inhibitory position, relieving the 
auto-inhibition. Interestingly, the NmFicE186G mutant of the inhibitory glutamate has a much 
lower affinity for both forms of dimers within the tetramer as observed by the shifted 
monomer-tetramer equilibrium towards higher concentration (Table 3). The helix α8 lies on 
the surface of the tetramer and is not involved in dimerization interfaces. Additionally, 
NmFicE186G is found endogenously auto-adenylylated. This observation indicates a putative 
link between oligomerization and auto-adenylylation, where adenylylation has an enhancing 
effect on monomerization. The auto-adenylylation of the mutant 1, mutant 2 and monomer 
mutant are required for the activity of these proteins, as evidenced by the experimental in vivo 
growth data. The monomer and dimer mutants are also active, showing that the auto-
adenylylation is not only involved in disrupting the oligomer but rather in an own activity. 
Altogether, the informations obtained on auto-adenylylation show that the auto-adenylylation 
per se is required for the activity of the protein, expulsing the inhibitory helix from the ATP 
binding site, but most likely needs the monomerization of NmFic beforehand. Commonly, 
auto-adenylylation has been observed for most Fic proteins investigated so far (10, 11, 13, 58-
60) but its putative role within the functional cycle of these proteins was not yet addressed. 
Therefore, the regulatory function of auto-adenylylation for class III Fic proteins may indicate 
that auto-modification is also involved in the control of catalytic activities of class I and 
class II FIC domains and could thus be a general feature of Fic proteins. 
In summary, our experiments suggest a model for Fic activation (Fig. 10). Upon an 
initiation signal that remains still elusive, the NmFic tetramer is disrupted which liberates the 
FLAP, enabling target binding. The disruption of the tetramer is followed by a second layer of 
regulation, auto-adenylylation. This modification of monomers leads to full activation of the 
protein by expulsion of the inhibitory alpha helix. Once a certain level of auto-adenylylated 
monomer is present in the cell, adenylylation of GyrB from the DNA gyrase subunit blocks 
efficiently the bacterial growth, resulting in a bacteriostatic effect. Our study revealed the 
tight two-step regulation of class III Fic proteins and identified its biological role as a 
negative regulator of the DNA-gyrase machinery. 
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Table 3. Dissociation constants for the dimerization of NmFic via the interface 1 (KD1) 
or interface 2 (KD2). 
 
 KD1 [µM] KD2 [µM] Effective KD [µM] ** 
NmFicE102R 
Local fitting 7.4 ± 1.1 - - 
Global fitting 7.6 ± 1.1 - - 
NmFicE156R 
Local fitting - 59.9 ± 11.8 - 
Global fitting - 61.3 ± 8.8 - 
NmFicwt 7.6 ± 1.1 61.3 ± 8.8 21.8 ± 1.0 
NmFicY183F * 7.2 ± N/A 56.2 ± 2.7 20.4 ± 1.0 
NmFicE186G * 66.1 ± N/A 511.9 ± 25.9 190.0 ± 9.5 
NmFicY183F,E186G * 3.6 ± N/A 28.1 ± 1.9 10.3 ± 0.7 
 
* Both dissociation constants were not fitted individually, but with a ratio of KD2 = 7.74 * KD1, 
assuming both interfaces are affected similarly by the mutations that are not part of the 
interface. 
** The effective KD (KDef) represents a value of the dissociation constant where KD1 = KD2.  
 
 
Table 4. Dissociation constants for the interaction of NmFic or auto-adenylylated 
NmFic with ATP for selected residues. 
 
Residue Native NmFic KD [mM] Auto-adenylylated NmFic KD [mM] 
K140 7.0 ± 0.7 5.7 ± 0.8 
T141 9.0 ± 1.4 4.8 ± 1.3 
I105 6.7 ± 0.3 3.0 ± 0.9 
G69 9.0 ± 0.4 3.2 ± 0.4 
G68 7.3 ± 0.7 3.2 ± 0.5 
Median 7.8 ± 1.1 4.0 ± 1.2 
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Figure 1. Tetrameric structure of the class III Fic protein NmFic. (a) Crystal structure of 
the NmFic 222 tetramer in P65 crystal form shown in surface representation. Local symmetry 
axes are indicated by black lines: monomer A in pink, B in brown, C in blue and D in green. 
The Fic active site motif is highlighted in yellow and the FLAP in light blue. Equivalent 
dimers within the tetramer are formed by AB, CD and AD, BC (b) Cartoon representation as 
in (a). (c) Close-up view of the AD dimerization interface, with contact area of ~ 826 Å2. (d) 
Close-up view of the AB dimerization interface, with contact area of ~ 421 Å2. Hydrogen-
bonds are depicted as dashed black lines. Indices of the labeled residues refer to the respective 
monomers. (e) Superimposition of the switch I region of Cdc42 (violet) on NmFic based on 
the IbpA/Cdc42 complex structure (PDB: 4ITR (10)). The main-chain of the target sterically 
clashes with the other subunits (shown as blue and green surfaces) of the NmFic tetramer 
(clashes indicated by black stars).  
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Figure 2. Dynamic monomer–oligomer equilibrium of NmFic. (a) Concentration 
dependence of the effective molecular weight as determined by MALLS for different variants 
of NmFic. The points are experimental data points, the lines are the result of a non-linear fit 
of the monomer–oligomer model of Figure S3. The resulting dissociation constants are shown 
in Table 3. (b) Molecular concentrations of oligomeric species of NmFicwt as a function of the 
total protein concentration, as calculated from the dissociation constants KD1 and KD2. (c) 
Concentration of monomeric protein as a function of total protein concentration for different 
variants of NmFic, as indicated. 
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Figure 3. Crystal structures of NmFicE102R and NmFicE156R. (a) Structure of NmFicE102R 
(pink/orange) superimposed with the AB dimer as part of the NmFicwt tetramer (dark/light 
gray). The active site is colored in yellow in both structures. The FLAP region is not observed 
in the crystal structure due its flexibility and absence of crystal contacts (top). Only the 
corresponding molecules are shown for clarity. (b) Close-up view of the conserved 
hydrophobic and hydrophilic interactions between the tetramer form and the NmFicE102R form. 
(c) Structure of NmFicE156R (pink/green) superimposed with the AD dimer as part of the 
NmFicwt tetramer (dark/light gray). (d) Details of the conserved interaction site.  
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Figure 4. In vitro adenylylation of DNA gyrase by NmFic and in vivo inhibition of 
negative supercoiling. (a) Autoradiogram of in vitro adenylylation assay using α-32P-ATP 
with crude cell lysates of E. coli ectopically expressing full-length and GST-tagged GyrB or 
ParE constructs from various organisms, incubated with pure inhibition-relieved NmFicE186G. 
The red arrow indicates the auto-adenylylation of NmFic, the blue arrow the adenylylation of 
endogenously expressed GyrB, the yellow arrow the adenylylation of GST-tagged GyrB from 
E. coli, the green arrow the adenylylation of GST-GyrB from N. meningitidis and black 
arrows the adenylylation of GST-GyrB from Bartonella species. (b) Complete in vivo 
inhibition of the negative supercoiling ((-)sc) activity of DNA gyrase by the inhibition-
relieved NmFicE186G protein at a similar level as the potent inhibitor novobiocin revealed by 
chloroquine agarose gel electrophoresis.   
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Figure 5. Growth defect of E. coli expressing NmFic variants. (a) Spotting experiment of 
E. coli MG1655 (λDE3) expressing NmFic derivatives on plates containing 0 or 2000 µM of 
the expression inducer IPTG. Note the remarkable growth defect, both in colony number and 
colony size, of the NmFicE102R, NmFicE156R and NmFicE102R,E156R mutants. (b) Quantification of 
E. coli growth defect. The bars represent the average of three independent experiments and 
the error bars represent the standard deviation. (c) In vitro adenylylation assay with purified 
NmFic proteins and purified GyrB43 (N-terminal 43-kDa fragment comprising the ATPase 
and transducer domains).  
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Figure 6. Bacterial growth defect correlates with the concentration of monomeric NmFic. 
(a) E. coli growth defect depending on IPTG concentration or equivalent of NmFic total 
concentration, assuming 100 µM IPTG correspond to 1 µM NmFic total protein (2nd 
horizontal axis). (b) E. coli growth defect depending on the monomer concentration of NmFic, 
assuming the same ratio as in (a).   
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Figure 7. Structural perturbations of NmFic by auto-adenylylation. (a) Combined 
chemical shifts difference of the backbone amide moiety, ∆δ(HN) between unmodified and 
auto-adenylylated NmFicE102R,H107A,E156R as function of the residue number. Unassigned 
residues are colored in black and residues exhibiting significant line-broadening in the 
adenylylated form are depicted in white. (b) Plot of the same chemical shift differences on the 
structure of monomeric NmFic using the same color code as in panel (a). The largest 
chemical shift differences cluster in helices α1 and α8 (αinh), and in the FLAP region. 
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Figure 8. Mutation of Y183 abolishes the growth defect of NmFic without affecting the 
local protein structure. (a) Quantification of the E. coli growth defect. The bars represent 
the average of two independent experiments and the error bars the standard deviation. (b) 
Superimposition of NmFicE186G (beige) and NmFicY183F,E186G (violet) with an RMSD of 0.306 Å 
for the Cα positions. (c) Superimposition of NmFicE156R (light gray) and NmFicE156R,Y183F 
(orange), with an RMSD of 0.228 Å for the Cα positions.  
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Figure 9. Dynamic monomer–oligomer equilibrium of NmFic mutants. (a) SEC-MALLS 
analysis of the oligomeric state of NmFic mutants of the auto-adenylylated tyrosine (Y183F, 
purple), of the inhibitory glutamate (E186G, black) or combination of both mutations (Y183F 
E186G, yellow). Respective dissociation constants are reported in Table 3. For comparison, 
wild-type, mutant 1, mutant 2, and monomer mutant are shown in the same colors as in Fig. 2. 
(b) Comparison of the monomer concentration (NmFicmonomer) versus total protein 
concentration (NmFicTotal) for the wild-type protein and mutants of the dimerization interface 
or of the auto-adenylylated tyrosine 183, using the same color code as in panel (a). 
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Figure 10. Regulation mechanism of class III Fic proteins. (a) In normal conditions, the 
monomer-tetramer equilibrium is in favor of the tetramer formation. (b) Upon a certain signal, 
the monomer-tetramer equilibrium is pushed towards the monomer. The monomer is then 
auto-adenylylated, which results in a conformational change of the helix α8 (αinh) and the 
neighboring helix α1. The Fic protein is now active and able to adenylylate its target GyrB, 
leading to the inhibition of negative supercoiling and inhibition of bacterial growth. 
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Figure S1. Dynamic equilibrium of NmFicwt from monomer to tetramer. (a) Dynamic 
equilibrium of NmFicwt on the time-scale of the Size Exclusion Chromatography (SEC) 
experiment. SEC analysis using an analytical S75 16/60 column (GE Healthcare) with a 
flowrate of 0.5 mL/min loaded with 50 µL of wild-type NmFic at various loading 
concentrations (gray-scale from dark-gray [1680 µM] to light-gray [1.7 µM]). (b) The NmFic 
222 tetramer observed in the P65 crystal form shown as ribbon representation (same as Fig. 1).  
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Figure S2. Amino acid conservation in class III Fic proteins. The alignment contains one 
representative sequence for each of 41 organisms. The alignment was calculated using 
MUSCLE (Multiple Sequence Comparison by Log-Expectation) (61) 
(http://www.geneious.com). 
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Figure S3. Thermodynamic model of NmFic multimerization. (a) Schematic view of the 
equilibrium and (b) set of mass action law equations. (M = monomer, D1 = dimer 1, D2 = 
dimer 2, T = trimer, Q = tetramer). 
  
Results | Research article V 
 200 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4. Dynamic equilibrium of NmFic tetramerization-deficient mutants. Species 
profile calculated with the equilibrium constants (a) KD1 for NmFicE102R, (b) KD2 for NmFicE156R 
and (c) NmFicE102R,E156R. The red curves represent the fitted experimental MALLS data.  
Results | Research article V 
 
 201 
 
 
 
Figure S5. Adenylylation assay with pure NmFic proteins and pure GyrB43. (a) SDS-
PAGE and (b) autoradiography of the SDS-PAGE gel after incubation of NmFic variants with 
[α-32P]-ATP and pure GyrB proteins. The dimerization interface mutants catalyze the 
adenylylation of the target protein GyrB. 
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Figure S6. Calculated IPTG/[NmFicmonomer] ratios. Different equivalence and the resulting 
plots as in Figure 6 (b), with (a) 100 µM IPTG = 0.01 µM NmFic, (b) 100 µM IPTG = 0.1 
µM NmFic and (c) 100 µM IPTG = 10 µM NmFic. 
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Figure S7. NMR fingerprint spectra of unmodified and auto-adenylylated NmFic. 
Overlay of 2D [15N,1H]-HSQC spectra of 0.5 mM [U-13C,15N]-labelled monomeric, inactive 
NmFic (NmFicE102R,H107A,E156R) (blue) and of 0.25 mM [U-13C,15N]-labelled adenylylated 
monomeric inactive NmFic (NmFicE102R,H107A,E156R) (red). Measurements were performed at 
700 MHz in(25 mM MES pH 6.5, 150 mM NaCl, at 25°C. The sequence specific resonance 
assignment is indicated.  
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Figure S8. Secondary structure analysis of unmodified and adenylylated NmFic. 
Combined secondary chemical shifts for 13Cα and 13Cβ of (a) unmodified and (b) 
adenylylated NmFicE102R,H107A,E156R, plotted against the amino acid residue number. A 1–2–1 
weighting function for residues (i-1) – i – (i+1) has been applied to the raw data. Consecutive 
stretches of positive and negative values indicate α-helix and β-sheet secondary structure 
elements, respectively. Heteronuclear NOE (left) and T1 relaxation (right) experiment of (c) 
unmodified NmFic and (d) auto-adenylylated NmFic.  
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Figure S9. Effect of ATP binding on the NmFic monomer. Backbone amide chemical shift 
perturbations for selected residues upon titrating of (a) ATP to [U-13C,15N]–
NmFicE102R,H107A,E156R (starting concentration 500 μM) and (b) ATP to adenylylated [U-
13C,15N]–NmFicE102R,H107A,E156R (starting concentration 250 μM). The lines represent nonlinear 
least–squares best–fits of the normalized changes in the 1H and 15N chemical shifts using a 
bimolecular equilibrium binding model. The optimized value of the equilibrium dissociation 
constant is 7.8 ± 1.2 mM for (a) and 4.0 ± 1.1 mM for (b). Chemical shift differences of the 
amide moiety of (c) native monomeric NmFic and (d) auto-adenylylated monomeric NmFic 
with Δδ(HN) as a function of the ATP concentration, relative to apo NmFic with a gradient 
from yellow (unchanged chemical shift) to purple (chemical shift change of 0.05 ppm and 
above). (c) Native monomeric NmFic and (d) auto-adenylylated monomeric NmFic.   
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3.6. Towards an understanding of the structure-function of Fic-
mediated inhibition of bacterial topoisomerases 
In research article III, we identified the bacterial topoisomerases GyrB and ParE as 
targets of VbhT from Bartonella schoenbuchensis. GyrB is part of the DNA gyrase complex 
(GyrA2GyrB2) that catalyzes the introduction of negative supercoils into covalently closed 
double-stranded DNA molecules. ParE, together with ParC, forms the molecular 
nanomachine topoIV specialized in the decatenation of DNA molecules, separating daughter 
chromosomes during replication. In research article V, we could show that NmFic 
specifically targets GyrB but not ParE.  
On the molecular level, GyrB and ParE are adenylylated on a conserved tyrosine, Y109 of 
E. coli GyrB or Y105 of E. coli ParE, that is part of the ATP lid-loop. In this chapter, I aim to 
reveal the molecular details of GyrB or ParE adenylylation. 
3.6.1. Enzymatic reactions 
GyrB + ATP ↔ GyrB•ATP → GyrB + ADP + Pi    (1) 
Fic + ATP + GyrB ↔ Fic•ATP•GyrB → Fic + GyrB-AMP + PPi    (2) 
GyrB-AMP + ATP ↔ GyrB-AMP•ATP    (3) 
 
 
3.6.2. Crystal structure of the adenylylated form of GyrB 
To understand the effect of the adenylylation of GyrB, I crystallized the adenylylated form 
of GyrB43 in complex with ATP. GyrB43 consists of the N-terminal 43-kDa fragment of 
GyrB comprising the ATPase and transducer domains (residues 1-392). The crystal diffracted 
to 2.6 Å and the structure was solved by molecular replacement. The structure reveals a 
conserved dimer between the native form (PDB: 1EI1) and the newly determined 
adenylylated form of GyrB (RMSD of 1.05 Å for the Cα positions). Strikingly, adenylylated 
GyrB adopts a different conformation of the ATP-lid loop (Figure 3.6.1 and Table 3.6.1), with 
an RMSD of 4.65 Å for the Cα positions of this region. The loop is expulsed from the cavity 
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that forms the ATP binding site. Intriguingly, the natural substrate ATP (not an ATP analog) 
is bound to the active site of the ATPase domain and not hydrolyzed. A weak H-bond has 
been described between the N3 of the adenine and the hydroxyl group of Y109123. 
Interactions between the ligand (ATP) in adenylylated GyrB or ligand analog (AMPPNP) in 
native GyrB are very similar (compare Figure 3.6.1.b and 3.6.1.c), except the loss of the weak 
interaction between the hydroxyl group of Y109 and the N3 of the adenine. The latter 
observation, i.e. non-hydrolyzed ATP, raises the question whether the adenylylation of GyrB 
has an effect on the catalytic activity of the ATPase domain. 
Table 3.6.1. Pair-wise fit of adenylylated GyrB43 and native GyrB43 after superposition of the 
ATPase domains of the subunit A. The values give the RMSD (Å) of the corresponding Cα positions.  
 
RMSD (Å) 
Dimer Monomer A Monomer B 
Residues 4-386 1.05 0.99 1.11 
Residues 4-103 and 113-386  
(all except the ATP lid loop) 
0.78 0.64 0.89 
Residues 104-112  
(ATP lid loop) 
4.65 4.95 4.32 
 
As shown in research article III (Figure 2B from research article III), adenylylation of 
GyrB by VbhTAE24G completely abolishes the ATPase activity of GyrB. Further, I tested 
different ratios of VbhTAE24G to GyrB, keeping GyrB constant (25 µM) and increasing 
VbhTAE24G from 0 to 50 µM (Figure 3.6.2). The rate of inhibition of GyrB by VbhTAE24G is 
concentration-dependent and a low concentration of VbhTAE24G completely blocks the 
ATPase activity of GyrB after an extended time, i.e. after full target adenylylation has been 
achieved. Adenylylation of GyrB acts as a non-competitive inhibition of the ATPase activity 
of GyrB. 
This shows that VbhTAE24G efficiently adenylylates GyrB and thus blocks its ATPase activity. 
Nonetheless, I was not able to observe a stable complex in vitro, even at high protein 
concentration (> 250 µM). 
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Figure 3.6.1. Crystal structure of adenylylated GyrB compared to native GyrB. (a) Super-
imposition of adenylylated GyrB and native GyrB reveals a conserved fold and conformation (light 
yellow for native GyrB and light red for adenylylated GyrB). The ATP lid-loop adopts a different 
conformation upon adenylylation (native GyrB colored in yellow and adenylylated GyrB colored in 
red). The Fo-Fc omit map (dark gray) is shown for adenylylated GyrB, where only the main chain has 
been observed due to lack of crystal contacts and high flexibility of the loop. (b) Details of the active 
site of native GyrB and (c) details of the active site of adenylylated GyrB, revealing a non-hydrolyzed 
ATP molecule in the Fo-Fc omit map (dark gray). The Fo-Fc omit map is also shown for the ATP lid-
loop (residues 103-112). Hydrogen bonds are depicted as black dashed lines in (b) and (c). 
GyrB43 in complex with AMPPNP (PBD: 1EI1) Adenylylated-GyrB43 in complex with ATP 
ATP lid loop 
Y109 
(a) 
(c) (b) 
S5* 
Y5* 
ATP lid loop 
ATP lid loop 
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Figure 3.6.2. Inhibition of the ATPase activity of GyrB by VbhTAE24G in a concentration-
dependent manner. (a) Full time course of the inhibition of GyrB by VbhTAE24G and (b) 
zoom-in on the early time points of (a). 
 
3.6.3. Crystallization strategies 
As a first crystallization strategy, I tried to form a GyrB:Fic (the Fic protein being here 
NmFic or VbhTA) complex using GyrB and Fic proteins purified in separate batches. Purified 
GyrB and Fic were mixed in a 1:1 ratio (250 µM each) with a 10-fold molar excess of ATP 
(or AMPPNP) and MgCl280. The protein mixture was incubated for 2 hours on ice and 
subjected to crystallization screening. No crystals containing GyrB:Fic complexes were 
obtained, only crystals containing either the Fic protein or GyrB. The structures of Fic 
proteins couldn’t be used further as these were identical to the already known structures, but 
GyrB structures revealed new conformations dependent on the nucleotide state that have been 
described in section 3.4., research article IV. 
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In order to enhance the chances of crystallization of a complex, I implemented or 
developed different strategies: (i) the fluorescent trace-labeling of GyrB or the Fic protein to 
monitor the crystallization of each partner in the crystal, (ii) the fusion of Fic-GyrB based on 
a model of putative interactions using a flexible (G4S)X linker, and (iii) the cross-linking of 
the Fic protein with GyrB via a functionalized ATP substrate that will be covalently attached 
to both proteins. 
3.6.2.1. Fluorescent trace-labeling of each protein 
Fluorescent trace-labeling has been developed by Forsythe et al.162 in the group of Marc 
Pusey163 to monitor the appearance of very small crystals and discriminate between salt 
crystals and protein crystals. However, the applicability of fluorescent trace-labeling of 
proteins for crystallization goes beyond these original applications. It can be adapted to 
monitor the appearance of crystals containing a complex of proteins for example. At the time 
of adapting the technique in the lab for this purpose, a ready-to-use kit was not available (now 
available from Molecular Dimensions, MD1-72). Therefore, I adapted the protocol from 
Forsythe et al. and also obtained advices from Marc Pusey. The labeling procedure allowed 
the labeling of 0.1-0.5% of the proteins on random lysine side chains, in good agreement with 
published values. I used carboxyrhodamine (CR) and tetramethylrhodamine carboxylic acid 
(TAMRA).  
To visualize the fluorescence, I used a Leica DM6000 microscope with the N2.1 filter 
(Figure 3.6.3.a). As a pilot experiment, I couldn’t find a better compromise in terms of 
fluorophore and filters with a fluorophore containing a succinimidyl ester group allowing the 
random labeling of lysine side chains. Importantly, flat bottom plates should be used for lower 
background fluorescence and better crystal detection. Despite the suboptimal setup, 
fluorescent crystals were obtained (Figure 3.6.3.b), both with CR or TAMRA. Each 
crystallization drop contained only one fluorophore, i.e. one drop contained labeled GyrB and 
unlabeled Fic protein, the next drop contained fluorescent Fic protein and non-fluorescent 
GyrB and as control, the last drop only contained unlabeled Fic protein and GyrB. 
Interestingly, the presence of fluorescent trace-labeled protein did not impede the 
crystallizability of the proteins. No crystals containing fluorescent GyrB and fluorescent Fic 
proteins could be obtained.  
Results | 3.6. 
 216 
Nonetheless, this technique is very powerful for the detection of crystals and can 
theoretically be applied to various different protein complexes. 
 
Figure 3.6.3. Crystallization of fluorescent trace-labeled proteins. (a) Absorption and emission 
spectrum of carboxyrhodamine (top) and TAMRA (bottom) compared to the setup of the Leica 
DM6000 microscope with filter N2.1. (b) Fluoresecent crystals obtained using the setup shown in (a). 
3.6.2.2. Fusion of GyrB-Fic proteins using a flexible linker 
Natural flexible linkers are found between domains of proteins, allowing conformational 
changes. Non-natural linkers can be used to produce chimeras, i.e. multi-domain proteins 
from two different proteins that are not naturally found together or are even from different 
organisms. Engineered fusion proteins can also be used for the crystallization of low-affinity 
complexes or for non-crystallizing components164. As an example, the full-length E. coli 
gyrase complex structure recently obtained by electron microscopy was a fusion protein of the 
GyrA and GyrB polypeptide chains of Thermus thermophilus122.  
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The superimposition of the adenylylated-GyrB on Cdc42 and NmFic or VbhTA on IbpA 
from the IbpA/Cdc42 complex (PDB: 4ITR) revealed that the C-terminus of the helix α8 of 
NmFic or the C-terminus of VbhA from the VbhTA complex are at about 21-25 Å of the N-
terminus of GyrB. Therefore, a chimera was engineered between NmFic-GyrB and VbhA-
GyrB using a flexible (GGGGS)2-4 linker165. Soluble fusion proteins were obtained and 
subjected to crystallization screening. Again, no crystals containing a full fusion protein could 
be obtained, only degradation products, e.g. GyrB. 
3.6.2.3. Cross-linking the Fic protein with its cognate target via a functionalized 
ATP substrate analog 
 
3.6.2.3.1. A serine interacts with the 2’-OH of the ribose 
In VbhTAE24G in complex with ATP, a serine interacts with the 2’-OH of the ribose via 
hydrogen-bond. In NmFic, the position of the serine is occupied by a methionine. Interesingly, 
the modeling of a cysteine in both proteins instead of the serine or methionine results in an 
appropriate distance for S-S cross-linking if a sulfur would be on the 2’ position of the ribose. 
Ligand cross-linking will here allow the trapping of a covalent complex between the Fic 
protein and the adenylylated GyrB via the transferred AMP moiety. 
3.6.2.3.2. 2’-SH-ATP custom synthesis  
2’-SH-ATP was custom synthesized by Trilink Biotechnologies, Inc. and obtained as a 
100 mM solution containing 10 mM of DTT to prevent the formation of 2’-SH-ATP dimers.  
3.6.2.3.3. Can 2’-SH-ATP be used by a Fic protein to adenylylate GyrB?  
A pre requisite for the feasability of this project is the binding of the modified ATP to the 
Fic protein, in particular to the mutated Fic protein containing a serine to cysteine mutation at 
position 175. The ATPase activity of GyrB was monitored using the same assay as described 
previously, with 2’-SH-ATP as substrate (see section 3.3., research article III and section 
3.6.1.). Additionally, the inhibition of GyrB by VbhTAE24G and VbhTS175CAE24G was tested 
using 2’-SH-ATP. First, GyrB is able to hydrolize 2’-SH-ATP, though slower than the natural 
substrate ATP (Figure 3.6.4). Noteworthy, 2’-SH-ATP is also a substrate for the Fic protein 
VbhT (VbhTS175CAE24G) as shown by the inhibition of substrate hydrolysis by GyrB (Figure 
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3.6.4). This result confirms the feasability of the protein-substrate-protein cross-link via the 
functionalyzed ATP molecule covalently transferred to GyrB as a functionalyzed AMP. 
 
Figure 3.6.4. Inhibition of GyrB by VbhTAE24G or VbhTS175CAE24G using functionalized ATP. (a) 
Inhibition of GyrB by VbhTAE24G using ATP or 2’-SH-ATP and (b) inhibition of GyrB by 
VbhTS175CAE24G using ATP or 2’-SH-ATP. 
 
3.6.2.3.4. Structure of VbhTS175CAE24G with covalently bound 2’-SH-ATP  
VbhTS175CAE24G was co-crystallized with the ligand analog 2’-SH-ATP and MgCl2. 
Crystals diffracted to 1.8 Å and well-defined electron density was obtained for the protein 
region and the ligand (Figure 3.6.5). The 2’-SH-ATP ligand was covalently bound to 
VbhTS175C via a disulfide bond (S-S) between the 2’SH group of the ligand and the SH group 
of cysteine 175. The ribose pucker is different in the natural ligand and the functionalized 
ligand 2’-SH-ATP, 2’-endo and 3’-endo respectively. Strikingly, the base (adenine) and the 
tri-phosphate superimposes very well despite the distortion of the ribose conformation. This 
flexibility of the ribose was anticipated by the few interactions observed between the ribose 
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and the protein in the structure of VbhTAE24G in complex with ATP (Figure 3.6.5). These 
interactions include a weak hydrogen bond between the 3’-OH of the ribose and the side 
chain of arginine R147 (3.2 Å distance) and a strong hydrogen bond between the 2’-OH of the 
ribose and the side chain of serine S175 (2.4 Å). The hydrogen bond between serine 175 and 
the 2’-OH of the ribose is replaced by a covalent disulfide bond between the cysteine 175 and 
the 2’-SH in VbhTS175CAE24G:2’-SH-ATP, as anticipated by the design of the functionalized 
ligand and mutant protein. The distance between the two sulfur atoms of the disulfide bond 
has been refined to 2.1 Å, slightly larger that the ideal value of 2.05 Å166 and is in good 
agreement with the electron density (Figure 3.6.5). The CS-SC dihedral angle is of 98°, close 
to the ideal value at which the S-S bond strength is the highest that had been determined to 
90°167. The comparison of the structure of VbhTS175CAE24G in a covalent complex with 2’-SH-
ATP with the structure of VbhTAE24G in complex with ATP (PDB: 3ZC7) reveals a competent 
binding of the substrate, now covalently cross-linked to the protein via a disulfide bond 
(Figure 3.6.5). This will be used for the crystallization of a covalent complex with the 
adenylylated target GyrB, on which the AMP moiety will act as a linker between the Fic 
protein and the DNA gyrase subunit. 
3.6.2.3.5. Formation of a covalent ternary complex between VbhTS175CAE24G, 2’-SH-
ATP and GyrB  
As mentioned in the previous paragraph, VbhTS175CAE24G forms a covalent complex with 
the functionalized ligand 2’-SH-ATP that binds in a competent conformation. This complex is 
then preformed in vitro (for a detailed protocol, see section 3.6.4. and Figure 3.6.7) and then 
mixed with the target GyrB in presence or absence of AMPPNP. 
As preliminary medium-throughput method, non-reducing SDS-PAGE analysis was used 
as readout to discriminate between covalently cross-linked complexes and non-complexed 
proteins (Figure 3.6.6). Using different concentrations of oxidizing agent (diamide or H2O2), I 
could show that a fraction of complex is obtained with a rather high concentration (10 mM) of 
diamide or H2O2 (oxidizing agent). There is a clear concentration correlation between 
complex formation and diamide concentration. To further prove that the band observed 
around 70 kDa is a covalent complex via a disulfide bond, the samples were compared using 
non-reducing (NR) or reducing (R) loading dye. As anticipated, the cross-linked complex is 
only observed in presence of non-reducing (NR) loading dye (Figure 3.6.6). 
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Figure 3.6.5. Crystal structure of VbhTS175CAE24G with covalently bound 2’-S-ATP. (a) Details of 
the active site of VbhTAE24G in complex with ATP (PDB code: 3ZCB). VbhT is colored in light gray 
with the active site loop colored in yellow. VbhA is colored in pink. (b) Stereoview of (a). (c) Active 
site details of VbhTS175CAE24G with covalently bound 2’-S-ATP via a disulfide bond between the γ-
sulfur of cysteine 175 and the 2’-sulfur of the functionalized ATP. A Fo-Fc omit map contoured at 3 σ 
is shown in dark gray, VbhT is colored in beige with the active site loop in yellow and VbhA is 
colored in blue. (d) Stereoview of (c). (e) Stereoview of the superimposition of VbhTAE24G in complex 
with ATP and VbhTS175CAE24G with covalently bound 2’-S-ATP. 
Unexpectedly, the covalent complex between VbhTS175CAE24G, 2’-SH-ATP and GyrB is 
only obtained in presence of AMPPNP, which is required for the formation of a GyrB 
homodimer. This suggests that VbhT will preferentially target GyrB in the dimer form, even 
though we could show in vitro by adenylylation assays that VbhT or NmFic targets a 
fragment of GyrB (15-392) that lacks the N-terminal arm and is therefore dimerization 
deficient (data not shown).  
These preliminary results are a proof of principle that the custom synthesized 2’-SH-ATP 
is a substrate for the Fic protein that can be covalently bound to the mutated Fic active site via 
a disulfide bond between an engineered cysteine and the thiol group on the 2’ position of the 
ribose. Further, the covalently bound 2’-SH-ATP is in a competent conformation for AMP 
transfer. 2’-S-AMP covalently bound to the Fic active site is transferred on GyrB, resulting in 
a covalent quaternary complex VbhAE24G/VbhTS175C-2’-S-AMP-GyrB. 
Varying reducing and oxidizing agents and their respective concentrations or optimizing 
the time and temperature of each step can improve the conditions in which the complex is 
obtained. Furthermore, the SDS-PAGE may be too harsh for the complex and the low amount 
of cross-linked complex may result as an artifact of the readout. Therefore, size exclusion 
chromatography will be used in the future to discriminate and separate the complex from the 
non-complexed proteins to obtain a homogeneous sample for further crystallization 
experiments. 
Because crystallization may not be straightforward for such a complex, a combination of 
cross-linking via the disulfide bond with fluorescent trace labeling may be an elegant way to 
discover small crystals. 
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Figure 3.6.6. Evaluation of the formation of a covalent VbhTS175CAE24G:2’-S-AMP-GyrB complex 
by SDS-PAGE analysis. (a) SDS-PAGE analysis of samples containing different concentrations of 
diamide, H2O2 or DTT. (b) Same samples as in (a) with the addition of 10 mM diamide in all reaction 
during the adenylylation reaction. (c) SDS-PAGE gel using non reducing (NR) or reducing (R) 
loading dye to confirm the covalent VbhTS175CAE24G:2’-S-AMP-GyrB complex. 
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3.6.4. Material and Methods related to section 3.6  
Cloning – Recombinant plasmids pFVS0065 (genes encoding VbhT and VbhAE24G) and 
pFVS0109 (gene encoding GyrB43 comprising residues 1-392) were described in section 3.2., 
research article II and section 3.3., research article III, respectively. A two-base pair 
mutation was introduced in plasmid pFVS0065 to obtain plasmid pFVS0229 (genes encoding 
VbhTS175C and VbhAE24G). 
Protein expression and purification – Proteins were expressed and purified as described in 
section 3.2., research article II for VbhT/VbhA complexes and as described in section 3.3., 
research article III for GyrB43.  
Crystallization – For crystallization, GyrB43, VbhTAE24G and VbhTS175CAE24G were 
concentrated to 10.75 mg/mL, 8 mg/mL and 4 mg/mL, respectively. Prior to the co-
crystallization of adenylylated-GyrB with ATP, GyrB43 was incubated for two hours at 4°C 
with an equimolar ratio of the adenylylator VbhTAE24G and a 10-fold molar excess of ATP 
and MgCl2. GyrB43 crystallized (without removal of VbhTAE24G or ligand/ion) in 0.2 M Tri-
ammonium citrate pH 7.5 and 22% (w/v) PEG 2000 MME. VbhTS175CAE24G co-crystallized 
with 5 mM 2’-SH-ATP, 5 mM MgCl2 and 5 mM DTT in a solution containing 0.2 M lithium 
acetate dihydrate pH 7.9 and 20% (w/v) PEG 3350. Crystals were cryo-protected by transfer 
in a reservoir solution supplemented with 30% glycerol and subsequently flash frozen and 
stored in liquid nitrogen until data collection. 
Structure determination – X-ray diffraction data were collected at the Swiss Light Source 
(Villigen, Switzerland) on beamline X06DA (PXIII) at 100 K and a wavelength of 1.0000 Å. 
Diffraction data were indexed and integrated using XDS168 and subsequently merged and 
scaled using XSCALE168 or Aimless169 for the structure of adenylylated-GyrB in complex 
with ATP or the structure of VbhTS175CAE24G in complex with 2’-SH-ATP. Data collection 
and processing statistics are summarized in Table 3.6.2. Structures were determined by 
molecular replacement using Phaser with GyrB43 (PDB: 1EI1124) and VbhTA 
(PDB: 3SHG170) respectively, devoid from ligand or ordered solvent, as search model. 
Several rounds of model building and refinement were performed using Coot171 and 
Refmac5172 or phenix.refine173. 5% of the data were excluded from refinement and used for 
cross-validation. The geometry of the final model was assessed using MolProbity174. Final 
refinement yielded models of adenylylated-GyrB in complex with ATP and VbhTS175CAE24G 
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in complex with 2’-SH-ATP with respective Rwork/Rfree (%) values of 19.6/26.9 and 16.1/21.1. 
Refinement statistics are summarized in Table 3.6.3. 
Quantification of Fic-mediated inhibition of the ATPase activity of GyrB by FPLC assay – 
The quantification of the inhibition of GyrB by VbhTAE24G was performed as described in 
section 3.3., research article III. Additionally, the ratio of GyrB:VbhTAE24G protein was 
increased from 1:50 to 1:1.  
Formation of a covalent VbhTS175CAE24G:2’-SH-AMP:GyrB complex via crosslink of the 
thiol group of the engineered ligand – 2’-SH-ATP was designed for the purpose of our 
experiment and ordered as a custom synthesized ATP analog from Trilink Biotechnologies, 
Inc. To ensure the monomerization of 2’-SH-ATP, the nucleotide was incubated in a 1:1 ratio 
with DTT for 2 hours at room temperature (adapted from Sigma Aldrich online protocol for 
thiol-modified oligonucleotide reduction). VbhTS175CAE24G is then incubated with a 40-fold 
molar excess of reduced 2’-SH-ATP for 5 hours at room temperature to allow complex 
formation. To form a covalent complex between the 2’-SH-ATP and VbhTS175CAE24G via the 
2’-SH group and the cysteine 175, increasing concentration of oxidizing agent (H2O2 or 
diamide) from 1 to 10 mM were incubated overnight at 4°C with VbhTS175CAE24G:2’-SH-ATP. 
The excess of nucleotide is then removed by size exclusion chromatography and the A260/A280 
absorption ratio is measured to evaluate the formation of covalent complex (varying between 
0.63 and 0.81). GyrB is then added to the sample with or without an 80-fold molar excess of 
AMPPNP. An aliquot of each sample supplemented with non-reducing loading dye (60 mM 
Tris-HCl pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 0.01% (w/v) bromophenol blue) is 
loaded on a 4-20% SDS-PAGE gel and stained. For a pictorial view of the protocol, see 
Figure 3.6.7. 
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Figure 3.6.7. Pictorial view of the complex formation protocol.  
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Table 3.6.2. Data collection statistics. 
 
Adenylylated GyrB43 in 
complex with ATP 
VbhTS175CAE24G in complex with 
2’-SH-ATP 
X-ray source SLS X06DA (PXIII) SLS X06DA (PXIII) 
X-ray detector Pilatus 2M Pilatus 2M 
Wavelength (Å) 1.0000 1.0000 
Space group P 2 21 21 P 1 21 1 
Cell dimensions 
a, b, c (Å) 
β (°) 
79.33 137.82 85.45 
 
43.805 64.309 45.633 
94.13 
Matthews coeff. (Å3/Da) 2.77 2.21 
Solvent content (%) 55.24 43.98 
Mol. per asym. unit 2 2 (1 VbhT, 1 VbhA) 
Resolution limits (Å) 72.62 - 2.6 (2.69 - 2.60) 45.51 - 1.80 (1.87 - 1.80) 
Total reflections 75’686 (6’157) 79’516 (7’554) 
Unique reflections 26’998 (2’501) 23’325 (2’273) 
Multiplicity 2.8 (2.5) 3.4 (3.3) 
Completeness (%) 91.45 (86.24) 99.52 (98.52) 
Mosaicity 0.58 0.24 
⟨ I / σ(I)⟩  7.94 (1.53) 7.5 (2.6) 
Rmerge † (%) 12.7 (64.7) 9.7 (42.5) 
Rmeas ‡ (%) 15.46 13.6 (59.5) 
CC1/2 98.9 (60.8) 99.0 (82.9) 
Numbers in parentheses belong to the outer shell. 
† Rmerge = ∑hkl∑i |Ii(hkl) - ⟨I(hkl)⟩| / ∑hkl∑i Ii(hkl), where Ii(hkl) is the observed intensity for a reflection 
and ⟨I(hkl)⟩ is the average intensity obtained from multiple observations of symmetry-related 
reflections.  
‡ Rmeas = ∑hkl [N/(N-1)]
1/2 ∑i |Ii(hkl) - ⟨I(hkl)⟩| / ∑hkl∑i Ii(hkl), where Ii(hkl) is the observed intensity for a 
reflection, ⟨I(hkl)⟩ is the average intensity obtained from multiple observations of symmetry-related 
reflections and N is the number of observations of intensity I(hkl). 
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Table 3.6.3. Refinement statistics. 
 Adenylylated GyrB43 in 
complex with ATP 
VbhTS175CAE24G in complex 
with 2’-SH-ATP 
PDB code N/A N/A 
Resolution limits (Å) 72.62 - 2.6 (2.69 - 2.60) 45.51 - 1.80 (1.87 - 1.80) 
Rwork * (%) 19.62 (24.40) 16.15 (18.80) 
Rfree ** (%) 26.92 (33.55) 21.06 (27.45) 
Number of non-H atoms 6’033 2’292 
           -  macromolecules 5’862 2’040 
           -  ligands 62 32 
           -  solvent 109 220 
Protein residues 766 248 
RMSD bond lengths (Å) 0.013 0.021 
RMSD bond angles (°) 1.61 1.99 
Ramachandran 
favored/allowed *** (%) 
93.7 (98.8) 99.2 (100.0) 
Ramachandran 
outliers *** (%) 
1.2 0.0 
Clashscore *** 7.11 5.21 
Average B values (Å2) 33.50 17.20 
           -  macromolecules 33.90 16.10 
           -  ligands 19.70 16.50 
           -  solvent 20.90 26.80 
Numbers in parentheses refer to the outer shell. 
* Rwork = ∑hkl|| Fobs| - |Fcalc|| / ∑hkl|Fobs| 
** Rfree is the R value calculated for 5% of the data set that was not included in the refinement. 
*** Molprobity 
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3.7. Research article VI (Stanger et al., in preparation for Acta Cryst. F)  
 
Crystal structure of the E. coli class I Fic protein EcFicT in complex with EcFicA 
 
Frédéric V. Stanger, Christoph Dehio & Tilman Schirmer 
 
Manuscript in preparation 
Format: Article for Acta Crystallographica Section F  
  
3.7.1. Statement of my own contributions 
I designed and performed all the experiments presented in the research article VI. I cloned, 
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4. Concluding remarks 
4.1. Regulation of Fic proteins 
Adenylylation is tightly regulated in Fic proteins. The presence of an α’-helix that is 
located either at the N-terminus or C-terminus compared to the Fic active site had been first 
mentioned by Kinch et al79 in a structure comparison. In section 3.1., research article I, we 
showed that this α-helix, named αinh, can also be found as part of a separate protein, 
exemplified by the VbhT/VbhA complex. 
4.1.1. The crucial role of the alpha inhibitory helix (αinh) 
The αinh helix (described in detail in section 3.1., research article I and section 3.2., 
research article II) can be found on a separate small protein that forms a tight complex with 
the Fic protein, or at the N-terminus or C-terminus to the Fic active site within the same 
polypeptide chain, resulting in the classification of Fic proteins into class I, II and III. The αinh 
helix acts in all three classes of Fic proteins via a conserved mechanism of active site 
obstruction. The helix contains an inhibition motif [S/T]xxxE[G/N], with the strictly 
conserved glutamate playing a key role by competing with the γ-phosphate binding sub-site. 
In the three classes of Fic proteins, the truncation of the conserved glutamate allows the 
substrate to bind in the active site in a conformation competent for the transfer of AMP onto a 
target protein. In turn, when the active site is obstructed by the inhibition motif, the substrate 
can still bind but is forced into a conformation in which the nucleophilic attack by the 
deprotonated hydroxyl group from the target side chain is impossible. 
Interestingly, Fic proteins target eukaryotic as well as prokaryotic proteins. It has first 
been revealed that VopS from Vibrio parahaemolyticus or IbpA from Histophilus somni 
targets Rho GTPases. We have later shown that the Fic proteins VbhT from Bartonella 
schoenbuchensis and NmFic from Neisseria meningitidis target bacterial proteins, which lead 
to a growth defect phenotype upon expression of the inhibition-relief mutant of these 
respective proteins (section 3.1., research article I). ParE of the topoIV complex and GyrB of 
the DNA gyrase complex have been identified as bacterial targets of the class I Fic protein 
VbhT (section 3.3., research article III). Interestingly, the class III Fic protein NmFic 
exclusively targets GyrB (section 3.5., research article V). 
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For class I Fic proteins (VbhT/VbhA), dissociation of the toxin-antitoxin complex allows 
the relief of inhibition (research article I). In section 3.3., research article III, we show that 
the Fic toxin-antitoxin system VbhTA, amongst others, promotes bacterial persister formation 
via a novel physiological pathway involving inhibition of both type IIA topoisomerases with 
concomitant collapse of DNA topology. For the class III Fic protein NmFic, an intramolecular 
conformational change resulting in loosening of the interactions between the αinh helix and the 
Fic core is needed to relieve the inhibition. In section 3.5., research article V, we show that 
the class III Fic protein NmFic is regulated by a double-lock mechanism, via oligomerization 
and auto-adenylylation. 
4.1.2. The unexpected role of the oligomeric state  
The oligomerization of Fic proteins had so far only been described for the Class II Fic 
protein SoFic from Shewanella oneidensis that contains a C-terminal winged-helix DNA 
binding domain77. SoFic forms a dimer that brings the two helix-turn-helix (HTH) domains in 
suitable distance for DNA binding77. This dimerization and DNA binding may be part of the 
regulation mechanism of this class II Fic protein, part of the largest sequence cluster of Fic 
proteins, but further investigations are required to confirm the putative role of the HTH 
domain or dimerization. 
The class III Fic protein NmFic belongs to the smallest class of Fic protein in terms of 
sequences, but these sequences are scattered through α- to ε-proteobacteria, resulting from 
horizontal gene transfer. NmFic undergoes a fast monomer-tetramer equilibrium on the time-
scale of size exclusion chromatography experiments. The crystal structure of NmFic reveals a 
tetramer in which the active site and target-binding site (FLAP, β-hairpin) are located towards 
the center of the tetramer with 222 symmetry. In this form, target binding is impossible due to 
steric hindrance. The 222 tetramer can be described as a dimer of dimers. Strikingly, mutation 
of residues located at the dimerization interface that disrupts the interface results in a growth 
defect of E. coli that expresses these mutants. In the monomeric state, the active site and 
target binding site are accessible. 
Oligomerization of NmFic acts as a sponge (buffer) that stores the active species, i.e. the 
monomers, within the tetramer where the active and target binding sites are not available for 
the adenylylation of a target protein. This elegant way of neutralizing the toxic protein was 
unexpected and deciphered by structure-function analysis of NmFic. The de-oligomerization, 
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i.e. monomerization of NmFic is necessary but not sufficient for the activity of NmFic. A 
second level of control of NmFic requires the auto-adenylylation of a conserved residue 
located on the αinh helix, tyrosine 183. 
4.1.3. Auto-adenylylation as a new player 
Auto-modification of Fic proteins has been observed since the first study revealing the 
catalytic role of these enzymes66 and subsequently for all Fic proteins that have been 
described to date (see section 1.5.2. and section 3.4., research article IV). It has been used as 
a convenient target-independent read-out for Fic protein activity that allowed investigating the 
role of the Fic active site residues80 and to reveal the inhibition mechanism of Fic 
proteins170,175. Auto-adenylylation, i.e. the transfer of an AMP moiety onto the Fic protein 
itself, is similar to the auto-phosphorylation process of kinases176. The well-described auto-
phosphorylation mechanism can occur intramolecularly (in cis) or intermolecularly (in trans). 
The occurrence of auto-modification in Fic proteins stimulated speculative discussion about 
its role as a putative transient intermediate82,100, about a nonspecific reaction or whether auto-
adenylylation has functional consequences80. The transient intermediate that would be 
supported by a ping-pong mechanism has been first disproven by Luong et al.,82, showing that 
VopS forms a ternary complex with ATP and the target and that direct AMP transfer occurs 
on the target.  
We investigated the role of auto-adenylylation using our class III model protein NmFic 
from Neisseria meningitidis. NmFic has been shown to be auto-adenylylated on tyrosine 
Y183 and tyrosine Y188, located within the inhibition motif (section 3.1., research article I). 
As described in section 3.4., research article IV, tyrosine Y183 is buried in the core of the Fic 
protein and strictly conserved in class III Fic proteins. Tyrosine Y188 is exposed to the 
solvent. Mutation of the conserved tyrosine Y183 abolishes the growth defect induced by the 
active Fic proteins without perturbation of the fold and without conformational change. 
Investigation of the structural effect of auto-adenylylation of NmFic by NMR revealed that 
upon auto-adenylylation, the helices 1 and 8 (αinh) are perturbed.  
Auto-adenylylation is likely the intrinsic factor that plays a key role in the relief of 
inhibition of auto-inhibited Fic proteins. Auto-adenylylation of the alpha-inhibitory helix 
(αinh) of NmFic (class III) likely expulses this αinh, resulting in a free gamma-phosphate 
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binding site that allows competent ATP binding in the Fic active site and efficient AMP 
transfer. 
4.2. Fic proteins preferentially recognize NTPases 
4.2.1. Adenylylation of GTPases disrupts effector binding 
Fic-mediated adenylylation has originally been described as a modification of the small 
GTPases Rho, Rac and Cdc4266,75. This modification occurs in the switch I region of the 
target. Fic-mediated phosphocholination of Rab proteins occurs in the switch II region of 
these GTPases52. Recently, it has been shown that Doc is a kinase that phosphorylates the 
translation elongation factor EF-Tu at the C-terminus of this GTPase97,98. Adenylylation of 
GTPases by IbpA or VopS results in collapse of the actin cytoskeleton and cell death. The 
addition of a bulky group on the Y32 or Rac and Cdc42 or Y34 or RhoA of the switch I 
region inhibits the interactions with downstream effectors, leading to the phenotype described 
above. 
4.2.2. Adenylylation of bacterial DNA gyrase blocks the ATPase activity of GyrB 
We have recently identified a new class of enzymes as Fic targets. The bacterial 
topoisomerases GyrB and ParE from the DNA gyrase complex and topo IV complex 
respectively are adenylylated by Fic proteins (section 3.3., research article III and section 3.5., 
research article V). The adenylylation occurs in the N-terminal part of GyrB and ParE, within 
the ATPase domain. The adenylylated residue (Y109 of GyrB and Y105 of ParE) is part of a 
flexible loop, called the ATP-lid loop that appears to be expulsed from the ligand-binding site 
upon binding of competitive inhibitors such as novobiocin (section 1.7.7.). Interestingly, also 
upon adenylylation, the ATP-lid loop of GyrB is distorted from its original position, being 
expulsed from the active site (section 3.6.1.) but adopting a different conformation than upon 
novobiocin binding. We have also shown that adenylylation of GyrB abolishes the catalytic 
activity of the ATPase domain of GyrB, i.e. ATP hydrolysis (section 3.3., research article III) 
but not the binding of ATP to the GyrB active site. ATP hydrolysis is required for DNA 
gyrase activity, since this molecular nanomachine introduces negative supercoils into 
covalently closed double-stranded DNA molecules using the free energy generated by ATP 
hydrolysis.  
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In the context of the DNA gyrase mechanism, the structural consequences of ATP 
hydrolysis were not yet understood by the community. As a brief aside, in a context unrelated 
to Fic-mediated adenylylation, I contributed to the understanding of the ATP hydrolysis 
mechanism in GyrB by crystallizing all nucleotide bound complexes along the ATP 
hydrolysis pathway (section 3.4., research article IV). GyrB undergoes an obligatory rigid 
body motion upon ATP hydrolysis, i.e. when going from the substrate complex to the 
immediate post-hydrolysis products ADP and Pi. This conformational change corresponds to 
an opening of the N-gate hole and it is well conceivable that the free energy generated by 
ATP hydrolysis may be used to actively push the T-segment through the DNA gate. 
GyrB adenylylation may then lock the gyrase in a closed conformation by inhibiting ATP 
hydrolysis. The unidirectionality of the T-segment would then be inhibited. Further 
experimental evidences are required to prove this tempting hypothesis. To further characterize 
the adenylylation of topoisomerases by Fic proteins, crystallization of a Fic/topoisomerase 
complex is of central interest. Extensive crystallization trials using different strategies have 
been tested (section 3.6.3.) without success so far. Nevertheless, the latest strategy using a 
cross-link of the modified target and the Fic protein via the ribose of the transferred AMP and 
a Fic active site residue seems very promising. For the first time, we were able to observe a 
complex in vitro. We suspect the adenylylation reaction to be a “kiss and run” reaction, in 
which the modified target gets released from the Fic protein quickly after the modification 
occurs.  
4.2.3. Do Fic proteins target other families of proteins?  
ATPase and GTPase, apart from their common catalytic activity of nucleotide hydrolysis, 
differ in fold or sequence identity. It cannot be excluded that Fic proteins also target unrelated 
proteins. For example, it has been shown recently that Bep2 from B. rochalimae targets 
tubulin which is a P-loop GTPase (K. Pieles, PhD thesis, 2013)112 but also targets vimentin99. 
Vimentin contains neither a GTPase fold nor an ATPase fold and the adenylylation of tubulin 
occurs distantly from the P-loop.  
Further investigations are required to find new targets of Fic proteins by combining our 
knowledge on Fic proteins and substrate binding, i.e. that it is highly likely that Fic proteins 
transfer a phosphate-containing group probably attached to a sugar and most likely requires a 
substrate that contains an energy-rich phosphodiester bond (see Appendix 8.3. for a 
Concluding remarks 
 248 
comprehensive list of diphosphate-containing molecules from E. coli). This strategy can be 
tested on the E. coli EcFicT protein, where we know that a hydrophobic pocket is in the 
vicinity of the Fic active motif. Neither the target nor the modification catalyzed by this Fic 
protein, if any, is known (section 3.7., research article VI). 
4.3. Is there a common scheme in Fic-mediated target inhibition? 
Adenylylation of small GTPases by VopS66 or IbpA75 blocks the binding to downstream 
effectors that lead to cell death177. Phosphocholination of Rab1 by the Legionella effector 
AnkX blocks the GTPase in the GTP bound state, which traps Rab1 at the membrane, where 
the bacterium resides during infection178. Phosphorylation of EF-Tu by Doc from the 
Bacteriophage P1 leads to an inefficient translation elongation that brings the cell to a 
dormant state97. The adenylylation of topoisomerases by Fic proteins that had been recently 
deciphered (section 3.3., research article III) results in bacteriostasis, promoting persister 
formation. We could show that the ATPase activity of GyrB is impaired by the adenylylation 
of Y109 in the ATP-lid loop (section 3.6.). A recent hypothesis (K. Pieles, PhD thesis, 
2013)112 proposed that adenylylation of tubulin by Bep2 from B. rochalimae may strengthen 
the interaction between tubulin and TOG, a protein required for fast microtubule growth115. 
This may also impede cell viability or promote bacterial infection and needs to be investigated 
further.  
Further investigations are required to understand the mechanism of target inhibition. By 
combining in vivo investigation with biochemical analysis and X-ray crystallography, we can 
aim to understand and dissect the specificity of recognition of Fic proteins with their cognate 
targets. The method developed in section 3.6.2.3., which uses covalent complex formation via 
a functionalized ATP molecule is very promising and may be used not only for the co-
crystallization of VbhT from B. schoenbuchensis or NmFic from N. meningitidis with 
bacterial topoisomerases but also for any other Fic proteins with known targets, like Bep1 
from B. rochalimae that specifically adenylylates Rac1109. 
As a general feature, FIC domain proteins investigated to date block the biological activity 
of their target, either by inhibiting downstream effector binding, by blocking the enzymatic 
activity of the target protein or maybe even by blocking the release of the target protein from 
partner binding. 
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8. Appendix 
8.1. Plasmids constructed  
A comprehensive list of the plasmids constructed in the frame of my PhD thesis work 
appears on the next pages using the following color code: 
 
 
Bartonella schoenbuchensis VbhT +/- VbhA 
Neisseria meningitidis NmFic 
Helicobacter pylori HpFic 
Shewanella oneidensis SoFic 
Homo sapiens HypE (Ficd) 
Escherichia coli EcoFic 
Escherichia coli GyrB 
Escherichia coli ParE 
Escherichia coli GyrA 
NmFic-(G4S)x-GyrB 
Vbht + Vbha-(G4S)x-GyrB 
Homo sapiens Rac1 
Homo sapiens Cdc42 
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8.3. Diphosphate-containing molecules from E. coli 
This section contains a list of putative substrates for Fic proteins. Note that this list is non-
comprehensive and still needs to be cured for phosphodiester containing molecules. 
Compound name Formula MW (Da) 
isopentenyl diphosphate C5H9O7P2 243.069 
dimethylallyl diphosphate C5H9O7P2 243.069 
2-amino-4-[(phosphonomethyl)hydroxy-phosphinyl]butanoate C4H9N1O7P2 245.065 
diimidotriphosphate H7N2O8P3 255.985 
1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate C5H9O8P2 259.069 
2,3-diphospho-D-glycerate C3H3O10P2 260.998 
1,3-bisphospho-D-glycerate C3H4O10P2 262.006 
hexanediol 1,6-bisphosphate C6H12O8P2 274.104 
2-C-methyl-D-erythritol-2,4-cyclodiphosphate C5H10O9P2 276.076 
5-phospho-&alpha;-D-ribose 1,2-cyclic phosphate C5H7O10P2 289.052 
4-amino-2-methyl-5-diphosphomethylpyrimidine C6H8N3O7P2 296.093 
alpha-D-ribose-1-methylphosphonate-5-phosphate C6H11O10P2 305.094 
alpha-D-ribose 1,5-bisphosphate C5H8O11P2 306.059 
geranyl diphosphate C10H17O7P2 311.188 
4-amino-2-methoxy-5-hydroxymethylpyrimidine pyrophosphate C6H8N3O8P2 312.092 
tetraphosphate O13P4 331.887 
alpha-glucose 1,6-bisphosphate C6H10O12P2 336.085 
beta-glucose-1,6-diphosphate C6H10O12P2 336.085 
beta-D-fructose 2,6-bisphosphate C6H10O12P2 336.085 
tagatose-1,6-bisphosphate C6H10O12P2 336.085 
fructose-1,6-bisphosphate C6H10O12P2 336.085 
bromohydrin of isopentenyl pyrophosphate C5H10O8P2Br1 339.981 
4-amino-2-trifluoromethyl 5-hydroxymethylpyrimidine 
pyrophosphate 
C6H5N3O7F3P2 350.064 
(2-amino-4-hydroxy-7,8-dihydropteridin-6-yl)methyl diphosphate C7H8N5O8P2 352.116 
D-<i>glycero</i>-&beta;-D-<i>manno</i>-heptose 1,7-
bisphosphate 
C7H12O13P2 366.112 
D-sedoheptulose-1,7-bisphosphate C7H12O13P2 366.112 
(2<i>E</i>,6<i>E</i>)-farnesyl diphosphate C15H25O7P2 379.306 
5-phospho-&alpha;-D-ribose 1-diphosphate C5H8O14P3 385.031 
ribose triphosphate C5H9O14P3 386.039 
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(S)-farnesyl thiopyrophosphate C15H25O6P2S1 395.366 
bis(glycerophosphoglycerol) C9H20O13P2 398.197 
6-phosphonouridine 5'-monophosphate C9H11N2O12P2 401.14 
6-azauridine diphosphate C8H10N3O12P2 402.127 
deoxyinosine diphosphate C10H11N4O10P2 409.165 
P1-uridyl-P2-methyl diphosphate C10H14N2O12P2 416.174 
2'-chloro-2'-deoxyuridine-5'-diphosphate C9H10N2O11P2Cl1 419.585 
thiamin diphosphate C12H16N4O7P2S1 422.288 
adenosine 3',5'-bisphosphate C10H11N5O10P2 423.172 
adenosine-2',5'-bisphosphate C10H11N5O10P2 423.172 
inosine diphosphate C10H11N4O11P2 425.165 
2'-azido-2'-deoxyuridine-5'-diphosphate C9H10N5O11P2 426.152 
2'-methoxythiamin pyrophosphate C12H16N4O8P2S1 438.288 
geranylgeranyl diphosphate C20H33O7P2 447.424 
all-<i>trans</i>-geranylgeranyl diphosphate C20H33O7P2 447.424 
thiamine thiothiazolone pyrophosphate C12H15N4O7P2S2 453.341 
&alpha;-D-ribose-1-methylphosphonate-5-triphosphate C6H12O16P4 464.046 
2-(&alpha;-hydroxyethyl)thiamine diphosphate C14H20N4O8P2S1 466.341 
P1-uridyl-P2-phenyl diphosphate C15H16N2O12P2 478.245 
7,8-dihydromonapterin triphosphate C9H12N5O13P3 491.141 
7,8-dihydroneopterin triphosphate C9H12N5O13P3 491.141 
uridine-5'-diphosphate chloroacetol C12H15N2O13P2Cl1 492.657 
2-thiouridine 5'-triphosphate C9H11N2O14P3S1 496.172 
thiamin triphosphate C12H16N4O10P3S1 501.26 
2-hydroxydeoxyadenosine 5'-triphosphate C10H12N5O13P3 503.152 
phosphoadenosine-5'-phosphosulfate C10H11N5O13P2S1 503.23 
di-<i>trans</i>,di-<i>cis</i>-pentaprenyl diphosphate C25H41O7P2 515.542 
geranylfarnesyl diphosphate C25H41O7P2 515.542 
8-hydroxydeoxyguanosine 5'-triphosphate C10H12N5O14P3 519.151 
4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol C14H23N3O14P2 519.295 
succinate semialdehyde-thiamine diphosphate C16H22N4O10P2S1 524.378 
uridine-5'-diphosphate bromoacetol C12H15N2O13P2Br1 537.108 
1-(5-phospho-&beta;-D-ribosyl)-AMP C15H19N5O14P2 555.288 
D-<i>myo</i>-inositol (1,3,4,5,6)-pentakisphosphate C6H7O21P5 569.977 
D-<i>myo</i>-inositol (1,2,4,5,6)-pentakisphosphate C6H7O21P5 569.977 
1D-<i>myo</i>-inositol (1,2,3,4,6)-penta<i>kis</i>phosphate C6H7O21P5 569.977 
D-<i>myo</i>-inositol (1,2,3,4,5)-pentakisphosphate C6H7O21P5 569.977 
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phosphoribulosylformimino-AICAR-P C15H21N5O15P2 573.303 
1-(5-phospho-&beta;-D-ribosyl)-5-[(5-
phosphoribosylamino)methylideneamino]imidazole-4-
carboxamide 
C15H21N5O15P2 573.303 
adenosine tetraphosphate C10H13N5O16P4 583.132 
di-<i>trans</i>,poly-<i>cis</i>-hexaprenyl diphosphate C30H49O7P2 583.66 
all-<i>trans</i>-hexaprenyl diphosphate C30H49O7P2 583.66 
2-phospho-4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol C14H22N3O17P3 597.259 
guanosine tetraphosphate C10H13N5O17P4 599.131 
p-(bromoacetamido)phenyl uridyl pyrophosphate C17H18N3O13P2Br1 614.193 
1D-<i>myo</i>-inositol 1,2,3,4,5,6-hexakisphosphate C6H6O24P6 647.942 
di-<i>trans</i>,poly-<i>cis</i>-heptaprenyl diphosphate C35H57O7P2 651.779 
all-<i>trans</i>-heptaprenyl diphosphate C35H57O7P2 651.779 
3'-dephospho-CoA C21H33N7O13P2S1 685.538 
1-(5-phospho-&beta;-D-ribosyl)-ATP C15H20N5O20P4 714.24 
di-<i>trans</i>,poly-<i>cis</i>-octaprenyl diphosphate C40H65O7P2 719.897 
all-<i>trans</i>-octaprenyl diphosphate C40H65O7P2 719.897 
adenosine thiamine triphosphate C22H28N9O13P3S1 751.497 
5',5'''-diadenosine triphosphate C20H24N10O16P3 753.388 
di-<i>trans</i>,poly-<i>cis</i>-nonaprenyl diphosphate C45H73O7P2 788.015 
all-<i>trans</i>-nonaprenyl diphosphate C45H73O7P2 788.015 
Phosphatidylglycerophosphate (dihexadec-9-enoyl, n-C16:1) C38H69O13P2 795.903 
1,2-dipalmitoyl-phosphatidylglycerol-phosphate C38H73O13P2 799.934 
5',5'''-diadenosine tetraphosphate C20H24N10O19P4 832.36 
phosphatidylglycerophosphate (dioctadecanoyl, n-C18:0) C42H81O13P2 856.042 
&omega;, mono-<i>trans</i>,octa-<i>cis</i>-decaprenyl 
diphosphate 
C50H81O7P2 856.133 
di-<i>trans</i>,poly-<i>cis</i>-decaprenyl diphosphate C50H81O7P2 861.173 
P1,P4-bis(5'-guanosyl) tetraphosphate C20H24N10O21P4 864.359 
2'-(5''-phosphoribosyl)-3'-dephospho-CoA C26H42N7O19P3S1 881.635 
5',5'''-diadenosine pentaphosphate C20H24N10O22P5 911.332 
<i>di-trans,octa-cis</i>-undecaprenyl diphosphate C55H89O7P2 924.251 
2'-(5''-triphospho-&alpha;-D-ribosyl)-3'-dephospho-CoA C26H41N7O26P5S1 1054.57 
N-acetyl-&alpha;-D-glucosaminyl-diphospho-trans,octacis-
decaprenol 
C58H95N1O12P2 1060.335 
<i>N</i>-acetyl-&alpha;-D-glucosaminyl-diphospho-
<i>ditrans,octacis</i>-undecaprenol 
C63H103N1O12P2 1128.454 
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8.4. Structure gallery of FIC domain proteins 
This appendix contains a comprehensive list of FIC domain structures that have been 
determined to date and are either deposited in the protein data bank (www.pdb.org) or have 
been determined in the frame of the collaboration between the Schirmer group and the Dehio 
group at the Biozentrum, University of Basel. 
 
 
Table A1. FIC domain structures determined to date.  
 
Organism Description Note PDB code Figure 
L. pneumophilae AnkX Apo 4BEP A1 
L. pneumophilae AnkX in complex with CDP-choline Substrate 4BET A1 
L. pneumophilae AnkX in complex with CMP and phosphocholine Products 4BES A1 
L. pneumophilae AnkX in complex with CMP Side-product 4BER A1 
P. syringae AvrB Apo 1NH1 A2 
P. syringae AvrB in complex with ADP Putative side-product? 2NUN A2 
P. syringae AvrB in complex with RIN4 Target peptide 2NUD A2 
B. henselae BepA FIC-OB Apo 2VY3 A3 
B. henselae BepA FIC-OB in complex with PPi Side-product 2JK8 A3 
B. quintana BepC Apo 4LU4 A3 
B. quintana BepC in complex with ADP Putative side-product? 4N67 A3 
B. rochalimae Bep1 in complex with its antitoxin Apo A. Goepfert, unpublished A4 
B. Clarridgeiae Bep1 FIC-OB Apo  A4 
B. sp. ar 15-3 Bep8 Apo 4M16 A4 
B. sp. ar 15-3 Bep8 Apo 4PY3 A4 
B. schoenbuchensis VbhT in complex with VbhA Apo 3SHG A5 
B. schoenbuchensis VbhT in complex with VbhA and ATP 
ATP, incompetent 
form 3ZC7 A5 
B. schoenbuchensis VbhT in complex with VbhAE24G and ATP (adenylylase form) 
ATP, adenylylase 
competent form 3ZCB A5 
B. schoenbuchensis VbhT in complex with VbhAE24G and ATP (kinase form) 
ATP, kinase 
competent form 
A. Goepfert, 
unpublished A5 
B. schoenbuchensis VbhTS175C in complex with VbhAE24G and 2’-S-ATP 
Covalently bound 
ATP, competent 
form 
F.V. Stanger, 
unpublished A5 
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E. coli EcFicTG55R in complex with EcFicA Apo 
F.V. Stanger, 
unpublished A6 
E. coli EcFicT in complex with EcFicAE28G Apo 
F.V. Stanger, 
unpublished A6 
S. oneidensis SoFic Apo 3EQX A7 
S. oneidensis SoFic in complex with ATP ATP, incompetent form 3ZCN A7 
S. oneidensis SoFic in complex with AMPPNP AMPPNP, competent form 3ZEC A7 
B. thetaiotaomicron BtFic Apo 3CUC A7 
V. 
parahaemolyticus VopS Apo 3LET A8 
H. somni IbpA Apo  A8 
H. somni IbpA in complex with Cdc42 
Complex with 
adenylylated-
target 
3N3V, 4ITR A8 
Bacteriophage P1 Doc in complex with PhD Complex with antitoxin PhD 3KH2, 3K33 A9 
Bacteriophage P1 DocH66Y in complex with PhD Disturbed fold 3DD9 A9 
N. meningitidis NmFic wt Apo 2G03 A10 
N. meningitidis NmFic wt in complex with AMPPNP ATP, incompetent form 3S6A A10 
N. meningitidis NmFic wt tetramer Tetramer F.V. Stanger, unpublished A10 
N. meningitidis NmFic S182A,E186A ATP, competent form 3SN9 A10 
N. meningitidis NmFic E186G in complex with AMPPNP 
ATP, competent 
form 3ZLM A10 
N. meningitidis NmFic Y183F,E186G ATP F.V. Stanger, unpublished A10 
N. meningitidis NmFic ∆8 Tetramer, ATP, competent form 3SE5 A10 
N. meningitidis NmFic E102R Dimer, apo F.V. Stanger, unpublished A11 
N. meningitidis NmFic E156R Dimer, apo F.V. Stanger, unpublished A11 
N. meningitidis NmFIc E102R,E156R Monomer, apo F.V. Stanger, unpublished A11 
N. meningitidis NmFic E156R in complex with ATP 
Dimer, ATP, 
competent kinase 
form 
F.V. Stanger, 
unpublished A11 
N. meningitidis NmFic E156R,Y183F in complex with ATP 
Dimer, ATP, 
competent kinase 
form 
F.V. Stanger, 
unpublished A11 
H. pylori HpFic Apo 2F6S A11 
 
 
In the following figures, note that the view slightly differs from one figure to the other, 
depending on the presence of additional domains (as a compromise to find a view in which 
most of the features of each structure are visible).  
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Figure A1. Structure of Legionella pneumophilae AnkX. (a) Overall structure. The FIC domain and insert 
domain are colored in red, the CMP domain is colored in magenta, the Fic active site motif is colored in yellow 
and ankyrin repeats are colored in orange. Details of the active site of (b) the apo structure of AnkX (PDB: 
4BEP), (c) AnkXH229A in complex with the substrate CDP-choline (PDB: 4BET), (d) AnkX in complex with the 
products CMP and phosphocholine (PDB: 4BES) and (e) AnkX in complex with CMP and phosphate (PDB: 
4BER). The substrate is shown with beige carbon atoms and residues part of the Fic active site motif or 
interacting with the substrate are displayed as sticks. 
(b) (c) 
(d) (e) 
(a) 
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Figure A2. Structure of AvrB from Pseudomonas syringae. (a) Overall structure of AvrB. The Fic core is 
colored in red, the Fic active site is colored in yellow and the additional domains are colored in magenta and 
light pink. (b) Active site details of the apo structure of AvrB (PDB: 1NH1). Note the absence of the histidine at 
the first position of the active site motif (replaced by a methionine). H217, part of the neighboring domain (light 
pink) may act as a general base in this case. (c) AvrB in complex with, presumably, the product of the reaction, 
ADP (PDB: 2NUN). AvrB is thought to act as a kinase. (d) AvrB in complex with the RIN4 peptide (PDB: 
2NUD). 
(a) 
(b) (c) 
(d) 
H217 H217 
RIN
4
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Figure A3. Structures of Bartonella effector proteins from lineage 4. (a) Overall structure of BepA from 
Bartonella henselae (PDB code: 2VY3). The Fic core is colored in red, the Fic active site is colored in yellow, 
the additional helices are colored in magenta and the OB (oligonucleotide-binding) fold in blue. (b) Overall 
structure of BepA from Bartonella henselae in complex with PPi (PDB code: 2JK8). (c) Details of the active site 
of BepA in complex with PPi and Mg2+ (as in (b)). (d) Overall structure of BepC from Bartonella quintana (PDB 
code: 4LU4) using the same color code as in (a). (e) Details of the active site of (d). (f) Details of the active site 
of BepC from Bartonella quintana in complex with ADP and Mg2+ (PDB code: 4N67). Note the modification of 
the lysine side chain in the active site.  
  
(a) (b) 
(c) (d) 
(e) 
(f) 
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(a) (b) 
(d) 
(f) 
(c) 
 
(d) 
 
(e) (f) 
(g) 
(h) 
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Figure A4. Structures of Bartonella effector proteins from lineage 3. (a) Overall structure of Bep1 from 
Bartonella rochalimae (Arnaud Goepfert, unpublished) in complex with its cognate antitoxin. The Fic core is 
colored in red, the Fic active site is colored in yellow, the additional helices are colored in magenta and the 
antitoxin is colored in aquamarine except the αinh-helix in dark green. (b) Details of the active site of (a). 
(c) Overall structure of Bep1 from Bartonella clarridgeiae (PDB code: 4NPS) using the same color code as in 
(a). Additionally, the OB-fold is colored in blue. (d) Details of the active site of (c). Note that the fold is highly 
similar between these two proteins with or without the antitoxin. (e) Overall structure of Bep8 from Bartonella 
sp. ar 15-3 (PDB code: 4M16). (f) Details of the active site of (e). (g) Overall structure of Bep8 from Bartonella 
sp. 1-1C. (PDB code: 4PY3). (h) Details of the active site of (g). 
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 Figure A5. Structures of Bartonella effector proteins from lineage 2: VbhT from B. schoenbuchensis in 
complex with its cognate antitoxin VbhA. (a) Superimposition of the five structures of VbhT/VbhA described 
in detail in (b-f). (b) Details of the active site of the apo structure of VbhT/VbhA (PDB code: 3SHG). Details of 
the active site of (c) VbhT/VbhA in complex with ATP (PDB code: 3ZC7), (d) VbhT/VbhAE24G (inhibition-
relieved mutant) in complex with ATP (PDB code: 3ZCB), (e) VbhT/VbhAE24G in complex with ATP in which 
the ATP adopts a kinase-competent conformation (Arnaud Goepfert, unpublished) and (f) VbhTS175CAE24G cross-
linked to 2’-S-ATP via a disulfide bond with cysteine 175 (unpublished). 
  
(a) (b) 
(c) (d) 
(e) (f) 
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Figure A6. Structures of the class I Fic protein EcFicT in complex with its cognate antitoxin EcFicA. 
(a) Overall structure of EcFicTG55R/EcFicA (unpublished) using the same color code as in Figure A4. Details of 
the active site of (b) EcFicTG55R/EcFicA (unpublished) and (c) EcFicT/EcFicAE28G (unpublished). 
  
(a) 
(b) (c) 
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Figure A7. Structures of the class II Fic protein SoFic from Shewanella oneidensis and BtFic from 
Bacteroides thetaiotaomicron. (a) Overall structure of the SoFic dimer (PDB code: 3EQX) using the same color 
code as the previous figures with the OB-fold in blue. (b) Details of the active site of (a). Details of the active 
site of (c) SoFic in complex with ATP (PDB code: 3ZCN) and (d) SoFicE73G (inhibition-relieved mutant) in 
complex with AMPPNP (PDB code: 3ZEC). (e) Overall structure of the BtFic dimer (PDB code: 3CUC) and 
(f) respective active site details.  
  
 
(a) (b) 
(c) (d) 
(e) (f) 
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(a) (b) 
(c) (d) 
(e) 
(f) 
IbpA 
Cdc42 
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Figure A8. Structures of VopS from Vibrio parahaemolyticus, IbpA from Histophilus somni and IbpA in 
complex with its target Cdc42. (a) Overall structure of the VopS dimer (PDB code: 3LET) using the same 
color code as the previous figures, the B-subunit of the dimer is colored in slightly different color hue. 
(b) Overall structure of IbpA in complex with Cdc42 (PDB code: 3N3V or 4ITR). (c) Details of the active site of 
(a). (d) Details of the active site of IbpA (PDB code: 3N3U). (e) Details of the active site of (b). Note that AMP 
is covalently attached to Y32 of Cdc42. (f) Stereoview of (e). 
 
 
 
 
Figure A9. Structures of Doc from Bacteriophage P1. (a) Overall structure of the Doc-PhD complex that 
forms an heterotetramer (2 Doc and 2 PhD) via dimerization of the antitoxin PhD (PDB code: 3KH2) using the 
same color code as the previous figures. (b) Overall structure of the DocH66Y dimer. Note that the Fic fold has 
been disrupted by this mutation and is now splitted within this dimeric structure. (c) Details of the active site of 
(a). 
  
(a) (b) 
(c) 
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Figure A10. Structures of NmFic from Neisseria meningitidis. (a) Overall structure of NmFic (PDB code: 
2G03) using the same color code as the previous figures. Active site details of (b) NmFic in complex with 
AMPPNP (PDB code: 3S6A), (c) NmFicS182A,E186G in complex with AMPPNP (PDB code: 3SN9), (d) 
NmFicE186G in complex with AMPPNP (PDB code: 3ZLM), (e) NmFicY183F,E186G in complex with ATP 
(b) 
(c) (d) 
(h) 
(a) 
(e) (f) 
(g) 
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(unpublished) and (f) NmFic∆8 in complex with AMPPNP (PDB code: 3SE5). Tetramer observed in the structure 
of (g) NmFic∆8 (PDB code: 3SE5) and (h) NmFicwt crystallized at high protein concentration (unpublished). 
 
 
Figure A11. Structures of NmFic from Neisseria meningitidis and HpFic from Helicobacter pylori. (a) 
Overall dimeric structure of NmFicE102R (unpublished) with the monomer A in pink and B in brown. The active 
site loop is colored is yellow and the residues involved in contacts are shown as sticks. Note that the FLAP 
region is not ordered in the crystal. (b) Overall dimeric structure of NmFicE156R (unpublished) with the monomer 
A in pink and B in green. The active site loop is colored is yellow, the FLAP in blue and the residues involved in 
contacts are shown as sticks. Details of the active site of (c) NmFicE156R in complex with ATP and (d) 
NmFicE156R,Y183F in complex with ATP. Note that ATP adopts a kinase conformation in these two structures. (e) 
Structure of monomeric NmFicE102R,E156R and (f) structure of HpFic. 
(b) 
(c) (d) 
(a) 
(e) (f) 
